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Polysaccharide-­‐decorated	   complexation	  hydrogels	  were	   investigated	   for	   use	   as	  
oral	   insulin	   delivery	   systems.	   	   Several	   different	   polysaccharide	   modifications	   of	  
poly(methacrylic	  acid-­‐grafted-­‐ethylene	  glycol)	  hydrogels	  were	  developed	  using	  dextran	  
and	   pullulan.	   	   Polymerizable	   groups	   were	   added	   to	   the	   polysaccharides,	   dextran	   and	  
pullulan,	   by	   methacrylation.	   	   These	   macromers	   were	   then	   copolymerized	   with	  
methacrylic	   and	   poly(ethylene	   glycol)	   to	   form	   P(MAA-­‐g-­‐EG-­‐co-­‐Dextran)	   and	   P(MAA-­‐g-­‐
EG-­‐co-­‐Pullulan)	   gels	   using	   a	  UV-­‐initiated	   free	   radical	   polymerization.	   	   The	   synthesis	   of	  
these	  materials	  was	  confirmed	  using	  Fourier	  transform-­‐infrared	  spectroscopy.	  	  	  
The	  pH-­‐responsive	  swelling	  of	  these	  systems	  was	  investigated	  using	  dynamic	  and	  
equilibrium	   swelling	   measurements.	   	   Swelling	   of	   polysaccharide-­‐modified	   hydrogels	  
occurred	  with	   increasing	  pH.	   	   In	  acidic	  conditions,	   these	  materials	  were	   in	  a	  collapsed	  
state	  while	  in	  neutral	  conditions	  these	  materials	  were	  swollen.	  	  	  	  
The	   ability	   to	   load	   insulin	   into	   these	   hydrogels	   using	   was	   demonstrated	   with	  
loading	   efficiencies	   as	   high	   as	   88%	   were	   observed	   for	   P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	   6000)	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hydrogel	   microparticles.	   	   Almost	   zero	   release	   of	   insulin	   occurred	   in	   acidic	   conditions	  
while	  an	  increase	  in	  pH	  was	  shown	  to	  trigger	  release.	  	  	  
The	   use	   of	   dextran	   and	   pullulan-­‐modified	   complexation	   hydrogels	   for	   oral	  
delivery	   applications	   was	   investigated	   using	   in	   vitro	   cellular	   viability	   assays	   and	  
mucoadhesion	  experiments.	   	  These	  systems	  were	  shown	   to	  cause	   little	   cytotoxicity	   to	  
an	   intestinal	  epithelium	  Caco-­‐2	  cell	  model	  over	  a	  range	  of	  concentrations	  as	  high	  as	  1	  
mg/ml.	   	  The	  adherence	  of	  polysaccharide-­‐modified	  hydrogels	   to	   reconstitituted	  mucin	  
gels	  was	  quantified	  with	  the	  P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	  6000)	  performing	  the	  best.	  
Further	   evaluation	   of	   polysaccharide-­‐modified	   complexation	   hydrogels	   for	   oral	  
insulin	   delivery	   was	   evaluated	   through	   in	   vitro	   insulin	   drug	   transport	   studies	   using	   a	  
mucus-­‐producing	   Caco-­‐2/HT29-­‐MTX	   co-­‐culture	   model.	   	   The	   results	   showed	   that	   the	  
P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	   6000)	   allowed	   transport	   of	   insulin	   across	   the	   cell	  monolayers	  
and	  did	  not	  adversely	  affect	  the	  integrity	  of	  the	  epithelial	  monolayer.	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Chapter	  1:	  	  
Introduction	  
Protein	  drugs	  have	  already	   revolutionized	   treatment	   for	  a	  number	  of	  diseases,	  
and	   the	   expected	   increase	   in	   protein-­‐based	   pharmaceutics	   brings	   a	   new	   set	   of	  
challenges	  for	  the	  pharmaceutics	  field.	  	  Due	  to	  their	  instability,	  size,	  and	  poor	  transport	  
properties,	   protein	   drugs	   are	   predominantly	   administered	   by	   either	   intravenous	   or	  
subcutaneous	  injection.	  	  	  
Patient	  compliance,	   the	  extent	   to	  which	  a	  patient	  adheres	   to	   the	   treatment,	   is	  
already	  a	  concern	  in	  diabetes	  treatment	  with	  insulin	  and	  is	   likely	  to	  become	  a	  growing	  
issue	  as	  protein	  drug	  treatments	  become	  more	  widely	  used.	  	  A	  number	  of	  studies	  have	  
underscored	   the	   relationship	   of	   traditional	   subcutaneous	   injections	  with	   patient	   non-­‐
adherence,	  and	   it	   is	  estimated	   that	  over	  half	  of	   insulin-­‐dependent	  adults	   intentionally	  
skip	   injections	   [1,	  2].	   	  We	  believe	   that	   the	  development	  of	  an	  oral	   insulin	   formulation	  
has	   the	   potential	   to	   address	   some	   of	   the	   issues	   associated	   with	   non-­‐adherence	  
(including	   the	   interference	  with	  daily	  activities,	  embarrassment,	  and	   injection	  pain)	  as	  
well	  as	  reduce	  the	  adverse	  effects	  of	  subcutaneous	  administration.	  	  	  
Oral	   administration	   of	   drugs	   is	   also	   preferred	   over	   subcutaneous	   injection	   for	  
other	  reasons.	  	  For	  example,	  oral	  administration	  is	  easier	  for	  patients,	  and	  it	  eliminates	  
the	   need	   for	   needles	   and	   disposal	   of	   sharps.	   	   Orally	   delivered	   insulin	   would	   be	  
advantageous	  over	  existing	  dosage	  forms	  because	  orally	  administered	  drugs	  absorbed	  in	  
the	  intestine	  enter	  the	  hepatic	  portal	  vein.	   	  The	  hepatic	  portal	  vein	  carries	  the	  drug	  to	  
the	   liver	  where	   it	   undergoes	   first	   pass	  metabolism.	   	   This	   pathway	   closely	   follows	   the	  
pathways	   insulin	  naturally	   takes	  after	   secretion	   from	  the	  pancreas.	   	  As	  a	   result,	  orally	  
administered	  insulin	  may	  more	  closely	  mimic	  the	  natural	  biodistribution	  of	  insulin.	  	  	  For	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these	  reasons,	  the	  development	  of	  an	  oral	  insulin	  formulation	  could	  significantly	  impact	  
the	  treatment	  of	  patients	  with	  diabetes.	  	  
Oral	  delivery	  of	  insulin	  and	  other	  protein	  drugs	  is	  not	  without	  challenges.	  	  Two	  of	  
the	  greatest	  challenges	  to	  oral	  protein	  delivery	  is	  maintaining	  the	  bioactivity	  of	  the	  drug	  
and	   achieving	   a	   therapeutic	   bioavailability.	   	   The	   secondary	   and	   tertiary	   structure	   of	  
protein	  drugs	  can	  be	  denatured	  in	  the	  GI	  tract,	  reducing	  the	  therapeutic	  activity	  of	  the	  
drug.	  	  Additionally,	  protein	  drugs	  can	  be	  degraded	  by	  proteolytic	  enzymes	  present	  in	  the	  
stomach	  and	  the	  small	  intestine.	  	  	  
Improving	   the	   absorption	   of	   protein	   drugs	   is	   a	   major	   obstacle	   to	   maintaining	  
high	  bioavailability	  using	  oral	   insulin	  delivery.	   	  Large,	  hydrophilic	  macromolecules	  such	  
as	   insulin	   have	   low	   permeabilities	   across	   the	   intestinal	   epithelium.	   	   In	   order	   to	  
overcome	  low	  absorption,	  a	  variety	  of	  methods	  have	  been	  explored.	   	  One	  of	  the	  most	  
promising	   strategies	   is	   the	   use	   of	  mucoadhesive	   carriers	   which	   can	   interact	   with	   the	  
intestinal	  mucosa	  and	  extend	  the	  residence	  time	  of	   the	  carrier	  and	  drug	  at	   the	  site	  of	  
absorption.	  	  
Because	  protection	  of	  protein	  drugs	  from	  enzymes	  in	  the	  stomach	  followed	  	  by	  
release	  in	  the	  small	  intestine	  is	  desirable,	  the	  use	  of	  protein	  drug	  carriers	  composed	  of	  
anionic	  complexation	  hydrogel	   is	  a	  promising	  strategy	  for	  oral	  protein	  delivery.	   	  These	  
hydrogels	   have	   been	   shown	   to	   effectively	   entrap	   protein	   drugs	   within	   their	   three-­‐
dimensional	  network.	  	  Anionic	  complexation	  hydrogels	  such	  as	  P(MAA-­‐g-­‐EG)	  have	  been	  
used	  for	  pH-­‐responsive	  protein	  delivery	  in	  the	  GI	  tract.	  	  	  
While	  these	  systems	  have	  been	  shown	  to	  be	  mucoadhesive,	  the	  incorporation	  of	  
additional	   adhesion	   promoters	   such	   as	   wheat	   germ	   agglutinin	   has	   been	   shown	   to	  
improve	   mucoadhesion.	   	   In	   this	   work,	   the	   incorporation	   of	   linear,	   neutral	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polysaccharides	   into	   P(MAA-­‐g-­‐EG)	   hydrogels	   was	   investigated	   for	   mucoadhesive	   oral	  
protein	  delivery.	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Chapter	  2:	  	  	  
Background	  
Since	   the	   entrance	   of	   insulin	   as	   the	   first	   FDA-­‐approved	   commercially	   available	  
recombinant	   protein	   drug	   in	   1982,	   protein	   drugs	   have	   become	   one	   of	   the	   fastest	  
growing	   classes	   of	   new	   therapeutics.	   	   Because	   of	   the	   size	   of	   protein	   drugs	   and	   their	  
stability,	   protein	   drugs	   are	   typically	   administered	   via	   injection	   systemically	   or	  
intravenously.	  	  	  
Alternative	   methods	   of	   protein	   drug	   administration	   which	   do	   not	   require	  
injection	  or	  intravenous	  access	  are	  highly	  desirable.	  	  The	  oral	  route	  is	  the	  most	  desirable	  
administration	  method	  for	  drugs	  as	  it	  is	  easy	  for	  patients	  and	  does	  not	  require	  injection.	  	  
However,	  there	  are	  several	  significant	  challenges	  to	  the	  successful	  development	  of	  oral	  
protein	   drug	   formulations:	   the	   instability	   of	   protein	   drugs	   in	   the	   gastrointestinal	   (GI)	  
tract,	   the	   low	   permeability	   of	   protein	   drugs,	   and	   a	   narrow	   absorption	  window	   in	   the	  
intestine.	   	   This	   chapter	   is	   divided	   into	   three	  major	   sections	   to	   review	   the	   application,	  
approach,	  and	  materials	  studied	  in	  this	  thesis	  by	  focusing	  on	  treatment	  of	  diabetes	  with	  
insulin,	  oral	  protein	  drug	  delivery,	  and	  biomaterials	  containing	  polysaccharides.	  
2.1	  DIABETES	  MELLITUS	  AND	  INSULIN	  
According	   to	   the	  World	  Health	  Organization,	   chronic	  diseases	   including	  cancer,	  
diabetes,	   and	   cardiovascular	   disease	   are	   the	   leading	   cause	   of	   death	   worldwide.	   	   The	  
majority	   of	   deaths	   (80%)	   related	   to	   chronic	   diseases	   occurs	   in	   low	   to	  middle	   income	  
nations	   [1].	   	  A	  disproportionate	   increase	   in	  chronic	  diseases	  was	  predicted	  by	  WHO	  in	  
low	   to	  middle	   income	  nations.	   	  Between	  2005	  and	  2007,	   it	  was	  expected	   that	  deaths	  
due	  to	  chronic	  diseases	  would	  increase	  by	  17%.	  	  In	  comparison,	  a	  3%	  decrease	  in	  deaths	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due	   to	   nutritional	   deficiencies,	   infectious	   diseases,	   and	   maternal	   and	   prenatal	  
conditions	  was	  predicted.	  	  This	  trend	  in	  increased	  chronic	  diseases	  in	  developing	  nations	  
is	  expected	  to	  continue.	  
	  Diabetes	   is	   a	   particularly	   concerning	   chronic	   disease	   because	   it	   is	   becoming	  
more	  prevalent	  both	   in	   the	  United	  States	  and	  abroad.	   	   In	  2007,	   it	  was	  estimated	   that	  
23.6	  million	  people	  in	  the	  United	  States	  or	  about	  7.8%	  of	  the	  population	  were	  living	  with	  
diabetes,	   and	   diabetes	   was	   the	   seventh	   leading	   underlying	   cause	   of	   death	   [2].	  	  
According	   to	   the	   World	   Health	   Organization,	   about	   6%	   of	   the	   global	   population	   has	  
diabetes.	  	  It	  is	  predicted	  that	  by	  2025,	  diabetes	  treatment	  and	  prevention	  will	  cost	  the	  
international	   community	  more	   than	   300	   billion	   US	   dollars	   and	   only	   a	   fraction	   of	   this	  
expenditure,	  20%,	  will	  be	  spent	  on	  patients	  outside	  the	  wealthiest	  countries	  [3].	  	  
Currently,	   the	   treatment	  and	  management	  of	  diabetes	   is	   challenging	  especially	  
in	   poorer	   nations	   where	   control	   over	   diet,	   monitoring	   of	   blood	   glucose	   levels,	   and	  
administration	  of	  drugs	  are	  less	  accessible.	  	  Limited	  access	  to	  insulin	  and	  limited	  health	  
care	  resources	  are	  significant	  concerns	  for	  treatment	  of	  diabetics.	  	  For	  example,	  access	  
to	   insulin	   in	   sub-­‐Saharan	   Africa	   is	   still	   not	   available	   continuously.In	   a	   study	   on	   the	  
availability	  of	  insulin,	  insulin	  was	  available	  only	  at	  the	  two	  national	  referral	  hospitals	  in	  
Mali,	  at	  most	  hospitals	  in	  Mozambique,	  and	  at	  some	  smaller	  Referral	  Health	  Centers	  in	  
Zambia	  [3].	  
In	   addition	   to	   concerns	   regarding	   insulin	   availability,	   cost	   is	   a	   significant	  
constraint	   in	   the	   treatment	   of	   diabetes	   in	   developing	   nations.	   	   The	   cost	   of	   insulin	   is	  
subsidized	  in	  some	  countries,	  but	  patients	  typically	  pay	  for	  their	  own	  syringes,	  which	  are	  
often	  difficult	  to	  obtain	  and	  range	  in	  cost.	  	  In	  sub-­‐Saharan	  Africa,	  syringes	  range	  in	  cost	  
from	  $0.04	  to	  $1.50	  each.	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With	  expected	  increases	  in	  diabetes	  globally	  and	  a	  disproportionate	  increase	  in	  
chronic	   diseases	   in	   developing	   nations,	   diabetes	   management	   and	   treatment	   is	   a	  
significant	   global	   challenge.	   	   Alternative	   methods	   to	   subcutaneous	   and	   intravenous	  
administration	  of	  protein	  drugs	  are	  needed.	  	  More	  convenient	  administration	  methods,	  
such	   as	   oral	   administration,	   would	   significantly	   impact	   the	   world	   through	   increased	  
patient	   adherence,	   improved	   quality	   of	   life	   for	   patients,	   and	   may	   alleviate	   some	  
expenses	  for	  patients	  in	  developing	  nations.	  
	  
2.1.1	  Physiology	  of	  Diabetes	  	  
Diabetes	   is	   a	   group	   of	   diseases	   associated	   with	   chronic	   hyperglycemia.	   The	  
underlying	   cause	   of	   diabetes	   can	   be	   a	   problem	   with	   insulin	   production,	   insulin	  
ineffectiveness,	   or	   both.	   	   Type	   1	   diabetes	   is	   characterized	   by	   an	   inability	   to	   produce	  
insulin	   and	   is	   also	   referred	   to	   as	   juvenile	   diabetes.	   	   Type	   2	   diabetes,	   or	   adult-­‐onset	  
diabetes,	   is	   characterized	   insulin	   resistance	   and	   can	   include	   problems	   with	   insulin	  
secretion.	   	   Gestational	   diabetes	   is	   diagnosed	   in	   hyperglycemic	   pregnant	   women	  who	  
were	  non-­‐diabetic	  prior	  to	  their	  pregnancy.	   	  Often,	  women	  diagnosed	  with	  gestational	  
diabetes	  develop	  Type	  2	  diabetes.	   	  This	  section	  will	   focus	  on	  the	  physiology	  of	  normal	  
glucose	   metabolism,	   the	   two	   most	   common	   types	   of	   diabetes	   (Type	   1	   and	   Type	   2	  
diabetes),	  and	  treatment	  of	  diabetes.	  
Insulin	  
Insulin	   is	   a	   hormone	   produced	   in	   β-­‐cells	   in	   the	   islets	   of	   Langerhans	   in	   the	  
pancreas.	   	   The	   primary	   function	   of	   insulin	   is	   to	   control	   glucose	   levels	   and	   the	  
metabolism	  of	  fats	  and	  steroids.	  	  Proper	  control	  of	  glucose	  is	  essential	  because	  glucose	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is	  required	  for	  the	  synthesis	  of	  adenosine	  triphosphate	  (ATP)	  which	  is	  involved	  in	  almost	  
every	  biological	  process.	  	  	  
Normal	  blood	  glucose	  levels	  are	  tightly	  maintained	  at	  approximately	  90	  mg/dL	  or	  
5	  mmol/L	  by	   several	  hormones.	   	   These	  hormones,	  most	  notably	   insulin	  and	  glucagon,	  
help	  balance	  glucose	   levels	  by	   regulating	  cellular	  glucose	  uptake	   in	   tissue	  and	  glucose	  
output	   from	   the	   liver	   into	   the	   bloodstream	   in	   response	   to	   glucose	   absorption	   from	  
nutrients	  (food)	  by	  the	  intestine	  and	  metabolic	  needs.	  	  	  
When	   glucose	   levels	   increase,	   insulin	   is	   released	   by	   β-­‐cells	   in	   the	   eyes	   of	  
Langerhans	   of	   the	   pancreas	   to	   return	   the	   blood	   glucose	   level	   to	   homeostasis	   by	  
increasing	   glucose	   uptake	   by	   muscle	   and	   adipose	   tissue.	   	   Insulin	   binding	   to	   insulin	  
receptors	   on	   adipocyte	   and	   muscle	   cell	   membranes	   stimulates	   the	   translocation	   of	  
GLUT4,	  an	  insulin-­‐dependent	  glucose	  transporter,	  from	  storage	  vesicles	  within	  the	  cell.	  	  
Vesicles	   that	   store	   GLUT4	   fuse	   with	   the	   cell	   membrane	   allowing	   GLUT4	   to	   facilitate	  
glucose	   uptake.	   	   	   Once	   glucose	   enters	   the	   cell,	   it	   is	   phosphorylated	   (by	   hexokinases),	  
which	   prevents	   glucose	   from	   leaving	   the	   cell.	   	   Glucose-­‐6-­‐phosphate	   can	   undergo	  
glycolysis.	   	   Energy	   released	   from	   glycolysis	   is	   used	   in	   the	   synthesis	   of	   ATP.	   	   Excess	  
glucose-­‐6-­‐phosphate	  can	  by	  polymerized	  into	  glycogen	  for	  energy	  storage.	  	  	  
In	  addition	  to	  decreasing	  blood	  glucose	   levels	  by	  stimulating	  glucose	  uptake	  by	  
peripheral	   tissues,	   insulin	   further	   decreases	   blood	   glucose	   levels	   by	   inhibiting	  
glycogenolysis	   and	   gluconeogenesis	   in	   the	   liver	   and	   promoting	   glycogenesis.	   	   While	  
insulin	  does	  not	  affect	   glucose	  uptake	  of	   the	   liver,	   it	  decreases	  glucose	  output	  by	   the	  
liver	   by	   inhibiting	   glucose-­‐6	   phosphatase.	   	   Insulin	   activates	   the	   enzymes	   involved	   in	  
glycogen	   synthesis	   including	   glycogen	   synthase	   and	   phosphofructokinase.	   	   The	   net	  
effect	  is	  a	  further	  decrease	  in	  blood	  glucose	  levels	  towards	  normal	  levels.	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Insulin’s	   effect	   on	   glucose	  metabolism	   is	   paralleled	   by	   its	   involvement	   in	   lipid	  
metabolism.	  	  In	  hepatocytes,	  glucose	  can	  be	  stored	  in	  glycogen	  or	  in	  fatty	  acids.	   	  Fatty	  
acids	   are	   released	   from	   hepatocytes	   into	   the	   bloodstream	   and	   can	   be	   uptaken	   by	  
adipocytes.	   	   Adipocytes	   can	   then	   convert	   uptaken	   fatty	   acids	   and	   glucose	   into	  
triglycerides.	   	   Because	   insulin	   inhibits	   lipolysis,	   these	   triglycerides	   are	   stored	   in	  
adipocytes	  leading	  to	  fat	  accumulation.	  	  
As	  blood	  glucose	   levels	  drop,	  glucagon	  secretion	   increases.	   	  Glucagon	  primarily	  
acts	   on	   hepatocytes	   to	   stimulate	   production	   of	   glucose	   from	  breakdown	   on	   glycogen	  
and	  gluconeogenesis,	  the	  synthesis	  of	  glucose	  from	  amino	  acids.	  	  	  
Naturally	   synthesized	   insulin	   is	   produced	   by	   enzymatic	   cleavage	   of	   proinsulin	  
(molecular	  weight	  of	  9	  kDa)	  stored	  in	  vesicles	  in	  the	  Golgi	  apparatus.	  	  As	  these	  vesicles	  
become	  maturing	  secretory	  granules,	  the	  vesicles	  leave	  the	  Golgi.	   	  During	  this	  process,	  
proinsulin	  is	  then	  enzymatically	  converted	  into	  insulin	  (molecular	  weight	  of	  5.8	  kDa)	  and	  
connecting	  peptide	  (C-­‐peptide)	  by	  endopeptidases.	   	  As	  a	  result,	   insulin	  is	  secreted	  at	  a	  
higher	  rate	  than	  proinsulin	  in	  normal	  patients.	  
Normal	  insulin	  secretion	  from	  β-­‐cells	  occurs	  continuously	  at	  a	  baseline	  level	  but	  
increases	   in	   response	   to	   elevated	   blood	   glucose	   levels.	   	   Insulin	   secretion	   following	   a	  
spike	   in	   glucose	   levels	   occurs	   in	   a	   biphasic	   pattern.	   	   The	   first	   phase	  of	   insulin	   release	  
occurs	   rapidly	   and	   lasts	   only	   a	   few	  minutes.	   	   This	   first	   phase	   release	   is	   caused	   by	   a	  
glucose-­‐dependent	   activation	   of	   voltage-­‐dependent	   Ca2+	   channels	   to	   increase	  
intracellular	  Ca2+.	   	  This	   influx	  of	  Ca2+	   (in	  addition	  to	  an	  ATP	  requirement)	  causes	  some	  
insulin	   storage	  vesicles	   to	   readily	  migrate	   to	   the	  β-­‐cell	  membrane	  and	  secrete	   insulin.	  	  
After	   this	   initial	   release	   of	   insulin,	   insulin	   release	   drops.	   	   The	   second	   phase	   release	  
increases	   insulin	   once	   again	   due	   to	   insulin	   release	   from	   long-­‐term	   storage	   vesicles.	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Insulin	  release	  by	  β-­‐cells	  can	  be	   influenced	  by	  other	   factors	   including	  amino	  acids	  and	  
other	  hormones.	  	  
Type	  1	  Diabetes	  
Type	  1	  diabetes,	  often	  referred	  to	  as	  juvenile	  diabetes,	  accounts	  for	  5-­‐10%	  of	  all	  
cases	  of	  diabetes	   [4].	   	  Type	  1	  diabetes	   is	   fatal	  without	   treatment	  with	   insulin.	   	  Type	  1	  
diabetics	  are	  deficient	  in	  insulin	  due	  to	  destruction	  of	  pancreatic	  β-­‐cells,	  which	  produce	  
insulin.	  	  Most	  cases,	  approximately	  90%,	  of	  type	  1	  diabetes	  are	  caused	  by	  autoimmune	  
destruction	  of	  β-­‐cells	  [4,	  5].	  	  Autoantibodies	  for	  islet	  cells,	  insulin,	  tyrosine	  phosphatase,	  
and	  glutamic	  acid	  decarboxylase	  are	  markers	  that	  may	  play	  a	  role	  in	  the	  development	  of	  
autoimmune	  related	  diabetes	  [5].	  	  	  
The	   risk	   of	   type	   1	   diabetes	   is	   higher	   in	   families	   indicating	   that	   genetics	   also	  
contribute	   to	   disease	  development	   [4].	   	  However,	   environmental	   factors	   such	   as	   viral	  
infections	  have	  been	  implicated	  as	  destroying	  or	  causing	  the	  destruction	  of	  β-­‐cells	  [4,	  5].	  	  
Other	   factors	   such	   as	   whether	   one	   was	   breast	   fed,	   diet,	   exposure	   to	   chemicals,	   and	  
stress	  have	  also	  been	  identified	  as	  possible	  causes	  of	  type	  I	  diabetes	  [4].	  	  	  	  
Type	  1	  diabetes	   is	   typically	  diagnosed	  during	  childhood.	   	   Some	  cases	  of	   type	  1	  
diabetes	  are	  diagnosed	  in	  adults,	  and	  it	  is	  acknowledged	  that	  type	  1	  diabetes	  can	  onset	  
after	   childhood.	   	   Typically,	   symptoms	   arise	   suddenly	   and	   are	   severe.	   	   Some	   of	   the	  
common	   symptoms	   of	   type	   1	   diabetes	   include	   frequent	   urination,	   thirst,	   extreme	  
hunger,	  weight	  loss,	  tiredness,	  and	  irritability.	  
A	  patient	   is	   diagnosed	  with	  diabetes	  when	   they	  have	   a	   fasting	  plasma	  glucose	  
level	   at	   or	   above	   7.0	   mmol/L;	   plasma	   glucose	   levels	   at	   or	   above	   11.1	   mmol/L	   in	   a	  
glucose	  tolerance	  test;	  or	  a	  hemoglobin	  A1C	  at	  or	  above	  6.5.	  	  At	  the	  time	  of	  diagnosis	  of	  
type	   1	   diabetes,	   many	   diabetics	   already	   have	   some	   form	   of	   ketoacidosis	   caused	   by	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unchecked	  fatty	  acid	  metabolism	  by	  lack	  of	  insulin,	  which	  causes	  the	  pH	  of	  the	  blood	  to	  
become	  acidic.	  	  
Type	  2	  Diabetes	  
Type	   2	   diabetes	   is	   a	   result	   of	   insulin	   resistance	   and,	   or	   problems	   with	   insulin	  
secretion.	   	  The	  causes	  of	  type	  2	  diabetes	  are	  not	  fully	  understood.	   	  Genetics	  do	  play	  a	  
role	   in	   one’s	   risk	   of	   developing	   diabetes,	   but	   environmental	   factors	   and	   lifestyle	  
significantly	  affect	  diabetes	  development.	  	  For	  example,	  obesity,	  smoking,	  inactivity,	  and	  
certain	  drugs	  can	  contribute	  to	  type	  2	  diabetes	  onset.	  	  	  	  
Type	  2	  diabetes	  disease	  progression	  typically	  begins	  with	  development	  of	  insulin	  
resistance.	   	   Development	   of	   insulin	   resistance,	   or	   an	   inability	   to	   respond	   to	   insulin,	  
includes	   hyperinsulinemia	   in	   the	   fasted	   state	   but	   also	   increased	   postprandial	   insulin.	  	  
Hyperinsulinemia	   is	   caused	   by	   a	   combination	   of	   increased	   insulin	   secretion	   by	   β-­‐cells	  
(due	  to	  blood	  glucose	  levels)	  or	  due	  to	  decreased	  liver	  uptake	  of	  insulin	  [6].	  	  	  
Excess	  circulating	   fatty	  acids	   from	   lipolysis	  of	   triglycerides	   in	  adipose	  tissue	  are	  
both	  an	  effect	  of	  insulin	  resistance	  and	  contributor	  to	  insulin	  resistance.	  	  Increased	  fatty	  
acids	  increase	  glucose	  output	  from	  the	  liver	  as	  well	  as	  reduce	  insulin’s	  inhibitory	  effect	  
on	   glucose	   output	   by	   the	   liver.	   	   Because	   insulin	   inhibits	   fatty	   acid	   production,	   an	  
increased	  amount	  of	  fatty	  acids	  in	  muscle	  provides	  more	  substrate	  rendering	  insulin	  less	  
effective,	   but	   increased	   fatty	   acids	   also	   affect	   downstream	   signaling	   the	   continues	   to	  
reduce	  insulin	  activity	  [7].	  	  There	  are	  a	  variety	  of	  other	  physiological	  changes	  that	  occur	  
as	  a	  result	  of	  insulin	  resistance	  which	  are	  discussed	  more	  in	  depth	  in	  Eckel	  et	  al.	  [7].	  	  
Continued	   exposure	   of	   β-­‐cells	   to	   elevated	   glucose	   levels	   and	   fatty	   acid	   levels	  
affects	  insulin	  secretion.	  	  Normally,	  elevated	  fatty	  acids	  can	  stimulate	  insulin	  secretion,	  
but	  β-­‐cell	  insulin	  secretion	  decreases	  after	  prolonged	  exposure	  to	  high	  fatty	  acid	  levels	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[6,	  7].	  	  Defects	  in	  insulin	  secretion	  can	  also	  be	  caused	  by	  decreases	  in	  insulin	  receptors	  
on	   β-­‐cells	   [7].	   	   One	   of	   the	   hallmarks	   of	   irregular	   insulin	   secretion	   is	   a	   much	   higher	  
secretion	  rate	  of	  proinsulin	  and	  insulin	  precursors	  than	  insulin	  [5].	  	  The	  higher	  secretion	  
rates	   of	   proinsulin	   and	   insulin	   precursors	   are	   caused	   when	   vesicles	   in	   β-­‐cells	   are	  
secreted	   prior	   to	   insulin	   cleavage.	   	   	   This	   occurs	  when	   these	   vesicles	   bypass	   the	  Golgi	  
apparatus	   and	   are	   secreted	   from	   the	   cell	   directly	   from	   the	   endoplasmic	   reticulum.	  	  
Insulin	   secretion	   by	   this	   altered	   mechanism	   occurs	   constitutively	   rather	   than	   in	   a	  
biphasic	  pattern	  associated	  with	  normal	  insulin	  secretion.	  	  In	  this	  case,	  the	  secretion	  of	  
insulin	  is	  not	  regulated	  but	  is	  constitutive.	  	  	  
Although	   most	   people	   with	   type	   2	   diabetes	   have	   no	   apparent	   symptoms,	  
symptoms	  may	  occur	   insidiously.	   	  Type	  2	  diabetes	  symptoms	  include	  the	  symptoms	  of	  
type	  1	  diabetes	  as	  well	  as	  frequent	  infections,	  blurred	  vision,	  hypertension,	  slow	  healing	  
cuts	   and	   bruises,	   tingling	   or	   numbness	   in	   the	   hands	   or	   feet,	   recurring	   skin,	   gum,	   or	  
bladder	  infections.	  	  	  
Complications	  of	  Diabetes	  
Diabetes	  can	  cause	  a	  range	  of	  serious	  complications	  resulting	  in	  disability	  or	  even	  
death	   [5].	   	   Some	  of	   the	  complications	   that	  are	  associated	  with	  diabetes	  are	  cataracts,	  
retinopathy,	   glaucoma,	   nephropathy,	   neuropathy,	   heart	   attack,	   stroke,	   blockage	   of	  
blood	  vessels	  in	  legs	  and	  feet,	  and	  gum	  disease.	  
As	   a	   result,	   diabetics	   are	   typically	   monitored	   for	   management	   of	   diabetes,	  
lifestyle,	   and	  onset	   of	   complications.	   	  Monitoring	  of	  weight	   and	  body	  mass	   index	   can	  
indicate	  the	  patient’s	   lifestyle,	  and	  abdominal	  obesity	  can	   indicate	  an	   increased	  risk	  of	  
cardiovascular	   disease.	   	   A	   good	   indicator	   of	   blood	   glucose	   management	   over	   the	  
preceding	   2-­‐3	   months	   is	   glycosylated	   hemoglobin	   (HbA1c)	   [8].	   	   As	   hemoglobin	   is	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exposed	  to	  plasma	  glucose,	  it	  becomes	  glycosylated.	  	  The	  extent	  to	  which	  hemoglobin	  A	  
is	  glycosylated	  is	  an	  indicator	  of	  blood	  glucose	  levels	  over	  the	  preceding	  2-­‐3	  months	  [8].	  	  	  
Long-­‐term	   management	   of	   diabetes	   includes	   management	   of	   the	   various	  
complications	   of	   the	   disease.	   Complications	   to	   diabetes	   are	   numerous	   and	   can	  
significantly	  impact	  a	  patient’s	  physical	  and	  mental	  heath.	  	  For	  example,	  diabetics	  have	  a	  
high	   risk	   of	   depression	   [8].	   	   Diabetes	   is	   associated	   with	   an	   increased	   risk	   of	   kidney	  
damage,	   which	   can	   be	   detected	   by	   several	   tests.	   	   The	   ratio	   of	   microalbumin	   to	  
creatinine	   levels	   in	   the	   urine	   levels	   may	   indicate	   kidney	   problems.	   	   In	   addition,	  
measurement	   of	   the	   estimated	   glomerular	   filtration	   rate	   (e-­‐GFR)	   can	   indicate	   issues	  
with	   the	  kidney	   that	  may	  be	  brought	  on	  by	  diabetes	  or	  may	  be	  a	   side	  effect	  of	   some	  
prescription	   drugs.	   	   Diabetics	   with	   a	   low	   e-­‐GFR	   may	   be	   placed	   on	   statins	   or	   their	  
medications	  may	  be	  switched.	  	  	  
Because	  diabetes	  affects	  both	   the	  circulatory	  and	  nervous	  systems,	  monitoring	  
for	  several	  related	  complications	  is	  very	  important.	  	  Blood	  pressure	  measurements	  can	  
indicate	   a	   variety	   of	   issues	   including	   onset	   of	   diabetic	   neuropathy	   [8].	   	   As	   high	  
cholesterol	  and	  triglycerides	  are	  a	  complication	  of	  diabetes,	  cholesterol	  and	  triglyceride	  
levels	   are	   monitored	   to	   reduce	   the	   risks	   of	   cardiovascular	   diseases	   and	   stroke.	  	  
Additional	   vascular	   and	   neural	   issues	  may	   be	   identified	   in	   an	   annual	   foot	   exam.	   	   The	  
combination	   of	   neural	   and	   vascular	   issues	   can	   result	   in	   blindness.	   	   Early	   detection	   of	  
retinopathy	   may	   be	   monitored	   using	   digital	   retinal	   photography	   and	   is	   especially	  
recommended	  for	  newly	  diagnosed	  type	  2	  diabetics	  [8].	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2.1.2	  Treatment	  of	  Diabetes	  
Treatment	  of	  Non-­‐Insulin-­‐Dependent	  Type	  2	  Diabetes	  
Many	   type	   2	   diabetes	   patients	   are	   not	   on	   dependent	   insulin,	   and	   there	   are	  
several	  treatment	  strategies	  for	  these	  patients.	  The	  treatment	  of	  type	  2	  diabetes	  begins	  
with	  lifestyle	  modification.	  	  Patients	  are	  recommended	  to	  exercise	  and	  adjust	  their	  diet	  
to	   reduce	   caloric	   intake,	   cholesterol,	   and	   sodium.	   	  Because	  obesity	   is	   a	   risk	   factor	   for	  
type	  2	  diabetes,	  patients	  are	  typically	  recommended	  to	  lose	  weight.	  	  	  
For	  patients	  whose	  blood	  glucose	  levels	  are	  not	  controlled	  by	  lifestyle	  changes,	  
there	   are	   a	   variety	   of	   drugs	   available	   which	   include	   insulin	   sensitizers,	   insulin	  
secretagogues,	   and	   agents	   to	   slow	   carbohydrate	   absorption	   (from	   digestion)	   [4].	  	  
Metformin	   and	   thiazolidinediones	   are	   often	   used	   as	   insulin	   sensitizers.	   	   Metformin	  
specifically	   reduces	   glucose	   produced	   by	   the	   liver	   and	   improves	   insulin-­‐mediated	  
glucose	   usage	   at	   the	   cellular	   level	   (improving	   insulin	   sensitivity).	   	   Thiazolidinediones	  
improve	  insulin	  sensitivity	  by	  increasing	  glucose	  usage	  through	  peroxisome	  proliferator-­‐
activated	  receptors	  although	  the	  specific	  mechanism	  is	  still	  not	  clear	  [4].	  	  	  
Improved	   insulin	   secretion	   is	  achieved	  with	   sulfonylureas	  or	  non-­‐sulfonylureas.	  	  
Sulfonylureas	   (metformin)	   bind	   to	   sulfonylurea	   receptors	   of	   β-­‐cells.	   	   Binding	   triggers	  
depolarization	  of	  the	  β-­‐cell	  membrane	  which	  causes	  secretion	  of	  insulin	  granules.	  	  	  Non-­‐
sulfonylureas	  increase	  insulin	  secretion	  at	  mealtimes.	  	  These	  drugs,	  such	  as	  repaglinide	  
and	  nateglinide,	  bind	  sulfonylurea	  receptors	  but	  act	  on	  much	  shorter	   time	  scales	  than	  
the	  sulfonylureas.	  
Reduction	   or	   delay	   of	   carbohydrate	   absorption	   in	   the	   intestine	   can	   also	   lower	  
blood	  glucose	  levels.	  	  One	  mechanism	  for	  doing	  this	  is	  through	  the	  use	  of	  α-­‐glucosidase	  
(AG)	   inhibitors.	   	   Inhibiting	   the	   enzymatic	   metabolism	   of	   disaccharides	   and	   complex	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carbohydrates	   leads	   to	   lower	   postprandial	   blood	   glucose	   increases	   and	   can	   lead	   to	  
decreased	  insulin	  secretion.	  	  
Because	   these	   drugs	   typically	   lead	   to	   weight	   gain	   (and	   can	   cause	   edema	   and	  
hypoglycemia),	   diabetes	   treatments	   that	   do	   not	   result	   in	   weight	   gain	   are	   highly	  
desirable.	   	   Incretins	   are	   gastrointestinal	   hormones	   secreted	   during	   eating	   that	   cause	  
insulin	  secretion	  before	  blood	  glucose	   levels	   rise.	   	  As	  a	   result,	   incretins	  are	  targets	   for	  
diabetes	   management.	   	   Glucagon-­‐like	   peptide	   1	   (GLP-­‐1)	   may	   be	   involved	   in	   β-­‐cell	  
health,	  appetite	  suppression,	  and	  slow	  gastric	  emptying	  [4].	  	  Although	  the	  role	  of	  GLP-­‐1	  
in	   metabolism	   is	   still	   being	   studied,	   GLP-­‐1	   therapy	   is	   a	   target	   of	   type	   2	   diabetes	  
treatment	   because	   GLP-­‐1	   levels	   tend	   to	   be	   lower	   in	   obese	   people	   and	   in	   type	   2	  
diabetics.	   	   Exenatide	   is	   a	  GLP-­‐1	   analogue	   that	  must	  be	   administered	  by	   injection	  as	   a	  
type	   2	   diabetes	   treatment	  without	   a	   side	   effect	   of	  weight	   gain.	   	   Exenatide	   and	   other	  
GLP-­‐1	   mimics	   must	   be	   administered	   by	   injection	   because	   they	   can	   be	   degraded	   by	  
dipeptidyl	  peptidase-­‐4	  (DPP-­‐4).	  	  As	  a	  result,	  a	  DPP-­‐4	  inhibitor,	  sitagliptin,	  is	  being	  used	  to	  
increase	  GLP-­‐1	  in	  patients.	  	  	  
	  Insulin	  Therapy	  for	  Diabetics	  
Type	  1	  and	  some	  type	  2	  diabetics	  require	  insulin	  replacement	  therapy.	  	  There	  are	  
several	   types	   of	   insulin	   and	   various	   insulin	   regimens.	   	   For	   example,	   there	   are	   animal	  
insulins,	   short-­‐acting	   insulins,	   very	   rapid-­‐acting	   insulin	   analogues,	   intermediate-­‐acting	  
insulins,	   long-­‐acting	   insulin	   zinc	   suspensions,	   long-­‐acting	   insulin	   analogues,	   and	   pre-­‐
mixed	  insulin	  mixtures.	  	  A	  discussion	  of	  the	  action	  of	  each	  of	  these	  insulins	  can	  be	  found	  
in	  several	  references	  [4,	  8].	  	  	  
For	   very	   young	   type	   1	   diabetes	   patients,	   the	   most	   common	   treatment	   is	   the	  
‘basal-­‐bolus’	   regimen	   consisting	   of	   multiple	   subcutaneous	   injections	   (multiple	   daily	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injections,	   MDI)	   of	   a	   short-­‐acting	   insulin	   and	   a	   long-­‐acting	   insulin	   to	   maintain	   basal	  
levels	  	  [5,	  8].	  	  	  
Insulin	  Administration	  
Insulin	  may	  be	  administered	  by	  syringe	  and	  needles,	  with	  insulin	  pens,	  by	  insulin	  
pumps,	  or	  by	  inhalation.	  	  Subcutaneous	  insulin	  injections	  can	  be	  done	  in	  the	  abdomen,	  
the	   thighs,	   and	  upper	  arms.	   	  Patients	  must	  be	   careful	   to	   rotate	   the	   injection	   site,	  but	  
over	   time	   lipohypertrophy	   still	   can	   occur.	   	   Lipohypertrophy	   is	   problematic	   in	   that	   it	  
decreases	  insulin	  transport	  or	  absorption	  and	  is	  a	  cosmetic	  issue	  for	  patients	  [8].	  	  	  
Insulin	  pens	  are	  an	  alternative	  to	  the	  traditional	  syringe	  subcutaneous	  method.	  	  
Insulin	  pens	  are	  pre-­‐filled	  devices	  that	  allow	  a	  metered	  dose	  from	  an	  insulin	  cartridge.	  	  
The	   dose	   is	   administered	   via	   a	   disposable	   pen	   needle	   which	   fits	   on	   the	   end	   of	   the	  
device.	   	  Currently,	  Novo	  Nordisk,	   Sanofi-­‐Aventis,	   and	  Eli	   Lilly	  have	   insulin	  pens	  on	   the	  
market.	   	  These	  devices	  are	  particularly	  popular	   in	  Europe	  and	  Asia	  and	  are	  growing	   in	  
popularity	  in	  the	  United	  States.	  	  	  
Insulin	  pumps	  are	  an	  alternative	  to	  subcutaneous	  administration.	  	  Insulin	  pumps	  
generally	   replace	  slow-­‐acting	   insulin	  with	  a	  continuous	   infusion	  of	   rapid-­‐acting	   insulin.	  	  
The	  most	  common	  insulin	  pumps	  use	  an	  external	  pump	  to	  administer	  insulin	  through	  a	  
cannula	   implanted	  under	   the	   skin.	   	   Pumps	   are	   loaded	  with	   insulin	   either	   by	  pre-­‐filled	  
cartridges	   or	   manually	   from	   vials	   of	   insulin.	   	   There	   are	   also	   completely	   implantable	  
pumps,	   which	   are	   implanted	   in	   the	   peritoneal	   cavity	   and	   controlled	   by	   an	   external	  
device.	  	  	  
The	   only	   FDA	   approved	   route	   of	   administration	   not	   requiring	   needles	   was	  
Pfizer’s	   Exubera.	   	   Exubera	  was	  withdrawn	   from	   the	  market	   after	   only	   one	   year.	   	   The	  
failure	   of	   Exubera	   is	   one	   of	   the	   biggest	   failures	   in	   the	   pharmaceutics	   industry	   with	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approximately	   $1	   billion	   lost	   [9].	   	   The	   failure	   of	   Exubera	   was	   due	   to	   a	   variety	   of	  
contributing	  factors.	  	  Exubera	  was	  not	  user-­‐friendly,	  it	  was	  not	  supported	  by	  insurance	  
companies,	   and	   it	   was	   expensive.	   	   More	   importantly,	   it	   was	   not	   demonstrated	   that	  
Exubera	  improved	  metabolic	  control	  over	  subcutaneous	  injection	  [9].	  	  	  
The	   inhaler	   device	   was	   somewhat	   large	   and	   offered	   little	   discreteness	   for	  
patients.	  	  In	  addition,	  it	  could	  take	  a	  long	  time	  (up	  to	  minutes)	  to	  administer	  a	  large	  dose	  
of	  insulin	  by	  inhalation.	  	  Administration	  of	  a	  desired	  dose	  was	  challenging	  as	  the	  insulin	  
dose	  was	  contained	  in	  blister	  packs.	   	  To	  change	  the	  dosage	  of	  insulin,	  the	  number	  and	  
combination	  of	  blister	  packs	  had	  to	  be	  changed.	  	  	  On	  top	  of	  this,	  the	  dosage	  of	  insulin	  in	  
the	  Exubera	  blister	  packs	  was	   reported	   in	  different	  units	   than	  patients	  and	  physicians	  
normally	  used	  (mg	  versus	  international	  units	  (IU))	  [9].	  
In	  addition	  to	  convenience	  and	  ease	  of	  use	  questions,	  the	  safety	  of	  Exubera	  was	  
not	  certain.	   	  During	  clinical	  trials,	  Exubera	  was	  shown	  to	  adversely	  affect	   lung	  function	  
(Exubera).	   	   The	   affects	   on	   lung	   function	  did	  not	   appear	   to	  worsen	  over	   the	   course	  of	  
Exubera	  usage,	  and	  were	  shown	  to	  reverse	  when	  Exubera	  use	  was	  terminated	  [9].	  	  As	  a	  
result,	   the	   FDA	   required	   lung	   function	   of	   patients	   taking	   Exubera	   to	   be	   monitored	  
regularly.	  	  	  
Since	   Exubera	   was	   not	   covered	   by	   insurance	   companies,	   the	   patient	   was	  
required	  to	  pay	  for	  the	  costs	  of	  lung	  function	  tests	  on	  top	  of	  the	  costs	  of	  Exubera.	  	  The	  
long-­‐term	   effects	   on	   the	   lungs	   and	   the	   progression	   of	   diabetes	   related	   complications	  
were	   not	   known.	   	   In	   ongoing	   clinical	   Exubera	   studies,	   Pfizer	   reported	   an	   increased	  
number	  of	  newly	  diagnosed	   lung	   cancer.	   	   Even	   though	   there	  was	  no	   clear	   correlation	  
(based	   on	   statistics)	   between	   Exubera	   use	   and	   lung	   cancer,	   Nektar	   chose	   to	   stop	  
development	  of	  their	  own	  inhaled	  insulin	  formulation	  [9].	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2.2	  ORAL	  PROTEIN	  DELIVERY	  
Protein	  drugs	  have	  become	  the	  fastest	  growing	  class	  of	  new	  pharmaceutics	  since	  
the	  FDA	  approval	  of	  recombinant	  insulin	  in	  1982.	  	  The	  field	  of	  protein	  therapeutics	  has	  
experienced	  tremendous	  growth	  in	  part	  due	  to	  recombinant	  biotechnology	  but	  also	  the	  
inherent	   advantages	   of	   proteins	   drugs	   over	   small	   drugs.	   	   Proteins	   carry	   out	   complex	  
functions,	   interact	  with	  biomolecules	  specifically	  with	  reduced	  risk	  of	  side	  effects,	  and	  
have	  low	  immunogenicity	  [10].	  
The	  first	  accounts	  of	  protein	  drugs	  in	  the	  treatment	  of	  diseases	  were	  in	  the	  form	  
of	  tissue	  extracts.	  	  For	  example,	  the	  first	  protein-­‐based	  vaccine	  was	  developed	  in	  1796	  
for	   small	   pox	   by	   Jenner	   using	   extracts	   from	   cowpox	   blisters	   of	   milkmaids.	   	   Over	   a	  
century	  later	  in	  1922,	  the	  first	  protein	  drug,	  insulin,	  was	  discovered	  by	  Banting	  et	  al.	  in	  
treatment	  of	  diabetes	  in	  humans	  with	  pancreatic	  extracts	  from	  dogs	  [11].	  	  A	  method	  for	  
extraction	   of	   pure	   insulin	   from	   bovine	   pancreas	   extracts	   was	   later	   developed.	   	   The	  
safety,	  quantity,	  and	  activity	  of	  these	  insulin	  extracts	  were	  determined	  by	  quantifying	  its	  
effects	  on	   rabbit	  blood	  glucose	   levels.	   	  Manufacturing	  of	   insulin	  by	  synthetic	  chemical	  
means	  was	  made	  possible	  by	  the	  work	  of	  Fred	  Sanger	  on	  sequencing	  insulin	  during	  the	  
mid	  1940s	  and	  1950s.	  
It	  was	  not	  until	   the	  1970s	   that	   the	   foundation	   for	  modern	  protein	   therapeutic	  
production	  and	  engineering	  was	  established.	  	  In	  1977,	  somatostatin	  was	  the	  first	  protein	  
to	  be	  cloned	  into	  Escherichia	  coli	  by	  insertion	  of	  the	  somatostatin	  gene	  into	  the	  pBR322	  
plasmid	   [12].	   	   A	   year	   later,	   the	   first	   recombinant	   protein,	   insulin,	   was	   reported	   by	  
Genentech.	  	  Goeddel	  et	  al.	  synthesized	  insulin	  from	  two	  separately	  cloned	  polypeptide	  
chains	  demonstrating	  for	  the	  first	  time	  synthetic	  recombinant	  technology	  to	  produce	  a	  
therapeutic	  protein	  [13].	   	  Over	  the	  next	  decade,	  protein	  therapeutics	   including	  human	  
growth	   hormone	   and	   interferon-­‐α	   were	   reported.	   	   Meanwhile,	   several	   other	   major	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breakthroughs,	   notably	   the	   discovery	   of	   polymerase	   chain	   reactions	   (PCR)	   for	   DNA	  
amplification	  and	  the	  development	  of	  chemical	  DNA	  sequencing	  methods	  transformed	  
biotechnology.	   	   These	   technologies	   along	   with	   the	   1982	   FDA	   approval	   of	   the	  
recombinant	  form	  of	  insulin	  set	  the	  stage	  for	  protein	  drug	  development.	  	  	  
Recombinant	  DNA	   technology	  has	  had	  a	   significant	   impact	  on	   the	  discovery	  of	  
new	   drugs	   but	   has	   also	   contributed	   to	   the	   safety	   and	   efficacy	   of	   protein	   drugs.	   	   For	  
example,	   recombinant	  production	  of	  protein	  drugs	   reduced	  supply	  and	   immunological	  
issues	   associated	   with	   protein	   drugs	   which	   were	   previously	   harvested	   then	   purified	  
from	  blood	  or	   tissues.	   	  Moreover,	   protein	   engineering	  has	   led	   to	   improved	  drug	  half-­‐
lives	  and	  activity	  over	  native	  forms.	  	  The	  impact	  of	  biotechnology	  is	  already	  apparent	  in	  
the	  more	  than	  130	  protein	  drugs	  approved	  by	  the	  Food	  and	  Drug	  Administration	  (FDA)	  
[10].	  	  Protein-­‐based	  pharmaceutics	  are	  expected	  to	  continue	  to	  expand.	  	  It	  is	  estimated	  
that	  by	  2015	  the	  protein	  drug	  market	  will	  exceed	  $150	  billion	  US	  dollars	  (Global	  Industry	  
Analysts,	  Inc.).	  
While	  protein	  drugs	  have	  revolutionized	  treatment	  for	  a	  number	  of	  diseases,	  the	  
expected	  increase	  in	  protein-­‐based	  pharmaceutics	  brings	  a	  new	  set	  of	  challenges	  for	  the	  
pharmaceutics	  field.	  	  Due	  to	  their	  instability,	  size,	  and	  poor	  transport,	  protein	  drugs	  are	  
predominantly	  administered	  by	  either	  intravenous	  or	  subcutaneous	  injection.	  	  	  
Patient	  compliance,	   the	  extent	   to	  which	  a	  patient	  adheres	   to	   the	   treatment,	   is	  
already	  a	  huge	  issue	  in	  diabetes	  treatment	  with	  insulin	  and	  is	  likely	  to	  become	  a	  growing	  
issue	  as	  protein	  drug	  treatments	  become	  more	  widely	  used.	  	  A	  number	  of	  studies	  have	  
underscored	   the	   relationship	   of	   traditional	   subcutaneous	   injections	  with	   patient	   non-­‐
adherence,	  and	   it	   is	  estimated	   that	  over	  half	  of	   insulin-­‐dependent	  adults	   intentionally	  
skip	  injections	  [14,	  15].	  	  We	  believe	  that	  the	  development	  of	  an	  oral	  insulin	  formulation	  
has	   the	   potential	   to	   address	   some	   of	   the	   issues	   associated	   with	   non-­‐adherence	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(including	   the	   interference	  with	  daily	  activities,	  embarrassment,	  and	   injection	  pain)	  as	  
well	  as	  the	  adverse	  effects	  of	  subcutaneous	  administration.	  	  The	  development	  of	  an	  oral	  
insulin	  formulation	  could	  significantly	  impact	  the	  treatment	  of	  patients	  with	  diabetes.	  	  	  	  
The	   successful	   development	   of	   oral	   protein	   delivery	   systems	   will	   significantly	  
impact	  health	  care	  costs	  and	  the	  quality	  of	  patients’	  lives	  as	  small	  improvements	  in	  the	  
ease	   of	   subcutaneous	   administration	   have	   translated	   to	  measurable	   improvements	   in	  
patient	  adherence	  and	  decreased	  health	  care	  costs	   in	  the	  case	  of	   insulin	  pen	   injectors	  
[16].	  	  
Orally	  administered	  drugs	  follow	  the	  same	  route	  through	  the	  digestive	  system	  as	  
food.	   	  The	  digestive	  system	  breaks	  down	  food,	  absorbs	  nutrients,	  and	  excretes	  waste.	  	  
For	   oral	   drug	   delivery	   systems,	   the	   physiology	   of	   the	   digestive	   system	   can	   hinder	  
performance	   but	   can	   potentially	   be	   exploited	   to	   improve	   drug	   delivery.	   	   Enzymes	  
present	  throughout	  the	  GI	  tract	  can	  act	  on	  drugs	  causing	  a	  loss	  of	  bioactivity,	  the	  ability	  
of	  the	  drug	  to	  carry	  out	  its	  function.	  	  On	  the	  other	  hand,	  the	  large	  surface	  area	  and	  high	  
vascularization	   of	   the	   small	   intestine	   is	   advantageous	   in	   drug	   absorption,	   but	   the	  
mucosa	  of	  the	  small	  intestine	  can	  serve	  as	  a	  barrier	  to	  drug	  absorption.	  	  In	  order	  for	  an	  
oral	  delivery	   system	  to	  be	  effective,	   the	  drug	  of	   interest	  must	   retain	   its	  activity	  and	  a	  
high	  bioavailability-­‐-­‐be	  absorbed	   in	  quantities	   large	  enough	  to	  elicit	  a	  pharmacological	  
effect.	  	  	  
Protein	   drugs	   are	   particularly	   challenging	   to	   successfully	   deliver	   orally	   due	   to	  
their	  instability	  in	  acidic	  environments,	  their	  susceptibility	  to	  proteolysis	  by	  enzymes	  in	  
the	  GI	   tract,	  and	  their	   large	  size.	   	  For	  example,	   the	  structure	  of	  protein	  drugs	  and	  the	  
amino	  acid	  sequence	  of	  the	  protein	  drug	  define	  its	  bioactivity.	  	  The	  stability	  of	  proteins	  
in	   the	   GI	   tract	   is	   particularly	   problematic.	   	   Protein	   degradation	   can	   be	   due	   to	   either	  
chemical	  or	  physical	  instability.	  	  Physical	  changes	  can	  result	  in	  denaturation,	  disruption	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of	   the	   secondary	   or	   tertiary	   structure	   of	   the	   protein	   in	   an	   irreversible	   or	   reversible	  
process.	  	  Denaturation	  can	  occur	  as	  a	  result	  of	  aggregation,	  precipitation,	  adsorption,	  or	  
unfolding.	  	  Chemical	  degradation	  can	  occur	  from	  deamidation,	  oxidation,	  racemisation,	  
proteolysis,	  and	  disulfide	  interchange	  [17].	  
The	   large	   molecular	   weight	   of	   protein	   drugs	   limits	   absorption.	   	   Protein	   drugs	  
must	  cross	  the	  intestinal	  lining	  by	  penetrating	  an	  unstirred	  water	  layer	  and	  then	  passing	  
across	  the	  cellular	  lining	  of	  the	  intestine.	  	  The	  mucus	  and	  glycocalyx	  of	  the	  intestine	  can	  
further	  cause	  degradation	  of	  protein	  drugs	  [18].	  	  Diffusion	  of	  large	  molecules	  is	  limited	  
across	  the	  cell	  membrane.	  	  Additionally,	  large	  protein	  drugs	  cannot	  easily	  pass	  between	  
cells	   due	   to	   tight	   junctions	   between	   adjacent	   cells.	   	   These	   junctions	   are	   estimated	   to	  
have	   pore	   sizes	   as	   small	   as	   10	  Å.	   	   As	   a	   result,	   protein	   drug	   absorption	   is	  much	  more	  
challenging	  than	  small	  molecule	  delivery.	  	  	  
Insulin	  is	  a	  good	  candidate	  for	  oral	  delivery	  because	  oral	  administration	  of	  insulin	  
has	   the	   potential	   to	   more	   closely	   mimic	   natural	   insulin	   biodistribution.	   	   Insulin	   is	  
secreted	  by	  β-­‐cells	   in	  the	  pancreas	  and	  enters	  the	  hepatic	  portal	  vein	  passing	   into	  the	  
hepatic	   portal	   system.	   	   The	   majority	   of	   insulin	   is	   metabolized	   in	   the	   liver	   where	   it	  
regulates	  glucose	  output.	   	  Because	  drug	  absorbed	  into	  the	  bloodstream	  of	  the	  GI	  tract	  
enters	  the	  hepatic	  portal	  system	  and	  passes	  to	  the	  liver,	  orally	  delivered	  insulin	  would	  
mimic	   the	   natural	   pathway	   for	   insulin	   distribution.	   	   With	   many	   drugs,	   first	   pass	  
metabolism	  by	  the	  liver	  can	  be	  a	  significant	  drawback	  to	  oral	  delivery,	  but	  this	  is	  a	  more	  
natural	   route	   for	   insulin	   delivery.	   	   Furthermore,	   passage	   of	   insulin	   through	   the	   liver	  
allows	   the	   overall	   biodistribution	   of	   insulin	   to	   more	   closely	   resemble	   that	   of	   natural	  
insulin	   biodistribution.	   	   Subcutaneous	   administration	   of	   insulin	   generates	   an	   equal	  
concentration	  of	  insulin	  in	  peripheral	  circulation	  and	  in	  the	  hepatic	  portal	  system.	  	  Yet,	  
insulin	  biodistribution	  is	  naturally	  higher	  in	  the	  liver	  than	  elsewhere.	  	  	  
	   22	  
Not	   only	   does	   oral	   insulin	   administration	   have	   the	   potential	   to	   more	   closely	  
mimic	   normal	   insulin	   secretion,	   an	   oral	   insulin	   formulation	   could	   significantly	   impact	  
patients.	   	   One	   of	   the	   major	   side	   effects	   of	   subcutaneous	   administration	   of	   insulin	   is	  
lipohypertrophy	   which	   has	   a	   cosmetic	   effect	   but	   also	   can	   reduce	   insulin	   absorption.	  	  
Oral	  insulin	  delivery	  may	  not	  alleviate	  the	  need	  for	  subcutaneous	  injections	  completely,	  
but	   it	   could	   significantly	   reduce	   the	   number	   of	   necessary	   injections	   for	   insulin-­‐
dependent	  diabetics.	   	  Generally,	   oral	   formulations	   are	  easier	   and	  more	   convenient	   to	  
administer	  than	  the	  more	  invasive	  subcutaneous	  route.	  	  Improvement	  of	  the	  method	  of	  
administration	   is	   hypothesized	   to	   improve	  patient	   compliance	   leading	   towards	  overall	  
better	  management	  of	  diabetes	  and	  an	  improved	  quality	  of	  life	  for	  the	  patient.	  	  	  
2.2.1	  The	  Oral	  Route	  
Both	   the	   anatomy	   and	   physiology	   of	   the	   digestive	   system	   reflect	   its	   range	   of	  
functions	   through	   contrasting,	   tailored	   environments.	   	   The	   digestive	   system	   is	  
composed	   of	   the	   mouth,	   the	   esophagus,	   the	   stomach,	   the	   small	   intestine,	   the	   large	  
intestine,	  the	  liver,	  and	  the	  pancreas.	  	  This	  organ	  system	  functions	  in	  concert	  to	  digest	  
food,	  absorb	  nutrients,	  and	  prevent	  pathogens	  from	  entering	  the	  bloodstream.	  	  	  
In	   the	   stomach,	   enzymes,	   such	   as	   pepsin	   and	   gelatinase,	   break	   down	   proteins	  
and	   other	   compounds	   in	   food.	   	   Enzymatic	   digestion	   is	   facilitated	   by	   the	   acidic	  
environment	  of	   the	   stomach	  which	  has	  a	  pH	  of	  approximately	  2.0	   in	   the	   fasted	   state.	  	  
The	  time	  scale	  for	  gastric	  emptying	  can	  be	  as	   long	  as	  2.5	  hours	  but	   is	  dependent	  on	  a	  
number	  of	  signals.	  	  	  
Next,	  food	  passes	  to	  the	  small	  intestine.	  	  The	  small	  intestine	  is	  approximately	  2.5	  
cm	   wide	   and	   6.5	   m	   long	   extending	   from	   the	   pylorus	   to	   the	   ileocecal	   valve	   where	   it	  
connects	  to	  the	   large	   intestine.	   	  Overall,	  the	  small	   intestine	  has	  a	  relatively	  neutral	  pH	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between	   7	   and	   8.	   	   The	   overall	   transit	   time	   for	   chyme	   in	   the	   small	   intestine	   varies	  
depending	  on	  a	  number	  of	  factors	  but	  is	  on	  average	  3-­‐4	  hours.	  	  
As	  food	  passes	  from	  the	  stomach	  to	  small	  intestine	  through	  the	  pylorus,	  it	  enters	  
the	  duodenum	  and	  is	  mixed	  with	  bile	  and	  pancreatic	  juices.	  	  The	  duodenum	  is	  the	  first	  
20-­‐30	  cm	  segment	  of	  the	  small	   intestine.	   	  The	  majority	  of	  the	  duodenum	  forms	  a	  loop	  
around	  the	  pancreas.	  	  One	  of	  the	  functions	  of	  the	  duodenum	  is	  to	  raise	  the	  pH	  of	  chyme	  
after	   it	   leaves	  the	  stomach.	   	  Duodenal	   luminal	  contents	  have	  a	  pH	  between	  6	  and	  6.5.	  	  
Generally,	   the	   transit	   time	   through	   the	  duodenum	   is	   rapid	   and	   can	  occur	   as	   fast	   as	   1	  
minute	  [19].	  	  	  	  	  
Chyme	   travels	   from	   the	   duodenum	   past	   the	   duodenojejunal	   flexure	   to	   the	  
jejunum,	   the	   middle	   section	   of	   the	   small	   intestine,	   which	   is	   approximately	   2.5	   m	   in	  
length	  and	   is	  about	  4	  cm	  wide.	   	  The	  structure	  of	  the	   jejunum	  is	  composed	  of	  mucosal	  
folds,	   valvulae	   conniventes.	   	   These	   folds	   increase	   the	   surface	   area	   of	   the	   jejunum	   to	  
improve	  nutrient	  absorption	  and	  may	  also	  aide	  in	  the	  mixing	  of	  chyme.	  	  The	  jejunum	  has	  
fewer	  enzymes	  in	  the	  luminal	  content	  than	  what	  is	  present	  in	  the	  duodenum.	  	  However,	  
there	  are	  enzymes	  associated	  with	  the	  brush	  border	  of	  epithelial	  cells	  that	  compose	  the	  
majority	  of	  the	  cellular	   lining.	   	  The	   jejunum	  is	  more	  highly	  vascularized	  than	  the	   ileum	  
and	  is	  more	  absorptive	  than	  the	  ileum.	  	  As	  chyme	  passes	  through	  the	  jejunum,	  the	  pH	  
rises	   to	   between	   6.0	   and	   7.0.	   	   The	   transit	   time	   through	   the	   jejunum	   is	   considerably	  
longer	  than	  the	  duodenal	  transit	  time	  and	  is	  on	  average	  3-­‐4	  h.	  	  The	  ileum	  is	  about	  3.6	  m	  
in	   length	  and	  is	  narrower	  (3.75	  cm)	  than	  the	  jejunum.	  	  The	  ileum	  has	  less	  pronounced	  
valvulae	  conniventes	  and	  is	  less	  vascularized.	  	  Then,	  chyme	  passes	  through	  the	  ileocecal	  
valve	  to	  the	  large	  intestine.	  	  The	  pH	  of	  the	  digestive	  tract	  continues	  to	  rise	  between	  7.0	  
and	  7.5	  in	  the	  large	  intestine,	  which	  regulates	  ion	  and	  fluid	  absorption.	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The	   microanatomy	   of	   the	   small	   intestine	   allows	   for	   the	   high	   absorption	   and	  
transport	  of	  nutrients	  providing	  about	  90%	  of	  the	  body’s	  nutrients.	  	  The	  small	  intestine	  
wall	  has	  a	  surface	  area	  of	  approximately	  200	  m2	  (Wilson	  TH	  1962,	  Intestinal	  Absorption	  
Saunders,	   Philadelphia)	   600	   times	   greater	   than	   a	   hollow	   cylinder	   of	   the	   same	  
dimensions	  because	  of	  intestinal	  villi,	  which	  are	  finger-­‐like	  projections	  of	  tissue	  covering	  
the	   luminal	   surface	   of	   the	   small	   intestine.	   	   Intestinal	   villi	   are	   highly	   vascularized	   as	  
shown	  in	  Figure	  1;	  each	  villus	  has	  its	  own	  capillary	  system	  feeding	  into	  an	  arteriole	  and	  
venule	  pair	  and	  its	  own	  lacteal	  feeding	  into	  the	  lymphatic	  system.	  	  The	  surface	  area	  of	  
the	   small	   intestine	   and	   its	   close	   coupling	  with	   vasculature	   give	   the	   small	   intestine	   its	  
absorptive	  properties.	   	   	   	  Because	  the	  small	   intestine	   is	   the	  site	  where	  most	  absorption	  
takes	  place,	  it	  is	  the	  ideal	  release	  site	  for	  orally	  delivered	  proteins.	  	  	  
The	   absorptive	   properties	   of	   the	   small	   intestine	   are	   counterbalanced	   with	  
physiological	  barriers	  for	  prevention	  of	  pathogen	  entry.	   	  The	  interface	  of	  the	  intestinal	  
wall	  and	  the	  lumen	  is	  composed	  of	  the	  mucosa,	  glycocalyx,	  and	  the	  brush	  border	  of	  the	  
intestinal	   epithelial	   cells	   which	   is	   the	   predominant	   cell	   type	   in	   the	   small	   intestine.	  	  
Columnar	  epithelial	  cells	  are	  polarized	  cells	  that	  have	  a	  brush	  border	  (microvilli)	  on	  their	  
apical	  surface.	  	  	  
The	  main	  component	  of	  the	  mucosa	  is	  water	  (up	  to	  95%	  by	  weight),	  mucin	  (less	  
than	  5%	  by	  weight),	  and	  inorganic	  salts	  (approximately	  1%	  by	  weight).	  	  Mucin	  itself	  is	  an	  
O-­‐linked	   glycoprotein.	   	   Branched	   regions	   of	   mucin	   are	   covered	   in	   highly	   branched	  
oligosaccharide	  chains	  (2	  to	  19	  residues).	  	  About	  25%	  of	  the	  amino	  acids	  in	  these	  regions	  
are	   linked	   to	   an	   oligosaccharide	   chain	   [20].	   	   Most	   of	   these	   oligosaccharide	   chains	  
terminate	   with	   fucose,	   sialic	   acid,	   and	   sulfate	   esters	   of	   galactose	   and	   N-­‐
acetylglucosamine	  [21].	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Below	  the	  mucosa	   is	   the	  glycocalyx,	  a	   filamentous	  glycoprotein	  network	  that	   is	  
anchored	  to	  the	  microvilli.	  The	  thickness	  of	  the	  glycocalyx	  ranges	  from	  400	  nm	  up	  to	  500	  
nm	  [22,	  23].	  	  The	  glycocalyx	  is	  anchored	  to	  the	  brush	  border	  of	  microvilli,	  the	  projections	  
of	  the	  apical	  side	  of	  intestinal	  enterocytes.	  	  The	  brush	  border	  has	  mostly	  digestive	  and	  
absorptive	   functions.	   	   Enzymes	   responsible	   for	   peptide	   and	   saccharide	   digestion	   and	  
membrane	  transporters	  that	  facilitate	  absorption	  of	  small	  molecules	  such	  as	  glucose	  are	  
closely	  associated	  with	  microvilli.	  	  	  
In	  addition	  to	  columnar	  epithelial	  cells,	  mucus-­‐secreting	  goblet	  cells,	  M	  cells,	  and	  
enteroendocrine	  cells	  are	  found	  in	  the	  cell	  lining	  of	  the	  small	  intestine.	  	  M	  cells	  are	  part	  
of	   Peyer’s	   patches	   which	   are	   found	   throughout	   the	   cell	   lining	   of	   the	   lower	   small	  
intestine.	   	  These	  structures	  appear	  as	  thickened	  portions	  of	  the	  cell	   lining	  and	  contain	  
lymphocytes,	  macrophages,	  and	  dendritic	  cells.	  	  Peyer’s	  patches	  have	  distinctly	  different	  
properties	  than	  surrounding	  tissues	  and	  have	  been	  used	  as	  specific	  targets	  for	  vaccine	  
delivery	  applications.	  	  
Absorption	  Mechanisms	  
Molecules	   that	   diffuse	   across	   the	   mucosa	   and	   the	   glycocalyx	   must	   cross	   the	  
intestinal	  epithelium	  before	  entering	   the	  bloodstream.	   In	  order	   for	  absorption	   to	   take	  
place,	   nutrients	   and	   even	   pathogens	   must	   penetrate	   the	   mucosa,	   which	   can	   be	  
compared	   to	  an	  unstirred	  water	   layer.	   	  After	  passing	   through	   the	  mucus	   layer,	  a	  drug	  
must	  cross	  through	  the	  glycocalyx,	  and	  reach	  the	  epithelial	   layer.	  Transport	  across	  the	  
epithelium	   can	   occur	   by	   either	   a	   paracellular	   route,	   between	   cells,	   or	   a	   transcellular	  
route,	  across	  cells.	  	  
In	   paracellular	   transport,	   the	   molecule	   may	   simply	   diffuse	   between	   the	   tight	  
junctions	   of	   adjacent	   cells.	   	   Typically,	   paracellular	   transport	   is	   controlled	   by	   the	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permeability	   of	   the	   tight	   junctions	   between	   neighboring	   epithelial	   cells.	   	   It	   has	   been	  
shown	  that	  the	  permeability	  of	  the	  tight	  junctions	  is	  dependent	  on	  divalent	  cations	  such	  
as	  Ca2+	  and	  Mg	  2+.	  	  As	  the	  concentration	  of	  divalent	  cations	  decreases,	  the	  permeability	  
of	  the	  tight	  junctions	  increases.	  	  	  
In	  contrast,	  transcellular	  transport	  allows	  transport	  through	  the	  cell.	  In	  order	  for	  
molecules	  to	  transport	  across	  the	  intestinal	  epithelium	  by	  transcellular	  mechanisms,	  the	  
molecule	   must	   cross	   the	   cell	   membrane.	   	   Permeation	   across	   the	   epithelium	   of	   the	  
intestinal	  lining	  is	  bi-­‐directional	  allowing	  for	  absorption	  and	  exorption.	  	  However,	  flow	  in	  
the	   intestine	   favors	   absorption	   rather	   than	  exorption	   [17].	   	   The	   intestinal	  wall	   can	  be	  
compared	   to	   a	   semi-­‐permeable	   porous	   lipid	   membrane.	   	   Water	   and	   polar	   small	  
molecules	  can	  transport	  easily	  whereas	  hydrophilic	  molecules	  cannot	  pass	  as	  easily.	  	  
There	   are	   several	   mechanisms	   by	   which	   molecules	   can	   transport	   across	   the	  
intestinal	  epithelial	   lining.	   	  For	  molecules	  that	  can	  easily	  pass	  through	  lipid	  membrane,	  
diffusion	   is	   the	  primary	  mechanism	  of	  diffusion,	  which	  can	  be	  described	  by	  Fick's	   law.	  	  
However,	  protein	  drugs	  are	  large,	  often	  hydrophilic	  macromolecules	  that	  cannot	  easily	  
diffuse	  across	  a	  cell	  membrane.	  	  	  
Several	  forms	  of	  carrier-­‐mediated	  transport	  can	  occur	  to	  facilitate	  the	  transport	  
of	  more	   polar,	   hydrophilic	  molecules.	   	   Facilitated	   diffusion,	   sometimes	   referred	   to	   as	  
facilitated	   transport	   or	   facilitated	   passive	   transport,	   involves	   an	   integral	   membrane	  
protein	  which	   allows	   the	   passage	   of	  molecules	   across	   the	   cell	  membrane	  without	   an	  
energy	   expenditure	   at	   the	   cellular	   level.	   	   	   Counter	   transport	   is	   similar	   to	   facilitated	  
diffusion	   in	   that	   a	   carrier	   protein	   is	   involved.	   	   However,	   in	   counter	   transport,	   the	  
transport	   of	   one	   molecule	   from	   the	   luminal	   side	   of	   the	   membrane	   is	   coupled	   with	  
facilitated	   transport	   of	   a	   second	  molecule	   in	   the	   opposite	   direction.	   	   Active	   transport	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allows	   facilitated	  passage	  of	  molecules	  across	   the	  cell	  membrane	  but	   requires	  energy.	  	  
Generally,	  active	  transport	  moves	  a	  molecule	  against	  a	  gradient.	  	  	  	  	  	  
Pinocytosis	  is	  another	  mechanism	  by	  which	  molecules	  may	  cross	  the	  apical	  side	  
of	   intestinal	  epithelium.	   	  Pinocytosis	  allows	   transport	  of	  molecules	  by	   formation	  of	  an	  
invagination	   in	   cell	   membrane.	   	   The	   invagination	   engulfs	   nearby	  molecules	   and	   then	  
breaks	  off	  the	  cell	  membrane	  forming	  a	  vesicle.	   	  The	  vesicle	  enters	  the	  cytoplasm	  and	  
can	   empty	   its	   contents	   or	   can	   fuse	  with	   the	   opposite	   side	   of	   the	   cell	  membrane	   and	  
empty	   its	   contents.	   	   Although	   this	   is	   a	   promising	   mechanism	   for	   transport	   of	   large	  
molecules,	  the	  regulatory	  mechanisms	  of	  pinocytotic	  transport	  are	  not	  well	  understood.	  	  	  
2.2.3	  Approaches	  to	  Oral	  Protein	  Delivery	  
An	   oral	   formulation	   for	   a	   protein	   drug	   must	   preserve	   the	   drug’s	   structure,	  
protect	   the	   drug	   from	   proteolysis,	   and	   allow	   for	   the	   drug	   to	   be	   absorbed	   into	   the	  
bloodstream.	   	  A	  variety	  of	  approaches	  to	  oral	  protein	  delivery	  have	  been	  proposed	  to	  
meet	  these	  needs.	   	  Of	  these,	  there	  are	  several	  predominant	  strategies	  for	  oral	  protein	  
delivery:	   co-­‐administering	   additional	   compounds	   for	   altering	   the	   physiology	   of	   the	   GI	  
tract,	  modifying	  the	  drug,	  and	  delivering	  the	  drug	  using	  a	  carrier.	  
The	  large	  size	  of	  protein	  drugs	  on	  the	  order	  of	  10	  to	  100	  kDa	  limits	  their	  ability	  to	  
diffuse	  across	  GI	  tract	  tissues.	   	   	  The	  permeability	  of	  the	   intestinal	  epithelium	  has	  been	  
shown	  to	  be	   lowest	   in	  the	  colon	  and	  highest	   in	  the	  upper	  small	   intestine.	   	  Even	  in	  the	  
upper	  small	  intestine,	  where	  the	  intestinal	  epithelium	  is	  most	  permeable	  and	  over	  90%	  
of	  nutrients	  are	  absorbed,	  protein	  drug	  absorption	  is	  still	   low	  in	  comparison	  to	  smaller	  
molecular	  weight	  drug	  counterparts.	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Permeation	  enhancers	  
The	  co-­‐administration	  of	  compounds,	  which	  alter	  conditions	   in	   the	  GI	   tract	  has	  
been	   investigated	   for	   improvement	   of	   protein	   bioavailability.	   	   Permeation	   enhancers	  
typically	  enhance	   intestinal	  permeability	  by	  disrupting	  the	  epithelium’s	  tight	   junctions.	  	  	  
A	  variety	  of	  permeation	  enhancers	  have	  been	  studied	  including	  surfactants,	  fatty	  acids,	  
medium	  chain	  glycerides	  (usually	  monoglycerides	  and	  diglycerides	  of	  caprylic	  and	  capric	  
acid),	   steroidal	   detergents,	   acylcarnitines	   and	   alkanoylcholines,	   N-­‐acetylated-­‐α-­‐amino	  
acids	   and	   N-­‐acetylated	   non-­‐α-­‐amino	   acids,	   and	   chitosans	   and	   other	   mucoadhesive	  
polymers	  [24].	  	  	  
Permeation	   enhancers	   have	   been	   studied	   as	   excipients	   in	   oral	   protein	  
formulations	   in	   a	   number	   of	   studies	   to	   allow	  passage	   of	   these	   large	   drugs	   across	   the	  
epithelium.	   	   For	   example,	   oral	   delivery	   of	   the	   nonapeptide	   leuprolide	   was	   shown	   to	  
increase	  4-­‐fold	  in	  bioavailability	  with	  the	  addition	  of	  sodium	  salicylate	  as	  a	  permeation	  
enhancer	  [25].	  	  The	  effect	  of	  tetradecylmaltoside	  (TDM)	  on	  the	  intestinal	  absorption	  of	  
low	  molecular	  weight	  heparins	  increased	  bioavailability	  [26].	  	  The	  presence	  of	  trimethyl	  
chitosan	  (TMC)	  in	  gas	  empowered	  drug	  delivery	  systems	  was	  shown	  to	  improve	  insulin	  
absorption	  in	  rabbits	  [27].	  	  	  
Fetih	   et	   al.	   compared	   the	   effects	   of	   several	   permeation	   enhancers	   on	  
carboxyfluorescein	  oral	  delivery	  at	  different	  sites	  of	  the	  intestine.	  	  Their	  studies	  showed	  
the	  greatest	  effect	  of	  permeation	  enhancers	  on	  the	  colonic	  delivery.	   	   In	  addition,	  they	  
found	  that	  n-­‐dodecyl-­‐β-­‐D-­‐maltopyranoside	  had	  the	  greatest	  effect	  on	  absorption	  in	  the	  
colon	  [28].	  	  	  	  	  
While	   permeation	   enhancers	   have	   been	   shown	   to	   improve	   oral	   protein	  
bioavailability	   [29],	   they	   have	   also	   been	   shown	   to	   damage	   the	   intestinal	   epithelium.	  	  
This	   damage	   has	   been	   suggested	   to	   be	   reversible	   but	   only	   after	   the	   removal	   of	   the	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permeation	   enhancer	   [29,	   30].	   	   Yang	   et	   al.	   showed	   that	   the	   effect	   of	   the	  permeation	  
enhancer	  TDM	  on	  transepithelial	  electrical	  resistance	  of	  monolayers	  of	  C2BBe1	  (a	  Caco-­‐2	  
clone)	   was	   dependent	   on	   the	   concentration	   of	   the	   permeation	   enhancer	   but	   full	  
recovery	   took	   nearly	   30	   h	   after	   removal	   [26].	   	   The	   disruption	   of	   tight	   junctions	   and	  
damage	  to	  the	  epithelium	  associated	  with	  permeation	  enhancers	  may	  also	  diminish	  the	  
immunoprotective	  function	  of	  the	  intestinal	  epithelium	  in	  preventing	  pathogen	  entry.	  
Protease	  Inhibitors	  
The	  use	  of	  protease	   inhibitors	  to	  reduce	  degradation	  of	  protein	  drugs	   in	  the	  GI	  
tract	   has	   also	   been	   investigated.	   	   Because	   protease	   inhibitors	   can	   reduce	   enzymatic	  
degradation	   of	   protein	   drugs,	   protease	   inhibitors	   have	   been	   used	   to	   improve	  
bioavailability	  and	  by	  maintaining	  the	  bioactivity	  of	  more	  of	  the	  drug.	  	  If	  more	  bioactive	  
protein	  drug	  is	  available	  for	  absorption,	  a	  higher	  bioavailability	  can	  be	  achieved.	  	  	  
A	   number	   of	   studies	   have	   shown	   that	   protease	   inhibitors	   affect	   bioavailability	  
and	  protein	  degradation.	  	  For	  example,	  Aoki	  et	  al.	  demonstrated	  that	  protease	  inhibitors	  
effectively	   reduced	   the	   activity	   of	   a	   variety	   of	   enzymes	   linked	   to	   protein	   drug	  
degradation	   [18].	   	  Other	   studies	   have	   confirmed	   the	   effects	   of	   protease	   inhibitors	   on	  
bioavailability	  in	  vivo.	  	  Morishita	  et	  al.	  studied	  the	  effects	  of	  several	  protease	  inhibitors	  
on	   insulin	   delivery	   in	   the	   small	   intestine.	   	   They	   observed	   an	   improved	   hypoglycemic	  
effect	   over	   insulin	   controls	   indicating	   a	   greater	   the	   absorption	  of	   active	   insulin	   in	   the	  
presence	  of	  protease	  inhibitor.	  	  In	  contrast,	  Yamamoto	  et	  al.	  only	  observed	  a	  noticeable	  
effect	  of	  protease	   inhibitor	  on	   insulin	  delivery	   in	   the	   large	   intestine	  and	  not	   the	  small	  
intestine.	  	  They	  cited	  variability	  in	  enzyme	  presence	  and	  activity	  between	  the	  small	  and	  
large	   intestine	   for	   the	   discrepancy	   between	   their	   findings	   and	   literature.	   	   They	   also	  
hypothesized	   that	   a	   key	   difference	   in	   experimental	   methods	   between	   the	   studies	   in	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which	  the	  lumen	  was	  washed	  in	  one	  study	  and	  not	  washed	  in	  the	  other	  as	  a	  contributing	  
factor	  in	  the	  two	  studies	  [31,	  32].	  	  	  
The	  use	  of	  protease	   inhibitors	  to	   improve	  oral	  protein	  formulations	  has	  several	  
main	  drawbacks.	  	  First,	  the	  variability	  in	  the	  performance	  based	  on	  enzyme	  quantity	  and	  
activity	  raises	  serious	  concerns	  over	  predictable	  dosing	  and	  patient-­‐to-­‐patient	  variability	  
in	   absorption.	   	   The	   long-­‐term	   effects	   of	   continued	   exposure	   to	   protease	   inhibitors,	  
which	  may	  include	  changes	  to	  food	  digestion,	  have	  not	  been	  fully	  investigated.	  	  	  
	  	  	  
Conjugation	  of	  protein	  drugs	  
Instead	  of	  altering	  properties	  of	  the	  GI	  tract,	  the	  conjugation	  of	  other	  molecules,	  
such	  as	  poly(ethylene	  glycol)	  (PEG)	  or	  a	  transporter	  molecule,	  have	  been	  used	  to	  impart	  
enhanced	   properties	   to	   the	   protein	   drug.	   	   The	   conjugation	   of	   PEG	   to	   a	   protein	   drug	  
through	   the	   process	   of	   PEGylation	   can	   lead	   to	   improved	   resistance	   to	   degradation	   as	  
well	  as	  an	  extended	  half-­‐life	   in	   the	  bloodstream.	   	  PEG	   is	   relatively	   resistant	   to	  protein	  
binding	  and	  hence	  may	   impart	   enzyme-­‐resistant	  properties	   to	   a	  protein	  drug	   through	  
conjugation.	   	   In	   general,	   it	   is	   thought	   that	   the	   hydrophilicity	   of	   PEG	   causes	   water	  
molecules	   to	   be	   closely	   associated	  with	   the	   polymer	   forming	   a	   hydration	   layer.	   	   This	  
hydration	   layer	  acts	  as	  a	  barrier	  and	   interferes	  with	  protein	  adsorption.	   	  For	  example,	  
PEG-­‐insulin	   conjugates	   have	   been	  developed	   for	   oral	   delivery	   applications	   to	   improve	  
enzyme	   resistance	   of	   insulin.	   	   Tuesca	   et	   al.	   demonstrated	   in	   vivo	   bioactivity	   of	   PEG-­‐
insulin	   conjugates	   and	   a	   prolonged	   circulation	   time	   in	   comparison	   to	   insulin	   after	  
intravenous	  administration	  [33].	  	  	  
The	  modification	  of	  protein	  drugs	  by	   conjugation	   to	   transporter	  molecules	  has	  
been	  investigated	  in	  order	  to	   improve	  protein	  absorption.	   	   In	  this	  method,	  the	  protein	  
drug	   is	   conjugated	   to	   molecules	   absorbed	   via	   receptor-­‐mediated	   endocytosis.	   	   The	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conjugation	  of	   the	  transporter	  molecule	  and	  the	  protein	  drug	  allows	  for	  absorption	  of	  
the	   protein	   drug	   by	   the	   same	   absorption	   pathway	   as	   the	   transporter	   molecule.	   	   For	  
example,	  transporter	  molecules	  of	  transferrin	  and	  vitamin	  B-­‐12	  have	  been	  investigated	  
for	  conjugation	  to	  protein	  drugs.	  	  Vitamin	  B-­‐12	  has	  been	  used	  to	  form	  conjugates	  with	  
granulocyte-­‐colony	  stimulating	  factor,	  erythropoietin	  [34],	  leutinizing	  hormone	  [35],	  and	  
insulin	  [36].	  	  It	  has	  been	  shown	  that	  these	  conjugates	  transport	  across	  Caco-­‐2	  cell	  layers	  
using	   the	   vitamin	   B-­‐12	   absorption	   pathway	   [34].	   	   Orally	   administered	   B-­‐12-­‐insulin	  
conjugates	   in	  the	  diabetic	  rat	  model	  had	  a	  4.7-­‐fold	  greater	  decrease	  in	  the	  area	  under	  
the	  blood	  glucose	  curve	  in	  comparison	  to	  orally	  administered	  insulin	  indicating	  that	  B-­‐12	  
conjugation	  improved	  oral	  bioavailability	  of	  active	  insulin	  [36].	  	  	  
Conjugation	  to	  transferrin	  has	  also	  been	  used	  to	  improve	  insulin	  transport.	  	  The	  
transferrin	   molecule	   typically	   transports	   iron	   across	   the	   intestinal	   epithelium	   via	  
receptor-­‐mediated	  endocytosis.	  	  Conjugates	  of	  insulin	  and	  transferrin	  have	  been	  shown	  
to	   improve	   drug	   transport	   in	   comparison	   to	   native	   insulin	   in	   intestinal	   epithelial	   cell	  
models	   [37,	   38].	   	   Insulin-­‐transferrin	   conjugation	   was	   also	   shown	   to	   have	   increased	  
transport	  over	  insulin	  in	  a	  mucus-­‐producing	  co-­‐culture	  model	  of	  Caco-­‐2	  and	  HT29-­‐MTX	  
cells	  [39].	  	  These	  studies	  have	  suggested	  that	  the	  ability	  for	  transferrin	  to	  be	  uptaken	  by	  
the	   transferrin	   receptor	   is	   imparted	   to	   the	   conjugate	   by	   competitive	   inhibition	  
experiments	  [37,	  38].	  	  	  
With	  the	  administration	  of	  protein-­‐transporter	  conjugates,	  the	  long-­‐term	  effects	  
of	   chronic	   administration	   still	   need	   to	   be	   evaluated.	   	   Furthermore,	   the	   effects	   of	  
administering	  additional	  transferrin	  and	  vitamin	  B-­‐12	  on	  iron	  absorption	  and	  vitamin	  B-­‐
12	  absorption,	   respectively,	  have	  not	  been	   investigated.	   	  Transferrin	  and	  vitamin	  B-­‐12	  
facilitated	  transport	  mechanisms	  could	  also	  affect	  cell	  signaling	  but	  have	  not	  yet	  been	  
investigated.	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Enteric	  Coatings	  
Protein	  drugs	  have	  also	  been	  encapsulated	  in	  polymeric	  delivery	  vehicles	  of	  two	  
kinds:	  enteric	  coatings	  and	  polymer	  networks.	  	  The	  main	  advantage	  of	  using	  a	  polymer	  
coating	   or	   matrix	   to	   encapsulate	   a	   protein	   drug	   is	   to	   protect	   the	   protein	   drug	   from	  
degradation	   in	  the	  stomach.	   	  Enteric	  coatings,	  such	  as	  the	  Eudragit®	  systems,	  are	  non-­‐
crosslinked	   polymers	   that	   dissolve	   to	   release	   the	   drug.	   	   Typically,	   enteric	   coatings	  
dissolve	   at	   a	   neutral	   pH	   to	   allow	   protection	   of	   the	   drug	   in	   the	   stomach	   at	   low	   pH.	  	  
Because	  dissolution	  of	  the	  coating	  occurs	  at	  specific	  pH	  values,	  coatings	  can	  be	  selected	  
such	  that	  release	  occurs	  in	  one	  segment	  of	  the	  small	  intestine.	  
One	  of	  the	  distinct	  disadvantages	  of	  this	  strategy	  is	  that	  enteric	  coatings	  can	  only	  
improve	   the	   amount	   of	   bioactive	   protein	   drugs	   available	   for	   absorption	   but	   do	   not	  
facilitate	   the	   absorption	   process.	   	   As	   a	   result,	   protease	   inhibitors	   and	   permeation	  
enhancers	   have	   been	   used	   in	   conjunction	   with	   enteric	   coatings	   to	   achieve	   improved	  
pharmacological	  availabilities	  [30,	  40,	  41].	  	  A	  strategy	  combining	  an	  enteric	  coating	  and	  
either	   a	   protease	   inhibitor	   or	   a	   permeation	   enhancer	   raises	   additional	   concerns	   over	  
long-­‐term	  safety.	  	  	  
2.2.4	  Polymeric	  Carriers	  for	  Oral	  Protein	  Delivery	  
In	  order	  to	  maintain	  bioactivity	  but	  also	   improve	  absorption,	  polymeric	  carriers	  
have	   been	   developed.	   	   A	   variety	   of	   designs	   have	   been	   studied	   including	   degradable	  
matrices,	   thiomers,	   and	   environmentally	   responsive	   polymer	   networks.	   	   Typically,	   the	  
protein	  drug	  is	  entrapped	  in	  the	  polymer	  network,	  and	  release	  is	  controlled	  by	  diffusion.	  	  
Diffusion	  of	  proteins	  through	  a	  polymer	  network	  is	  strongly	  dependent	  on	  the	  mesh	  size	  
(ξ)	  of	  the	  polymer	  network,	  the	  hydrodynamic	  radius	  of	  the	  protein,	  and	  the	  strength	  of	  
polymer-­‐drug	  interactions.	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Degradable	  Carriers	  
In	   the	   case	   of	   degradable	   polymers,	   drug	   diffusion	   out	   of	   the	   carrier	   is	  
dependent	   on	   the	   extent	   of	   degradation.	   	   For	   the	   oral	   delivery	   of	   protein	   drugs,	  
degradable	  carriers	  can	  limit	  release	  prior	  to	  degradation	  but	  allow	  for	  increased	  release	  
with	  degradation.	  	  The	  ideal	  degradable	  system	  would	  remain	  intact	  in	  the	  stomach	  and	  
start	   degrading	   in	   either	   the	   small	   or	   large	   intestine.	   Degradation	   products	   from	  
breakdown	   of	   the	   carrier	   may	   interact	   with	   GI	   tissue,	   be	   absorbed,	   or	   be	   excreted.	  	  
Characterization	   of	   the	   effect	   of	   degradation	   products	   on	   the	   GI	   tract	   is	   a	   critical	  
challenge	  to	  oral	  delivery	  using	  degradable	  carriers.	  	  	  
A	  variety	  of	  degradable	  carriers	  have	  been	  investigated	  for	  oral	  protein	  delivery.	  	  
Of	  the	  most	  widely	  studied	  degradable	  polymer	  carriers	  is	  poly(lactide-­‐co-­‐glycolide),	  or	  
PLGA.	   	   For	   example,	   PEG-­‐coated	   PLGA	   nanoparticles	   were	   shown	   to	   deliver	   intact	  
tetanus	   toxoid	  orally	   [42].	   	   Insulin	  delivery	   from	  PLGA	  particles	   co-­‐loaded	  with	   insulin	  
and	  magnetite	  nanoparticles	  were	  shown	  to	  decrease	  blood	  glucose	  levels	  even	  though	  
bioavailabilities	  were	  less	  than	  2%	  [43].	  	  PLGA	  was	  also	  used	  to	  deliver	  an	  insulin-­‐sodium	  
oleate	   complex	   orally	   generating	   a	   decrease	   in	   blood	   glucose	   [44].	   	   In	   another	   study,	  
PLGA	  particles	  with	  and	  without	  an	  enteric	  coating	  of	  hypromellose	  phthalate	  achieved	  
bioavailabilities	  of	  6.27%	  and	  3.68%	  [45].	   	  Oral	   formulations	  composed	  of	  PLGA-­‐COOH	  
with	  olive	  oil	  filler	  were	  used	  to	  orally	  deliver	  glucagon-­‐like	  peptide-­‐1.	  	  This	  formulation	  
had	  a	  positive	  effect	  after	  an	  oral	  glucose	  challenge	  [46].	   	  These	  studies	  demonstrated	  
that	   a	   variety	   of	   PLGA-­‐based	   particles	   effectively	   deliver	   pharmacologically	   active	  
protein	  drugs	  via	  the	  oral	  route.	  	  	  
Another	   degradable	   polymer	   carrier	   that	   has	   been	   studied	   extensively	   in	   drug	  
delivery	   applications	   is	   poly(epsilon-­‐caprolactone)	   yet	   there	   are	   few	   studies	   that	  
demonstrate	   oral	   protein	   delivery	   in	   vivo.	   	   Poly(epsilon-­‐caprolactone)/Eudragit	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nanoparticles	  were	  shown	  to	  decrease	  blood	  glucose	  levels	  after	  oral	  delivery	  of	  either	  
aspart-­‐insulin	  [47]	  and	  insulin	  [48].	  	  For	  the	  insulin	  delivery	  system,	  the	  bioavailability	  of	  
insulin	  was	  calculated	  to	  be	  13%	  [48].	  	  	  	  	  
Mucoadhesive	  Delivery	  
One	   strategy	   for	   improving	   oral	   delivery	   of	   challenging	   molecules,	   such	   as	  
proteins,	   is	   the	   use	   of	   mucoadhesive	   drug	   carriers.	   	   Mucoadhesion	   is	   a	   form	   of	  
bioadhesion	   that	   involves	   a	   mucus	   substrate.	   	   The	   use	   of	   mucoadhesive	   carriers	   to	  
interact	  with	  mucus	   at	   the	   site	   of	   absorption	  was	   proposed	   to	   prolong	   the	   residence	  
time	  of	  carriers	  at	  the	  site	  of	  absorption.	  	  Extension	  of	  the	  residence	  time	  would	  allow	  
for	  an	  increase	  in	  drug	  bioavailabilty.	  	  	  
There	   are	   five	   main	   theories	   that	   describe	   the	   mechanisms	   of	   bioadhesion.	  	  	  
Often,	   adhesion	   is	   described	   as	   a	   combination	   of	   these	  mechanisms.	   	   The	   electronic	  
theory	   of	   adhesion	   involves	   the	   transfer	   of	   electrons	   between	   the	   polymer	   and	   the	  
tissue.	  	   The	   adjacent	   electrons	   form	  a	   double	   layer	   of	   charge	   at	   the	   interface	   causing	  
adhesion	   between	   the	   two	   materials	   based	   on	   charge	   attraction.	  	   Adsorption	   theory	  
describes	  adhesion	  as	  occurring	  based	  on	  secondary	   forces	   such	  as	  hydrogen	  bonding	  
van	   der	  Waals	   forces.	   	   Unlike	   electronic	   theory	   and	   adsorption	   theory,	   the	   theory	   of	  
wettability	  typically	  describes	  a	  system	  in	  which	  one	  substrate	  is	  a	  liquid	  and	  the	  other	  
substrate	  is	  a	  solid.	  	  Wettability	  describes	  adhesion	  based	  on	  the	  ability	  of	  the	  liquid	  to	  
spread	   on	   the	   surface	   of	   the	   solid.	   	   Chain	   interpenetration	   theory	   describes	   the	  
mechanism	  of	  adhesion	  between	  polymer	  gels	  and	   tissue.	  	  Polymer	  chains	  can	  diffuse	  
across	  the	  interface.	  	  These	  interpenetrating	  polymer	  chains	  anchor	  the	  two	  substrates	  
together	  causing	  adhesion	  between	  the	  polymer	  and	  biological	  substrate.	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Mucoadhesive	  Hydrogel	  Carriers	  
Specifically	   engineered	   carriers	   with	   the	   ability	   to	   form	   interactions	   with	   the	  
intestinal	   environment	   have	  made	   improvements	   in	   oral	   drug	   delivery.	   	   For	   example,	  
carriers	   have	   been	   designed	   to	   exhibit	   mucoadhesive	   interactions	   with	   the	   intestinal	  
lining.	   	  These	   interactions	  are	  believed	  to	  enhance	  the	  residence	  time	  of	  the	  carrier	   in	  
the	   intestine	   so	   that	   there	   is	   a	   greater	   period	   of	   time	   for	   controlled	   release	   at	   the	  
intestinal	   lining	   where	   absorption	   takes	   place.	   	   Improving	   the	   residence	   time	   of	   the	  
carrier	  and	  extending	  the	  time	  period	  over	  which	  release	  can	  occur	  in	  the	  small	  intestine	  
is	  desirable,	  because	  protein	  drug	  released	  beyond	  the	  small	  intestine,	  in	  the	  colon	  for	  
example,	  has	  a	  lower	  absorption	  and	  can	  result	   in	  a	  lower	  overall	  bioavailability	  of	  the	  
drug.	  
Surface	  decoration	  of	  the	  carrier	  as	  shown	  in	  Figure	  4	  has	  been	  suggested	  as	  a	  
means	  to	  enhance	  cellular	  interactions	  between	  the	  carrier	  and	  the	  intestine	  by	  forming	  
mucoadhesive	  interactions.	  	  Synthetic	  polymers	  such	  as	  PEG	  have	  been	  used	  to	  promote	  
mucoadhesion	  by	   interpenetration	  of	  PEG	  chains	   into	   the	  mucosa.	   	   The	  ability	  of	  PEG	  
tethers	   to	   promote	   adhesive-­‐like	   behavior	   by	   chain	   interpenetration	   into	   the	  mucosa	  
has	   been	   confirmed	   both	   experimentally	   and	   theoretically	   [41,	   49,	   50].	   	   Additionally,	  
PEG	   chains	   have	   been	   used	   in	   other	   drug	   delivery	   applications	   for	   protecting	   drug	  
delivery	   systems	   from	   immune	   recognition	   and	   shielding	   drugs	   from	   enzymatic	  
degradation	  [51,	  52].	  	  	  
While	  the	  mechanism	  behind	  mucoadhesion	  of	  PEG	  tethers	  is	  due	  to	  penetration	  
of	   the	   PEG	   chains	   into	   the	   mucosa	   and	   interactions	   between	   PEG	   chains	   and	   the	  
mucosa,	  other	  systems	  have	  been	  studied	  that	  can	  form	  more	  specific	  interactions.	  	  For	  
example,	   polymer	   carriers	   have	   been	   decorated	  with	   lectins,	   which	   are	   proteins	   that	  
bind	  specific	  carbohydrates,	  in	  order	  to	  bind	  to	  carbohydrate	  residues	  found	  on	  mucus	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glycoproteins.	   	   The	   decoration	   of	   wheat	   germ	   agglutinin	   onto	   P(MAA-­‐g-­‐EG)	  
microspheres	  was	  shown	  to	  improve	  the	  bioavailability	  of	  orally	  delivered	  insulin	  (Wood	  
et	  al).	  	  Likewise,	  this	  concept	  of	  binding	  components	  of	  the	  mucosa	  has	  been	  applied	  to	  
forming	   covalent	   interactions.	   	   Thiol	   groups	   have	   been	   added	   to	   carriers	   to	   form	  
thiomers	  that	  can	  form	  covalent	  bonds	  between	  thiol	  groups	  of	  the	  carrier	  and	  cysteine	  
groups	   in	   mucus	   glycoproteins	   [53].	   	   In	   vivo	   studies	   on	   the	   oral	   delivery	   of	   insulin	  
showed	   that	   thiolated	   polymers	   reduced	   the	   blood	   glucose	   more	   than	   non-­‐thiolated	  
polymers	  [54].	  	  	  	  	  	  	  
Chitosan-­‐based	  drug	  delivery	  systems	  are	  some	  of	  the	  most	  studied	  systems	  for	  
oral	   delivery	  of	  macromolecules	   and	  are	   the	   subject	   of	   several	   extensive	   reviews	   [55,	  
56].	  	  One	  of	  the	  prevailing	  reasons	  that	  chitosan	  has	  been	  the	  focus	  of	  so	  many	  studies	  
is	   chitosan’s	   ability	   to	   interact	  with	   intestinal	  mucus	   through	   charge	   attraction.	   	   	  Oral	  
delivery	   of	   insulin	   using	   chitosan	   nanoparticles	   achieved	   a	   pharmacological	   activity	  
ranging	  from	  14%	  to	  15.6%	  [57].	  	  Lower	  pharmacological	  availabilities	  were	  observed	  for	  
oral	   delivery	   using	   nanoparticles	   composed	   of	   a	   chitosan	   shell	   and	   alginate	   core.	  	  
However,	   insulin	   pharmacological	   activity	   was	   higher	   when	   delivered	   using	   the	  
nanoparticles	   (3.4%	   and	   6.8%)	   in	   comparison	   to	   free	   insulin	   (1.6%)	   [58].	  	  
Pharmacological	  availabilities	  as	  high	  as	  5.4%	  were	  obtained	   from	   insulin	  oral	  delivery	  
using	   carriers	   of	   nanoparticles	   composed	   of	   dextran	   sulfate/chitosan	   [59].	   	   Calcitonin	  
oral	   delivery	  was	   also	  demonstrated	  using	   liposomes	   composed	  of	  protease	   inhibitor-­‐
chitosan	  conjugates	  [60].	  	  	  
Complexation	  Hydrogels	  
For	  controlled	  release	  of	  orally	  delivered	  protein	  drugs,	  hydrogels	  have	  become	  
attractive	   candidates	   for	   carrier	   design.	   	   Hydrogels	   are	   crosslinked,	   three-­‐dimensional	  
	   37	  
networks	   composed	  of	   hydrophilic	   polymers.	   	  Hydrogels	   have	   the	   ability	   to	   swell	   and	  
imbibe	  water.	  	  Hydrogels	  are	  water	  insoluble	  and	  typically	  exhibit	  good	  biocompatibility.	  	  
One	  of	  the	  unique	  properties	  of	  hydrogels	   is	  that	  hydrogels	  can	  be	  tailored	  to	  swell	   in	  
response	  to	  various	  stimuli	  including	  pH,	  ionic	  strength,	  electric	  field,	  and	  temperature.	  	  
Control	  of	  swelling	  is	  synonymous	  with	  control	  of	  diffusion	  into	  and	  out	  of	  the	  hydrogel	  
network.	  	  	  
Control	  of	  diffusion	  processes	  of	  a	  carrier	  material	  allows	  for	  temporal	  and	  even	  
spatial	   control	   of	   the	   release	   of	   protein	   drugs.	   	   This	   ability	   to	   tailor	   hydrogels	   is	  
particularly	  advantageous	   for	  oral	  protein	  delivery.	   	  For	  oral	  delivery	  of	  protein	  drugs,	  
release	   of	   the	   protein	   drug	   should	   be	   minimal	   in	   the	   stomach	   where	   degradation	   is	  
likely	   to	   occur.	   	   Drug	   release	   in	   the	   intestine	   at	   the	   absorption	   site	  will	   allow	   for	   the	  
maximal	   amount	   of	   active	   drug	   to	   be	   available	   for	   absorption.	   	   Hydrogels	   with	   pH-­‐
dependent	  swelling	  can	  be	  used	  to	  release	  the	  protein	  drug	  based	  on	  the	  increase	  in	  pH	  
between	  the	  stomach	  and	  the	  intestine	  based	  on	  complexation	  behavior.	  	  	  	  	  
To	  use	  this	  pH	  transition	  from	  the	  stomach	  to	  the	  small	  intestine	  as	  a	  trigger	  for	  
release,	   anionic	   complexation	   hydrogels	   have	   been	   developed	   which	   rely	   on	   the	  
complexation	   properties	   of	   the	   cross-­‐linked	   polymeric	   carrier	   to	   control	   release.	  	  
Anionic	  complexation	  hydrogels,	  such	  as	  poly(methacrylic	  acid-­‐grafted-­‐ethylene	  glycol)	  
(P(MAA-­‐g-­‐EG)),	  are	  composed	  of	  a	  methacrylic	  acid	  (MAA)	  backbone	  and	  grafts	  of	  PEG.	  	  
In	   acidic	   conditions,	   the	   carboxylic	   acid	   residues	   of	   MAA	   are	   protonated	   and	   form	  
hydrogen	   bonds	  with	   the	   etheric	   groups	   of	   PEG.	   	   Hydrogen	   bonds	   between	   adjacent	  
polymer	  chains	  form	  physical	  crosslinks	  causing	  the	  polymer	  to	  be	  in	  a	  collapsed	  state.	  	  
As	   a	   result,	   diffusion	   into	   and	   out	   of	   the	   polymer	   network	   is	   limited.	   	   An	   entrapped	  
protein	  drug	  is	  shielded	  from	  degradation,	  and	  release	  is	  prevented	  in	  the	  stomach.	  	  The	  
physical	   crosslinks	   formed	  by	   the	  hydrogen	  bonding	  breaks	  down	   in	   the	  more	  neutral	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pH	  values	  of	   the	  small	   intestine.	   	  With	  an	   increase	   in	  pH,	   the	  carboxylic	  acids	  become	  
deprotonated.	   	   Deprotonation	   causes	   hydrogen	   bonding	   to	   break	   down.	   	  Meanwhile,	  
steric	  repulsions	  between	  polymer	  chains	  cause	  the	  polymer	  network	  to	  relax,	  and	  the	  
polymer	  mesh	   size	   to	   increase.	   	  With	   this	   process	   comes	  macroscopic	   swelling.	   	   The	  
protein	  drug	  is	  allowed	  to	  diffuse	  out	  of	  the	  polymer	  network	  and	  release	  in	  the	  small	  
intestine.	  	  	  
P(MAA-­‐g-­‐EG)	   hydrogels	   were	   developed	   by	   Peppas	   and	   co-­‐workers	   and	   have	  
been	  investigated	  for	  oral	  delivery.	  	  Peppas	  et	  al.	  have	  demonstrated	  successful	  loading	  
of	  a	  number	  of	  protein	  drugs	  including	  insulin,	  calcitonin	  [61,	  62],	  growth	  hormone	  [62],	  
interferon-­‐beta	   [61],	   and	   chemotherapeutics.	   	   These	   hydrogels	   effectively	   protect	  
protein	  drugs	  in	  acidic	  conditions	  and	  from	  proteolytic	  degradation	  [63].	  	  The	  ability	  of	  
P(MAA-­‐g-­‐EG)	   to	   retain	   protein	   drugs	   and	   shield	   them	   from	   proteolytic	   degradation	  
allows	  for	  delivery	  of	  bioactive	  drug.	   	  Control	  of	  release	  based	  on	  the	  pH	  change	  from	  
the	  stomach	  to	  the	  small	  intestine	  allows	  for	  site-­‐specific	  delivery	  of	  the	  payload.	  	  	  
In	   addition	   to	  protecting	   the	  bioactivity	  of	  protein	  drugs,	  P(MAA-­‐g-­‐EG)	   carriers	  
have	  been	  shown	  to	   improve	  absorption	  of	   insulin.	   	  The	  ability	   to	   improve	  absorption	  
stems	   from	   the	   ability	   of	   these	   carriers	   to	   interact	   with	   intestinal	   mucosa	   as	   well	   as	  
interact	  with	   the	   tight	   junctions	   of	   enterocytes.	   	   The	  mechanism	  of	  mucoadhesion	   of	  
P(MAA-­‐g-­‐EG)	  is	  that	  of	  chain	  interpenetration	  where	  PEG	  diffuse	  into	  the	  mucosa.	  	  The	  
ability	   to	   interact	  with	  the	   intestinal	  mucosa	  has	  been	  shown	  to	  be	  dependent	  on	  the	  
size	  of	  the	  particles	  and	  the	  composition	  of	  the	  polymer.	  	  Prolonging	  the	  residence	  time	  
of	  the	  carrier	  allows	  for	  an	  extended	  time	  period	  for	  the	  drug	  to	  release	  from	  the	  carrier	  
and	  to	  be	  absorbed.	   	  One	  of	  the	  other	  benefits	  of	  mucoadhesive	  delivery	  systems	   is	  a	  
reduction	  in	  the	  path	  length	  towards	  absorption.	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The	  ability	  of	  P(MAA-­‐g-­‐EG)	  carriers	  to	   influence	  paracellular	   transport	   is	   largely	  
based	   on	   experimental	   evidence	   from	   in	   vitro	   studies.	   	   Confocal	   studies	   on	   insulin	  
transport	   across	  Caco-­‐2	  monolayers	   showed	   that	   insulin	   transport	  was	  predominantly	  
paracellular	  [64].	  	  	  P(MAA-­‐g-­‐EG)	  carriers	  can	  reversibly	  open	  tight	  junctions	  by	  chelating	  
Ca2+.	   	   Since	   tight	   junction	   proteins	   are	   dependent	   on	   Ca2+,	   the	   junctions	   loosen	  with	  
depletion	   of	   Ca2+	   concentrations.	   	   Studies	   by	   Peppas	   and	   co-­‐workers	   have	   shown	   the	  
recovery	  of	  tight	  junction	  integrity	  using	  transepithelial	  electrical	  resistance	  (TEER)	  [65].	  	  	  
In	   vivo,	   P(MAA-­‐g-­‐EG)	   systems	   have	   improved	   bioavailability	   over	   orally	  
administered	  insulin.	  	  The	  hypoglycemic	  effect	  of	  orally	  delivered	  insulin	  from	  P(MAA-­‐g-­‐
EG)	  was	   first	   studied	  by	  Lowman	  et	  al.	   	  Oral	   insulin	  bioavailability	   from	  these	  systems	  
was	   found	   to	  be	  3.40%	   in	  healthy	   rats	   and	  2.44%	   in	  diabetic	   rats	   for	   a	  25	   IU/kg	  dose	  
[66].	   	  Higher	  bioavailabilities	  of	   12.8%	  were	  observed	   in	  optimized	   systems	   [67].	   	   The	  
size	  of	  P(MAA-­‐g-­‐EG)	  microparticles	  was	  shown	  to	  affect	  drug	  bioavailability	  with	  smaller	  
particles	  performing	  better	  [67].	  	  	  	  	  
2.3	  POLYSACCHARIDES	  AS	  BIOMATERIALS	  
Carbohydrates	  are	  the	  most	  abundant	  natural	  biomaterials,	  more	  abundant	  than	  
nucleic	  acids	  and	  peptides.	  	  They	  form	  polymers	  with	  a	  number	  of	  repeat	  units	  including	  
monosaccharides,	  disaccharides,	  oligosaccharides,	  and	  polysaccharides.	  	  Carbohydrates	  
decorate	  a	  variety	  of	  molecules	  to	  form	  glycolipids,	  glycosaminoglycans,	  glycoproteins,	  
and	   proteoglycans.	   	   Additionally,	   they	   are	   important	   components	   of	   many	   other	  
biomolecules	   including	   ribonucleic	   acid	   (RNA)	   and	   deoxyribonucleic	   acid	   (DNA).	  	  	  	  
Because	   of	   their	   integration	   into	   so	  many	   biomolecules,	   carbohydrates	   play	   essential	  
roles	  in	  cellular	  communication,	  inflammation,	  infection,	  development,	  and	  disease	  [68-­‐
71].	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While	   the	   goals	   of	   genomics	   and	   proteomics,	   which	   look	   at	   the	   biological	  
information	  ‘stored’	  in	  the	  genetic	  code	  of	  organisms	  and	  the	  amino	  acid	  sequences	  of	  
proteins,	   are	   familiar,	   glycomics	   is	   a	   much	   more	   recent	   topic	   in	   biotechnology.	  	  
Glycomics	   seeks	   to	   understand	   glycans	   as	   bioinformatics	   molecules	   [71-­‐73].	  	  
Researchers	  theorize	  that	  the	  coding	  capacity	  of	  polysaccharides	  is	  far	  greater	  than	  that	  
of	   nucleic	   acids	   and	   amino	   acids	   because	   of	   the	   numerous	  ways	   that	   polysaccharides	  
can	  form	  glycosidic	  bonds	  with	  one	  another	  and	  the	  different	  isomers	  these	  molecules	  
may	  assume	  [68,	  69,	  71,	  73].	  	  There	  is	  a	  tremendous	  amount	  of	  information	  to	  be	  gained	  
from	   polysaccharide	   sequences	   and	   their	   interactions	  with	   proteins	   and	   nucleic	   acids	  
[70].	   	   Glycomics	   seeks	   to	   understand	   the	   role	   that	   polysaccharides	   play	   in	   cellular	  
processes	  for	  advancing	  biotechnology.	  
Many	   fields	   within	   biotechnology	   stand	   to	   gain	   enormous	   rewards	   from	  
glycomics	   research.	   	   More	   information	   on	   polysaccharides’	   roles	   in	   cell	   signaling,	  
development,	   inflammation,	   and	   disease	   states	   is	   anticipated	   to	   be	   generated	   by	  
glycomics.	   	   The	  applications	  of	   this	   knowledge	   in	  drug	  delivery	  and	   tissue	  engineering	  
are	  innumerable.	  	  	  
	  
2.3.2	  The	  Role	  of	  Carbohydrates	  in	  Adhesion	  
Carbohydrate	  interactions	  are	  typically	  weak	  [69,	  74-­‐76].	  	  However,	  they	  can	  be	  
enhanced	   by	  multivalent	   interactions	  where	  multiple	   saccharides	   are	   involved[77-­‐80].	  	  
Two	   phenomena	   are	   at	   play	   in	   multivalent	   carbohydrate	   interactions:	   chelate	   effect	  
where	  multiple	  interactions	  occur	  after	  an	  initial	  interaction	  and	  ligand-­‐induced	  protein	  
clustering	  [69,	  77,	  81].	   	  These	  properties	  and	  effects	  of	  carbohydrate	   interactions	  with	  
other	  biomolecules	  make	  polysaccharides	  versatile	  biomaterials.	  With	  recent	  advances	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in	  glycomics,	  the	  critical	  roles	  of	  carbohydrates	   in	  physiology	  are	  becoming	  even	  more	  
apparent.	  	  	  
Cellular	   processes	   of	   adhesion	   and	   recognition	   are	   often	   mediated	   by	  
carbohydrate-­‐carbohydrate	   and	   carbohydrate-­‐protein	   interactions	   [82].	   	   Single	  
carbohydrate-­‐carbohydrate	   interactions	  are	  considered	  weak	   interactions.	   	  Of	   the	   few	  
studies	   that	  have	  quantified	   these,	   carbohydrate-­‐carbohydrate	   interactions	  have	  been	  
shown	   to	  have	  dissociation	   constants	   (Kd)	   of	   1	   x	   10-­‐4	  M	   [83].	   	  However,	   the	   adhesion	  
forces	  of	  glycan-­‐glycan	   interactions	  are	  considerably	  strong	  with	  190-­‐310	  pN	  adhesion	  
forces	   which	   are	   in	   the	   range	   of	   antibody-­‐antigen	   interactions	   (244	   pN)	   [82].	   	   	   It	   is	  
generally	   thought	   that	   the	   strength	   of	   carbohydrate	   interactions	   increases	   with	  
multivalency	   as	   more	   carbohydrate	   interactions	   occur	   in	   close	   proximity	   [84].	   	   For	  
example,	  monovalent	  carbohydrate-­‐protein	  interactions	  have	  affinities	  of	  Ka	  =	  103-­‐4	  M-­‐1	  
and	  increase	  2	  to	  6	  fold	  with	  multivalency	  [81].	  
	  
2.3.1	  Lectins	  and	  Analysis	  of	  Carbohydrates	  
Advances	   in	   carbohydrate	   research	   have	   largely	   been	   driven	   by	   the	   use	   of	  
lectins.	   	   Lectins	   are	   proteins	   with	   affinities	   for	   specific	   saccharide	   residues.	   	   Many	  
proteins	  classified	  as	  lectins	  are	  found	  decorating	  cell	  surfaces	  and	  are	  involved	  in	  many	  
cell-­‐carbohydrate	  interactions.	  	  Studies	  have	  shown	  that	  selectins,	  a	  subclass	  of	  lectins,	  
mediate	  lymphocyte	  rolling	  and	  adhesion	  [85].	  	  In	  addition,	  lectins	  have	  been	  shown	  to	  
play	  a	  role	  in	  cancer	  cell	  migration	  [86,	  87].	  	  	  
Because	  of	   their	   specificity	   for	   saccharide	  units,	   lectins	  have	  also	  been	  used	   to	  
study	  the	  roles	  of	  carbohydrates	  in	  biology.	  	  One	  of	  the	  primary	  uses	  of	  lectins	  has	  been	  
to	   understand	   glycosylation	   patterns.	   	   Labeled	   lectins	   have	   been	   used	   for	   imaging	  
carbohydrates	   in	   cellular	  matrices,	   on	   the	   surface	  of	   cells,	   and	   intracellularly.	   	   Recent	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microarray	   technology	   has	   been	   used	   to	   develop	   lectin	  microarrays.	   	   These	   powerful	  
new	   tools	   require	   only	   small	   amounts	   of	   carbohydrate	   ligands	   and	   can	   be	   used	   for	  
quantitative,	   simultaneous	   detection	   of	   different	   carbohydrates.	   	   These	   microarrays	  
have	  been	  used	  to	  study	  the	  cell	  surface	  glycome	  of	  bacteria	  and	  mammalian	  cells	  [88,	  
89].	  	  	  	  	  
	  
2.3.3	  Carbohydrate	  Biomaterials	  for	  Applications	  in	  Tissue	  Engineering	  
Polysaccharide	   biomaterials	   have	   been	   investigated	   for	   a	   variety	   of	   tissue	  
engineering	   applicationsand	   scaffold	   engineering	   is	   almost	   synonymous	   with	   tissue	  
engineering.	  	  Selection	  of	  the	  biomaterials	  in	  scaffold	  design	  plays	  an	  integral	  role	  in	  the	  
overall	  success	  of	  the	  implant	  by	  modulating	  cellular	  adhesion,	  cellular	  proliferation,	  and	  
the	  inflammatory	  response.	  	  Biodegradable	  materials	  are	  especially	  attractive	  materials	  
for	   tissue	  engineering	  scaffolds	  because	   they	  may	  help	   to	   limit	  a	  chronic	   foreign	  body	  
response	  that	  could	  ensue	  from	  a	  permanent	  implant	  [90].	  	  Polysaccharide	  biomaterials	  
have,	   therefore,	   been	   used	   in	   a	   variety	   of	   tissue	   engineering	   fields:	   cartilage,	  
cardiovascular,	  neural,	  and	  hepatics.	  	  	   	  
Cartilage	  Engineering	  Applications	  
Cartilage	  is	  a	  connective	  tissue	  that	  provides	  support	  to	  other	  tissue	  and	  can	  also	  
cushion	   joints.	   	   Hyaline	   cartilage	   is	   the	  most	   predominant	   form	   of	   cartilage,	  which	   is	  
present	   at	   joints.	   	   Natural	   hyaline	   cartilage	   repair	   is	   very	   slow	   because	   cartilage	   is	  
avascular.	   	  Articular	  cartilage	   is	  composed	  of	  chondrocytes	  (cells)	  and	  the	  extracellular	  
matrix	  they	  produce.	  	  The	  primary	  components	  of	  the	  cartilage	  ECM	  are	  type	  II	  collagen	  
and	  GAGs	  which	  include	  hyaluronic	  acid,	  chondroitin	  sulfate,	  dermatan	  sulfate,	  keratin	  
sulfate,	  and	  heparin	  sulfate	  [91].	  	  The	  phenotype	  of	  chondrocytes	  determines	  the	  ECM	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that	  they	  produce	  [91,	  92].	  	  Maintaining	  chondrocyte	  expression	  of	  the	  appropriate	  ECM	  
components	   is	   essential	   in	   properly	   producing	   articular	   cartilage.	   	   (A	   more	   in	   depth	  
review	  of	  issues	  in	  cartilage	  repair	  may	  be	  found	  in	  [Ref.	  [91]]).	  	  	  	  	  	  	  	  	  	  	  
Tissue	  engineering	  schemes	  have	  proposed	  using	  bioactive	  scaffolds	  to	  support	  
chondrocyte	   growth	   and	   control	   chondrocyte	   phenotype	   [93].	   	   Scaffolds	   may	   be	  
designed	  to	  support	  ingrowth	  of	  chondrocytes	  from	  surrounding	  tissues	  or	  may	  be	  used	  
to	  encapsulate	  implanted	  chondrocytes.	  	  Material	  selection	  for	  these	  scaffolds	  must	  be	  
careful	   as	   the	   scaffold’s	   properties	   can	   influence	   chondrocyte	   expression	   and	   the	  
produced	   cartilage	   [91,	   92].	   	   Because	   glycosaminoglycans	   (GAGs)	   are	   a	   major	  
component	  of	  the	  chondrocyte	  extracellular	  matrix,	  GAGs	  and	  GAG-­‐like	  materials	  have	  
been	  mimicked	  in	  chondrocyte	  scaffold	  design	  [92].	  	  As	  a	  result,	  several	  polysaccharide-­‐
based	   biomaterials	   have	   been	   investigated	   for	   chondrocyte	   scaffolding	   including	  
alginate,	  chitosan,	  and	  hyaluronic	  acid.	  
Alginate	  has	  been	  used	  in	  several	  studies	  to	  evaluate	  its	  potential	  use	  in	  cartilage	  
scaffolds.	   	   Diduch	   et	   al	   used	   agarose,	   alginate,	   and	   type	   I	   collagen	   to	   encapsulate	  
marrow	   stromal	   cells	   (which	   produce	   cartilage	   like	   chondrocytes)	   [94].	   	   This	   study	  
recommended	   alginate	   as	   the	   optimal	  material	   selection	   for	   this	   application	   because	  
alginate	   had	   better	   mechanical	   properties	   than	   agarose	   and	   maintained	   the	  
chondrocyte-­‐like	  morphology	   of	  marrow	   stromal	   cells	   [94].	   	   Caterson	   et	   al	   examined	  
poly(lactic	  acid)	  and	  alginate	  constructs	   for	  marrow	  stromal	  cell	  growth.	   	  Results	   from	  
this	   study	   indicated	   that	   the	   poly(lactic	   acid)/alginate	   constructs	   supported	  
chondrogenesis	   and	   limited	   fibrous	   capsule	   formation	   over	   poly(lactic	   acid)	   [95].	  	  
Iwasaki	   et	   al.	   formed	  an	   alginate-­‐chitosan	  hybrid	  material	   that	   increased	   chondrocyte	  
adhesion	   (over	  alginate	   controls)	   and	  did	  not	   influence	   chondrocyte	  morphology	   [96].	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This	   study	  demonstrated	   that	   the	   addition	  of	   chitosan	   to	   alginate	  materials	   improved	  
the	  material	  properties	  for	  application	  in	  cartilage	  tissue	  engineering.	  	  	  
Chitosan	  scaffolds	  have	  been	  the	  focus	  of	  multiple	  studies	  because	  of	  their	  GAG-­‐
like	   structure	   that	   may	   mimic	   the	   cartilage	   ECM.	   	   Lu	   et	   al.	   used	   in	   vivo	   studies	   of	  
chitosan	  implants	  to	  assess	  its	  use	  in	  cartilage	  therapeutics.	  	  Chitosan	  was	  injected	  into	  
the	  knees	  of	  Wistar	   rats	   [97].	   	   Subsequent	   results	  were	  promising:	   chitosan	   increased	  
the	   number	   of	   chondrocytes	   in	   the	   articular	   cavity	   and	   maintained	   the	   thickness	   of	  
epiphyseal	   cartilage	   better	   than	   controls	   [97].	   	   This	   study	   showed	   that	   chitosan	   was	  
biocompatible	   causing	   no	   inflammation	   and	   may	   contribute	   to	   chondrogenesis	   and	  
hence	  cartilage	  repair	  [97].	  	  	  
Modified	  chitosans	  have	  also	  been	  investigated	  for	  cartilage	  tissue	  engineering,	  
and	  	  Sechriest	  et	  alinvestigated	  chitosan	  for	  cartilage	  repairing	  applications.	  	  They	  found	  
that	  membranes	  of	  chitosan	  and	  chondroitin	  sulfate-­‐A	  (a	  chondroitin	  sulfate	  precursor)	  
maintained	   chondrocyte	   phenotype	   by	   showing	   that	   chondrocytes	   cultured	   on	   these	  
surfaces	  predominantly	  produced	  type	  II	  collagen	  [98].	  	  By	  creating	  new	  materials	  with	  
chondroitin	  sulfate-­‐A	  and	  chitosan,	  Sechriest	  et	  al	  were	  able	   to	   influence	  chondrocyte	  
expression	   towards	   producing	   the	   appropriate	   type	   of	   collagen	   for	   articular	   cartilage	  
ECM.	   	   More	   recently,	   Masuko	   et	   al.	   modified	   chitosan	   with	   a	   peptide	   sequence	  
containing	   RGDS,	   an	   adhesion	   promoting	   peptide	   sequence	   [99].	   	   Their	   work	  
demonstrated	  that	  conjugated	  chitosan-­‐RGDSGGC	  materials	  increased	  chondrocyte	  and	  
fibroblast	   adhesion	   and	   proliferation	   [99].	   	   Masuko	   et	   al	   also	   proposed	   that	   their	  
procedure	   for	   conjugating	   RGDSGGC	   to	   chitosan	   could	   be	   used	   to	   conjugate	   other	  
peptides	   and	   proteins	   to	   chitosan.	   	   This	   research	   demonstrated	   that	   tailoring	   a	  
polysaccharide	   scaffold	   with	   peptides	   added	   more	   control	   over	   cellular	   adhesion.	   	   It	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suggests	   that	   further	   modifications	   of	   polysaccharides	   with	   other	   materials	   such	   as	  
proteins	  may	  add	  another	  method	  towards	  controlling	  chondrocyte	  behavior.	  	  	  	  
Hyaluronic	  acid	  has	  also	  been	   investigated	   for	   chondrocyte	   scaffolding.	   	  Unlike	  
chitosan,	   hyaluronic	   acid	   is	   a	   natural	   component	   of	   the	   extracellular	  matrix	   (ECM)	   of	  
chondrocytes.	  	  It	  has	  been	  suggested	  that	  hyaluronic	  acid	  is	  an	  ideal	  candidate	  material	  
for	   chondrocyte	   scaffolding	   based	   on	   its	   natural	   presence	   in	   the	   ECM	   as	   well	   as	   its	  
biodegradability	  and	  biocompatibility.	  	  	  
Advances	   have	   been	  made	   in	   synthesis	   of	   hyaluronic	   acid	  materials	   and	   novel	  
modification	  methodologies	  have	  been	  explored	  that	  may	  expand	  the	  potential	  uses	  of	  
hyaluronic	   acid	   in	   cartilage	   engineering.	   	   Bulpitt	   and	   Aeschlimann	   developed	   several	  
methods,	   notably	   amine	   and	   aldehyde	   functionalization,	   for	   covalent	   coupling	   of	  
proteins	  to	  hyaluronic	  acid	  [100].	  	  Crosslinked	  hyaluronic	  acids	  were	  implanted	  in	  a	  rat	  
subcutaneous	   model	   to	   show	   that	   the	   cross-­‐linker	   and	   functionalization	   of	   the	  
hyaluronic	   acid	   affected	   inflammation	   and	   cartilage	   generation.	   	   Bulpitt	   and	  
Aeschlimann’s	   work	   was	   novel	   in	   that	   it	   allowed	   functionalization	   and	   in	   situ	  
polymerization	  of	  hyaluronic	  acid	  materials.	   	  More	  recently,	  Burdick	  et	  al.	  developed	  a	  
photopolymerizable	   hyaluronic	   acid	   that	   supported	   chondrocyte	   growth	   and	  
neocartilage	  formation	  [100].	   	  Burdick	  et	  al.	   improved	  upon	  Bulpitt	  and	  Aeschlimann’s	  
work	   by	   simplifying	   the	   synthesis	   process	   with	   photopolymerization	   that	   could	   be	  
carried	  out	  in	  situ.	  	  	  
Other	   studies	   have	   shown	   that	   hyaluronic	   acid-­‐containing	   biomaterials	   are	  
biocompatible	   and	   contribute	   to	   cartilage	   regeneration	   in	   vivo	   [101,	   102].	   	   With	  
improvement	  of	  its	  synthesis	  process	  and	  its	  natural	  occurrence	  in	  cartilage,	  hyaluronic	  
acid	  has	  been	  shown	  to	  be	  an	  important	  biomaterial	  in	  cartilage	  tissue	  engineering.	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  Vascular	  Applications	   	  
Like	   cartilage	   tissue	   engineering,	   carbohydrate-­‐based	   biomaterials	   have	   been	  
used	   in	  a	  number	  of	   cardiovascular	   tissue	  engineering	  applications.	   	   The	  use	  of	   tissue	  
engineering	  scaffolds	  to	  repair	  capillaries	  and	  larger	  blood	  vessels	  is	  one	  of	  the	  main	  foci	  
of	  cardiovascular	  tissue	  engineering.	  	  Tissue	  engineering	  constructs	  for	  vascular	  implants	  
may	  be	  implanted	  to	  recruit	  the	  formation	  of	  new	  blood	  vessels	  or	  may	  be	  implanted	  as	  
part	  of	  a	   support	  of	   tissue	  generation	  ex	  vivo.	   	   Some	  of	   the	  current	  vascular	   implants	  
include	  but	   are	  not	   limited	   to	   stents	   and	  blood	  vessel	   grafts.	   	   The	  main	   challenges	   to	  
implant	   design	   in	   cardiovascular	   tissue	   engineering	   include	   thrombosis,	   inflammation,	  
re-­‐endothelialization,	  and	  smooth	  muscle	  cell	  hyperplasia.	  	  	  
Polysaccharide-­‐based	   biomaterials	   have	   been	   investigated	   for	   several	   different	  
implants.	   	   For	   example,	   Matthew	   et	   al.	   investigated	   chitosan	   scaffolds	   for	   small-­‐
diameter	  blood	  vessel	  grafts	  showing	  that	  tubular	  scaffolds	  desirable	  for	  cardiovascular	  
implants	  could	  be	  created	  with	  a	  nonporous	   luminal	   layer	  and	  a	  porous	  external	   layer	  
[103].	   	   SEM	   images	   verified	   that	   heparin	   could	   be	   incorporated	   into	   the	   chitosan	  
scaffold	   by	   rehydrating	   the	   scaffold	   in	   a	   solution	   containing	   heparin	   [103].	   	   A	  
subsequent	   study	   expanded	   on	   this	   heparin-­‐chitosan	   complex.	   	   	   Chitosan	   scaffolds	  
containing	   additional	   GAGs	  were	   evaluated.	   	   In	   vitro	   cellular	   studies	   showed	   that	   the	  
spreading	   and	   growth	   rate	   of	   smooth	   muscle	   cells	   and	   endothelial	   cells	   could	   be	  
controlled	   by	   the	   GAG-­‐chitosan	   complexes	   [104].	   	   Smooth	  muscle	   cell	   spreading	  was	  
more	  restricted	  on	  chitosan	  and	  chitosan-­‐GAG	  structures	  than	  that	  of	  endothelial	  cells	  
which	   may	   be	   additionally	   beneficial	   for	   cardiovascular	   applications	   where	   smooth	  
muscle	  cell	  control	  is	  of	  the	  utmost	  importance.	  	  These	  same	  implants	  were	  examined	  in	  
vivo	  through	  evaluation	  tissue	  ingrowth	  14	  days	  following	  subcutaneous	  implantation	  of	  
GAG-­‐chitosan	   scaffolds.	   	   Of	   these,	   heparin-­‐chitosan	   samples	   developed	   a	   granulation	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layer	   containing	   new	   vasculature	   [104].	   	   The	   demonstrated	   ability	   of	   chitosan-­‐based	  
biomaterials	  to	  elicit	  different	   in	  vitro	  responses	  of	  cardiovascular	  cells	  as	  well	  as	  their	  
ability	   to	   support	   tissue	   ingrowth	   and	   angiogenesis	   in	   vivo	   shows	   that	   these	  
polysaccharide	  biomaterials	  may	  be	  further	  used	  in	  cardiovascular	  implants.	  	  	  
	  
Neural	  Applications	  
Development	  of	  a	  degradable	  conduit	  to	  facilitate	  neural	  regeneration	  and	  repair	  
is	  one	  of	  the	  primary	  goals	  in	  neural	  tissue	  engineering	  today.	  	  The	  material	  properties	  
of	   such	   a	   construct	   are	   essential	   to	   the	   implant’s	   success.	   	   Based	   on	   their	  
biocompatibility	  and	  mechanical	  similarities	  to	  soft	  tissue,	  several	  polysaccharide-­‐based	  
biomaterials	  have	  been	  investigated	  for	  use	  in	  such	  scaffolds	  for	  nerve	  repair.	  	  	  
Zhang	   et	   al.	   have	   investigated	   chitosan	   biomaterials	   for	   use	   in	   nerve	   guidance	  
channels.	  	  Their	  work	  has	  focused	  primarily	  on	  using	  chitosan	  to	  create	  polymer	  blends	  
with	  several	  proteins	  to	  form	  new	  materials.	   	   	   	   In	  one	  study,	  gelatin	  incorporation	  into	  
chitosan	  films	  increased	  the	  film’s	  hydrophilicity	  and	  elastic	  properties.	  	  Differentiation	  
of	  PC12	  cells	   in	  vitro	  showed	  that,	   indeed,	  the	  combined	  film	  had	  an	  improved	  affinity	  
for	  neural	  cells	  over	  chitosan	  controls	  [105].	  	  Albumin,	  collagen,	  and	  poly-­‐L-­‐lysine	  were	  
also	  blended	  with	  chitosan.	   	  Results	   indicated	  that	  poly-­‐L-­‐lysine	  blended	  chitosan	  films	  
were	  the	  most	  effective	  in	  improving	  PC12	  cell	  adhesion,	  differentiation,	  and	  extension	  
over	  chitosan	  controls	  [106].	   	   It	  was	  proposed	  that	   increasing	  the	  hydrophilicity	  of	  the	  
chitosan	  films	  with	  GAGs	  and	  poly-­‐L-­‐lysine	  was	  responsible	  for	  an	  increased	  neural	  cell	  
affinity.	  	  	  
Other	   combination	   materials	   using	   chitosan	   have	   been	   investigated.	   	   For	  
example,	  Gu	  et	  al.	  studied	  nerve	  grafts	  composed	  of	  poly(glycolic	  acid)	  (PGA)	  fibers	  on	  
the	   inner-­‐surface	   and	   an	   outer	   layer	   of	   chitosan.	   	   Six	   months	   following	   implant	   in	   a	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canine	   severed	   sciatic	   nerve	  model,	   the	   implants	   had	   degraded	   and	   nerve	   tissue	   had	  
formed	  to	  reconnect	  the	  severed	  nerve.	   	  Dogs	  that	  received	  the	  chitosan-­‐PGA	  scaffold	  
recovered	  similarly	  to	  dogs	  that	  received	  an	  autologous	  nerve	  graft.	  	  Gu	  et	  al	  proposed	  
that	  the	  success	  of	  the	  grafts	  was	  due	  in	  part	  to	  the	  chitosan	  component	  which	  allowed	  
blood	  vessel	  in-­‐growth,	  allowed	  nutrients	  to	  enter	  the	  graft,	  and	  served	  as	  a	  barrier	  to	  
keep	  out	  other	  cells	  [107].	  	  This	  study	  clearly	  demonstrated	  that	  chitosan	  may	  be	  used	  
in	   neural	   tissue	   engineering	   schemes	   and	   illustrates	   the	   clinical	   significance	   of	  
polysaccharide	  biomaterials.	  
Hyaluronic	  acid	  as	  a	  nerve	  guidance	  channel	  component	  has	  been	   investigated	  
by	   Schmidt	   et	   al.	   	   Their	   work	   has	   taken	   a	   novel	   approach	   to	   neural	   biomaterials	  
development	   combining	   natural	   materials	   with	   electrically	   conductive	   materials	   to	  
stimulate	   neural	   regeneration	   chemically,	   mechanically,	   and	   electrically	   [108].	   	   They	  
developed	  films	  of	  photocrosslinkable	  hyaluronic	  acid	  and	  polypyrrole	  that	  maintained	  
the	   electrical	   conductivity	   of	   polypyrrole.	   	   PC12	   adhesion	   and	   morphology	   were	  
comparable	   to	   controls.	   	   These	   films	   were	   also	   shown	   to	   be	   biocompatible	   in	   vivo	   6	  
weeks	  after	  subcutaneous	  implantation	  using	  a	  rat	  model.	  	  This	  study	  also	  showed	  that	  
hyaluronic	   acid-­‐containing	   biomaterials	   have	   the	   unique	   ability	   to	   stimulate	  
angiogenesis	   near	   the	   site	   of	   the	   implant	   [108].	   	   With	   the	   capacity	   to	   electrically	  
stimulate	  neurite	  extension,	  the	  ability	  to	  mechanically	  support	  nerve	  growth,	  and	  the	  
capability	  to	  promote	  angiogenesis,	  these	  biomaterials	  are	  advanced	  material	  solutions	  
in	  neural	  tissue	  engineering.	  	  	  	  	  
Hepatic	  Applications	  
Hepatic	   tissue	   engineering	   has	   already	   begun	   to	   incorporate	   protein-­‐
carbohydrate	   interactions	   into	  scaffold	  design.	   	  Hepatic	  tissue	   itself	   is	  one	  of	  the	  most	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complex	   tissues	   found	   in	   the	   body	   structurally	   because	   of	   its	   large	   amount	   of	  
vasculature.	   	   Control	   of	   cell	   morphology	   and	   differentiation	   as	   well	   as	   blood	   vessel	  
ingrowth	  is	  essential	  for	  hepatic	  tissue	  scaffolds.	  	  Cho	  et	  al.	  and	  Griffith	  et	  al.	  have	  done	  
pioneering	  work	   towards	  hepatic	   tissue	  engineering.	   	  Their	  work	  has	  centered	  around	  
the	  fact	  that	  liver	  cells	  are	  known	  to	  express	  lectins	  (asialyglycoprotein	  receptor	  (ASGP-­‐
R))	  with	   galactose	   affinities	   [109,	   110].	   	   Therefore,	   their	   research	   has	   used	   galactose-­‐
containing	   scaffolds	   as	   a	   natural	   control	  mechanism	   for	   tissue	   engineering	   of	   hepatic	  
tissue.	  	  	  
Cho	   et	   al.	   have	   examined	   several	   galactosylated	  materials.	   	   In	   one	   study,	   they	  
used	   galactosylated	   chitosan/	   alginate	   scaffolds	   for	   hepatic	   cell	   growth	   [111].	   	   In	  
additional	  work,	  they	  have	  examined	  the	  effect	  that	  different	  carbohydrate-­‐containing	  
materials	  may	  have	  on	  hepatic	  cell	  morphology	  and	  spreading	  [112].	   	  A	  nice	  review	  of	  
their	   work	  may	   be	   found	   in	   [Ref.	   [111]].	   	   They	   have	   shown	   that	   their	   carbohydrate-­‐
containing	   scaffold	   performed	   better	   than	   alginate	   controls.	   	   Results	   suggest	   that	  
carbohydrate-­‐containing	  scaffolds	  are	  a	  possible	  choice	  for	  a	  hepatic	  tissue	  scaffold.	  
Griffith	   et	   al.	   have	   focused	   on	   a	   synthetic	   scaffolds	   modified	   with	   galactose.	  	  
They	  have	   synthesized	  poly(ethylene	  oxide)	   star	  polymers	  modified	  with	  galactose	   for	  
hepatic	  tissue	  engineering	  [113,	  114].	  	  Results	  showed	  that	  galactose	  modification	  led	  to	  
specific	  mediation	   between	   the	   polymer	   substrate	   and	   ASGP-­‐R	   of	   hepatic	   cells	   [113].	  	  
Galactose	  modified	  polymers	  improved	  hepatic	  cell	  attachment	  and	  growth	  and	  proved	  
formidable	  scaffolds	  for	  hepatic	  tissue	  engineering	  [113,	  114].	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2.3.4	  Carbohydrates	  in	  Drug	  Delivery	  
Carrier	  Systems	  
Chitosan	  has	  been	  used	   in	   several	   successful	  drug	  delivery	   studies	  with	  one	  of	  
the	  most	   important	  being	  gene	   therapy	  delivery	   systems	   [115-­‐118].	   	  Chitosan	  has	   the	  
distinct	   advantage	   to	   complex	   with	   DNA	   because	   of	   its	   positive	   charge	   and	   DNA’s	  
negative	   charge.	   	  Roy	  et	   al	  developed	  chitosan	  nanoparticles	   to	  deliver	   gene	   therapy-­‐
based	   vaccines	   [119].	   	   Chitosan	  particles	   containing	   a	   genetic	   vaccine	   (against	   peanut	  
allergy)	   were	   orally	   administered	   to	   mice.	   	   In	   sensitization	   studies,	   the	   resulting	  
anaphylaxis	  of	  vaccinated	  mice	  with	  the	  chitosan	  drug	  delivery	  system	  was	  much	  lower	  
than	  samples	  which	  were	  vaccinated	  with	  only	  the	  gene	  (without	  the	  chitosan	  carrier)	  
and	  controls	  that	  were	  not	  vaccinated	  at	  all	  [119].	   	  Roy	  et	  al	  showed	  promising	  results	  
that	  chitosan	  drug	  delivery	  systems	  can	  successfully	  deliver	  gene-­‐based	  therapies	  orally.	  	  
Senel	   et	   al	   examined	   chitosan	   for	   protein	   drug	   delivery	   across	   buccal	  mucosa.	   	   Their	  
results	   suggested	   that	   chitosan	   enhanced	   the	   permeability	   of	   transforming	   growth	  
factor-­‐β	  [120].	  	  Janes	  et	  al	  outline	  several	  other	  drugs	  that	  chitosan	  was	  used	  as	  a	  carrier	  
for.	  	  These	  included	  bovine	  serum	  albumin	  and	  insulin	  [121].	  	  	  
Alginates	   have	   been	   studied	   for	   drug	   delivery	   as	   well	   [122].	   	   Bouhadir	   et	   al	  
oxidized	  sodium	  aliginate	  to	  form	  a	  new	  monomer	  [123].	   	  They	  were	  able	  to	  engineer	  
this	   polysaccharide	   delivery	   system	   to	   release	   three	   different	   model	   drugs	   in	   a	  
controlled	   fashion	   via	   three	   different	   mechanisms	   of	   release:	   diffusion,	   ionic	  
dissociation,	  degradation	  of	  a	  covalent	  bond	  [123].	  	  Alginate	  has	  been	  used	  to	  release	  a	  
variety	  of	  proteins	  as	  well	   including	  but	  not	   limited	  to	  fibroblast	  growth	  factor,	  bovine	  
serum	  albumin,	  nerve	  growth	  factor,	  and	  interleukin-­‐2	  [124].	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While	   this	   is	   just	   a	  miniscule	   sampling	   of	   the	   research	   on	   carbohydrate-­‐based	  
drug	   carriers,	   several	   reviews	   discuss	   polysaccharide	   drug	   delivery	   systems	   including	  
amylose,	  dextran,	  and	  pectin	  in	  more	  detail	  [125,	  126].	  	  
	  
Targeted	  Delivery	   	  
Lectin-­‐carbohydrate	  interactions	  are	  beginning	  to	  be	  exploited	  for	  targeted	  drug	  
delivery.	   	   The	   strength	   of	   their	   interactions	  with	   carbohydrates	   increases	   significantly	  
with	  multivalency	  as	  outlined	  earlier	  in	  the	  paper.	  	  Both	  lectins	  and	  their	  polysaccharide	  
counterparts	  may	  be	  used	  for	  targeting	  and	  adhesion	  [127].	  	  In	  designing	  these	  targeting	  
modalities	  for	  drug	  delivery	  systems,	  carbohydrates	  may	  be	  used	  to	  target	  lectins	  or	  vice	  
verse.	  	  The	  exciting	  research	  into	  drug	  polysaccharide	  targeting	  systems	  shows	  promise	  
for	  transforming	  drug	  delivery.	  	  	  
Several	   lectin-­‐mediated	   drug	   delivery	   systems	   have	   been	   developed	   that	   use	  
lectins	   to	   target	   specific	   tissues	   and	   systems	   [127,	   128].	   	   Umamaheshwari	   et	   al.	  
demonstrated	   that	   lectin-­‐modified	   nanoparticles	   could	   be	   used	   to	   prevent	   H.	   pylori	  
infection	  of	  human	  stomach	  cells	  [129].	  	  Lectins	  have	  been	  used	  to	  target	  drug	  delivery	  
to	   epithelial	   M-­‐cells	   and	   Caco-­‐2	   cells	   [65,	   130-­‐133].	   	   Wood	   et	   al	   used	   wheat	   germ	  
agglutinin	  (a	   lectin)	  to	  target	  an	  insulin	  complexation	  hydrogel	  drug	  delivery	  system	  to	  
carbohydrate	   residues	   found	   in	   intestinal	   mucosa.	   	   Results	   showed	   enhanced	  
permeability	  towards	  insulin	  transport	  and	  indicated	  that	  wheat	  germ	  agglutinin	  led	  to	  
improved	  bioavailability	  of	  insulin	  [132].	  	  
Xu	  et	  al	  also	  investigated	  lectin-­‐mediated	  oral	  delivery	  of	  insulin.	  	  In	  addition	  to	  
wheat	   germ	   agglutinin,	   Xu	   et	   al	   also	   investigated	   tomato	   lectin	   and	   Ulex	   europaeus	  
agglutinin	   1	   (UEA1)	   [134].	   	   Liposomes	   were	   modified	   with	   lectins	   and	   loaded	   with	  
insulin.	  	  In	  vivo	  drug	  delivery	  studies	  showed	  that	  lectins	  increased	  insulin	  delivery	  over	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controls.	   	   Of	   the	   lectin	   modifications	   examined	   by	   Xu	   et	   al,	   wheat	   germ	   agglutinin	  
performed	  the	  best	  [134].	  	  
Delivery	   of	   imaging	   modalities	   to	   cancer	   via	   lectins	   has	   been	   investigated	   by	  
Hama	  et	  al	  [135,	  136].	  	  Hama	  et	  al	  showed	  that	  avidin	  conjugated-­‐BODIPY	  could	  be	  used	  
to	  bind	  asialo-­‐receptors	  on	  cancer	   cell	   lines	  and	  used	   fluorescence	  emission	   to	  detect	  
cancerous	   cells.	   	   Nine	   different	   cancer	   cell	   lines	   were	   observed:	   ovarian,	   colon,	  
pancreatic,	  gastric,	  breast,	  and	  prostate.	  	  Images	  from	  each	  culture	  showed	  that	  lectins	  
may	  be	  used	  to	  target	  cancer	  cells	  for	  delivery	  imaging	  systems.	  	  	  	  	  	  	  
Drug	  delivery	  systems	  that	  use	  carbohydrateshave	  also	  been	  studied	  [137-­‐139].	  	  
Cho	   et	   al	   have	   investigated	   galactose	   containing	   particles	   to	   target	   the	  
asialoglycoprotein	   receptors	   (containing	   a	   lectin	   domain)	   on	   hepatic	   cells.	   	   Their	  
research	  investigated	  poly(L-­‐lactic	  acid)	  particles	  coated	  with	  polystyrene	  and	  galactose	  
for	  targeted	  drug	  delivery	  of	  trans-­‐retinoic	  acid	  [138].	  	  	  
Another	  team	  of	  researchers	   investigated	  lectin-­‐ligand	  chemistry	  as	  a	  means	  to	  
deliver	  anti-­‐inflammatory	  drugs	  to	  the	  blood	  vessel	  lining	  by	  targeting	  P-­‐selectin	  which	  
plays	   a	   significant	   role	   in	   blood	   vessel	   inflammation	   [140].	   	   P-­‐selectin	   is	   expressed	  by	  
endothelial	   cells	   and	   supports	   neutrophil	   rolling	   mediated	   by	   Sialyl-­‐Lewisx	   (sLex),	   a	  
sialylated	  and	  fucosylated	  carbohydrate.	  	  These	  drug	  delivery	  systems	  were	  designed	  to	  
mimic	   this	   neutrophil	   rolling	   to	   deliver	   anti-­‐inflammatory	   drugs.	   	   PLGA	  microparticles	  
were	   synthesized	   and	   decorated	   with	   sLex	   through	   avidin-­‐biotin	   chemistry	   [140].	  	  
Laminar	  flow	  studies	  showed	  that	  drug	  delivery	  system	  supported	  rolling	  on	  P-­‐selectin	  
coated	  surfaces	  and	  that	  it	  was	  dependent	  on	  the	  density	  of	  carbohydrates	  on	  the	  PLGA	  
microspheres	  [140].	  	  This	  study	  took	  an	  innovative	  approach	  to	  anti-­‐inflammatory	  drug	  
delivery	  systems	  and	  indicates	  that	  carbohydrate-­‐decorated	  drug	  delivery	  systems	  may	  
be	   used	   to	   target	   lectins	   on	   cell	   surfaces	   in	   other	   therapies	   as	   well.	   	   Both	   systems	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described	   used	   carbohydrates	   to	   target	   lectins	   on	   cell	   surfaces	   for	   cell-­‐specific	   drug	  
delivery.	  
	   	  	  	  
Other	  Polysaccharide-­‐Related	  Targeting	  Strategies	  
Bertozzi	   et	   al.	   have	   proposed	   an	   innovative	   strategy	   for	   drug	   delivery	   using	  
polysaccharides.	   	  They	  have	  used	  polysaccharides	  to	  selectively	  modify	  cell	  surfaces	  so	  
that	   these	  modified	   cells	  may	  be	   targeted	  by	  drug	  delivery	   systems	   [141,	   142].	   	   They	  
utilized	   natural	   oligosaccharide	   (metabolism	   and)	   synthesis	   to	   incorporate	   a	   ketone	  
containing	  N-­‐levulinoyl	  mannosamine	  into	  sialic	  acids	  on	  cell	  surfaces	  instead	  of	  the	  N-­‐
acetylmannosamine.	  	  Biotin	  was	  then	  bound	  to	  these	  ketone	  groups	  on	  sialic	  acid,	  and	  	  
Avidin-­‐coupled	  toxins	  were	  used	  to	  target	  and	  kill	  the	  cells	  that	  were	  biotinylated	  [141].	  	  
They	   suggested	   that	   their	   methodology	   for	   engineering	   the	   cell	   surface	   for	   drug	  
targeting	   may	   be	   further	   developed	   to	   selectively	   target	   tumor	   cells	   which	   tend	   to	  
express	  high	  levels	  of	  sialic	  acid.	  	  	  
2.3.5	  Carbohydrate-­‐Mediated	  Adhesion	  in	  the	  Intestine	  
Studies	   have	   shown	   that	   carbohydrates	   are	   involved	   in	   adhesion	   processes	  
involving	  both	  carbohydrates	  and	  proteins,	  and	  that	  many	  occur	  at	   the	   intestinal	  wall.	  	  
For	  example,	  many	  bacteria	  that	  colonize	  the	  small	  intestine	  rely	  on	  polysaccharides	  on	  
their	   surfaces	   for	   adhesion	   to	   the	   intestinal	   wall.	   	   Gram-­‐negative	   bacteria,	   which	   are	  
often	   pathogenic,	   adhere	   to	   the	   mucosa	   with	   lipolysaccharides	   (LPS)	   found	   on	   their	  
membranes.	  	  While	  LPS	  interacts	  strongly	  with	  the	  intestinal	  wall,	  LPS	  have	  been	  shown	  
to	  be	  immunogenic	  [143-­‐145].	  	  	  
O-­‐linked	  polysaccharides	  are	  known	  to	  play	  roles	   in	  cellular	  adhesion	  especially	  
in	   cancer	   (Fukuda	   2002).	   	   Studies	   have	   suggested	   that	   O-­‐linked	   polysaccharides	   can	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serve	  as	  ligands	  for	  cell	  binding	  via	  selectins,	  but	  to	  our	  knowledge,	  there	  are	  no	  studies	  
linking	   this	   class	   of	   polysaccharides	   to	   adhesive	   interactions	   with	   the	   intestinal	   wall	  
[146].	  	  	  
Teichoic	   acids	   are	   polysaccharides	   found	   in	   the	   cell	   wall	   of	   Gram-­‐positive	  
bacteria	   (often	  non-­‐pathogenic).	   	  Research	  has	   shown	   that	   teichoic	  acid	   is	   involved	   in	  
the	  adhesion	  of	  bacteria	  to	  stomach	  epithelial	  cells.	  	  A	  more	  recent	  study	  investigating	  a	  
Caco-­‐2	  model	  showed	  that	  lipoteichoic	  acids	  of	  L.	  johnsii	  La1	  were	  involved	  in	  adhesion	  
to	  the	  intestinal	  epithelial	  cell	  model	  (Granato,	  et	  al).	  	  Several	  studies	  have	  investigated	  
the	   role	   of	   teichoic	   acid	   in	   septic	   shock	   and	   immune	   responses	   highlighting	   that	   the	  
bacterial	  source	  is	  a	  determining	  factor	  in	  immunogenicity	  [147-­‐149].	  	  	  
The	   presence	   of	   hyaluronic	   acid	   (HA)	   in	   the	   extracellular	   matrix	   and	   the	  
expression	   of	   hyaluronic	   acid	   on	   a	   wide	   variety	   of	   cell	   types	   make	   HA	   an	   attractive	  
candidate	   for	   in	   vivo	   applications.	   	   HA	   has	   been	   shown	   to	   be	   a	   suitable	   tissue	  
engineering	   construct	   for	   intestinal	   epithelial	   cells	   [150].	   	   Because	   intestinal	   epithelial	  
cells	  adhered	   to	   the	  HA	  substrate,	  HA	  may	  be	  a	  good	  candidate	   for	   facilitating	  carrier	  
interactions	   with	   the	   intestinal	   wall.	   	   It	   is	   important	   to	   note	   that	   HA	   served	   as	   a	  
substrate	   for	   Caco-­‐2	   cells,	   meaning	   that	   the	   basolateral	   side	   of	   the	   polarized	   cells	  
adhered	  well	  to	  HA.	  	  	  
Drug	  delivery	  systems	  of	  pectin,	  which	  contains	  polygalacturonic	  acid,	  have	  been	  
investigated	  for	  ocular	  and	  colonic	  delivery	  [151,	  152].	   	   In	  addition,	  rheological	  studies	  
have	  shown	  that	  pectin	  can	  interact	  with	  mucin	  [153].	  	  These	  interactions	  depended	  on	  
mucin	  concentration	  but	  also	  on	  the	  degree	  of	  esterification	  of	  pectin	  [153].	  	  	  
	  Galectins,	   a	   type	  of	   lectin,	  have	  affinities	   for	  β-­‐galactosides	  and	  are	  expressed	  
on	  the	  apical	  side	  of	  the	  intestinal	  epithelium.	  	  To	  the	  best	  of	  our	  knowledge,	  the	  ability	  
of	  β	  -­‐galactosides	  to	  interact	  with	  the	  intestinal	  epithelium	  in	  a	  receptor-­‐ligand	  fashion	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has	  not	  yet	  been	   investigated.	   	  However,	   galectin-­‐3	   is	  expressed	  on	   the	  apical	   side	  of	  
intestinal	  epithelial	  cells	  and	  has	  been	  shown	  to	  bind	  glycosaminoglycans	  containing	  β	  -­‐
galactose	  [154-­‐157].	  	  	  
Dextran	   and	   pullulan	   are	   neutral	   polysaccharides	   composed	   of	   glucose	   units.	  	  
These	   polysaccharides	   have	   been	   used	   in	   a	   variety	   of	   drug	   delivery	   applications.	  	  
Dextran	   is	  especially	  well	   characterized	   for	   in	  vivo	   applications	  and	   is	   considered	  non-­‐
immunogenic.	  	  These	  polysaccharides	  are	  not	  considered	  to	  be	  strongly	  mucoadhesive.	  	  
However,	   they	   are	   typically	   long,	   mostly	   linear,	   hydrophilic	   chains.	   	   Their	   structure	  
would	   allow	   for	   the	   tethers	   of	   dextran	   and	   pullulan	   to	   diffuse	   into	   the	   mucosa	   and	  






























Figure	  2.1	  Schematic	  of	  the	  intestinal	  epithelium.	  	  	  
Each	  intestinal	  villus	  has	  its	  own	  arteriole	  and	  venule	  pair	  as	  well	  as	  a	  lacteal.	  	  The	  cell	  




























Figure	  2.2	  	   	   Schematic	  representation	  of	  a	  protein	  drug	  conjugate.	  
Protein	  drugs	  (green)	  may	  be	  conjugated	  to	  another	  molecule	  (purple)	  via	  a	  covalent	  



























Figure	  2.3	   Comparison	  of	  enteric	  coatings	  and	  crosslinked	  polymer	  matrices	  for	  oral	  
drug	  delivery	  systems.	  	  
Enteric	  coatings	  are	  non-­‐crosslinked	  polymers	  which	  allow	  them	  to	  fully	  dissolve	  while	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Figure	  2.4	   Complexation	  behavior	  of	  P(MAA-­‐g-­‐EG)	  hydrogels.	  
In	  acidic	  conditions,	  P(MAA-­‐g-­‐EG)	  hydrogels	  are	  in	  a	  collapsed	  state	  with	  a	  small	  mesh	  
size	  due	  to	  hydrogen	  bonding	  between	  carboxylic	  acid	  groups	  and	  etheric	  groups.	  	  At	  
neutral	  pH,	  deprotonation	  of	  the	  carboxylic	  acid	  groups	  leads	  to	  electrostatic	  and	  steric	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Chapter	  3:	  	  	  
Objectives	  
With	   the	   completion	   of	   the	   human	   genome	   project	   and	   advances	   in	   protein	  
engineering,	   protein	   drugs	   are	   poised	   to	   become	   more	   widely	   used	   for	   disease	  
treatment.	  	  Protein	  drugs,	  such	  as	  insulin,	  calcitonin,	  growth	  hormone,	  and	  interferon-­‐β,	  
have	   traditionally	   been	   administered	   by	   injection	   because	   of	   their	   large	   molecular	  
weights	  and	  the	  dependence	  of	  their	  bioactivity	  on	  structure.	  	  While	  injection	  has	  been	  
an	  effective	  administration	  route	  for	  protein	  drugs,	  administration	  via	  the	  oral	  route	  is	  
more	  desirable.	  	  Avoidance	  of	  needles	  or	  sharps	  waste,	  convenience	  in	  travel,	  and	  ease	  
of	  administration	  are	  some	  of	  the	  reasons	  behind	  the	  need	  for	  an	  oral	  formulation	  as	  an	  
alternative	  to	  administration	  by	  injection.	  	  	  
However,	   the	   oral	   administration	   of	   protein	   drugs	   has	  major	   challenges.	   	   The	  
activity	  of	  the	  protein	  drug	  must	  be	  maintained	  in	  the	  GI	  tract,	  and	  therapeutic	  levels	  of	  
the	   active	   drug	   must	   make	   their	   way	   into	   the	   bloodstream	   leading	   to	   a	   therapeutic	  
bioavailability.	  	  To	  meet	  these	  challenges,	  an	  oral	  delivery	  system	  must	  protect	  the	  drug	  
in	  the	  stomach	  from	  proteolytic	  enzymes	  and	  acid	  but	  allow	  absorption	  of	  the	  drug	   in	  
either	   the	  small	  or	   large	   intestine.	   	  The	   target	   site	  of	  absorption	   is	   the	  small	   intestine	  
which	   is	   typically	   preferred	   for	   absorption	   of	   hydrophilic	   proteins	   due	   to	   a	   more	  
permeable	  epithelium	  than	  the	  colon.	  	  	  
We	   propose	   orally	   delivered	   protein	   drugs	   using	   an	   anionic	   complexation	  
hydrogel	  composed	  of	  a	  methacrylic	  acid	  backbone	  with	  grafts	  of	  poly(ethylene	  glycol)	  
and	  carbohydrate	  tethers.	  	  Poly(methacrylic	  acid-­‐grafted-­‐ethylene	  glycol),	  P(MAA-­‐g-­‐EG),	  
gels	   are	   particularly	   suited	   for	   oral	   protein	   delivery	   because	   they	   have	   the	   ability	   to	  
swell	  dependent	  on	  pH	  allowing	  for	  drug	  release	  to	  be	  triggered	  by	  a	  change	  in	  pH.	  	  For	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example,	   in	  more	   acidic	   environments,	   diffusion	   into	   and	   out	   of	   P(MAA-­‐g-­‐EG)	   gels	   is	  
limited	   due	   to	   physical	   crosslinks	   composed	   of	   hydrogen	   bonds	   between	  methacrylic	  
acid	  and	  ethylene	  glycol.	   	   In	  the	  neutral	  conditions	  of	  the	  small	   intestine	  P(MAA-­‐g-­‐EG)	  
gels	  swell	  allowing	   for	  diffusion	  of	  entrapped	  drugs	  out	  of	   the	  gel.	   	   	   	  These	  properties	  
allow	  for	  protection	  of	  the	  protein	  in	  the	  stomach	  but	  release	  in	  the	  small	  intestine.	  	  
In	  this	  work,	  we	  seek	  to	  enhance	  the	  interactions	  between	  P(MAA-­‐g-­‐EG)	  gels	  and	  
the	  intestinal	  wall	  to	   improve	  bioavailability	  using	  tethers	  composed	  of	  carbohydrates.	  	  
A	  biomimetic	  approach	  based	  on	  the	  mediation	  of	  carbohydrates	  and	  polysaccharides	  in	  
many	  adhesion	  and	  recognition	  processes	  is	  used	  to	  improve	  interactions	  of	  the	  carrier	  
and	   intestinal	  wall.	   	   Improved	   interactions	  between	   the	  carrier	  and	   the	   intestinal	  wall	  
will	  increase	  the	  residence	  time	  of	  the	  carrier	  allowing	  more	  time	  for	  the	  protein	  drug	  to	  
release	   at	   the	   site	   of	   absorption.	   	   Furthermore,	   previous	   studies	   have	   shown	   that	  
P(MAA-­‐g-­‐EG)	   carriers	   modified	   to	   interact	   with	   the	   intestinal	   lining	   have	   increased	  
protein	  bioavailability.	  	  	  
The	   hypothesis	   of	   this	   thesis	   is	   that	   the	   addition	   of	   carbohydrate	   tethers	   to	  
P(MAA-­‐g-­‐EG)	  gels	  will	  enhance	  carrier	   interactions	  with	   the	   intestinal	   lining	   leading	   to	  
an	   improvement	   in	  bioavailability	  of	  protein	  drugs.	   	   In	   this	   research,	  we	  will	   focus	  on	  
creating	  carbohydrate	  tethers	  from	  a	  variety	  of	  polysaccharides.	  	  These	  polysaccharides	  
will	   then	   be	   covalently	   incorporated	   into	   P(MAA-­‐g-­‐EG)	   gels.	   	   The	   properties	   of	   these	  
materials	  will	  be	  optimized	  for	  the	  oral	  delivery	  of	  insulin	  which	  we	  will	  use	  as	  a	  model	  
protein.	  	  Furthermore,	  we	  will	  evaluate	  the	  in	  vitro	  performance	  of	  these	  systems.	  	  	  
Towards	   the	   development	   and	   evaluation	   of	   P(MAA-­‐g-­‐EG)	   gels	   decorated	  with	  
carbohydrate	  tethers	  for	  oral	  protein	  delivery,	  we	  have	  several	  aims:	  
• To	   investigate	   the	   incorporation	   of	   polysaccharides	   into	   the	   bulk	   of	  
P(MAA-­‐g-­‐EG)	  hydrogels	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• To	  study	  these	  systems	  for	  pH-­‐responsive	  delivery	  of	  protein	  drugs	  
• To	   evaluate	   and	   optimize	   the	   properties	   of	   these	   hydrogels	   for	  
mucoadhesive	  oral	  	  delivery	  of	  proteins.	  
	  
We	   present	   our	   work	   on	   developing	   and	   optimizing	   carbohydrate	   decorated-­‐
P(MAA-­‐g-­‐EG)	  hydrogel	  microparticles	   and	  nanoparticles	   for	  oral	   protein	  delivery.	   	  Our	  
work	   towards	   these	   aims	   is	   organized	   by	   the	  material	   used.	   	   Chapter	   4	   presents	   our	  
work	   on	   the	   design	   of	   complexation	   hydrogels	   with	   polysaccharides	   incorporated	  
throughout	  the	  material	  and	  discusses	  the	  potential	  for	  these	  hydrogels	  as	  oral	  protein	  
delivery	   systems.	   	   The	   pH-­‐responsive	   swelling	   of	   these	   systems	   is	   investigated	   in	  
Chapter	  5.	  	  The	  evaluation	  of	  the	  loading	  and	  release	  of	  insulin	  from	  these	  hydrogels	  as	  
well	   as	   the	   evaluation	   of	   the	   cytotoxicity	   of	   these	   systems	   is	   presented	   in	   Chapter	   6.	  	  	  	  
Our	   work	   on	   characterizing	   interactions	   of	   polysaccharide-­‐modified	   P(MAA-­‐g-­‐EG)	  
hydrogels	  with	  cells	  and	  mucus	  membranes	  for	  oral	  protein	  delivery	  is	  in	  Chapter	  7.	  	  In	  
vitro	   evaluation	   of	   the	   insulin	   transport	   and	   the	   effect	   on	   epithelial	   monolayers	   is	  
discussed	   in	   Chapter	   8.	   	   Finally,	   Chapter	   8	   presents	   a	   parallel	   project	   in	   which	   we	  
investigated	  the	  use	  of	  P(MAA-­‐g-­‐EG)	  for	  the	  oral	  delivery	  of	  ovalbumin.	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Chapter	  4:	  	  	  
Synthesis	  and	  Characterization	  of	  Complexation	  Hydrogels	  Containing	  
Polysaccharides	  	  
4.1	  INTRODUCTION	  
Maintaining	   bioactivity	   of	   protein	   drugs	   and	   improving	   absorption	   of	   orally	  
administered	  protein	  drugs	  are	  the	  two	  major	  challenges	  to	  oral	  protein	  bioavailability.	  	  
Disruption	  of	  the	  secondary	  structure	  of	  protein	  drugs	  and	  degradation	  by	  enzymes	   in	  
the	   stomach	   are	   significant	   issues	   for	   maintaining	   the	   function	   of	   protein	   drugs.	  	  
Because	   disruption	   of	   the	   structure	   of	   these	   drugs	   significantly	   affects	   bioactivity,	  
protein	  drugs	  must	  be	  protected	  from	  the	  environment	  of	  the	  GI	  tract	  [1].	  	  Achieving	  a	  
therapeutic	   bioavailability	   in	   the	   bloodstream	   is	   dependent	   on	   the	   absorption	   of	   the	  
protein	   drug	   along	   the	   GI	   tract	   [1].	   	   However,	   absorption	   of	   large	   undigested	  
macromolecules	  such	  as	  proteins	  is	  uncommon.	  	  Both	  the	  mucosa	  and	  glycocalyx	  serve	  
as	  physical	  barriers	  between	   the	   lumen	  of	   the	   intestine	  and	   the	  epithelium,	  while	   the	  
tight	  junctions	  of	  the	  epithelium	  limit	  passive	  diffusion.	  	  	  	  
To	  overcome	  these	  challenges	   to	  oral	  protein	  delivery,	  polymeric	  drug	  delivery	  
systems	   composed	   of	   anionic	   complexation	   hydrogels	   were	   synthesized	   for	   the	   oral	  
delivery	   of	   protein	   drugs	   [2-­‐15].	   	   P(MAA-­‐g-­‐EG)	   hydrogels	   have	   been	   shown	   to	   be	  
effective	  in	  maintaining	  the	  bioactivity	  of	  protein	  drugs	  in	  the	  GI	  tract.	  	  These	  hydrogels	  
protect	  protein	  drugs	   from	  degradation	   in	  acidic	   stomach	  conditions	  due	   to	  hydrogen	  
bonding	  between	  PMAA	  and	  PEG	  polymer	  chains	  [15,	  16].	  	  Hydrogen	  bonding	  between	  
adjacent	  polymer	  chains	  act	  as	  physical	  crosslinks—limiting	  diffusion	  into	  and	  out	  of	  the	  
mesh.	  	  The	  pH-­‐dependent	  dissociation	  of	  these	  physical	  crosslinks	  allows	  control	  of	  drug	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release	   at	   higher	   pH.	   	   For	   example,	   the	   release	   of	   protein	   drugs	   from	   P(MAA-­‐g-­‐EG)	  
networks	  at	  pH	  values	  of	  the	  intestine	  has	  been	  demonstrated	  [17,	  18].	  	  	  
The	   ability	   of	   protein	   drugs	   to	   be	   absorbed	   from	   the	   GI	   tract	   after	   release	   is	  
essential.	  	  The	  absorption	  of	  insulin	  delivered	  via	  P(MAA-­‐g-­‐EG)	  microparticles	  has	  been	  
confirmed	   in	   vivo	   through	   measurement	   of	   serum	   insulin	   levels	   and	   a	   measured	  
reduction	   in	  blood	  glucose	   levels	   [8].	   	   The	  decrease	   in	  blood	  glucose	   level	   proves	   the	  
absorbed	   insulin	   is	   pharmacologically	   active.	   	   The	  amount	  of	   drug	   absorbed	  has	  been	  
measured	  in	  terms	  of	  its	  bioavailability.	  	  Increased	  bioavailability	  is	  highly	  desirable	  as	  a	  
higher	   bioavailability	   results	   in	   more	   efficient	   delivery	   with	   less	   wasted	   drug.	   	   For	  
delivery	  of	  insulin	  from	  P(MAA-­‐g-­‐EG)	  microparticles,	  a	  bioavailability	  as	  high	  as	  12%	  has	  
been	  achieved	  in	  rodent	  models	  indicating	  that	  these	  systems	  are	  promising	  candidates	  
for	  an	  oral	  insulin	  delivery	  system	  [17].	  	  	  	  	  
One	   promising	   strategy	   for	   improving	   bioavailability	   of	   protein	   delivery	   is	  
improving	  mucoadhesion	  of	  the	  carrier	   in	  the	  upper	  small	   intestine.	   	   Increases	   in	  drug	  
absorption	   from	   mucoadhesive	   carriers	   have	   been	   attributed	   to	   a	   prolonged	   carrier	  
residence	  time	  at	  the	  site	  of	  absorption	  allowing	  for	  more	  release	  and	  hence	  absorption	  
of	   the	   drug	   locally	   [5,	   19].	   	   Several	   methods	   of	   improving	   mucoadhesion	   of	   the	  
polymeric	  drug	  delivery	  systems	  have	  been	  studied	  including	  incorporation	  of	  thiolated	  
polymer	  [20,	  21],	  incorporation	  of	  cationic	  polymers	  such	  as	  chitosan	  [22,	  23],	  addition	  
of	  polymer	  tethers	  [24],	  and	  the	  addition	  of	  lectins	  [25,	  26].	  	  	  
Because	  many	  polysaccharides	  are	  considered	  biocompatible	  and	  may	  degrade	  
in	   vivo,	   polysaccharides	   such	   as	   chitosan,	   dextran,	   alginate,	   and	   hyaluronic	   acid	   have	  
been	   used	   in	   a	   variety	   of	   drug	   delivery	   and	   tissue	   engineering	   applications.	   	   Many	  
polysaccharide	   based	   biomaterials	   have	   been	   investigated	   for	   oral	   delivery	   including	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materials	   formed	   by	   ionic	   crosslinking	   of	   polysaccharides	   and	   covalent	   crosslinking	   of	  
polysaccharides	  in	  both	  homopolymers	  and	  copolymers.	  	  	  
Hydrogel	   networks	   have	  been	   formed	   from	  polymerizable	   polysaccharides	   and	  
used	   in	   a	   wide	   variety	   of	   biomedical	   applications.	   	   The	   most	   common	   method	   of	  
polymerizing	  hydrogel	  networks	  of	  polysaccharides	   is	  by	   free	  radical	  polymerization	  of	  
vinyl	  groups	  added	  along	  the	  backbone	  of	  the	  polysaccharide.	   	  For	  example,	  acrylation	  
and	   methacrylation	   of	   dextran	   has	   been	   developed	   for	   polymerization	   of	   dextran	  
hydrogels	   or	   copolymers	   [27-­‐30].	   	   Photopolymerizable	   chitosans	   have	   also	   been	  
developed	   for	   a	   number	   of	   applications	   in	   drug	   delivery	   and	   tissue	   engineering.	  	  
Likewise,	   hyaluronic	   acid	   gels	   have	   been	   prepared	   for	   tissue	   engineering	   and	   wound	  
healing	  applications	  [31-­‐34].	  	  	  	  	  
Dextrans	  have	  been	  investigated	  for	  a	  number	  of	  drug	  delivery	  applications.	  	  For	  
example,	   crosslinked	   hydrogel	   networks	   of	   dextran	   have	   been	   studied	   [35].	   	   Co-­‐
polymers	   of	   dextran	   and	  methacrylic	   acid	   have	   been	   shown	   to	   exhibit	   pH-­‐sensitivity.	  	  
Furthermore,	  dextran	  has	  been	  investigated	  for	  applications	  involving	  mucoadhesion.	  	  	  	  
In	   the	   work	   presented	   in	   this	   chapter,	   a	   synthesis	   method	   for	   polysaccharide	  
decorated-­‐complexation	   hydrogels	   for	   the	   oral	   delivery	   of	   insulin	   is	   presented.	   	   This	  
strategy	   involves	  polymerizing	  dextrans,	  with	  a	  molecular	  weight	  of	  6000	  Daltons	  (Dex	  
6)	  or	  100000	   (Dex	  100),	   and	  pullulans,	  with	  a	  molecular	  weight	  of	  75000	  Daltons	   (Pul	  
75),	   to	   form	   hydrogel	   networks	   with	   polysaccharide	   and	   PEG	   tethers.	   	   These	   gels,	  
poly(methacrylic	   acid-­‐double	   grafted-­‐ethylene	   glycol-­‐X)	   (P(MAA-­‐g-­‐EG-­‐co-­‐X))	   with	   X	  
denoting	   the	   polysaccharide	   graft,	   consisted	   of	   a	   crosslinked	   polymer	   network	  with	   a	  
poly(methacrylic	  acid)	  backbone	  and	  grafts	  of	  PEG	  and	  either	  Dex	  6,	  Dex	  100,	  or	  Pul	  75).	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4.2	  MATERIALS	  AND	  METHODS	  
4.2.1	  Functionalization	  of	  Polysaccharides	  with	  Polymerizable	  Vinyl	  Groups	  
Methacrylation	  of	  Dextrans	  
The	   synthesis	   procedure	   for	  methacrylation	  of	  dextran	  was	   adapted	   from	  van-­‐
Dijk	  Wolthius	  et	  al	  [36].	  	  Briefly,	  Dextran	  (3	  g,	  Sigma	  Aldrich)	  with	  a	  molecular	  weight	  of	  
either	   6000	   or	   100,000	  was	   dissolved	   in	   anhydrous	   dimethyl	   sulfoxide	   (DMSO,	   Sigma	  
Aldrich)	   to	   yield	   a	   concentration	   of	   100	   mg/ml.	   	   After	   dissolution,	  
dimethylaminopyridine	   (DMAP,	   Sigma	   Aldrich)	   was	   added	   at	   a	   concentration	   of	   20	  
mg/ml.	   	   Glycidyl	  methacrylate	   (GMA,	   Sigma	   Aldrich)	  was	   slowly	   added	   dropwise	   at	   a	  
ratio	   of	   8	   mol%	   in	   relation	   to	   total	   saccharide	   units.	   	   The	   reaction	   was	   allowed	   to	  
proceed	  at	  room	  temperature	  for	  48	  hours.	  	  The	  reaction	  was	  quenched	  by	  neutralizing	  
the	  basic	  solution	  with	  1	  N	  hydrochloric	  acid	  (HCl).	  	  To	  remove	  any	  excess	  reagent,	  the	  
solution	  was	  dialyzed	  against	  water	  for	  at	  least	  one	  week	  in	  a	  3500	  Da	  molecular	  weight	  
cut-­‐off	  dialysis	   tube	   (Spectrapor).	   	   The	  water	  was	   changed	   twice	  a	  day.	   	   The	   resulting	  
product	  was	  lyophilized.	   	  The	  lyophilized	  product	  was	  white	  to	  cream	  in	  color	  and	  was	  
fluffy	  in	  texture.	  	  	  
Methacrylation	  of	  Pullulan	  
A	  methacrylate	   group	  was	   added	   to	   pullulan	   by	   a	   similar	   procedure.	   	   Pullulan	  
with	  an	  average	  molecular	  weight	  of	  75,000	   (Sigma)	  was	   solubilized	   in	  DMSO.	   	  DMAP	  
was	   added	   to	   the	  pullulan	   solution.	   	   After	   dissolution	  of	  DMAP,	   glycidyl	  methacrylate	  
was	  added	  drop	  wise	  to	  the	  solution.	  	  The	  solution	  was	  stirred	  at	  room	  temperature	  for	  
48	  hours.	   	  The	  reaction	  was	  stopped	  by	  addition	  of	  1	  N	  hydrochloric	  acid.	   	  The	  viscous	  
liquid	  was	   placed	   in	   a	   dialysis	   tube	  with	   a	  molecular	  weight	   cut-­‐off	   of	   3500	  Da.	   	   The	  
dialysis	   tube	  was	   cut	   longer	   than	   the	   recommended	   length	   (for	   the	   given	   volume)	   to	  
	   86	  
prevent	  the	  osmotic	  pressure	  from	  breaking	  the	  dialysis	  tube.	  	  The	  product	  was	  dialyzed	  
against	  Ultrapure	  water	   for	   at	   least	   a	  week.	   	   The	  water	  was	   changed	   twice	  each	  day.	  	  
During	  replacement	  of	  the	  dialysate,	  the	  dialysis	  bag	  and	  clips	  were	  carefully	  inspected.	  	  	  
4.2.2	  Hydrogel	  Synthesis	  
Polymerization	  of	  P(MAA-­‐g-­‐EG)	  Hydrogels	  
P(MAA-­‐g-­‐EG)	  films	  were	  prepared	  by	  a	  free	  radical	  UV-­‐initiated	  polymerization.	  	  
The	   monomers,	   crosslinker,	   and	   initiator	   are	   shown	   in	   Figure	   4.2.	   	   Briefly,	   a	   1:1	   (by	  
weight)	  solution	  of	  ethanol	  and	  water	  was	  prepared.	  	  To	  the	  solvent,	  an	  equal	  mass	  of	  
monomers	   was	   added.	   	   The	   monomers	   consisted	   of	   methacrylic	   acid	   (MAA,	   Sigma	  
Aldrich)	   and	   poly(ethylene	   glycol)	   monomethyl	   ether	   monomethacrylate	   (PEGMMA,	  
Polysciences	  Inc)	  with	  an	  average	  molecular	  weight	  of	  1000	  Da	  combined	  in	  a	  ratio	  of	  1	  
mole	   methacrylic	   acid	   to	   1	   mole	   ethylene	   glycol.	   	   To	   the	   monomers	   and	   solvent,	   a	  
crosslinker	  and	  initiator	  were	  then	  added.	  	  	  
The	  crosslinker	  poly(ethylene	  glycol)	  dimethacrylate	  (PEGDMA,	  Polysciences	  Inc.)	  
with	  an	  average	  molecular	  weight	  of	  400	  Da	  was	  added	  to	  comprise	  a	  desired	  percent	  of	  
the	  total	  monomer,	  the	  percent	  crosslinker.	  	  The	  initiator,	  Irgacure	  184,	  was	  added	  to	  be	  
0.1	  wt%	  of	  the	  total	  monomer	  weight.	   	  The	  pre-­‐polymer	  solution	  was	  sonicated	  for	  20	  
minutes.	  	  The	  solution	  was	  then	  purged	  with	  nitrogen	  for	  30	  minutes	  inside	  a	  glove	  box	  
which	  was	  purged	  for	  the	  same	  amount	  of	  time.	  	  	  
The	   pre-­‐polymers	   solution	   was	   then	   placed	   in	   a	   mold	   consisting	   of	   two	   glass	  
slides	  and	  a	  Teflon	  spacer.	  	  The	  mold	  was	  placed	  under	  an	  ultraviolet	  (UV)	  light	  with	  an	  
intensity	   of	   16-­‐17	   mW/cm2	   for	   30	   minutes.	   	   The	   film	   was	   then	   washed	   in	   ultrapure	  
water	   for	   7	   days	   and	   the	  water	  was	   exchanged	   twice	   daily	   to	   remove	   any	   unreacted	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components.	   	   Films	   were	   dried	   in	   a	   vacuum	   oven	   and	   then	   crushed	   and	   sieved	   to	  
achieve	  diameters	  less	  than	  53	  μm.	  	  	  
Polymerization	  of	  P(MAA-­‐g-­‐EG-­‐Dex)	  Hydrogels	  
In	   order	   to	   solubilize	   dextran	   in	   the	   pre-­‐polymer	   solution,	  modifications	   were	  
made	  to	  the	  P(MAA-­‐g-­‐EG)	  synthesis	  outlined	  previously.	  	  The	  solvent	  was	  changed	  from	  
a	   1:1	   water	   to	   ethanol	   solution	   to	   a	   73%	   0.1	   N	   sodium	   hydroxide	   and	   27%	   ethanol	  
solution.	   	  MAA	  was	   first	   solubilized	   in	   sodium	  hydroxide,	   followed	   by	  Dex-­‐acrylate	   or	  
Dex-­‐methacylate,	  PEGMMA,	  PEGDMA,	  ethanol,	  and	  then	  Irgacure	  184.	  	  	  
The	   solution	   was	   sonicated	   for	   20	   minutes	   or	   until	   the	   reactants	   were	   fully	  
dissolved.	  	  The	  solution	  was	  then	  placed	  in	  a	  glove	  box	  and	  purged	  for	  30	  minutes	  with	  
ntirogen.	   	   Next,	   the	   solution	   was	   pipetted	   into	   a	   glass	   mold	   in	   the	   oxygen	   free	  
environment.	   	   The	  polymerization	  was	   initiated	  by	  UV	   light	  with	  an	   intensity	  of	  16-­‐17	  
mW/cm2	  and	  allowed	  to	  proceed	  for	  30	  minutes.	  	  	  
Polymerization	  of	  P(MAA-­‐g-­‐EG-­‐Pl)	  Hydrogels	  
Pullulan-­‐methacrylate	   was	   polymerized	   into	   complexation	   hydrogels	   using	   the	  
same	  method	  used	   for	  dextran-­‐methacrylates	   and	  dextran-­‐acrylates.	   	   The	  amounts	  of	  
each	  component	  were	  determined	  relative	  to	  the	  chosen	  mass	  of	  PEGMMA	  (2.0	  g).	  	  For	  
each	  mole	  of	  ethylene	  glycol,	  one	  mole	  of	  MAA	  was	  used.	  	  The	  molar	  feed	  ratio	  of	  the	  
crosslinker,	  PEGDMA,	  relative	  to	  the	  total	  moles	  of	  monomer	  was	  1%.	  	  A	  solvent,	  equal	  
in	   weight	   to	   the	   total	   monomers,	   consisted	   of	   73%	   0.1	   N	   NaOH	   and	   27%	   ethanol.	  	  
Pullulan-­‐methacrylate	  (1	  %	  by	  weight	  of	  the	  total	  mass	  of	  monomers)	  was	  dissolved	  in	  
0.1	  N	  sodium	  hydroxide	  (73	  %	  by	  weight	  of	  the	  total	  mass	  of	  solvent).	  	  Methacrylic	  acid	  
was	   added	   and	   allowed	   to	   dissolve.	   	   Ethanol,	   PEGMMA,	   and	   PEGDMA	   were	   slowly	  
added	  along	  with	  Irgacure	  184.	  	  The	  solution	  was	  sonicated	  for	  at	  least	  20	  minutes	  until	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all	  of	  the	  components	  were	  fully	  dissolved,	  then	  placed	  in	  a	  glove	  box	  and	  purged	  with	  
nitrogen	  for	  20	  minutes.	   	  Following	  purge,	   the	  solution	  was	  placed	  between	  two	  glass	  
slides	  separated	  by	  a	  Teflon	  spacer.	  	  The	  polymerization	  was	  carried	  out	  for	  30	  minutes	  
under	  UV	  light.	  	  The	  resulting	  polymer	  film	  was	  washed	  in	  ultrapure	  water	  for	  5-­‐7	  days.	  	  
The	  water	  was	  changed	  twice	  each	  day.	  	  	  	  	  
4.2.3	  Fourier	  Transform	  Infrared	  Spectroscopy	  
Fourier	   transform	   infrared	   spectroscopy	   was	   used	   to	   evaluate	   the	   functional	  
groups	  of	  the	  various	  materials	  prepared	  in	  this	  chapter.	   	  Hydrogel	  films	  were	  dried	  in	  
ambient	   conditions	   for	   at	   least	   24	   hours	   and	   placed	   in	   a	   vacuum	  oven	  maintained	   at	  
37⁰C	  for	  at	   least	  24	  hours.	   	  Dried	  films	  were	  then	  crushed	  with	  a	  mortar	  and	  pestle	  to	  
obtain	  microparticles	   less	   the	   90	   μm	   in	   diameter.	   	  Microparticles	   used	   for	   FTIR	  were	  
placed	  back	   in	   the	  vacuum	  oven	   for	  a	  minimum	  of	  24	  hours.	   	  Potassium	  bromide	  was	  
dried	  by	  heating	  over	  100	  ⁰C	  for	  more	  than	  2	  hours.	  	  A	  dry	  hydrogel	  sample	  (2	  mg)	  was	  
mixed	  with	   KBr	   (198	  mg)	   for	   a	   total	  mass	   of	   200	  mg	  using	   a	   small,	   agate	  mortar	   and	  
pestle.	  	  A	  13	  mm	  pellet	  was	  prepared	  from	  the	  sample	  powder	  using	  a	  laboratory	  press	  
and	  a	  13mm	  steel	  die	  and	  placed	  in	  an	  FT-­‐IR	  sample	  holder.	  	  Measurements	  were	  taken	  
using	  a	  Nicolet	  FT-­‐IR	  with	  a	  resolution	  of	  4	  cm-­‐1	  and	  64	  scans.	  	  	  
4.3	  RESULTS	  AND	  DISCUSSION	  
4.3.1	  Hydrogel	  Synthesis	  
In	  order	  to	  covalently	  incorporate	  polysaccharides	  into	  an	  anionic	  complexation	  
hydrogel	   with	   a	   poly(methacrylic	   acid)	   (PMAA)	   backbone	   and	   PEG	   tethers,	  
polymerizable	   groups	  were	   first	   added	   to	   the	  polysaccharides.	   	   There	   are	   a	   variety	  of	  
methods	   for	   adding	   functional	   groups	   to	   polysaccharides.	   	   The	  most	   popular	  method	  
involves	   the	   oxidation	   of	   the	   polysaccharide	   using	   periodates.	   	   The	   addition	   of	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methacrylate	   polymerizable	   using	   glycidyl	   methacrylate	   groups	   was	   first	   reported	   by	  
van-­‐Dijk	  Wolthius	  et	  al	  [36].	   	  This	  method	  uses	  a	  base	  catalyst	  (DMAP)	  and	  an	  epoxide	  
(GMA)	  to	  react	  with	  hydroxyl	  groups	  on	  the	  polysaccharide.	  	  This	  method	  has	  been	  used	  
by	  a	  number	  of	  other	  researchers	  and	  adapted	  for	  addition	  of	  methacrylate	  groups	  to	  
pullulan.	  
The	   hydrogel	   system	   was	   designed	   to	   create	   long	   macromolecular	   tethers	  
composed	   of	   polysaccharides.	   	   As	   a	   result,	   a	   low	   degree	   of	   substitution	   of	   the	  
polysaccharide	   was	   desired.	   	   Because	   we	   were	   interested	   in	   adding	   only	   a	   few	  
polymerizable	   groups	   per	   chain,	   analysis	   of	   the	   polysaccharide	   component	   was	   very	  
difficult.	  	  For	  example,	  feed	  ratios	  of	  GMA	  that	  would	  result	  in	  a	  degree	  of	  substitution	  
of	  8%	  were	  chosen.	  	  Most	  uses	  of	  methacryloyl	  dextran	  have	  been	  formation	  of	  dextran	  
hydrogels	  requiring	  relatively	  larger	  degrees	  of	  substitution	  as	  high	  as	  20-­‐30%.	  	  Degrees	  
of	  substitution	  as	  low	  as	  1	  have	  been	  reported	  in	  literature	  for	  dextrans	  using	  the	  same	  
reaction	  mechanism.	  	  	  
In	   order	   to	   synthesize	   P(MAA-­‐g-­‐EG-­‐co-­‐Dextran)	   and	   P(MAA-­‐g-­‐EG-­‐co-­‐Pullulan)	  
hydrogels,	  the	  synthesis	  method	  of	  P(MAA-­‐g-­‐EG)	  was	  modified.	  	  Typically,	  P(MAA-­‐g-­‐EG)	  
hydrogels	  are	  polymerized	  in	  a	  solvent	  consisting	  of	  50	  wt%	  water	  and	  50	  wt%	  ethanol.	  	  
It	   is	   well	   known	   that	   alcohols	   such	   as	   ethanol	   and	   methanol	   can	   be	   used	   for	  
precipitation	  of	  polysaccharides	  such	  as	  dextran	  and	  serve	  as	  anti-­‐solvents.	  	  As	  a	  result,	  
a	  solvent	  system	  with	  a	  reduced	  amount	  of	  ethanol	  was	  used.	  	  	  
The	  combination	  of	  both	  PEG	  and	  dextran	  was	  an	  additional	   challenge.	   	  Phase	  
separations	   were	   observed	   with	   higher	   ethanol	   concentrations	   in	   the	   polymerization	  
solvent	   and	   especially	   at	   pH	   values	   lower	   than	   the	   pKa	   of	   methacrylic	   acid.	   	   It	   was	  
observed	  that	   the	  replacement	  of	  water	  with	  0.1	  N	  NaOH	  and	  reduction	  of	  ethanol	   in	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the	  polymerization	  eliminated	  phase	  separation	  and	  allowed	  for	  the	  polymerization	  of	  a	  
homogeneous	  hydrogel	  film.	  	  	  
The	   difficulty	   in	   obtaining	   a	   homogenous	  monomer	  mixture	   was	   likely	   due	   to	  
phase	  separations	  between	  PEG	  and	  dextran.	  	  It	  has	  been	  reported	  in	  literature	  that	  PEG	  
and	   dextran	   are	   partially	  miscible	   in	   aqueous	   solution	   [37-­‐39].	   	   However,	   in	   polymer	  
blends,	   PEG	   and	   dextran	  were	   shown	   to	   be	   immiscible	   [40].	   	  Moriyama	   and	   Yui	   [35]	  
successfully	  synthesized	  hydrogels	  composed	  of	  PEG	  and	  dextran	  but	  showed	  regions	  of	  
phase	   separation	   within	   the	   materials.	   	   These	   phase	   separations	   resulted	   in	   regions	  
composed	   predominantly	   of	   either	   PEG	   or	   dextran.	   	   Some	   degree	   of	   favorable	  
interactions	  between	  the	  two	  polymers	  has	  been	  shown	  in	  FT-­‐IR	  studies.	  	  	  
In	   designing	   these	   systems,	   the	   dependence	   of	   dextran-­‐PEG	   separations	   on	  
molecular	  weight	  was	  taken	  into	  consideration.	   	  Because	  separation	  between	  PEG	  and	  
dextran	  is	  more	  pronounced	  as	  the	  molecular	  weight	  of	  the	  polymers	  increases	  [38],	  the	  
synthesis	  method	  was	  developed	  using	  the	  highest	  molecular	  weight	  dextran	  (100	  kDa).	  	  
For	  all	  of	  the	  compositions	  reported	  in	  this	  thesis,	  the	  polymerization	  reaction	  solutions	  
were	   optimized	   so	   that	   the	   solutions	   obtained	   after	   sonication	   were	   clear	   with	   no	  
observable	  phase	  separations	  occurring	  during	  polymerization.	  	  	  
4.3.2	  FT-­‐IR	  Spectroscopy	  
FT-­‐IR	  is	  a	  technique	  that	  allows	  identification	  of	  organic	  functional	  groups	  based	  
on	   energy	   absorption.	   	   This	   technique	   is	   commonly	   used	   for	   identification	   of	   organic	  
compounds,	   identification	   of	   polymer	   composition,	   as	   well	   as	   studying	   molecular	  
interactions.	  	  In	  this	  work,	  FT-­‐IR	  was	  used	  to	  confirm	  synthesis	  of	  various	  hydrogels.	  	  	  
The	   synthesis	   of	   P(MAA-­‐g-­‐EG)	   hydrogel	   films	   and	   copolymers	   with	  
polysaccharides	  was	  verified	  by	  FT-­‐IR.	  	  Figure	  4.3	  shows	  the	  spectra	  of	  P(MAA-­‐g-­‐EG)	  and	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P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	  6000	  (1%)).	  	  A	  comparison	  of	  the	  two	  shows	  few	  differences	  in	  
absorbance	   peak	   locations	   indicating	   matching	   functional	   groups.	   	   For	   example,	   the	  
presence	  of	  carbonyl	  groups	  is	  clearly	  evident	  in	  the	  range	  of	  1700-­‐1750	  cm-­‐1	  as	  well	  as	  
etheric	   groups	   in	   the	   1090-­‐1180	   cm-­‐1	   region.	   	   A	   peak	   corresponding	   to	  methyl	   group	  
vibration	  appears	  from	  2890-­‐3050	  cm-­‐1.	  	  Other	  studies	  have	  reported	  hydrogen	  bonding	  
can	  shift	  a	  peak	  from	  1700	  to	  1730	  cm-­‐1	  [41].	   	   In	  this	  work,	  distinct	  peaks	  occurring	  at	  
1700	   and	   1733	   cm-­‐1	   are	   observed	   for	   both	   P(MAA-­‐g-­‐EG)	   and	   P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	  
6000).	   	   The	   ratio	   of	   these	   two	   peaks	   changes	   with	   addition	   of	   the	   polysaccharide	  
comonomer	  suggesting	  increased	  hydrogen	  bonding	  of	  carbonyl	  groups.	  
Likewise	   in	   Figure	   4.3,	   hydroxyl	   group	   stretching	   is	   evident	   in	   the	   3300-­‐3500	  
range	  cm-­‐1.	   	   	   	  The	  copolymer	  containing	  dextran	  6000	  shifts	  the	  center	  of	  the	  hydroxyl	  
group	  vibration	  as	  shown	   in	  Figure	  4.6	  and	  Table	  4.1	   from	  3481	  cm-­‐1	   to	  3446	  cm-­‐1.	   	  A	  
shift	   in	   the	   peak	   in	   hydroxyl	   group	   stretching	   region	   was	   also	   observed	   in	   PEG	   and	  
dextran	  polymer	  blends	  due	  to	  hydrogen	  bonding	  [40].	  
The	  absorbance	  spectra	  of	  P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	  100000	  (1%))	  and	  P(MAA-­‐g-­‐
EG)	   in	  Figure	  4.7	   indicate	  the	  presence	  of	  methacrylic	  acid	  and	  ethylene	  glycol	   in	  both	  
polymers.	   	   For	   example,	   both	   carbonyl	   groups	   (1700-­‐1750	   cm-­‐1)	   and	   etheric	   groups	  
(1090-­‐1180	   cm-­‐1)	   are	   present	   in	   both	   samples	   corresponding	   to	  methacrylic	   acid	   and	  
PEG,	  respectively.	  	  	  A	  shift	  in	  the	  hydroxyl	  group	  stretching	  shown	  in	  Figure	  4.8	  similar	  to	  
that	  observed	   for	   the	  P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	  6000)	   system	   indicates	   the	  presence	  of	  
Dextran	  100000	  in	  the	  hydrogel.	   	  The	  center	  of	  the	  absorbance	  peak	  corresponding	  to	  	  
hydroxyl	   group	   stretching	   decreases	   in	   wavenumber	   (3481	   cm-­‐1	   to	   3467	   cm-­‐1)	   (Table	  
4.2).	  	  	  This	  decrease	  is	  smaller	  than	  the	  shift	  observed	  in	  P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	  6000)	  
which	  may	  indicate	  that	  hydrogen	  bonding	  occurs	  to	  a	  lesser	  extent	  in	  the	  system	  with	  
the	   higher	   molecular	   weight	   dextran.	   	   Similar	   to	   P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	   100000)	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samples,	   the	   hydroxyl	   group	   stretching	   was	   observed	   at	   lower	   wavenumbers	   for	  
pullulan	  copolymers	  shifting	  the	  peak	  from	  3481	  to	  3469	  cm-­‐1	  (Table	  4.3).	  	  	  
4.4	  CONCLUSIONS	  
In	  this	  work,	  a	  novel	  method	  for	  synthesizing	  complexation	  hydrogels	  containing	  
poly(methacrylic	  acid),	  poly(ethylene	  glycol),	  and	  polysaccharides	  was	  developed.	   	  The	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Figure	  4.1.	  Reaction	  scheme	  for	  methacrylation	  of	  dextran.	  	  	  
Methacrylate	  groups	  were	  covalently	  attached	  to	  dextran	  by	  transesterification	  using	  



































































Figure	  4.2.	  Components	  for	  P(MAA-­‐g-­‐EG)	  hydrogels.	  
P(MAA-­‐g-­‐EG)	  hydrogels	  were	  polymerized	  using	  methacrylic	  acid	  (MAA),	  poly(ethylene	  
glycol)	  monomethyl	  ether	  monomethacrylate	  (PEGMMA),	  poly(ethylene	  glycol	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Figure	  4.4.	  FT-­‐IR	  absorbance	  spectra	  of	  Dextran	  6000-­‐Methacrylate,	  P(MAA-­‐g-­‐EG),	  and	  
P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	  6000	  (1%))	  in	  the	  3100-­‐3600	  cm-­‐1	  range.	  
	  
	  
	   	  
	  
	  













Figure	   4.5.	   FT-­‐IR	   spectra	   of	   P(MAA-­‐g-­‐EG)	   hydrogels	   and	   P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	  























Figure	   4.6.	   FT-­‐IR	   absorbance	   spectra	  of	  Dextran	  100000-­‐Methacrylate,	   P(MAA-­‐g-­‐EG),	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Table	  4.1.	  FT-­‐IR	  absorbance	  peak	  locations	  corresponding	  to	  hydroxyl	  stretching	  for	  
P(MAA-­‐g-­‐EG),	  P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	  6000	  (1%),	  and	  Dextran	  6000-­‐methacrylate.	  
	  
	   Hydroxyl	  group	  stretching	  (cm-­‐1)	  
P(MAA-­‐g-­‐EG)	   3481	  
P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	  6000	  (1%))	   3446	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Table	  4.2.	  FT-­‐IR	  absorbance	  peak	  locations	  corresponding	  to	  hydroxyl	  stretching	  for	  
P(MAA-­‐g-­‐EG),	  P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	  100000	  (1%),	  and	  Dextran	  100000-­‐
methacrylate.	  
	  
	   Hydroxyl	  group	  stretching	  (cm-­‐1)	  
P(MAA-­‐g-­‐EG)	   3481	  
P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	  100000	  (1%))	   3467	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Table	  4.3.	  FT-­‐IR	  absorbance	  peak	  locations	  corresponding	  to	  hydroxyl	  stretching	  for	  




	   Hydroxyl	  group	  stretching	  (cm-­‐1)	  
P(MAA-­‐g-­‐EG)	   3481	  
P(MAA-­‐g-­‐EG-­‐co-­‐Pullulan	  (1%))	   3469	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Chapter	  5:	  	  	  
Analysis	  of	  Complexation	  Behavior	  of	  Polysaccharide-­‐Modified	  Hydrogels	  
5.1	  INTRODUCTION	  
Changes	  in	  the	  molecular	  structure	  of	  hydrogels	  can	  have	  a	  significant	  impact	  on	  
the	  properties	  of	  the	  resulting	  material.	  For	  example,	  the	  addition	  of	  more	  hydrophobic	  
or	  more	   hydrophilic	   comonomers	   during	   polymerization	  with	   crosslinking	   agents	  may	  
change	  the	  ability	  of	  the	  hydrogel	  to	  swell	  in	  aqueous	  solvents.	  	  Additionally,	  the	  mesh	  
size	  of	  the	  hydrogel	  network	   in	  a	  particular	  environment	  may	  change.	   	   	   	  For	  biological	  
applications,	  changes	  in	  the	  hydrogel’s	  ability	  to	  swell	  and	  the	  mesh	  size	  of	  the	  network	  
are	   very	   important.	   	   Both	   hydrogel	   swelling	   and	   mesh	   size	   are	   commonly	   used	   in	  
controlled	  drug	  delivery,	  and	  their	  effects	  on	  drug	  release	  have	  been	  extensively	  studied	  
[1-­‐3].	  	  	  	  
The	   molecular	   structure	   of	   a	   hydrogel	   network	   includes	   crosslinking	   of	   the	  
network,	   chain	   entanglements,	   and	   interpolymer	   interactions	   as	   well	   as	   the	   polymer	  
chain	  lengths	  between	  any	  of	  these	  junctions.	  	  The	  molecular	  structure	  of	  hydrogels	  can	  
be	   changed	   by	   the	   addition	   of	   comonomers	   [4]	   that	   experience	   intermolecular	  
interactions	   such	   as	   hydrogen	   bonding	   [5].	   	   The	   distance	   between	   junctions	   and	  
network	  flexibility	  is	  often	  increased	  as	  the	  amount	  of	  crosslinker	  decreases	  [3,	  6].	  	  	  	  	  
In	  this	  research,	  polysaccharides	  were	  incorporated	  into	  the	  structure	  of	  P(MAA-­‐
g-­‐EG)	  complexation	  hydrogels.	  	  The	  maintenance	  of	  interpolymer	  complexation	  for	  pH-­‐
responsive	  oral	  protein	  delivery	  would	  be	  highly	  desirable	   for	  this	  application.	   	  One	  of	  
the	  major	  concerns	  addressed	  in	  the	  subsequent	  studies	  is	  whether	  the	  polysaccharide	  
tethers	  significantly	  change	  pH-­‐responsive	  swelling.	  	  For	  example,	  dextran	  and	  pullulan	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can	  potentially	  participate	   in	  hydrogen	  bonding	  between	  adjacent	  polymer	  chains	  due	  
to	  their	  hydroxyl	  groups	  and	  etheric	  groups.	  	  	  	  	  
In	  this	  chapter,	  the	  effect	  of	  large	  polysaccharide	  comonomers	  on	  pH-­‐dependent	  
swelling	  is	  analyzed	  for	  P(MAA-­‐g-­‐EG)	  hydrogels	  using	  dynamic	  and	  equilibrium	  swelling	  
studies	   along	   with	   analysis	   of	   the	   hydrogel	   mesh	   sizes	   using	   physical	   data	   and	   the	  
Peppas-­‐Merrill	  equation.	  	  Because	  these	  systems	  were	  designed	  for	  applications	  in	  pH-­‐
responsive	   oral	   protein	   delivery,	   the	   goal	   of	   this	   work	   was	   to	   confirm	   pH-­‐dependent	  
swelling	  and	  evaluate	  swelling	  behavior	  as	  it	  relates	  to	  oral	  insulin	  delivery.	  
5.2.	  MATERIALS	  AND	  METHODS	  
P(MAA-­‐g-­‐EG)	  hydrogels	  were	  modified	  with	  polysaccharide	  tethers	  of	  dextran	  or	  
pullulan.	   	   Photopolymerizable	   vinyl	   groups	  were	   added	   to	   the	   polysaccharide	   tethers	  
first	   and	   the	   resulting	  monomers	  were	  added	   to	   the	  polymerization	  and	   incorporated	  
into	  the	  hydrogel	  network.	  	  The	  synthesized	  hydrogel	  films	  were	  then	  used	  to	  evaluate	  
pH-­‐responsive	  swelling.	  
5.2.1	  Functionalization	  of	  Polysaccharides	  with	  Polymerizable	  Vinyl	  Groups	  
Addition	  of	  Polymerizable	  Groups	  to	  Dextrans	  and	  Pullulans	  
The	   synthesis	   procedure	   for	   methacrylation	   of	   dextran	   was	   adapted	   from	  
published	  procedures	  [7].	  	  Either	  dextran	  (3	  g,	  Sigma	  Aldrich)	  with	  an	  average	  molecular	  
weight	   of	   either	   6000	   Da	   or	   100,000	   Da	   or	   pullulan	   (Sigma	   Aldrich)	   with	   an	   average	  
molecular	  weight	  of	  75,000	  Da	  was	  dissolved	   in	  anhydrous	  dimethyl	   sulfoxide	   (DMSO,	  
Sigma	  Aldrich)	  to	  yield	  a	  concentration	  of	  100	  mg/ml.	  	  After	  dissolution,	  dimethylamino	  
pyridine	   (DMAP,	   Sigma	   Aldrich)	  was	   added	   at	   a	   concentration	   of	   20	  mg/ml.	   	   Glycidyl	  
methacrylate	  (GMA,	  Sigma	  Aldrich)	  was	  slowly	  added	  drop	  wise	  at	  a	  ratio	  of	  8	  mol%	  of	  
the	  total	  saccharide	  units.	   	  The	  reaction	  was	  allowed	  to	  proceed	  at	  room	  temperature	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for	   48	   hours.	   	   The	   reaction	   was	   quenched	   by	   neutralizing	   the	   DMAP	   with	   1	   N	  
hydrochloric	  acid	  (HCl).	  	  The	  product	  was	  dialyzed	  against	  water	  for	  at	  least	  one	  week	  in	  
a	   3500	   molecular	   weight	   cut-­‐off	   dialysis	   tube	   (Spectrapor).	   	   The	   water	   was	   changed	  
twice	  a	  day	  for	  7	  days	  and	  then	  lyophilized.	  	  	  
For	  formation	  of	  hydrogels	  using	  dextran	  with	  an	  acrylate	  group,	  dextran	  with	  a	  
molecular	  weight	  of	  100,000	  Da	  was	  solubilized	  in	  ultrapure	  water	  and	  placed	  in	  an	  ice	  
bath.	   	   After	   30	   minutes,	   acryloyl	   chloride	   (Acros	   Organic)	   was	   then	   added	   to	   the	  
solution,	  and	  the	  solution	  was	  allowed	  to	  stir	  for	  two	  hours.	  	  The	  product,	  acryl-­‐Dex,	  was	  
dialyzed	  for	  48	  hours	  against	  ultrapure	  water	  in	  a	  3,500	  molecular	  weight	  cut-­‐off	  dialysis	  
membrane	  (Spectrapor).	  	  The	  product	  was	  then	  frozen	  and	  lyophilized.	  	  	  
5.2.2	  Hydrogel	  Synthesis	  
Polymerization	  of	  P(MAA-­‐g-­‐EG)	  Hydrogels	  
P(MAA-­‐g-­‐EG)	  films	  were	  prepared	  by	  a	  free	  radical,	  UV-­‐initiated	  polymerization.	  	  
This	  polymerization	  was	  carried	  out	  in	  solution	  with	  a	  solvent	  of	  50	  wt	  %	  ethanol	  and	  50	  
wt	  %	  water.	   	  To	  the	  solvent,	  an	  equal	  mass	  of	  monomers	  was	  added.	   	  The	  monomers	  
consisted	   of	   methacrylic	   acid	   (MAA,	   Sigma	   Aldrich)	   and	   poly(ethylene	   glycol)	  
monomethyl	   ether	   monomethacrylate	   (PEGMMA,	   Polysciences	   Inc)	   with	   an	   average	  
molecular	  weight	   of	   1000	  Da	   combined	   in	   a	   ratio	   of	   1	  mol	  methacrylic	   acid	   to	   1	  mol	  
ethylene	   glycol.	   	   To	   the	  monomers	   and	   solvent,	   a	   crosslinker	   and	   initiator	  were	   then	  
added.	  	  	  
A	  crosslinking	  agent	  poly(ethylene	  glycol)	  dimethacrylate	  (PEGDMA,	  Polysciences	  
Inc.)	  with	  an	  average	  molecular	  weight	  of	  400	  Da,	  was	  added	  at	  a	  crosslinking	  feed	  ratio	  
of	   0.75	  mol%	   .	   	   The	  UV-­‐initiator,	   Irgacure	   184,	  was	   0.1	  wt%	   of	   the	   total	  mass	   of	   the	  
monomers.	   	   The	   pre-­‐polymer	   solution	   was	   sonicated	   for	   20	  minutes	   and	   placed	   in	   a	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sealed	  glove	  box.	  	  The	  solution	  were	  purged	  with	  nitrogen	  for	  30	  minutes.	  	  The	  solution	  
was	  then	  placed	  in	  a	  mold	  consisting	  of	  two	  glass	  slides	  and	  a	  Teflon	  spacer.	  	  The	  mold	  
was	   placed	   under	   an	   ultraviolet	   (UV)	   light	  with	   an	   intensity	   of	   16-­‐17	  mW/cm2	   for	   30	  
minutes.	   	   The	   film	  was	   then	  washed	   in	  ultrapure	  water	   for	  7	  days	  and	   the	  water	  was	  
exchanged	  twice	  daily	  to	  remove	  any	  unreacted	  components.	  	  	  
Polymerization	  of	  P(MAA-­‐g-­‐EG-­‐Dex)	  and	  P(MAA-­‐g-­‐EG-­‐co-­‐Pul)	  	  Hydrogels	  
The	  reaction	  solvent	  was	  changed	  from	  a	  1:1	  water	  to	  ethanol	  solution	  to	  a	  73	  
wt	  %	  0.1	  N	  sodium	  hydroxide	  and	  27	  wt	  %	  ethanol	  solution.	  	  MAA	  was	  first	  solubilized	  in	  
sodium	   hydroxide,	   followed	   by	   the	   polysaccharide,	   PEGMMA,	   PEGDMA,	   ethanol,	   and	  
then	   Irgacure	   184.	   	   The	   solution	  was	   sonicated	   for	   20	  minutes	   or	   until	   the	   reactants	  
were	  fully	  dissolved.	  	  The	  reaction	  was	  carried	  out	  as	  described	  in	  the	  previous	  section	  
for	  P(MAA-­‐g-­‐EG).	  	  	  
5.2.3	  Swelling	  Studies	  
Two	  types	  of	  hydrogel	  swelling	  studies,	  dynamic	  and	  equilibrium,	  were	  used	  to	  
measure	  pH-­‐responsive	  swelling	  of	  polysaccharide-­‐modified	  hydrogels.	  
Dynamic	  Swelling	  Studies	  
Hydrogel	  disks	  with	  a	  diameter	  of	  15	  mm	  were	  punched	  from	  hydrogel	  films	  that	  
had	  been	  washed	  in	  ultrapure	  water	  for	  5-­‐7	  days	  to	  remove	  any	  unreacted	  components.	  	  
The	  hydrogel	  disks	  were	  dried	  overnight	  in	  a	  vacuum	  oven.	  	  The	  initial	  mass	  of	  the	  dried	  
disks	  was	  recorded	  before	  the	  swelling	  study.	  	  	  
Dimethylglutaric	   acid	   (DMGA,	   Sigma	   Aldrich,	   St.	   Louis,	   MO)	   buffers	   (0.01	   M)	  
were	   prepared	   with	   constant	   ionic	   strength	   and	   different	   pHs.	   	   The	   buffer	   pH	   was	  
adjusted	  between	  3.2	  and	  7.6	  to	  simulate	  GI	  tract	  fluids.	  	  For	  dynamic	  swelling	  studies,	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disks	  were	  placed	  in	  a	  series	  of	  dimethyl	  glutaric	  acid	  (DMGA)	  buffers	  of	   increasing	  pH	  
(pH	   =	   3.2	   to	   7.6)	   at	   37	   ⁰C	   and	   constant	   ionic	   strength	   for	   5	  minutes.	   	   Each	   disk	   was	  
placed	  first	  in	  the	  buffer	  with	  a	  pH	  of	  3.2	  for	  5	  minutes.	  	  The	  disks	  were	  removed	  from	  
the	   swelling	   media,	   and	   excess	   water	   was	   removed.	   	   The	   mass	   of	   the	   disk	   was	  
measured,	  and	  the	  disk	  was	  placed	  in	  the	  next	  buffer.	  	  This	  process	  was	  repeated	  until	  
the	  disks	  had	  been	  allowed	   to	   swell	   in	   each	  of	   the	  10	  buffers	  with	  different	  pH	   for	   5	  
minutes.	   	   The	  mass	   swelling	   ratios	  of	   the	   films	  after	  each	  5	  minute	   incubation	  period	  
were	  calculated.	  	  	  
Equilibrium	  Swelling	  Studies	  
Equilibrium	  swelling	  studies	  were	  performed	  on	  P(MAA-­‐g-­‐EG)	  gels	  modified	  with	  
polysaccharides.	  	  Disks	  (15	  mm	  in	  diameter)	  were	  cut	  from	  hydrogel	  films	  immediately	  
following	  polymerization.	  	  The	  mass	  of	  the	  hydrogel	  in	  the	  relaxed	  state	  was	  measured	  
in	  air.	  	  The	  mass	  of	  the	  hydrogel	  in	  a	  non-­‐solvent	  in	  the	  relaxed	  state	  was	  then	  obtained	  
in	  heptanes	  using	  a	  hanging	  basket	  system	  apparatus.	  	  The	  hydrogel	  disks	  were	  washed	  
in	   ultrapure	   water	   for	   5-­‐7	   days	   with	   a	   twice	   daily	   replacement	   of	   the	   water.	   	   The	  
hydrogel	  disks	  were	  then	  allowed	  to	  dry	  at	  room	  temperature	  for	  at	  least	  24	  hours	  and	  
then	  placed	  in	  a	  vacuum	  oven	  maintained	  at	  37	  ⁰C	  to	  continue	  drying.	  	  	  
The	   initial	   mass	   of	   the	   dry	   hydrogel	   disks	   was	   recorded	   both	   in	   air	   and	   in	  
heptanes	   using	   the	   hanging	   basket	   apparatus.	   	   Gels	  were	   then	   incubated	   in	   50	  ml	   of	  
0.01	   M	   DMGA	   buffers	   with	   various	   pHs	   (pH	   =	   3.2	   to	   7.6)	   maintained	   at	   37⁰C	   and	  
constant	   ionic	   strength	   for	   24	   hours.	   	   The	   disks	   were	   carefully	   removed	   from	   the	  
swelling	  media.	   	   Excess	  water	  was	  wicked	   from	   the	   surface	   of	   the	   hydrogels	   prior	   to	  
measurements.	   	   The	  mass	   of	   the	   gels	   in	   the	   swollen	   state	  was	   recorded	   in	   air	   and	   in	  
heptanes	  using	  the	  same	  methods	  for	  relaxed	  stated	  and	  dry	  state	  measurements.	  	  The	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final	  mass	  of	  the	  swollen	  gels	  was	  used	  to	  calculate	  the	  equilibrium	  mass	  swelling	  ratio.	  	  
Measurements	  of	   the	  mass	  of	   the	  hydrogel	  disks	   in	  air	  and	   the	  mass	  of	   the	  disks	   in	  a	  
non-­‐solvent	   were	   obtained	   for	   each	   disk	   in	   the	   relaxed	   state,	   the	   dry	   state,	   and	   the	  
swollen	  state.	  	  	  
	  
5.3.	  RESULTS	  AND	  DISCUSSION	  
Because	   the	  complexation	  behavior	  of	   these	  hydrogels	   is	  an	  essential	  property	  
for	   use	   as	   an	   oral	   protein	   delivery	   system,	  we	   verified	   the	   pH-­‐dependent	   swelling	   by	  
comparing	  the	  swelling	  of	  these	  hydrogels	  in	  different	  simulated	  physiological	  fluids.	  In	  
this	   work,	   polysaccharide-­‐modified	   hydrogels	   were	   examined	   using	   several	  
measurements	   including	   the	  mass	   swelling	   ratio,	   the	   polymer	   volume	   fraction	   in	   the	  
relaxed	  state,	  and	  the	  polymer	  volume	  fraction	  in	  the	  swollen	  state.	  	  	  
The	   mass	   swelling	   ratio	   of	   these	   gels	   was	   analyzed	   using	   dynamic	   and	  
equilibrium	  swelling.	  	  
The	  swelling	  of	  P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	  100000)	  gels	  with	  different	  amounts	  of	  
dextran	   in	   the	   gel	   was	   investigated	   using	   dynamic	   swelling	   studies.	   	   For	   dynamic	  
swelling	  studies	  shown	  in	  Figure	  5.1,	  hydrogels	  polymerized	  with	  Dextran	  100000	  have	  
increased	   swelling	   in	   comparison	   to	   P(MAA-­‐g-­‐EG)	   controls.	   	   Three	   different	   dextran	  
100,000	   feed	   ratios	   were	   examined	   to	   determine	   if	   an	   increase	   in	   the	   amount	   of	  
polysaccharide	   in	   the	   polymer	   affected	   swelling.	   	   While	   all	   gels	   had	   higher	   swelling	  
ratios	   than	   P(MAA-­‐g-­‐EG),	   no	   specific	   trend	  was	   observed	   in	   relation	   to	   increasing	   the	  
polysaccharide	  content.	  
In	   contrast	   to	   dynamic	   swelling	   measurements,	   equilibrium	   swelling	   studies	  
measure	  the	  extent	  of	  hydrogel	  swelling	  at	  equilibrium.	  	  These	  studies	  typically	  require	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incubation	  periods	  on	  the	  order	  of	  hours	  to	  days.	   	  Additionally,	   these	  studies	  are	  very	  
relevant	   for	   analysis	   of	   hydrogel	   drug	   delivery	   systems	   composed	   of	   microparticles.	  	  	  	  
Because	   complexation	   hydrogels	   used	   for	   drug	   delivery	   systems	   are	   commonly	   in	   the	  
form	   of	   microparticles,	   the	   equilibrium	   swelling	   of	   the	   films	   is	   a	   more	   accurate	  
representation	   of	   microparticle	   swelling	   in	   response	   to	   pH	   changes.	   	   Microparticles	  
swell	  much	   faster	   than	   films	  due	   to	   their	   significantly	   smaller	   size.	   	  Estimation	   for	   the	  
time	  required	  for	  water	  to	  diffuse	  dry,	  glassy	  microparticles	  is	  on	  the	  order	  of	  minutes.	  	  
Both	   Wood	   and	   Carr	   have	   shown	   estimates	   for	   this	   time	   scale	   [8,	   9].	   	   In	   both	  
calculations,	  a	  diffusion	  coefficient	  of	  10-­‐6	  cm2/s	  was	  assumed,	  and	  100	  μm	  was	  used	  as	  
an	  approximate	  diffusion	  path	  length	  for	  a	  particle	  with	  a	  100	  μm	  diameter.	  	  Here,	  the	  
approximate	  calculation	  is	  shown	  based	  on	  a	  microparticle	  with	  a	  200	  μm	  diameter	  (100	  












rt µ 	   	   	   	   	   (5.1)	  
From	  this	  expression,	  the	  approximate	  swelling	  of	  a	  microparticle	  from	  the	  dry,	  
glassy	  state	  occurs	  on	  the	  order	  of	  minutes.	   	  (It	   is	   important	  to	  note	  that	  the	  diffusion	  
coefficient	   in	   this	   analysis	   in	   Equation	   5.1	   is	  merely	   an	   estimate	   and	   is	   typically	   time	  
variant.)	   	   Because	   diffusion	   of	   aqueous	   solvents	   into	  micro-­‐scale	   hydrogels	   occurs	   on	  
such	   short	   time	   scales,	   the	   time	   to	   reach	   a	   swelling	   equilibrium	  on	   the	  micro-­‐scale	   is	  
also	  short.	  
	  To	  better	  understand	  how	  microparticles	  composed	  of	  polysaccharide-­‐modified	  
complexation	   hydrogels	   swell	   with	   pH	   for	   oral	   delivery	   applications,	   the	   equilibrium	  
swelling	  of	   these	  gels	  was	  analyzed	   in	  simulated	  physiological	   fluids.	   	   	  The	  equilibrium	  
mass	  swelling	  ratios	  of	  each	  of	  these	  polysaccharide-­‐modified	  hydrogels	  were	  compared	  
to	  unmodified	  P(MAA-­‐g-­‐EG).	   	  Comparison	  of	  modified	  gels	  to	  unmodified	  P(MAA-­‐g-­‐EG)	  
	   114	  
allow	   the	   effects	   of	   the	   large	   polysaccharide	   tethers	   to	   be	   more	   fully	   evaluated.	   	   In	  
addition,	  P(MAA-­‐g-­‐EG)	  systems	  are	  well	  characterized	  for	  oral	  delivery	  applications,	  and	  
its	  swelling	  properties	  have	  been	  extensively	  studied.	  	  Results	  from	  this	  study	  show	  the	  
addition	   of	   polysaccharide	   tethers	   increased	   the	   swelling	   ratio	   in	   comparison	   to	  
unmodified	  P(MAA-­‐g-­‐EG)	  materials.	   	  The	  equilibrium	  mass	   swelling	   ratios	  of	  P(MAA-­‐g-­‐
EG-­‐co-­‐Dextran	   6000)	   and	   P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	   100000(1%))	   gels	   were	   significantly	  
higher	  than	  P(MAA-­‐g-­‐EG)	  gels	  (Figures	  5.2	  and	  5.3).	  	  Similarly,	  P(MAA-­‐g-­‐EG-­‐co-­‐Pullulan)	  
gels	   reached	  a	   greater	   equilibrium	  mass	   swelling	   ratio	   than	  P(MAA-­‐g-­‐EG)	   as	   shown	   in	  
Figure	  5.4,	  but	  the	  difference	  was	  not	  as	  pronounced	  as	  observed	  for	  the	  P(MAA-­‐g-­‐EG-­‐
co-­‐Dextran)	  materials.	  	  	  
One	  of	  the	  concerns	  with	  polysaccharide	  tethers	  is	  their	  hydrophilicity	  and	  ability	  
to	   hydrogen	   bond.	   	   The	   hydrophilic	   nature	   of	   polysaccharides	   may	   cause	   increased	  
swelling	   at	   low	  pH	  which	   is	   not	   desirable	   for	   these	   applications.	   	   A	   comparison	   of	   all	  
three	   gels	   shows	   that	   each	   had	   similar	   swelling	   ratios	   at	   pH	   values	   below	   4.5	   (Figure	  
5.4).	   	   As	   the	   pH	   increased,	   we	   observed	   more	   significant	   differences	   in	   the	   swelling	  
behavior	  of	  the	  gels.	  	  P(MAA-­‐dg-­‐EG-­‐co-­‐Dextran	  6000)	  showed	  the	  overall	  greatest	  mass	  
swelling	  ratio	  (Figure	  5.5).	   	  Gels	  of	  P(MAA-­‐dg-­‐EG-­‐co-­‐Pullulan)	  had	  lower	  swelling	  ratios	  
than	  P(MAA-­‐dg-­‐EG-­‐co-­‐Dextran	  6000)	  and	  P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	  100000)	  at	  pH	  7.6	  in	  
the	  swollen	  state.	  	  The	  general	  trend	  of	  the	  swelling	  curves	  show	  that	  as	  the	  molecular	  
weight	  of	  the	  polysaccharide	  gel	  component	  decreased,	  the	  swelling	  ratio	  increased	  for	  
pHs	  beyond	  the	  pKa	  of	  methacrylic	  acid	  which	  is	  reported	  between	  a	  pH	  of	  4.8	  and	  4.9	  
[10].	  	  	  
All	  three	  of	  these	  polysaccharides	  are	  very	  hydrophilic.	  	  These	  data	  demonstrate	  
that	  the	  polysaccharide	  is	  not	  disrupting	  complexation	  behavior	  as	  the	  glycosidic	  bonds	  
along	  the	  backbone	  of	  the	  polysaccharide	  and	  the	  hydroxyl	  groups	  on	  each	  saccharide	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mer	   unit	   can	   participate	   in	   hydrogen	   bonding	   with	   the	   methacrylic	   acid	   and	   PEG	  
components	  of	   the	  gel.	   	  Each	  gel	  was	  prepared	  with	  the	  same	  mass	  of	  polysaccharide	  
(and	  hence	  the	  same	  molar	  feed	  ratio	  of	  glucose	  mer	  units).	  	  	  
In	  order	  to	  gain	  insight	  into	  whether	  these	  gels	  could	  be	  used	  to	  load	  and	  release	  
a	   protein	   drug,	  measurements	   of	   the	   volume	   fraction	   of	   the	   hydrogel	   in	   the	   relaxed	  
state	  and	   swollen	   state	  were	  determined.	   	   The	  volume	   fraction	  of	   the	  polymer	   in	   the	  
relaxed	  state	  (ν2,r)	  was	  calculated	  using	  the	  Equation	  5.2	  using	  the	  mass	  of	  the	  hydrogels	  
(W)	   in	  either	  the	  dry	  or	  relaxed	  state	  denoted	  by	  a	  subscript	  d	  or	  r,	   respectively.	   	  The	  









=ν 	   	   	   	   	   	   	   	   (5.2)	  
The	  polymer	  volume	  fractions	  for	  each	  of	  the	  hydrogels	  in	  the	  relaxed	  state	  are	  
shown	   in	   Figure	   5.5.	   	   In	   general,	   the	   volume	   fraction	   in	   the	   relaxed	   state	   of	   the	  
hydrogels	  is	  similar	  falling	  in	  the	  range	  of	  0.527	  to	  0.599.	  	  	  
The	  equilibrium	  polymer	  volume	  fraction	  in	  the	  swollen	  state,	  υ2,s,	  was	  measured	  
as	  a	   function	  of	  pH	  and	  calculated	  using	   the	  mass	  of	   the	  hydrogel	  disk	   in	   the	  dry	  and	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   (5.3)	  
Based	   on	   calculations	   from	   Equation	   5.3,	   the	   equilibrium	   polymer	   volume	  
fractions	  in	  the	  swollen	  state  υ2,s	  of	  the	  different	  polymer	  compositions	  are	  compared.	  	  
In	   Figure	   5.6,	   the	   equilibrium	   polymer	   volume	   fraction	   in	   the	   swollen	   state, υ2,s	  
decreases	   as	   pH	   increases	   for	   P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	   100000)	   and	   P(MAA-­‐g-­‐EG)	  
hydrogels.	   	   There	   are	   some	   subtle	   differences	   in	   the	   equilibrium	   polymer	   volume	  
fraction	  in	  the	  swollen	  state	  υ2,sfor	  the	  formulations.	  	  Notably,	  at	  low	  pH,	  P(MAA-­‐g-­‐EG-­‐
co-­‐Dextran	   100,000	   (1%))	   has	   the	   highest	   υ2,s	   while	   P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	   100000	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(2%))	  has	  a	   lower	  υ2,s	   than	  P(MAA-­‐g-­‐EG).	   	   In	  acidic	   conditions,	   it	   is	  highly	  desirable	   to	  
have	  an	   increased	  υ2,s	   that	   indicates	  that	  there	   is	   less	  solvent	  present	   in	  the	  hydrogel.	  	  
Less	  solvent	  in	  the	  hydrogel	  corresponds	  to	  a	  lower	  degree	  of	  swelling	  and	  suggests	  that	  
entrapped	   molecules,	   such	   as	   a	   protein	   drug,	   may	   be	   better	   protected	   from	   the	  
environment	  surrounding	  the	  gel.	  	  Likewise,	  a	  decrease	  in	  the	  polymer	  volume	  fraction	  
at	  neutral	  conditions	  is	  desirable	  for	  applications	  in	  oral	  protein	  drug	  delivery.	  	  	  	  	  
For	   example,	   P(MAA-­‐g-­‐EG-­‐co-­‐Pullulan)	   gels	   exhibit	   decreased	   equilibrium	  
polymer	   volume	   fraction	   in	   the	   swollen	   state	   υ2,s	   with	   increased	   pH	   (Figure	   5.7).	   	   A	  
decrease	   in	   the	   polymer	   volume	   fraction	   indicates	   a	   greater	   degree	   of	   swelling	   and	  
increased	  diffusion	  into	  and	  out	  of	  the	  gel.	  	  In	  comparing	  P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	  6000)	  
gels	   to	  P(MAA-­‐g-­‐EG),	   the	  dextran-­‐modified	  hydrogels	  have	  the	   lowest	  υ2,s	   (Figure	  5.8).	  	  	  
The	   polysaccharide-­‐modified	   hydrogels,	   therefore,	   have	   swelling	   properties	   that	   are	  
desirable	  for	  oral	  protein	  drug	  delivery	  applications.	  	  
These	  trends	   in	  υ2,s	   	  are	  expected	  based	  on	  equilibrium	  swelling	  studies.	   	   In	  all	  
cases,	  the	  swelling	  ratio	  and	  the	  volume	  fraction	  of	  the	  polymer	  in	  the	  swollen	  state	  are	  
inversely	  related.	  	  As	  the	  mass	  of	  water	  imbibed	  increases	  the	  mass	  of	  the	  hydrogel,	  the	  
polymer	   network	   swells.	   	   As	   a	   result,	   the	   fraction	   of	   the	   volume	   that	   is	   the	   polymer	  
network	  is	  decreased	  in	  relation	  to	  the	  volume	  accounted	  for	  by	  the	  imbibed	  water.	  	  	  	  	  
The	   Peppas-­‐Merrill	   equation	   can	   be	   used	   to	   estimate	   the	   molecular	   weight	  
between	   crosslinks,	   cM ,	   and	   hence	   the	   mesh	   size,	   ξ,	   of	   a	   hydrogel	   network.	   	   This	  
equation	   is	   a	   modification	   of	   Flory-­‐Rehner	   theory	   to	   account	   for	   the	   presence	   of	   a	  
solvent	   during	   crosslinking.	   	   To	   obtain	   the	   molecular	   weight	   between	   crosslinks,	   the	  
following	  equation	  is	  used.	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   (5.4)	  
The	   volume	   fraction	   of	   the	   polymer	   in	   the	   swollen	   state,	  υ2,s,	   and	   the	   volume	  
fraction	  of	  the	  polymer	  in	  the	  relaxed	  state,	  υ2,r,	  (Equations	  5.2	  and	  5.3)	  are	  used	  in	  the	  
Peppas-­‐Merrill	  equation	  (Equation	  5.4).	  	  	  
The	   Flory	   interaction	   parameter	   for	   polysaccharide-­‐modified	   P(MAA-­‐g-­‐EG)	   can	  
be	  calculated	  by	  a	  weighted	  average	  of	   the	  Flory	   interaction	  parameters	   for	  MAA	  and	  
PEG	  assuming	  that	  there	  is	  not	  a	  significant	  contribution	  from	  the	  polysaccharide	  using	  
the	  molar	  feed	  ratio	  in	  the	  polymerization	  of	  methacrylic	  acid	  and	  poly(ethylene	  glycol)	  
where	  χ	  for	  methacrylic	  acid	  is	  given	  by	  Equation	  5.5	  [11,	  12]	  and	  χ	  for	  PEG	  is	  0.436.	  	  	  
s,26.044.0 υχ += 	   	   	   	   	   	   	   	   (5.5)	  
In	  this	  work,	  χ	  was	  determined	  for	  the	  experimental	  data	  using	  Equation	  5.5.	  	  For	  
swelling	  measurements	  below	  pH	  5.2,	   the	  χ	  values	  were	  greater	   than	  0.5	  while	   χ	  was	  
less	   than	  0.5	  at	  more	  neutral	  pH.	   	  The	  Flory	   interaction	  parameter	   indicates	  how	  well	  
the	  solvent	  and	  polymer	  interact.	  	  A	  Flory	  interaction	  parameter	  less	  than	  0.5	  indicates	  
favorable	  interactions	  between	  the	  polymer	  and	  the	  solvent.	  	  Generally,	  solvents	  with	  a	  
χ	  less	  than	  0.5	  are	  considered	  good	  solvents	  while	  solvents	  with	  χ	  greater	  than	  0.5	  are	  
considered	  poor	  solvents.	  	  	  
The	  Flory	  interaction	  parameter	  plays	  a	  significant	  role	  in	  the	   cM 	  analysis	  using	  
the	  Peppas-­‐Merrill	  equation	  because	  one	  of	  the	  assumptions	  is	  that	  there	  is	  a	  favorable	  
interaction	  between	  the	  solvent	  and	  the	  polymer	  (χ	  <0.5).	  	  As	  a	  result	  of	  χ	  calculations	  
based	   on	   the	   data	   presented	   in	   this	   chapter,	   the	   Peppas-­‐Merrill	   equation	   is	   a	   more	  
representative	   analysis	   for	   the	   hydrogels	   in	   the	   swollen	   state	   above	   the	   swelling	  
transition	  point	  (pH	  >	  5).	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The	  specific	  volume	  of	  the	  polymer	  can	  be	  calculated	  using	  Equation	  5.6	  based	  
on	  the	  mass	  of	  the	  hydrogels	  in	  air	  and	  heptane	  in	  the	  dry	  state	  and	  the	  density	  of	  the	  








υ 	   	   	   	   	   	   	   	   (5.6)	  
In	  this	  analysis,	  the	  molar	  volume	  of	  the	  solvent	  (V1)	  is	  assumed	  to	  be	  the	  molar	  
volume	  of	  water	  (18.1	  cm3/mol)	  because	  water	   is	  the	  major	  component	  of	  the	  buffers	  
used	  during	  the	  swelling	  measurements.	  	  	  
In	   the	   case	   of	   these	   gels,	   it	   is	   not	   possible	   to	   measure	   the	   number	   average	  
molecular	   weight,	   nM ,	   of	   the	   polymer	   chains	   using	   traditional	   gel	   permeation	  
chromatography.	  	  Because	  the	  polysaccharides	  may	  have	  more	  than	  one	  polymerizable	  
group	   per	  molecule,	   they	   can	   act	   as	   crosslinkers.	   	   In	   typical	   nM 	   determinations,	   the	  
polymer	  samples	  are	  prepared	  by	  polymerization	  under	  normal	  reaction	  conditions	  but	  
with	  the	  omission	  of	  the	  crosslinker.	  	  The	  reason	  the	  crosslinker	  is	  not	  used	  is	  that	  it	  can	  
affect	   the	   hydrodynamic	   diameter	   of	   the	   polymer	   chains	   which	   is	   correlated	   to	  
molecular	  weight.	  	  Additionally,	  crosslinked	  polymer	  chains	  may	  not	  elute	  from	  the	  GPC	  
set-­‐up	  resulting	  in	  a	  skewed	  molecular	  weight.	  	  	  
The	  mesh	   size	   of	   the	   hydrogel	   network	   can	   be	   calculated	   from	   the	   cM of	   the	  
hydrogel.	   	   The	   mesh	   size	   of	   the	   hydrogel	   is	   advantageous	   in	   analyzing	   the	   space	  























υαζ 	   	   	   	   	   	   (5.7)	  
For	   example,	   Equation	   5.7	   allows	   the	   approximation	   of	   the	   length	   associated	  
with	  the	   cM where	  α	  is	  the	  elongation	  ratio	  of	  gel	  and	   ( ) 2/120r 	   is	  the	  root	  mean	  square	  
	   119	  
end-­‐to-­‐end	  distance	  of	   the	  polymer	   in	   the	  unperturbed	  state.	   	  Based	  on	  the	   following	  
assumptions,	  the	  right-­‐hand	  side	  of	  the	  Equation	  5.7	  can	  be	  obtained.	  	  	  
For	  example,	   the	   root	  mean	   square	  end-­‐to-­‐end	  distance	  of	   the	  polymer	   in	   the	  
unperturbed	  state,	   ( ) 2/120r ,	  can	  be	  calculated	  using	  the	  following	  expression:	  	  	  
( ) ( ) 2/122/120 rCr n= 	   	   	   	   	   	   	   	   (5.8)	  
Equation	   5.8	   uses	   the	   characteristic	   ratio,	   Cn,	   of	   the	   polymer	   and	   root	   mean	  
square	   end-­‐to-­‐end	   distance	   of	   the	   polymer	   in	   the	   freely	   jointed	   state,	   ( ) 2/12r ,	   to	  
calculate	  the	  root	  mean	  square	  end-­‐to-­‐end	  distance	  of	  the	  polymer	  in	  the	  unperturbed	  
state.	  	  Using	  Equation	  5.9,	  the	  root	  mean	  square	  end-­‐to-­‐end	  distance	  of	  the	  polymer	  in	  
the	  unperturbed	  state,	   ( ) 2/12r ,	   can	  be	  calculated	   from	  the	  bond	   length	  of	   the	  polymer	  
backbone	  (l),	  which	  is	  predominantly	  carbon-­‐carbon	  bonds	  (1.54	  Å)	  for	  these	  materials,	  
and	  the	  number	  of	  bonds	  associated	  with	  the	   cM estimated	  in	  Equation	  5.4.	  	  	  
( ) nlr =2/12 	   	   	   	   	   	   	   	   	   (5.9)	   	  
The	  final	  assumption	  used	  to	  arrive	  at	  the	  expression	  in	  Equation	  5.7	  is	  that	  the	  
gel	  swelling	   is	   isotropic.	   	   Isotropic	  swelling	  of	  the	  gel	  allows	  the	  elongation	  ratio	  to	  be	  
calculated	  based	  on	  the	  volume	  swelling	  ratio	  of	  polymer	  using	  Equation	  5.10.	  
3/1
,2
−= sυα 	   	   	   	   	   	   	   	   	   (5.10)	  
In	   this	   work,	   we	   have	   analyzed	   the	  mesh	   size,	   ξ,	   for	   a	   range	   of	   nM using	   the	  
Equation	  5.4	  and	  5.7.	  	  Similar	  analyses	  have	  been	  previously	  published	  in	  which	  the	   cM 	  
for	  hydrogels	  was	  analyzed	   in	  terms	  of	   nM and	  was	  shown	  to	   increase	  with	   increasing	  
nM 	   before	   reaching	   a	   plateau	   cM .	   	   Therefore,	   the	  mesh	   size	   was	   determined	   with	  
respect	   to	  molecular	  weight	  between	  crosslinks	  with	  varying	   nM 	   as	   shown	   in	   Figures	  
5.11-­‐5.12	  for	  all	  three	  polymer	  formulations.	   	  The	   cM for	  the	  polymers	  was	  calculated	  
for	  a	  pH	  of	  7.6	  and	  used	  for	  calculation	  of	  ξ.	  	  For	  P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	  100000	  (1%))	  
and	  P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	  6000)	  gels,	  the	  mesh	  size	  was	  larger	  than	  the	  mesh	  size	  of	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P(MAA-­‐g-­‐EG)	   gels.	   	   In	   Figure	   5.11,	   the	   opposite	   is	   true	   for	   P(MAA-­‐g-­‐EG-­‐co-­‐Pullulan).	  	  
These	  results	  indicate	  that	  at	  neutral	  conditions,	  the	  mesh	  size	  of	  the	  gel	  increases	  more	  
for	   dextran-­‐modified	   P(MAA-­‐g-­‐EG)	   than	   for	   unmodified	   gels	   with	   corresponding	   nM .	  	  
Generally,	  polymerization	  of	  P(MAA-­‐g-­‐EG)	  gels	  has	  resulted	  in	   nM greater	  than	  75	  kDa.	  	  
From	   the	  calculations	  presented	   in	  Figures	  5.9-­‐5.11,	   the	  mesh	   size	  of	   the	  hydrogels	   is	  
sufficient	   to	   allow	   release	   of	   insulin,	   which	   has	   a	   diameter	   of	   12-­‐13	   Å	   in	  monomeric	  
form,	  rapidly	  at	  neutral	  pH.	  	  	  
The	  incorporation	  of	  large	  biomolecules	  into	  hydrogels	  is	  a	  new	  topic	  in	  the	  field	  
of	  biomaterials,	   and	   the	   influence	  of	   large	  pendant	  polymer	   tethers	  on	   the	  molecular	  
structure	  of	  hydrogels	   is	  not	  yet	  well	  understood.	   	  Despite	  a	   limited	  understanding	  of	  
large	   biomolecular	   tethers	   on	   the	   molecular	   structure	   of	   hydrogel	   networks,	   the	  
polymerization	   of	   biomolecules	   into	   hydrogels	   has	   become	   a	   popular	   strategy	   for	  
imparting	   biological	   functionality	   into	   hydrogels	   for	   biological	   applications.	   	   For	  
example,	  avidin	  [13]	  and	  biotin	  [14]	  have	  been	  polymerized	  into	  hydrogel	  networks	  for	  
further	  modification	  after	  gel	  formation.	  	  
Tissue	   engineering	   scaffolds	   incorporating	   larger	   macromolecules	   into	   the	  
synthetic	   hydrogel	   matrix	   have	   also	   been	   developed.	   	   Immobilization	   of	   vascular	  
endothelial	   growth	   factor	   in	   PEG	   hydrogels	   has	   been	   shown	   to	   promote	  
endothelialization	  [15,	  16].	  	  	  
In	   drug	   delivery	   application,	   enzymes	   have	   also	   been	   immobilized	   in	   three-­‐
dimensional	   hydrogels	   for	   detection	   of	   glucose	   and	   for	   pulsatile	   release	   of	   insulin	   in	  
response	   to	  elevated	  glucose	   levels	   [17,	  18].	   	   In	  other	  applications,	   such	  as	  molecular	  
imprinting	   and	   recognition,	   the	   presence	   of	   large	   macromolecules	   during	  
polymerization	   has	   been	   utilized	   as	   a	  means	   to	   synthesize	   crosslinked	   polymers	   with	  
recognitive	   properties.	   	   Polymerization	   of	   a	   hydrogel	   network	   in	   the	   presence	   of	   a	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template	   molecule	   impacts	   the	   molecular	   structure	   of	   hydrogel	   network	   allowing	  
subsequent	  recognition	  of	   the	  template	  molecule.	   	  Template	  recognition	  by	   imprinted	  
hydrogels	   has	   been	   attributed	   to	   the	   formation	   of	   nanocavities	   around	   the	   template	  
molecule	   [19].	   	   These	   nanocavities	   allow	   preferential	   recognition	   of	   the	   template	  
molecule	  based	  on	  structural	  changes	  in	  the	  hydrogel	  [20,	  21].	  	  	  	  
Crosslinking,	   polymerization	   kinetics,	   interpolymer	   interactions,	   and	  mesh	   size	  
are	   parameters	   that	   are	   affected	   by	   the	   addition	   of	   comonomers	   during	   hydrogel	  
polymerization.	   	   These	   same	   parameters	   are	   likely	   to	   be	   influenced	   by	   the	  
polymerization	   of	   large	  molecule	   tethers	   into	   hydrogel	   networks	   although	   how	   these	  
parameters	  change	  is	  likely	  specific	  for	  the	  size,	  shape,	  and	  composition	  of	  tether.	  	  The	  
size	   of	   synthetic	   copolymer	   tethers	   has	   been	   shown	   to	   affect	   swelling	   properties	   of	  
hydrogels.	   	   For	   example,	   large	  biomolecules	  may	  physically	   interfere	  with	   crosslinking	  
and	  may	  thereby	  influence	  mesh	  size.	  	  Likewise,	  interactions,	  such	  as	  hydrogen	  bonding,	  
between	  neighboring	  polymer	  chains	  may	  be	  disrupted	  by	  large	  tethers.	  	  
	  These	   large	   tethers	   may	   also	   form	   new	   interactions	   with	   adjacent	   polymer	  
chains	  through	  hydrogen	  bonding,	  van	  der	  Waals	  forces,	  and	  hydrophobic-­‐hydrophobic	  
interactions.	   	   The	   affect	   that	   large	   comonomers	   have	   on	   complexation	   hydrogels	   in	  
which	   the	  mesh	   size	   changes	  with	  pH,	   for	  example,	   is	  unknown	  yet	   very	   important	   in	  
certain	  applications	  including	  oral	  protein	  delivery.	  	  	  
	  
5.4	  CONCLUSIONS	  
Based	  on	  analysis	  of	  the	  swelling	  of	  these	  hydrogels	  modified	  with	  either	  dextran	  
or	  pullulan,	  pH-­‐responsive	  swelling	   is	  conserved	   in	   the	  presence	  of	   the	  polysaccharide	  
comonomers.	   	  These	  systems	  form	  collapsed	  structures	  with	  minimal	  swelling	  in	  acidic	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conditions	  and	  swell	  significantly	  in	  more	  neutral	  conditions.	  	  Analysis	  of	  the	  mesh	  size	  
indicates	  that	  these	  gels	  could	  sufficiently	  entrap	  and	  release	  drugs	  as	  large	  as	  protein	  
drugs	   including	   insulin.	   	   In	   comparison	   to	   unmodified	   P(MAA-­‐g-­‐EG)	   hydrogels,	  
polysaccharide-­‐modified	   P(MAA-­‐g-­‐EG)	   hydrogels	   exhibited	   similar	   trends	   in	   swelling.	  	  
Several	  differences	   such	  as	   increased	  υ2,s	   at	   low	  pH	  and	  decreased	  υ2,s	   	   at	  neutral	  pH	  
suggest	  that	  polysaccharide-­‐modified	  P(MAA-­‐g-­‐EG)	  gels	  may	  have	  some	  advantages	  for	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Figure	   5.1	   Dynamic	   weight	   swelling	   behavior	   of	   P(MAA-­‐g-­‐EG)	   and	   	   P(MAA-­‐dg-­‐EG-­‐
Dex100)	  gels	  with	  varying	  amounts	  of	  dextran	  including	  0.5	  wt	  %,	  1	  wt%,	  and	  2	  wt	  %.	  	  

























































Figure	  5.2	  Equilibrium	  weight	   	  swelling	  ratios	  of	  P(MAA-­‐dg-­‐EG-­‐co-­‐Dextran	  6000	  (1%))	  
hydrogels	  and	  P(MAA-­‐g-­‐EG)	  hydrogels	  in	  DMGA	  buffer	  at	  different	  pH.	  	  	  
Data	  reported	  are	  the	  mean	  ±	  standard	  deviation.	  
	  
	  


































Figure	   5.3	   Equilibrium	   weight	   swelling	   ratios	   of	   P(MAA-­‐dg-­‐EG-­‐co-­‐Dextran	   100000	  
(1%)),	  P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	  100000	  (2%)),	  and	  P(MAA-­‐g-­‐EG)	  hydrogels	  at	  different	  
pH.	  	  	  
Data	  reported	  are	  the	  mean	  ±	  standard	  deviation.	  
	  
	  































Figure	  5.4	  Equilibrium	  weight	  swelling	  ratios	  of	  P(MAA-­‐g-­‐EG-­‐co-­‐Pullulan)	  and	  P(MAA-­‐
g-­‐EG)	  hydrogels	  in	  DMGA	  buffer	  with	  different	  pH	  values.	  	  	  






















































Figure	  5.5	  Polymer	  volume	  fraction	  of	  hydrogels	  in	  the	  relaxed	  state	  at	  37	  ⁰	  C.	  	  	  
Data	  reported	  are	  the	  mean	  ±	  standard	  deviation.	  
	  











































Figure	   5.6	   Volume	   fraction	   of	   P(MAA-­‐dg-­‐EG-­‐co-­‐Dex	   100)	   in	   the	   swollen	   state	   at	  
equilibrium	  after	  incubation	  in	  DMGA	  buffers	  of	  varying	  pH.	  	  	  



























































Figure	   5.7	   Volume	   fraction	   of	   P(MAA-­‐dg-­‐EG-­‐co-­‐Pullulan	   in	   the	   swollen	   state	   at	  
equilibrium	  after	  incubation	  in	  DMGA	  buffers	  of	  varying	  pH.	  	  	  



























































Figure	   5.8	   Volume	   fraction	   of	   P(MAA-­‐dg-­‐EG-­‐co-­‐Dex	   6000)	   in	   the	   swollen	   state	   at	  
equilibrium	  after	  incubation	  in	  DMGA	  buffers	  of	  varying	  pH.	  	  	  





































Figure	   5.9	   Estimated	   mesh	   size	   for	   P(MAA-­‐dg-­‐EG-­‐co-­‐Dex	   100000)	   hydrogels	   in	  
comparison	  to	  P(MAA-­‐g-­‐EG)	  at	  pH	  7.6	  for	  various	  polymer	  number	  average	  molecular	  
weights.	  	  	  



























Figure	   5.10	   Estimated	   mesh	   size	   for	   P(MAA-­‐dg-­‐EG-­‐co-­‐Dex	   6000)	   and	   P(MAA-­‐g-­‐EG)	  
hydrogels	  at	  pH	  7.6	  for	  various	  polymer	  number	  average	  molecular	  weights.	  	  	  







































Figure	   5.11	   Estimated	   mesh	   size	   for	   P(MAA-­‐dg-­‐EG-­‐co-­‐Pullulan)	   and	   P(MAA-­‐g-­‐EG)	  
hydrogels	  for	  various	  polymer	  number	  average	  molecular	  weights.	  	  	  
Hydrogels	  were	  swollen	  at	  pH	  7.6,	  and	  the	  mesh	  size	  was	  calculated.	  	  Data	  reported	  are	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Chapter	  6:	  	  	  
Loading	  and	  Release	  of	  Insulin	  from	  Polysaccharide-­‐Modified	  Hydrogels	  
6.1	  INTRODUCTION	  
Analysis	  of	   the	   loading	  and	   release	  of	  drugs	   from	  controlled	   release	  systems	   is	  
essential	   in	   evaluating	   and	   optimizing	   their	   performance	   in	   vitro.	   	   In	   the	   case	   of	   oral	  
protein	  drug	  delivery	  of	  therapeutics	  such	  as	  insulin,	  the	  bioactivity	  of	  the	  protein	  drug	  
must	   be	   preserved	   in	   the	   GI	   tract	   and	   sufficient	   absorption	   of	   the	   drug	   into	   the	  
bloodstream	  must	  take	  place.	  	  	  
The	   use	   of	   anionic	   complexation	   hydrogels	   of	   P(MAA-­‐g-­‐EG)	   to	   orally	   deliver	  
insulin	   has	   been	   investigated	   by	   Peppas	   and	   co-­‐workers	   [1-­‐4].	   	   One	   of	   the	   unique	  
properties	  of	  P(MAA-­‐g-­‐EG)	  systems	  that	  lends	  itself	  to	  oral	  protein	  delivery	  applications	  
is	   their	   complexation	  behavior.	   	  Hydrogen	  bonding	  between	   the	  PMAA	  backbone	  and	  
PEG	  tethers	  in	  acidic	  conditions	  similar	  to	  the	  stomach	  allows	  limited	  diffusion	  into	  and	  
out	  of	   the	  gel	   [5].	   	  Release	   is	  caused	  by	  the	  dissociation	  of	  these	  hydrogen	  bonds	  and	  
subsequent	  swelling	  at	  higher	  pH.	  	   In	  vitro	   loading	  studies	  have	  shown	  that	  insulin	  can	  
be	  loaded	  into	  P(MAA-­‐g-­‐EG)	  hydrogels	  [6].	  	  These	  studies	  have	  previously	  demonstrated	  
pH-­‐triggered	  release	  of	   insulin	  from	  P(MAA-­‐g-­‐EG)	  hydrogels	  [7].	   	   In	  addition,	  P(MAA-­‐g-­‐
EG)	   systems	   have	   been	   shown	   to	   maintain	   the	   bioactivity	   of	   protein	   drugs	   in	  
physiological	  fluids	  present	  in	  the	  GI	  tract	  [8].	  	  	  
Modifications	  to	  P(MAA-­‐g-­‐EG)	  hydrogels	  have	  been	  previously	   investigated	  and	  
were	  shown	  to	  influence	  the	  loading	  and	  release	  of	  protein	  drugs.	  	  For	  example,	  in	  the	  
work	  of	  Shofner	  and	  Peppas	  [9],	  changing	  the	  length	  of	  the	  crosslinker	  in	  P(MAA-­‐g-­‐EG)	  
gels	   allowed	   optimization	   of	   insulin-­‐transferrin	   loading	   and	   release.	   	   Wood	   et	   al.	   [7]	  
examined	   functionalization	   of	   P(MAA-­‐g-­‐EG)	   with	   wheat	   germ	   agglutinin	   (WGA)	   using	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avidin-­‐biotin	   binding.	   	   Lower	   loading	   efficiencies	   were	   observed	   for	   modified	  
microparticles.	   	   It	  was	  hypothesized	  that	  the	  presence	  of	  the	   large	  avidin	  molecules	   in	  
the	  hydrogels	  were	  interfering	  with	  release.	  	  It	  is	  also	  possible	  that	  large	  pendant	  groups	  
changed	  the	  mesh	  size	  of	  the	  hydrogel	  network.	  	  	  
In	   this	   work,	   the	   influence	   of	   polysaccharide-­‐modifications	   on	   loading	   and	  
release	   of	   insulin	   from	   complexation	   hydrogels	   modified	   with	   large	   pendant	  
polysaccharides	  was	  examined.	  	  One	  of	  the	  concerns	  addressed	  in	  this	  work	  is	  whether	  
these	  large	  tethers	  limit	  drug	  diffusion	  out	  of	  the	  gel	  or	  interfere	  with	  hydrogen	  bonding	  
in	   acidic	   conditions	   resulting	   in	   less	   protection	   of	   the	   protein	   drug.	   	   Specifically,	  
polysaccharide-­‐modified	   P(MAA-­‐g-­‐EG)	   complexation	   hydrogels	   were	   investigated	   to	  
evaluate	  the	  effect	  of	  dextran	  and	  pullulan	  comonomers	  on	  the	  loading	  and	  release	  of	  
insulin	   in	   vitro.	   	   The	   insulin	   loading	   was	   examined	   for	   several	   different	   polymer	  
formulations	  including	  P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	  6000),	  P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	  100000),	  
P(MAA-­‐g-­‐EG-­‐co-­‐Pullulan	   75000),	   and	   P(MAA-­‐g-­‐EG)	   as	   a	   control.	   	   Furthermore,	   the	  
insulin	  release	  profiles	  for	  several	  formulations	  are	  presented	  to	  evaluate	  the	  potential	  
use	   of	   polysaccharide-­‐modified	   P(MAA-­‐g-­‐EG)	   complexation	   hydrogels	   for	   the	   oral	  
delivery	  of	  insulin.	  
6.2	  MATERIALS	  AND	  METHODS	  
6.2.1	  Loading	  Studies	  
P(MAA-­‐dg-­‐EG-­‐co-­‐Dextran	  6000),	  P(MAA-­‐dg-­‐EG-­‐co-­‐Dextran	  100000),	  and	  P(MAA-­‐
dg-­‐EG-­‐co-­‐Pullulan	   75000)	  microparticles	   were	   prepared	  with	   size	   between	   53	   and	   75	  
µm.	   	   Hydrogel	   films	   with	   corresponding	   compositions	   were	   dried	   overnight	   in	   air	   at	  
room	  temperature	  and	   then	  placed	   in	  a	  vacuum	  oven	  maintained	  at	  37	  °C	   for	   further	  
drying.	   	  Microparticles	  were	  crushed	  from	  these	  dry	  hydrogel	  films	  using	  a	  mortar	  and	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pestle	  and	  then	  passed	  through	  a	  sieve	  to	  obtain	  the	  desired	  microparticle	  diameters.	  	  
All	   formulations	   were	   synthesized	   with	   0.75	   mol%	   of	   PEGDMA	   (with	   an	   average	  
molecular	  weight	  of	  400	  Da).	  	  Each	  polymer	  was	  synthesized	  with	  a	  polysaccharide	  feed	  
ratio	  of	  1	  wt%	  unless	   indicated	  otherwise.	   	  Additional	   formulations	  of	  P(MAA-­‐g-­‐EG-­‐co-­‐
Dextran	  100000)	  were	  prepared	  with	  dextran	  feed	  ratios	  of	  0.5	  wt%,	  1	  wt%,	  and	  2	  wt	  %	  
to	  examine	  the	  effect	  of	  polysaccharide	  feed.	  	  
Loading	  studies	  were	  carried	  out	  in	  silanized	  glassware	  prepared	  using	  Sigmacote	  
(Sigma	  Aldrich)	   according	   to	   the	  manufacturers	   recommendations.	   	   First,	   a	   0.5	  mg/ml	  
solution	  of	  bovine	   insulin	   (Sigma	  Aldrich,	  St.	   Louis,	  MO)	   in	  pH	  7.4	  phosphate	  buffered	  
saline	  (PBS)	  was	  prepared	  by	  solubilizing	  bovine	  insulin	  in	  PBS	  with	  a	  pH	  of	  5	  and	  raising	  
the	  pH	  with	  the	  addition	  of	  0.1	  N	  sodium	  hydroxide.	  	  A	  200	  μl	  sample	  of	  the	  insulin	  stock	  
solution	  was	  taken	  and	  passed	  through	  a	  0.22	  μm	  PVDF	  syringe	  filter	  (Millipore).	  	  While	  
stirring	   the	   insulin	   solution,	   dry	   microparticles	   were	   slowly	   added	   to	   obtain	   a	   final	  
microparticle	   concentration	   of	   2	   mg/ml.	   	   The	   solutions	   were	   covered	   to	   prevent	  
evaporation.	  	  
	  The	  particles	  were	  allowed	  to	  imbibe	  drug	  	  for	  2	  hours	  with	  continuous	  stirring.	  	  
Then,	   a	   200	   μl	   sample	   of	   the	   loading	   solution	   was	   taken	   before	   collapsing	   the	  
microparticles.	   	   The	   particles	   were	   collapsed	   by	   the	   addition	   of	   1N	   HCl,	   and	   an	  
additional	  200	  μl	  sample	  of	  the	  loading	  solution	  was	  collected.	  	  The	  collapsed	  particles	  
were	  filtered	  with	  a	  22	  µm	  filter.	  	  	  The	  microparticles	  were	  washed	  with	  water	  (30%	  of	  
the	   loading	   volume)	   to	   remove	   any	   insulin	   adsorbed	   to	   the	   surface	   of	   the	   particles.	  	  
Particles	  were	  lyophilized	  and	  stored	  at	  -­‐80	  ºC	  until	  use.	  	  	  
During	  the	  loading	  process,	  the	  initial	  insulin	  and	  final	  insulin	  concentration	  were	  
sampled	  and	  measured	  by	  aqueous	  high	  throughput	  liquid	  chromatography	  (HPLC).	  	  
	   140	  
6.2.2	  Release	  of	  Insulin	  
Insulin	   release	   from	   polysaccharide-­‐modified	   P(MAA-­‐g-­‐EG)	   hydrogels	   was	  
evaluated	  during	  in	  vitro	  release	  studies.	  	  Release	  studies	  were	  carried	  out	  using	  a	  USP	  2	  
dissolution	  apparatus.	  	  	  
All	   glassware	   including	   the	   release	   vessels	   were	   coated	   with	   Sigmacote	   to	  
prevent	  protein	  adsorption	  to	  the	  glassware.	  	  Prior	  to	  the	  release	  study,	  the	  water	  bath	  
of	   the	   dissolution	   apparatus	   was	   pre-­‐heated	   to	   37	   °C.	   	   In	   these	   studies,	   a	   1	   mg/ml	  
solution	  of	   loaded	  microparticles	  was	  prepared.	   	  For	  example,	  30	  mg	  of	   insulin-­‐loaded	  
particles	   were	   added	   to	   30	   ml	   of	   1X	   PBS	   at	   37	   °C	   and	   were	   stirred	   with	   impellers	  
rotating	  at	  100	  rpm.	  	  The	  release	  solutions	  were	  sampled	  at	  0,	  5,	  10,	  15,	  30,	  60,	  and	  120	  
minutes	  after	  the	  addition	  of	  the	  microparticles.	  	  As	  the	  200	  µl	  samples	  were	  removed,	  
the	  sample	  volume	  was	  replaced	  with	  pre-­‐warmed	  PBS.	  	  The	  concentration	  of	  insulin	  in	  
each	  sample	  was	  determined	  by	  HPLC.	  	  	  
6.2.2	  Dynamic	  Insulin	  Release	  
The	   pH-­‐responsive	   release	   of	   insulin	   from	   P(MAA-­‐g-­‐EG-­‐Dextran	   100000)	  
hydrogels	  was	  evaluated.	  	  This	  release	  study	  followed	  the	  preceding	  procedure	  using	  an	  
initial	   solvent	   of	   30	   ml	   of	   0.01	   M	   DMGA	   with	   a	   pH	   of	   3.2.	   	   After	   addition	   of	   the	  
microparticles,	  the	  release	  solution	  was	  sampled	  at	  5,	  10,	  15,	  30,	  and	  60	  min.	  	  At	  60	  min,	  
100	  µl	  of	  3	  N	  sodium	  hydroxide	  was	  added	  to	  bring	  the	  pH	  of	  the	  release	  solution	  up	  to	  
7.2.	   	  The	  release	  solution	  was	  sampled	  using	  a	  1	  ml	  syringe	  and	  needle	  at	  0,	  5,	  10,	  15,	  
30,	   60,	   120	   min	   following	   the	   addition	   of	   the	   base.	   	   Each	   sample	   was	   then	   passed	  
through	   a	   0.2	   µm	   PVDF	   syringe	   filter.	   	   The	   concentration	   of	   each	   sample	   was	  
determined	  by	  HPLC.	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6.2.4	  High	  Throughput	  Liquid	  Chromatography	  
HPLC	  was	  used	  to	  determine	  the	  concentration	  of	  insulin	  in	  loading	  and	  release	  
studies.	   	  A	  Waters	  Alliance	  HPLC	  unit	  equipped	  with	  a	  Symmetry	  C4	  5	  μm	  column	  was	  
used	   to	   run	   gradient	   elution	   in	   the	   reverse	   direction.	   	   The	  mobile	   phase	   consisted	   of	  
70%	  water	   with	   0.1%	   trifluoroacetic	   acid	   (TFA)	   and	   30%	   acetonitrile	   with	   0.08%	   TFA.	  	  
The	  column	  temperature	  was	  40	  ⁰C.	   	  A	  gradient	  was	  run	   in	  the	  reverse	  direction	  from	  
30%	   to	   60%	   acetonitrile	   over	   a	   6	  minute	   time	   period.	   	   The	   sample	   run	   time	   was	   10	  
minutes,	   and	   the	   sample	   injection	   volume	  was	   20	  μl.	   	   The	   protein	   concentration	  was	  
measured	  by	  UV	  absorbance	  at	  220	  nm.	  	  	  
6.3	  RESULTS	  AND	  DISCUSSION	  
The	   loading	   and	   release	   of	   insulin	   from	   polysaccharide-­‐modified	   P(MAA-­‐g-­‐EG)	  
hydrogels	   were	   investigated	   in	   vitro	   to	   evaluate	   the	   use	   of	   these	   hydrogels	   as	   oral	  
protein	  drug	  delivery	  systems.	  	  	  Complexation	  hydrogel	  microparticles	  have	  been	  shown	  
to	   successfully	  entrap	  and	   release	   insulin,	  human	  growth	  hormone,	   salmon	  calcitonin,	  
interferon-­‐β,	  PEG-­‐insulin,	  and	  insulin-­‐transferrin	  conjugates.	  	  
	  The	   loading	   of	   P(MAA-­‐g-­‐EG)	   complexation	   hydrogels	   with	   protein	   drugs	  
wasaccomplished	  by	  allowing	  swelling	  of	  the	  hydrogel	  microparticles	  in	  a	  solution	  of	  the	  
protein	   drug	   at	   neutral	   pH.	   	   The	   loading	   of	   protein	   drugs	   in	   anionic	   complexation	  
hydrogels	   was	   attributed	   to	   equilibrium	   partitioning	   as	   well	   as	   favorable	   interactions	  
between	   the	  protein	  drug	   and	   the	  hydrogel.	   	   After	   several	   hours	  of	   incubation	   in	   the	  
protein	  drug,	  collapsing	  the	  hydrogel	  by	  addition	  of	  an	  acid	  entrapped	  the	  drug	   in	  the	  
hydrogel	  network.	  	  The	  addition	  of	  an	  acid	  caused	  protonation	  of	  PMAA	  and	  allowed	  the	  
formation	   of	   hydrogen	   bonding	   with	   PEG.	   	   These	   hydrogen	   bonds	   form	   physical	  
crosslinks	  around	  the	  entrapped	  protein	  drug.	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The	   addition	   of	   large	   molecular	   tethers	   of	   polysaccharides	   could	   potentially	  
interfere	  with	  loading	  by	  limiting	  diffusion	  of	  drug	  into	  the	  hydrogel	  network	  and	  reduce	  
the	  overall	  efficiency	  of	  loading.	  	  	  	  	  
The	  efficiency	  of	  loading	  can	  by	  calculated	  based	  on	  the	  mass	  of	  the	  drug	  loaded	  
as	  a	  fraction	  of	  the	  initial	  mass	  of	  the	  protein	  drug	  using	  Equation	  6.1.	  	  	  








EfficiencyLoading 	   	   	   (6.1)	  
In	   this	   case,	   the	   concentration	   of	   each	   sample	   and	   the	   volume	   were	   used	   to	  
determine	  the	  loading	  efficiency.	  	  Other	  protein	  loading	  studies	  [7,	  10]	  of	  complexation	  
hydrogels	  have	  done	   the	   loading	  efficiency	   calculation	  with	  a	   small	   difference.	   	   These	  
studies	  report	  the	  loading	  efficiency	  as	  shown	  in	  Equation	  6.2.	  







EfficiencyLoading 	   	   	   	   	   (6.2)	  
The	   caveat	   between	   the	   two	   calculations	   is	   due	   to	   a	   difference	   in	   the	  
experimental	  methods.	   	   In	   other	   studies,	   samples	   of	   the	   loading	   solution	  were	   taken	  
and	   the	   volume	   replaced	   with	   buffer	   so	   that	   concentration	   alone	   could	   be	   used	   to	  
calculate	   the	   loading	   efficiency	   because	   the	   volume	   was	   kept	   constant	   [7,	   10].	  	  
However,	   the	   final	   concentrations	  were	   typically	   adjusted	   to	   account	   for	   the	  mass	   of	  
protein	  drug	  removed	  in	  prior	  samples	  that	  could	  not	  be	  replaced	  through	  the	  addition	  
of	   buffer.	   	   Experimental	   and	   measurement	   errors	   can	   propagate	   and	   influence	   the	  
overall	  loading	  efficiency.	  	  For	  example,	  an	  inaccurate	  measurement	  of	  the	  protein	  drug	  
concentration	  prior	  to	  collapse	  of	  the	  microparticles	  will	  result	  in	  an	  inaccurate	  mass	  to	  
be	   accounted	   for	   in	   subsequent	   calculations	   and	   will	   change	   the	   calculated	   loading	  
efficiency.	   	  Whereas,	   in	   the	  study	  and	  calculations	  presented	   in	   this	  work,	   the	  protein	  
drug	   concentration	   prior	   to	   collapse	   and	   the	   final	   protein	   drug	   concentration	   are	  
calculated	  independently	  of	  each	  other.	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Insulin	   loading	   of	   polysaccharide-­‐modified	   hydrogels	   was	   examined	   to	  
understand	   the	   influence	   of	   polysaccharide	   tethers	   on	   the	   efficiency	   of	   loading	   of	  
bovine	   insulin.	   	   Loading	   studies	   showed	   that	   the	   polysaccharide	   modifications	   to	  
P(MAA-­‐g-­‐EG)	   hydrogels	   affected	   loading	   and	   that	   this	   was	   dependent	   on	   the	   type	   of	  
polysaccharide,	   either	   Dextran	   6000,	   Dextran	   100000,	   or	   Pullulan	   75000	   as	   shown	   in	  
Figure	  6.1.	  	  	  
In	   these	   studies,	   bovine	   insulin	  was	   imbibed	   at	   neutral	   pH,	   and	   the	  microgels	  
were	  collapsed	  by	  addition	  of	  HCl.	  	  Prior	  to	  collapse	  of	  the	  microparticles,	  the	  amount	  of	  
insulin	  loaded	  into	  the	  gels	  was	  similar	  and	  greater	  than	  80%.	  	  However,	  when	  the	  gels	  
were	   collapsed,	   the	   P(MAA-­‐g-­‐co-­‐EG-­‐Dextran	   100000)	   and	   P(MAA-­‐g-­‐co-­‐EG-­‐Pullulan	  
75000)	  loading	  efficiencies	  dropped	  (Figure	  6.1).	  	  The	  smaller	  molecular	  weight	  dextran	  
copolymers,	   P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	   6000),	   had	   better	   loading	   efficiencies	   following	  
collapse	  of	  the	  microgels.	  	  	  
The	   values	   of	   the	   P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	   6000)	   loading	   efficiency	   were	   not	  
statistically	  different	  than	  P(MAA-­‐g-­‐EG)	  loading	  efficiencies	  after	  addition	  of	  HCl	  (using	  a	  
student	  t-­‐test	  with	  p>0.05).	  	  The	  hydrogel	  formulations	  containing	  the	  higher	  molecular	  
weight	   polysaccharides	   of	   Dextran	   100000	   and	   Pullulan	   75000	   appeared	   to	   squeeze	  
most	   of	   the	   drug	   out	   of	   the	   polymer	   network.	   	   Collapse	   of	   the	   microparticles	   by	  
formation	   of	   hydrogen	   bonds	   within	   the	   polymer	   network	   may	   have	   caused	   large	  
polysaccharides	   to	   reorient	   towards	   the	   core	  of	   the	  microparticles,	   thereby	  displacing	  
some	  of	  the	  loaded	  insulin.	  	  
	  It	   is	   also	  possible	   that	   during	   loading	   a	   large	  percentage	  of	   the	   loaded	   insulin	  
may	  have	  been	  associated	  with	  the	  surface	  of	  the	  microparticles	  and	  then	  dissociated	  or	  
desorbed	  from	  the	  microparticles	  once	  the	  microparticles	  collapsed.	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To	   better	   understand	   the	   influence	   of	   large	   polysaccharide	   tethers	   on	   the	  
loading	  efficiency	  of	  insulin	  three	  formulations	  of	  P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	  100000)	  were	  
compared.	   	  The	   three	   formulations	  consisted	  of	   three	  different	   feed	   ratios	  of	  Dextran	  
100000	  in	  the	  polymerization	  feed	  which	  were	  0.5	  wt%,	  1	  wt%,	  and	  2	  wt%.	  	  The	  loading	  
efficiencies	   of	   the	   different	   P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	   100000)	   are	   compared	   in	   Figure	  
6.2.	   	   The	   formulations	   are	   denoted	   by	   the	   polysaccharide	   and	   content	   such	   as	   0.5%	  
Dextran	  100000.	  	  
A	   comparison	   of	   insulin	   loading	   in	   polysaccharide-­‐modified	   hydrogels	   with	  
different	  Dextran	  100000	  contents	  shows	  that	  insulin	  is	   loaded	  prior	  to	  collapse	  of	  the	  
microparticles	  but	  that	  the	  final	  loading	  efficiency	  is	  much	  lower	  (Figure	  6.2).	  	  The	  final	  
loading	  efficiencies	  of	  Dextran	  100000-­‐modified	  hydrogels	  were	  similar	  with	  the	  18.4%,	  
22.3%,	   or	   22.7%	   corresponding	   to	   the	   0.5	   wt%,	   the	   1	   wt%,	   and	   2	   wt%	   formulations,	  
respectively.	   	  Only	   the	  0.5	  wt%	  Dextran	  100000	   formulation	  was	   statistically	  different	  
(ANOVA,	  p	  <	  0.05)	  from	  the	  others.	  
To	  examine	  the	  affect	  of	  the	  polysaccharide	  tethers	  on	  the	  release	  of	  insulin,	  the	  
release	   profiles	   for	   each	   hydrogel	   formulation	   was	   compared	   against	   P(MAA-­‐g-­‐EG)	  
hydrogel	  controls.	  	  In	  these	  studies,	  microparticles	  were	  slowly	  added	  to	  PBS	  buffer	  with	  
a	  pH	  of	  7.4.	  	  At	  this	  pH,	  these	  hydrogels	  readily	  swell	  (Chapter	  5).	  	  It	  was	  expected	  that	  
loaded	   insulin	   should	   readily	   release	   from	   the	   polysaccharide-­‐modified	   hydrogels.	  	  
Release	  data	  shown	  in	  Figure	  6.3	  confirms	  this	  hypothesis.	  	  	  
All	  of	  the	  polysaccharide-­‐modified	  hydrogels	  release	  insulin	  faster	  than	  P(MAA-­‐g-­‐
EG)	   (Figure	   6.3).	   	   Of	   the	   formulations	   tested,	   the	   P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	   100000)	  
released	  insulin	  the	  fastest	  with	  the	  majority	  of	  release	  occurring	  in	  the	  first	  5	  minutes.	  	  	  	  
The	  percentage	  of	  insulin	  released	  from	  P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	  6000)	  released	  insulin	  
faster	   than	   P(MAA-­‐g-­‐EG)	   but	   was	   the	   slowest	   of	   all	   polysaccharide-­‐modified	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formulations	   as	   shown	   in	   Figure	   6.3.	   	   Similarly,	   P(MAA-­‐g-­‐EG-­‐co-­‐Pullulan	   75000)	   gels	  
released	  insulin	  faster	  than	  the	  P(MAA-­‐g-­‐EG)	  control.	  	  	  
The	   release	   profiles	   of	   insulin	   from	   polysaccharide-­‐modified	   hydrogels	   are	  
steeper	  with	   increasing	  molecular	  weight	   of	   the	   hydrogel	   (Figure	   6.2).	   	   A	   faster	   drug	  
release	  would	  be	  expected	  for	  hydrogels	  containing	  large,	  hydrophilic	  molecular	  weight	  
tethers.	  	  Swelling	  data	  presented	  in	  Chapter	  5	  which	  showed	  increased	  swelling	  ratios	  of	  
polysaccharide-­‐modified	   hydrogels	   over	   P(MAA-­‐g-­‐EG)	   at	   neutral	   pH	   supports	   this	  
hypothesis.	  	  As	  the	  microgels	  hydrate,	  the	  network	  expands	  due	  to	  the	  influx	  of	  water.	  	  
Greater	   swelling	   is	   associated	  with	   increased	  diffusion.	   	   Swelling	  of	   these	  hydrogels	   is	  
estimated	  to	  occur	  rapidly,	  on	  the	  order	  of	  minutes,	  which	  may	  explain	  the	  rather	  fast	  
release	  of	  insulin	  from	  these	  gels.	  
The	   much	   faster	   release	   of	   insulin	   from	   P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	   100000)	   gels	  
may	  also	  be	  explained	  by	  dissolution	  of	   insulin	   that	  was	   loaded	  on	   the	   surface	  of	   the	  
hydrogel.	  	  .	  	  These	  gels	  were	  generously	  washed	  following	  collapse	  of	  the	  microgels	  and	  
filtered	  to	  remove	  any	  adsorbed	  protein.	  	  This	  technique	  of	  washing	  the	  microparticles	  
after	   loading	   has	   been	   used	   during	   loading	   of	   proteins	   in	   hydrogels	   especially	   by	   the	  
Peppas	  lab	  [10].	   	  However,	  strong	  interactions	  between	  the	  protein	  and	  the	  surface	  of	  
the	   gels	   may	   explain	   both	   the	   quick	   release	   of	   insulin	   and	   the	   decreased	   loading	  
efficiencies	  obtained	  after	  collapse	  of	  the	  microparticles.	  	  	  
A	  dynamic	  release	  study	  was	  performed	  to	  analyze	  insulin	  release	  from	  P(MAA-­‐
g-­‐EG-­‐co-­‐Dextran	  100000)	  gels	  in	  response	  to	  pH.	  	  There	  was	  concern	  that	  the	  presence	  
of	  the	  large	  polysaccharide	  tethers	  may	  disrupt	  hydrogen	  bonding	  during	  complexation	  
and	  may	  hence	  leave	  the	  entrapped	  protein	  drug	  less	  protected	  from	  GI	  tract	  fluids.	  	  In	  
addition,	   the	   ability	   of	   the	   polysaccharide-­‐modified	   hydrogels	   to	   release	   insulin	   in	  
response	  to	  increased	  pH	  was	  unknown.	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In	   this	   study,	   P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	   100000)	  microparticles	  were	   placed	   in	   a	  
release	  medium	  of	  DMGA	  buffer	  with	  a	  pH	  of	  3.2.	  	  At	  this	  pH,	  these	  hydrogels	  are	  in	  a	  
collapsed	  state	  (Chapter	  5),	  and	  insulin	  release	  from	  these	  microparticles	  would	  not	  be	  
desirable	   for	   oral	   protein	   delivery.	   	   After	   1	   hour,	   the	  pH	  was	   neutralized	   to	   7.4	   using	  
sodium	   hydroxide	   to	   simulate	   the	   pH	   increase	   between	   the	   stomach	   and	   the	   small	  
intestine.	   	   At	   this	   pH,	   the	   P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	   100000)	   hydrogels	   swell	   and	  were	  
hypothesized	  to	  release	  insulin.	  	  
The	  results	  from	  this	  study	  presented	  in	  Figure	  6.4	  show	  that	  virtually	  no	  insulin	  
is	  released	  at	  acidic	  conditions.	  	  Based	  on	  the	  HPLC	  spectra,	  only	  1	  sample	  showed	  any	  
insulin	  was	  released	  in	  the	  1	  hour	  acid	  incubation	  period	  which	  was	  less	  than	  3	  %.	  	  The	  
shift	  in	  pH	  to	  more	  neutral	  conditions	  results	  in	  insulin	  release	  shown	  in	  Figure	  6.4.	  	  The	  
pH	  increase	  is	  marked	  by	  the	  position	  of	  the	  y-­‐axis	  in	  Figure	  6.4.	   	  This	  data	  shows	  that	  
within	  the	  first	  30	  minutes	  following	  the	  increase	  in	  pH,	  most	  of	  the	  insulin	  is	  released.	  	  
This	  release	  time	  period	   is	  highly	  desirable	  for	  oral	  protein	  delivery	   in	  the	  upper	  small	  
intestine	  based	  on	  GI	  transit	  times.	  	  In	  addition,	  HPLC	  spectra	  of	  the	  release	  showed	  that	  
the	   elution	   time	   of	   insulin	   was	   nearly	   constant	   (4.59	  min	   ±	   0.01	  min)	   indicating	   that	  
insulin	  denaturation	  was	  not	  an	  issue.	  	  	  
6.4	  CONCLUSIONS	  
The	   data	   presented	   in	   this	   work	   show	   that	   polysaccharide-­‐modified	   hydrogels	  
are	  promising	  materials	  for	  oral	  insulin	  delivery	  systems.	  	  These	  systems	  can	  be	  used	  to	  
entrap	  insulin,	  protect	  insulin	  in	  acidic	  conditions,	  release	  insulin	  in	  response	  to	  changes	  
in	   pH,	   and	   the	   release	   profile	   can	   be	   controlled	   by	   the	   amount	   and	   type	   of	  
polysaccharide	  tether.	  	  	  
	  






























Figure	   6.1.	   Loading	   efficiency	   of	   insulin	   in	   unmodified	   P(MAA-­‐g-­‐EG)	   hydrogels	   and	  
modified	   hydrogels	   of	   P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	   6000),	   P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	  
100000),	  and	  P(MAA-­‐g-­‐EG-­‐co-­‐Pullulan	  75000)	  during	  the	  loading	  process	  and	  after	  the	  
addition	  of	  acid	  to	  collapse	  the	  microparticles.	  	  	  
Data	  are	  presented	  as	  mean	  ±	  standard	  deviation.	  
	  

























Figure	   6.2.	   Insulin	   loading	   efficiencies	   for	   P(MAA-­‐g-­‐EG-­‐co-­‐Dextran)	   hydrogel	  
microparticles	  with	  Dextran	   100000	   feed	   ratios	   of	   0.5%,	   1%,	   and	   2%	   during	   loading	  
and	   following	   addition	   of	   acid	   to	   collapse	   the	   hydrogels.	   	   The	   microparticles	   had	  
diameters	  between	  90	  and	  120	  μm.	  	  	  
Data	  are	  presented	  as	  mean	  ±	  standard	  deviation.	  
	  































Figure	  6.3.	  Cumulative	   release	  of	   insulin	   in	  pH	  7.4	  PBS	  buffer	   from	  microparticles	  of	  
P(MAA-­‐g-­‐EG),	   P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	   6000),	   P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	   100000),	   and	  
P(MAA-­‐g-­‐EG-­‐co-­‐Pullulan	  75000)	  with	  diameters	  between	  53	  and	  75	  μm.	  














































Figure	  6.4.	  Cumulative	   release	  of	   insulin	   in	  pH	  7.4	  PBS	  buffer	   from	  microparticles	  of	  
P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	  100000)	  with	  diameters	  between	  90	  and	  120	  μm.	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Chapter	  7:	  	  	  
Investigation	  of	  Mucoadhesion	  and	  Cytotoxicity	  of	  Polysaccharide-­‐
Modified	  Complexation	  Hydrogels	  
7.1	  INTRODUCTION	  
In	   the	   design	   of	   oral	   protein	   drug	   delivery	   systems,	   it	   is	   very	   important	   to	  
evaluate	  how	   these	  materials	  may	   interact	  with	   tissues	  of	   the	  GI	   tract.	   	   For	   example,	  
materials	   that	   are	   cytotoxic	   are	   not	   desirable	   for	   a	   safe	   and	   effective	   therapeutic	  
delivery	  system.	  	  How	  the	  drug	  delivery	  system	  interacts	  with	  the	  intestinal	  mucosa	  can	  
not	  only	  affect	  safety	  but	   it	  can	  also	  influence	  drug	  absorption.	   	  Drug	  delivery	  systems	  
that	   interact	   favorably	   with	   the	   intestinal	   mucosa	   through	   mucoadhesion	   are	   highly	  
desirable	  as	  mucoadhesive	  drug	  delivery	  systems	  are	  associated	  with	  prolonged	  carrier	  
residence	  times	  in	  the	  upper	  small	  intestine	  and	  improved	  bioavailabilities.	  	  
In	  order	  to	  evaluate	  how	  oral	  drug	  delivery	  systems	  will	   interact	  with	  biological	  
tissues,	  a	  variety	  of	  tests	  to	  measure	  cytoxicity	  and	  mucoadhesion	  can	  be	  done	  in	  vitro.	  	  
For	   evaluation	   of	   the	   cytotoxicity	   of	   microparticle	   and	   nanoparticle	   drug	   delivery	  
systems,	   cell	  proliferation	  assays	  are	  commonly	  used	  such	  as	  3-­‐(4,5-­‐dimethylthiazol-­‐2-­‐
yl)-­‐5-­‐(3-­‐carboxymethoxyphenyl)-­‐2-­‐(4-­‐sulfophenyl)-­‐2H-­‐tetrazolium	  (MTS)	  [1-­‐3].	  	  Likewise,	  
the	  mucoadhesion	   of	   drug	   delivery	   systems	   can	   be	   evaluated	   using	   a	  wide	   variety	   of	  
experimental	  techniques	  in	  vitro	  [4-­‐8].	  	  
Complexation	  hydrogels	  of	  P(MAA-­‐g-­‐EG)	  have	  been	  extensively	  studied	  for	  oral	  
drug	   delivery	   systems	   by	   Peppas	   and	   coworkers.	   	   For	   these	   systems,	   there	   is	   strong	  
experimental	  evidence	  of	  the	  correlation	  between	  the	  mucoadhesive	  measurements	  in	  
vitro	   [9]	   and	   confirmed	   mucoadhesive	   behavior	   in	   the	   small	   intestine	   [10].	   	   Cellular	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cytotoxicity	   studies	   have	   indicated	   that	   these	   systems	   do	   not	   significantly	   affect	   cell	  
viability.	  	  To	  date,	  issues	  with	  cytotoxicity	  have	  not	  been	  observed	  in	  vivo.	  
Therefore,	   in	   vitro	   evaluations	   of	   polysaccharide-­‐modified	   P(MAA-­‐g-­‐EG)	  
hydrogels	   are	   essential	   for	   developing	   an	   understanding	   of	   how	   these	  materials	  may	  
interact	   with	   the	   upper	   small	   intestine.	   	   In	   this	   work,	   the	   cellular	   compatibility	   and	  
mucoadhesion	   of	   polysaccharide-­‐decorated	   complexation	   hydrogels	   are	   evaluated	   in	  
vitro	  to	  asses	  how	  these	  materials	  may	  interact	  with	  biological	  tissue	  in	  the	  upper	  small	  
intestine.	  
7.2	  MATERIALS	  AND	  METHODS	  
7.2.1	  General	  Cell	  Culture	  
Caco-­‐2	   cells	   (ATCC,	   Rockwell,	   MD)	   were	   grown	   in	   Dulbecco’s	   modified	   Eagle	  
medium	  (DMEM,	  Mediatech,	  Herndon,	  VA)	  with	  high	  glucose	  and	  sodium	  pyruvate.	  	  The	  
DMEM	  media	  was	   supplemented	  with	  10	  %	  heat	   inactivated	   fetal	  bovine	   serum	   (FBS,	  
Cambrex,	   East	   Rutherford,	   NJ),	   1	  %	   non-­‐essential	   amino	   acids	   (Mediatech),	   penicillin,	  
streptomycin,	   and	  amphotericin	  B.	   	   Freshly	   thawed	  cells	  were	  grown	   in	  DMEM	  media	  
with	  20%	  FBS	  until	  the	  first	  passage.	  
Caco-­‐2	  cells	  were	  allowed	  to	  grow	  in	  a	  humidified	  incubator	  maintained	  at	  37	  ⁰C	  
and	  5%	  CO2.	  	  	  The	  cell	  media	  was	  refreshed	  every	  other	  day.	  	  Cells	  were	  passaged	  prior	  
to	  90%	  confluency.	  	  To	  passage	  cells,	  the	  media	  was	  removed	  and	  the	  cells	  were	  washed	  
with	  pre-­‐warmed	  Dulbecco’s	  phosphate	  buffered	  saline	  without	  Ca2+	  and	  without	  Mg2+.	  	  
Trypsin	  was	  placed	  on	   the	  cells	   and	  allowed	   to	   incubate	   for	  10	  minutes.	   	   Then,	   fresh,	  
pre-­‐warmed	  media	  was	   added	   to	   inhibit	   trypsin	   activity.	   	   A	   small	   volume	  of	   cells	  was	  
removed	  and	  counted.	   	  Cells	  were	   resuspended	   then	  seeded	  at	  a	  density	  of	  3.0	  x	  103	  
cells/cm2.	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7.2.2	  Preparation	  of	  Materials	  
In	   this	   study,	   P(MAA-­‐g-­‐EG),	   P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	   6000),	   P(MAA-­‐g-­‐EG-­‐co-­‐
Dextran	   100000),	   and	   P(MAA-­‐g-­‐EG-­‐co-­‐Pullulan	   75000)	   were	   synthesized	   using	   the	  
procedure	   described	   in	   Chapter	   4.	   	   Several	   different	   P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	   100000)	  
hydrogels	   were	   prepared	   with	   different	   feed	   ratios	   of	   Dextran.	   	   For	   the	   cytotoxicity	  
study,	   unmodified	   and	   polysaccharide-­‐modified	   microparticles	   were	   obtained	   by	  
crushing	  and	  sieving	  dry	  hydrogel	  films	  of	  the	  same	  composition.	  	  	  
7.2.3	  Cell	  Viability	  Assay	  
Caco-­‐2	  cells	  with	  20	  to	  35	  passages	  were	  seeded	  on	  96-­‐well	  plates	  at	  a	  seeding	  
density	   of	   1.4	   x	   104	   cells/cm2.	   	   The	   cells	  were	   allowed	   to	   grow	   for	   at	   least	   48	   hours.	  	  
Once	  cells	  reached	  approximately	  90%	  confluency,	  the	  assay	  was	  started.	  	  	  
One	   hour	   before	   the	   experiment,	   the	  media	   from	   the	   cells	   was	   removed	   and	  
replaced	  with	  only	  150	  μl.	   	  Microparticle	  samples	  were	  prepared	   first	  by	  exposing	   the	  
gels	   to	   UV	   light	   to	   ensure	   sterility.	   	   Then,	   microparticle	   suspensions	   four	   times	   the	  
desired	  concentration	  were	  prepared.	   	  For	  example,	  4	  mg/ml,	  2	  mg/ml,	  1	  mg/ml,	  and	  
0.5	  mg/ml	   solutions	  were	  prepared	  by	   serial	   dilution	   in	  Hank’s	   Balanced	   Salt	   Solution	  
(HBSS).	   	  Then,	  50	  μl	  of	   the	  microparticle	  suspensions	  was	  added	  to	  each	  well	   to	  bring	  
the	   final	   volume	   to	   200	  μl	   and	   the	   final	  microparticle	   concentrations	   to	   1	  mg/ml,	   0.5	  
mg/ml,	  0.25	  mg/ml,	   and	  0.125	  mg/ml.	   	   In	   this	   study,	  50	  μl	  of	  HBSS	  was	  added	   to	   the	  
wells	  instead	  of	  50	  μl	  of	  a	  microparticle	  suspension.	  	  	  
The	  cells	  were	  incubated	  for	  2	  hours.	  	  The	  microparticle	  solutions	  were	  removed	  
from	  each	  well	   followed	  by	  3	  washes	  with	  HBSS.	   	  A	  CellTiter	  96®	  Aqueous	  MTS	  assay	  
was	   then	   performed	   according	   to	   the	   manufacturer’s	   directions	   (Promega,	   Madison,	  
WI).	   	  The	  MTS	  solution	  was	   incubated	  with	  the	  cells	   for	  90	  minutes	  before	  the	  optical	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absorbance	  at	  490	  nm	  of	   the	  samples	  was	   recorded	  using	  a	  UV-­‐Vis	  plate	   reader.	   	  The	  
ratio	  of	  viable	  cells	  relative	  to	  control	  wells	  was	  calculated.	  
7.2.4	  Preparation	  of	  Fluorescently	  Labeled	  Microparticles	  
The	  fluorescently	   labeled	  microparticle	   formulations	  of	  P(MAA-­‐g-­‐EG),	  P(MAA-­‐g-­‐
EG-­‐co-­‐Dextran	   6000),	   P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	   100000),	   and	   P(MAA-­‐g-­‐EG-­‐co-­‐Pullulan	  
75000)	   were	   synthesized	   from	   fluorescently	   labeled	   hydrogel	   films.	   	   Briefly,	   the	  
fluorescent	  hydrogels	  were	  prepared	  using	  the	  same	  polymerization	  conditions	  outlined	  
in	  Chapter	  4	  with	  the	  addition	  of	   fluorecein-­‐o-­‐methacrylate	   (Sigma	  Aldrich)	  at	  a	  molar	  
feed	  ratio	  of	  0.1	  mol%.	   	  The	  fluorescently	   labeled	  hydrogels	  were	  protected	  from	  light	  
and	  washed	  for	  5-­‐7	  days	  with	  the	  water	  being	  refreshed	  twice	  a	  day.	  	  The	  fluorescently	  
labeled	   hydrogels	   were	   then	   dried.	   	   Microparticles	   were	   obtained	   by	   crushing	   and	  
sieving	  the	  dry	  fluorescent	  hydrogel	  films.	  	  	  	  	  
7.2.5	  Mucoadhesion	  Experiments	  
For	  mucoadhesion	   experiments,	  mucin	   gels	  were	   prepared	   from	   reconstituted	  
porcine	   mucin	   (2	   wt%)	   (Sigma	   Aldrich)	   and	   (3	   wt	   %)	   hydroxyl	   ethyl	   cellulose	   (Sigma	  
Aldrich)	   in	   PBS	   in	   tissue	   culture	   plates.	   	   In	   the	   work	   presented	   here,	   48-­‐well	   plates	  
(Corning)	  were	  used	  and	  the	  initial	  volume	  of	  the	  mucin	  solution	  added	  to	  each	  well	  was	  
100	   μl/well.	   	   Suspensions	   of	   fluorescently	   labeled	   complexation	   hydrogels	   were	  
prepared	   in	  PBS	   (pH	  7.4)	   at	   a	   concentration	  of	   0.25	  mg/ml.	   	   The	   reconstituted	  mucin	  
gels	  were	  prepared	   immediately	  before	  use	  and	  allowed	  to	  sit	   for	  15	  minutes	  prior	   to	  
the	  experiment.	   	  Next,	  a	  300	  μl	  sample	  of	  the	  fluorescently	   labeled	  microparticles	  was	  
added	  to	  each	  reconstituted	  mucin	  gel.	   	  The	  samples	  were	  allowed	  to	   incubate	   for	  30	  
minutes	   before	   removing	   the	   samples	   from	  each	  well.	   	   Each	  well	  was	   then	  washed	  3	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times	  with	  a	  300	  μl	  volume	  of	  PBS.	  	  As	  a	  control,	  each	  hydrogel	  formulation	  was	  placed	  
in	  a	  well	  without	  a	  reconstituted	  mucin	  gel.	  	  	  
To	  quantify	  the	  adherence	  of	  the	  microparticles	  to	  the	  reconstituted	  mucin	  gels,	  
the	   samples	   were	   imaged	   using	   fluorescence	   microscopy.	   	   At	   least	   3	   images	   were	  
obtained	   from	   randomly	   selected	   positions	   in	   the	   well.	   	   The	   number	   of	   fluorescent	  
microparticles	  per	  image	  was	  quantified	  and	  the	  average	  number	  of	  particles	  per	  image	  
was	  obtained.	  	  	  For	  these	  studies,	  all	  sample	  sizes	  were	  greater	  than	  10.	  	  	  
7.3	  RESULTS	  AND	  DISCUSSION	  
The	  use	  of	   polysaccharide-­‐decorated	  P(MAA-­‐g-­‐EG)	  hydrogels	  microparticles	   for	  
oral	  protein	  drug	  delivery	   systems	  applications	  was	   investigated	   in	   vitro	   by	  measuring	  
cell	  viability	  after	  exposure	  to	  these	  materials	  as	  well	  as	  the	  materials’	  mucoadhesion.	  	  
In	   vitro	   measurements	   allow	   a	   variety	   of	   materials	   to	   be	   tested	   and	   the	   design	  
optimized	  prior	  to	  in	  vivo	  studies.	  
In	   this	   work,	   an	  MTS	   cell	   viability	   assay	   was	   used	   to	   compare	   the	   fraction	   of	  
viable	   Caco-­‐2	   cells	   relative	   to	   controls.	   	   Caco-­‐2	   cells	   were	   chosen	   as	   an	   enterocyte	  
model	  because	  enterocytes	  compose	  almost	  90%	  of	  the	  cells	  comprising	  the	   intestinal	  
epithelium.	   	   For	   these	   studies,	   MTS	   cell	   viability	   assays	   were	   used	   to	   quantify	   cell	  
viability	   based	   on	   dehydrogenase	   activity	   of	   living	   cells.	   	   Dehydrogenase	   activity	   was	  
detected	  based	  on	  production	  of	  formazan	  reduced	  from	  3-­‐(4,5-­‐dimethylthiazol-­‐2-­‐yl)-­‐5-­‐
(3-­‐carboxymethoxyphenyl)-­‐2-­‐(4-­‐sulfophenyl)-­‐2H-­‐tetrazolium	   (MTS)	   in	   the	   presence	   of	  
phenazine	  methosulfate.	  	  	  
Based	   on	   cell	   viability	   measurements	   obtained,	   polysaccharide-­‐decorated	  
P(MAA-­‐g-­‐EG)	  microparticles	  do	  not	  significantly	  affect	  cell	  viability.	  	  Figure	  7.1	  shows	  the	  
fraction	  of	  viable	  cells	  relative	  to	  controls	  for	  P(MAA-­‐g-­‐EG-­‐Dextran	  6000),	  P(MAA-­‐g-­‐EG-­‐
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Dextran	  100000),	  P(MAA-­‐g-­‐EG-­‐Pullulan	  75000),	  and	  P(MAA-­‐g-­‐EG).	   	  For	  all	   formulations	  
investigated,	   the	  cell	   viability	  was	  greater	   than	  1	   indicating	   that	   the	   ratio	  of	   formazan	  
production	  from	  samples	  was	  greater	  than	  control	  wells.	  	  These	  values	  indicate	  that	  the	  
control	   wells	   had	   fewer	   viable	   cells	   than	   the	   wells	   exposed	   to	   microparticles.	   	   It	   is	  
possible	   that	   the	   addition	   of	   the	   pH-­‐responsive	  microparticles	   changed	   the	   pH	  of	   the	  
cell	  media	  and	  affected	  enzyme	  activity.	  	  In	  other	  MTS	  assays	  on	  P(MAA-­‐g-­‐EG),	  this	  was	  
not	   observed,	   but	   in	   the	   study	   by	   Wood	   et	   al.	   [4],	   the	   pH	   of	   the	   P(MAA-­‐g-­‐EG)	  
microparticle	   suspensions	  was	   adjusted	   to	   a	   pH	   value	   of	   7.4	   prior	   to	   incubation	  with	  
cells.	  	  	  	  
In	  order	  to	  better	  understand	  the	  influence	  of	  the	  polysaccharide	  content	  on	  cell	  
viability,	   microparticles	   with	   different	   amounts	   of	   Dextran	   100000	   tethers	   were	   also	  
tested.	  	  Figure	  7.2	  shows	  that	  the	  relative	  cell	  viability	  for	  Dextran	  100000	  materials	  had	  
similar	  cellular	  viabilities	  to	  P(MAA-­‐g-­‐EG)	  materials.	  	  All	  concentrations	  of	  0.5%,	  1%,	  and	  
2%	  Dextran	  100000	  were	  not	   significantly	   lower	   than	  control	  wells.	   	  However,	   the	  2%	  
Dextran	   100000	   0.125	  mg/ml	   suspensions	   had	   a	   significantly	   higher	   fraction	   of	   viable	  
cells	   than	  controls.	   	   In	  analyzing	   the	  data	   from	  these	  samples,	   the	   ratio	  of	  viable	  cells	  
relative	   to	   the	   controls	   is	   a	   bimodal	   distribution,	   which	   explains	   the	   large	   error	   bar	  
associated	  with	  this	  sample.	  	  	  
The	   mucoadhesion	   of	   polysaccharide-­‐modified	   P(MAA-­‐g-­‐EG)	   to	   reconstituted	  
mucin	   gels	   was	   determined	   in	   vitro.	   	   	   There	   are	   a	   variety	   of	   assays	   that	   have	   been	  
developed	  for	  measuring	  adhesion	  to	   intestinal	  mucus.	   	  The	  method	  presented	   in	   this	  
work	   was	   developed	   because	   we	   wanted	   to	   quantify	   the	   mucoadhesion	   of	   swollen	  
hydrogels	  to	  mucus,	  and	  we	  wanted	  to	  avoid	  unnecessary	  use	  of	  animal	  resources.	  	  For	  
example,	   the	   use	   of	   harvested	   intestinal	   mucosa	   for	   more	   traditional	   mucoadhesion	  
studies	   such	   as	   the	   falling	   liquid	   film	   method	   would	   require	   a	   significant	   amount	   of	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tissue.	  	  Based	  on	  the	  amount	  of	  tissue	  that	  would	  need	  to	  be	  harvested,	  we	  chose	  to	  use	  
reconstituted	   mucin	   as	   an	   alternative	   to	   harvested	   tissue	   and	   recommend	   a	  
mucoadhesive	  study	  in	  situ	  in	  conjunction	  with	  in	  vivo	  bioavailability	  studies.	  	  	  
Several	   other	   alternative	   methods	   have	   been	   developed	   for	   the	   in	   vitro	  
evaluation	  of	  mucoadhesion	  including	  a	  tensile	  test	  [6]	  to	  measure	  the	  work	  of	  adhesion	  
as	  well	  as	  a	  flow	  test.	  	  The	  tensile	  test	  allows	  the	  measurement	  of	  the	  work	  of	  adhesion	  
based	  on	  the	  force	  required	  to	  separate	  two	  plates,	  one	  of	  which	  is	  coated	  with	  mucin	  
or	  excised	   tissue	  and	   the	  other	  with	   the	  material	  of	   interest.	   	   Thomas	  et	  al.	  used	   this	  
method	   to	   quantify	   the	   mucoadhesion	   of	   nanogels	   composed	   of	   complexation	  
hydrogels.	  	  One	  of	  the	  disadvantages	  of	  this	  method	  is	  that	  the	  nanogels	  are	  not	  in	  the	  
hydrated	   state.	   	   Because	   hydration	   of	   the	   polysaccharide	   tethers	  may	   influence	   their	  
ability	  to	  diffuse	  into	  the	  mucosa,	  this	  method	  was	  not	  used.	  	  	  
Other	   studies	   by	   Mikos	   and	   Peppas	   [7]	   examined	   the	   adhesion	   of	   hydrogel	  
microgels	  using	  a	  flow	  chamber.	  	  In	  this	  set-­‐up,	  the	  microparticle	  was	  placed	  on	  a	  mucus	  
substrate	   and	  maintained	   at	   a	   constant	   temperature.	   	   Then,	   nitrogen	   air	   was	   flowed	  
across	  the	  surface	  of	  the	  mucus.	  	  Both	  the	  time	  and	  flow	  rate	  required	  to	  dislodge	  the	  
particle	  were	  measured.	  	  One	  of	  the	  disadvantages	  of	  this	  method	  is	  that	  analysis	  of	  the	  
forces	  exerted	  on	  the	  microparticles	  was	  based	  on	  smooth,	  spherical	  particles.	   	   In	   the	  
case	  of	  the	  materials	  developed	  in	  this	  thesis,	  the	  microparticles	  are	  irregular	  in	  shape.	  	  
Wood	   et	   al.	   [4]	   used	   an	   in	   vitro	   method	   to	   quantify	   mucoadhesion	   using	  
fluorescently-­‐labeled	  complexation	  hydrogels.	   	  Mucin	  was	  adsorbed	  on	  96-­‐well	  plates,	  
and	   microparticles	   were	   incubated	   on	   these	   plates.	   	   After	   incubation,	   non-­‐adhered	  
microparticles	  were	  removed,	  and	  the	  fluorescence	   intensity	  of	  each	  well	  was	  used	  to	  
determine	   the	   percentage	   of	   adhered	   particles	   relative	   to	   the	   initial	   concentration	   of	  
microparticles.	   	   	   This	   study	   was	   used	   primarily	   to	   study	   the	   effects	   of	   wheat	   germ	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agglutinin	   on	   the	   adhesion	   of	   complexation	   hydrogels.	   	   The	   alternative	   method	   was	  
chosen	   based	   on	   the	   difficulty	   in	   obtaining	   fluorescence	   measurements	   without	   the	  
impact	  of	  light	  scattering	  by	  microparticles.	  	  In	  addition,	  the	  mechanism	  of	  adhesion	  of	  
polysaccharide-­‐modified	  hydrogels	  was	   hypothesized	   to	   be	   caused	  by	   the	  diffusion	  of	  
polysaccharides	   into	   the	  mucus	   gel.	   	  Measurement	   of	   adsorbed	  microparticles	  would	  
not	  account	  for	  this	  mechanism	  of	  adhesion.	  	  	  
In	   the	   results	   obtained	   from	   these	   experiments,	   shown	   in	   Figure	   7.3,	   the	  
mucoadhesion	   measurements	   of	   polysaccharide-­‐modified	   hydrogels	   is	   compared	   to	  
unmodified	   P(MAA-­‐g-­‐EG)	   microparticles.	   	   Of	   the	   material	   formulations	   tested,	   the	  
P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	   6000)	   formulation	   had	   the	   highest	   number	   of	   adhered	  
microparticles	  per	  area.	  	  Although	  this	  was	  not	  statistically	  different	  than	  P(MAA-­‐g-­‐EG)	  
controls,	  the	  results	  are	  promising.	  	  P(MAA-­‐g-­‐EG-­‐co-­‐Pullulan	  75000)	  microparticles	  were	  
the	  least	  adherent	  of	  the	  formulations	  tested	  (Figure	  7.3).	   	  Likewise,	  there	  were	  fewer	  
adherent	   P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	   100000)	   microparticles	   than	   P(MAA-­‐g-­‐EG)	  
microparticles.	   	   The	  decrease	   in	   adhesion	  may	  be	   a	   result	   of	   the	   large	   tethers,	  which	  
may	  require	  a	  longer	  time-­‐scale	  for	  diffusion	  into	  the	  mucus	  gel	  to	  occur.	  	  To	  the	  best	  of	  
our	  knowledge,	  the	  diffusion	  coefficients	  of	  dextran	  and	  pullulan	  in	  mucin	  solutions	  are	  
unknown.	  	  However,	  the	  diffusion	  coefficient	  of	  FITC-­‐Dextran	  with	  a	  molecular	  weight	  of	  
40	  kDa	  is	  1.87	  x	  10-­‐7	  μm2/s	  [11]	  while	  a	  150	  kDa	  FITC-­‐Dextran	  has	  a	  diffusion	  coefficient	  
of	  2.06	  x	  10-­‐11	  μm2/s	  in	  water.	  	  Longer	  time	  scales	  for	  tether	  penetration	  in	  mucus	  may	  
not	  be	  desirable	  for	  oral	  protein	  drug	  delivery	  as	  microparticles	  may	  contact	  the	  GI	  tract	  
for	   only	   a	   brief	   time	   period	   in	   which	   the	   particles	   either	   adhere	   or	   desorb.	   	   Overall,	  
results	   from	   this	   study	   show	   that	   all	   formulations	   adhere	   to	   reconstituted	  mucin	   gels	  
preferentially	  over	  tissue	  culture	  plates	   in	  which	   less	  than	  1	  adhered	  microparticle	  per	  
area	  was	  observed	  for	  any	  given	  formulation.	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7.	  4	  CONCLUSIONS	  
Based	  on	   the	   in	   vitro	  assessments	  of	  polysaccharide-­‐modified	  hydrogels,	   these	  
materials	  appear	  to	  be	  promising	  for	  the	  oral	  delivery	  of	  protein	  drugs.	  	  These	  materials	  
do	   not	   cause	   a	   significant	   increase	   in	   cell	   death	   as	  measured	   by	   an	  MTS	   assay	   and	   a	  
Caco-­‐2	   enterocyte	   model.	   	   In	   addition,	   these	   materials	   were	   shown	   to	   adhere	   to	  
reconstituted	  mucin	  gels.	  	  The	  ability	  to	  adhere	  to	  mucus	  membranes	  and	  cause	  limited	  







































Figure	   7.1	   Fraction	   of	   viable	   cells	   relative	   to	   control	   wells	   for	   various	  microparticle	  
formulations	   including	   P(MAA-­‐g-­‐EG),	   P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	   6000),	   P(MAA-­‐g-­‐EG-­‐co-­‐
Dextran	  100000),	  and	  P(PMAA-­‐g-­‐EG-­‐co-­‐Pullulan	  75000)	  over	  a	  range	  of	  concentrations	  
(1	  mg/ml,	  0.5	  mg/ml,	  0.25	  mg/ml,	  and	  0.125	  mg/ml).	  
Data	  are	  represented	  by	  mean	  ±	  standard	  deviation.	  
	  

























Figure	  7.2	  Fraction	  of	  viable	  cells	  relative	  to	  control	  wells	  for	  various	  P(MAA-­‐g-­‐EG-­‐co-­‐
Dextran	  100000)	  microparticle	  formulations	  with	  Dextran	  100000	  feed	  ratios	  of	  0.5	  %,	  
1%,	  and	  2%	  in	  comparison	  to	  P(MAA-­‐g-­‐EG)	  microparticles.	  	  A	  range	  of	  concentrations	  
was	  investigated	  including	  1	  mg/ml,	  0.5	  mg/ml,	  0.25	  mg/ml,	  and	  0.125	  mg/ml.	  
Data	  are	  represented	  by	  mean	  ±	  standard	  deviation.	  
	  
	  































Figure	   7.3	   Mucoadhesion	   of	   fluorescently	   labeled	   polysaccharide-­‐modified	  
complexation	  hydrogel	  microparticles	  of	  P(MAA-­‐g-­‐EG),	  P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	  6000),	  
P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	   100000),	   and	   P(PMAA-­‐g-­‐EG-­‐co-­‐Pullulan	   75000)	   to	  
reconstituted	  mucin	  gels	   is	  quantified	  by	  the	  number	  of	  adherent	  microparticles	  per	  
area.	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Chapter	  8:	  	  	  
In	  Vitro	  Drug	  Transport	  Studies	  and	  Measurement	  of	  Transepithelial	  
Electrical	  Resistance	  in	  an	  Intestinal	  Epithelium	  Model	  
8.1	  INTRODUCTION	  
In	  developing	  and	  optimizing	  drug	  delivery	  systems,	  in	  vitro	  tests	  are	  useful	  tools	  
for	   selecting	  which	   formulations	   are	   the	  most	   likely	   to	  be	   successful	   in	   vivo.	   	   For	  oral	  
delivery	   applications,	   drug	   absorption	   across	   the	  mucosa	   and	   intestinal	   wall	   into	   the	  
bloodstream	   is	   a	   major	   factor	   contributing	   to	   the	   performance	   of	   the	   drug	   delivery	  
system	   in	   vivo.	   	   The	   absorption	   of	   large	   molecular	   weight	   drugs	   such	   as	   proteins	   is	  
especially	   important	   because	   these	   drugs	   typically	   have	   low	   bioavailabilities	   [1,	   2].	  	  
Furthermore,	   interactions	  between	  the	  oral	  drug	  delivery	  systems	  and	  the	  mucosa	  are	  
very	   important	   as	   many	   materials	   can	   disrupt	   the	   tight	   junctions	   of	   the	   intestinal	  
epithelium.	   	  Damage	   to	   the	  epithelium	  can	  allow	  pathogens	   to	   cross	   the	   lining	  of	   the	  
intestine.	   	   Therefore,	   in	   vitro	   evaluation	   of	   an	   oral	   delivery	   system’s	   effect	   on	   the	  
opening	  of	   the	   tight	   junctions	  or	   damage	   to	   the	  epithelium	   is	   highly	  desirable	   from	  a	  
safety	   standpoint.	   	   However,	   reversible	   interactions	   that	   cause	   temporary	   opening	   of	  
the	   tight	   junctions	   is	   hypothesized	   to	   improve	   absorption	   of	   low-­‐solubility	   and	   large	  
drugs	  [3-­‐5].	  	  	  
The	  most	  widely	  used	  in	  vitro	  model	  to	  study	  oral	  drug	  delivery	  systems	  consists	  
of	   Caco-­‐2	   cells	   which	   are	   human	   colon	   adenocarcinoma	   cells.	   	   These	   cells	   have	   the	  
ability	  to	  differentiate	  into	  columnar	  epithelial	  cells	  with	  polarized	  membranes.	  	  On	  the	  
apical	   side	   of	   these	   cells,	   the	   cells	   can	   produce	   a	   brush	   border	   and	   secrete	   enzymes	  
associated	   with	   the	   intestinal	   epithelium.	   	   While	   Caco-­‐2	   cells	   have	   many	   similar	  
properties	   to	   native	   intestinal	   epithelia,	   these	   cells	   are	   of	   colonic	   origin.	   	   One	   of	   the	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disadvantages	  of	   the	  Caco-­‐2	   cell	  model	   is	   that	   it	   is	   a	   single	   cell	  model	  with	  an	  overall	  
lower	   permeability	   than	   native	   human	   tissue	   of	   the	   small	   intestine.	   	   A	   lower	  
permeability	  means	   that	   transport	   of	  molecules	   from	   the	   apical	   to	   basolateral	   side	   is	  
slower	  than	  in	  normal	  tissue.	   	  As	  a	  result,	  drug	  permeability	  across	  these	  cells	   is	  often	  
lower	  than	  what	  is	  observed	  in	  normal	  tissue.	  
As	  an	  alternative	  to	  Caco-­‐2	  cell	  models,	  a	  co-­‐culture	  model	  consisting	  of	  Caco-­‐2	  
cells	  and	  HT29-­‐MTX	  goblet	  cells	  has	  been	  developed	  by	  Hilgendorf	  et	  al	  [6].	  	  This	  model	  
has	  several	  advantages	  over	  the	  Caco-­‐2	  model.	  	  First,	  the	  absorptive	  properties	  of	  Caco-­‐
2/HT29-­‐MTX	   monolayers	   are	   more	   similar	   to	   native	   tissue	   including	   the	   electrical	  
resistance.	   	   Additionally,	   the	   incorporation	   of	   mucus-­‐secreting	   goblet	   cells	   into	   the	  
model	  allows	  the	  effects	  of	  mucus	  on	  drug	  absorption	  to	  be	  studied	  in	  vitro.	  	  	  	  	  	  	  
In	  addition	  to	  analyzing	  drug	  absorption	  across	  intestinal	  epithelium	  cell	  models,	  
understanding	   the	   effect	   of	   the	   oral	   drug	   delivery	   systems	   on	   the	   integrity	   of	   the	  
intestinal	  epithelium	  is	  essential	  in	  designing	  more	  effective	  systems.	  	  For	  example,	  the	  
structure	   of	   the	   epithelium	   can	   be	   characterized	   by	   analyzing	   the	   tight	   junctions	   of	  
enterocytes.	   	  Disruption	  of	  the	  cellular	  monolayer	  corresponds	  to	  opening	  of	  the	  tight	  
junctions	  between	  adjacent	  cells	  which	  can	  be	  measured	  by	  the	  transepithelial	  electrical	  
resistance	   (TEER)	   of	   the	   cell	   monolayer.	   TEER	   studies	   have	   been	   used	   to	   better	  
understand	  the	  interactions	  between	  drug	  delivery	  systems	  and	  GI	  tract	  tissue	  in	  vitro.	  
In	  the	  research	  presented	  in	  this	  chapter,	  polysaccharide-­‐modified	  hydrogels	  are	  
evaluated	   for	  potential	  use	  as	  oral	  protein	  drug	  delivery	   systems	  using	  drug	   transport	  
and	  TEER	  measurements	  in	  vitro.	  	  Insulin	  transport	  across	  Caco-­‐2/HT29-­‐MTX	  cells	  in	  the	  
presence	  of	  P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	  6000)	  was	  compared	  to	  transport	   in	  the	  presence	  
of	   unmodified	   P(MAA-­‐g-­‐EG)	   microparticles.	   	   Furthermore,	   P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	  
6000)	  and	  P(MAA-­‐g-­‐EG)	  microparticles	  that	  were	  loaded	  with	  insulin	  were	  also	  studied.	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The	   effect	   of	   all	   of	   these	   systems	   on	   the	   TEER	   of	   Caco-­‐2/HT29-­‐MTX	   cells	   was	   also	  
measured.	  
8.2	  MATERIALS	  AND	  METHODS	  
8.2.1	  General	  Cell	  Culture	  	  
Caco-­‐2	  cells	   (ATCC,	  Rockwell,	  MD)	  and	  HT29-­‐MTX	  cells	   (which	  were	  a	  generous	  
gift	   from	   Prof.	   Thecla	   Lesuffleur,	   INSERM,	   Paris,	   France)	   were	   grown	   in	   Dulbecco’s	  
modified	   Eagle	   medium	   (DMEM,	   Mediatech,	   Herndon,	   VA)	   with	   high	   glucose	   and	  
sodium	  pyruvate.	  	  The	  DMEM	  media	  was	  supplemented	  with	  10	  %	  heat	  inactivated	  fetal	  
bovine	   serum	   (FBS,	   Cambrex,	   East	   Rutherford,	   NJ),	   1	   %	   non-­‐essential	   amino	   acids	  
(Mediatech),	   penicillin,	   streptomycin,	   and	   amphotericin	   B.	   	   Freshly	   thawed	   cells	  were	  
grown	  in	  DMEM	  media	  with	  20%	  FBS	  until	  the	  first	  passage.	  
Caco-­‐2	   cells	   and	   HT29-­‐MTX	   cells	   were	   grown	   separately	   in	   a	   humidified	  
incubator	  maintained	  at	  37	  ⁰C	  and	  5%	  CO2.	  	  	  The	  cell	  media	  was	  refreshed	  every	  other	  
day.	   	   Cells	  were	   passaged	   prior	   to	   90%	   confluency.	   	   To	   passage	   cells,	   the	  media	  was	  
removed	  and	   the	  cells	  were	  washed	  with	  pre-­‐warmed	  Dulbecco’s	  phosphate	  buffered	  
saline	  without	  Ca2+	  and	  without	  Mg2+.	   	  Trypsin	  was	  placed	  on	  the	  cells	  and	  allowed	  to	  
incubate	  for	  10	  minutes.	   	  Then,	   fresh,	  pre-­‐warmed	  media	  was	  added	  to	   inhibit	  trypsin	  
activity.	   	   A	   small	   volume	   of	   cells	   was	   removed	   and	   counted.	   	   Caco-­‐2	   cells	   were	  
resuspended	   then	   seeded	  at	   a	   density	  of	   3.0	   x	   103	   cells/cm2	  whereas	  HT29-­‐MTX	   cells	  
were	  seeded	  at	  a	  density	  of	  2	  	  x	  104	  cells/cm2.	  
8.2.2	  Material	  Preparation	  
P(MAA-­‐g-­‐EG)	   and	   P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	   6000)	   hydrogel	   microparticles	   with	  
diameters	   between	   53	   and	   75	   μm	  were	   prepared	   as	   described	   in	   previous	   chapters.	  	  
P(MAA-­‐g-­‐EG)	  and	  P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	  6000)	  microparticles	  were	  loaded	  with	  insulin	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as	  outlined	  in	  Chapter	  6.	  	  Insulin-­‐loaded	  particles	  were	  lyophilized	  and	  stored	  at	  -­‐80	  ⁰C	  
until	  use.	  	  	  
8.2.3	  Caco-­‐2/HT29-­‐MTX	  Co-­‐Culture	  	  
Caco-­‐2	  and	  HT29-­‐MTX	  co-­‐cultures	  were	  formed	  by	  combining	  both	  cell	  types	  and	  
seeding	   them	  on	   the	   same	   tissue	   culture	   substrate.	   	   For	   the	   studies	  presented	   in	   this	  
work,	   cells	   were	   seeded	   on	   polycarbonate	   Transwell®	   permeable	   supports	   (Corning,	  
Lowell,	  MA)	  with	  a	  pore	  size	  of	  0.4	  μm.	  	  Transwell®	  plates	  (with	  12-­‐wells)	  were	  seeded	  
using	  equal	  numbers	  of	  Caco-­‐2	  and	  HT29-­‐MTX	  cells.	  	  The	  total	  cell	  seeding	  density	  was	  
1.0	  x	  105	  cells/cm2	  with	  5	  x	  104	  Caco-­‐2	  cells/cm2	  and	  5	  x	  104	  HT29-­‐MTX	  cells/cm2.	  	  The	  
co-­‐cultures	  were	  allowed	  to	  grow	  for	  21-­‐24	  days	  to	  allow	  differentiation	  and	  formation	  
of	  a	  confluent	  monolayer.	  	  The	  cell	  media	  was	  refreshed	  every	  other	  day.	  	  	  	  	  	  	  	  
8.2.4	  Transepithelial	  Electrical	  Resistance	  Measurements	  
The	   formation	   and	   integrity	   of	   tight	   junctions	   of	   the	   cell	   monolayers	   was	  
monitored	   using	   transepithelial	   electrical	   resistance	   measurements	   (TEER)	   with	   a	  
chopstick	   electrode	   (World	   Precision	   Instrument,	   Sarasota,	   FL).	   	   During	   TEER	  
measurements,	   the	  temperature	  of	   the	  cell	  cultures	  were	  maintained	  at	  37	  ⁰C	  using	  a	  
heated	  mat.	   	  The	  chopstick	  electrode	  was	  placed	  in	  the	  Transwell®	  plate	  such	  that	  the	  
longer	   electrode	   was	   placed	   in	   contact	   with	   the	   bottom	   of	   the	   lower	   Transwell®	  
chamber,	  which	  allowed	  consistent	  positioning	  of	  the	  electrode.	  	  The	  shorter	  electrode	  
was	  carefully	  positioned	  in	  the	  upper	  chamber	  so	  that	  it	  did	  not	  damage	  the	  membrane	  
or	  touch	  the	  sides	  of	  the	  chamber.	  	  The	  electrical	  resistance	  between	  the	  two	  electrodes	  
was	  recorded.	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8.2.5	  Drug	  Transport	  Studies	  
Transport	   studies	   were	   used	   to	   measure	   insulin	   permeability	   across	   Caco-­‐
2/HT29-­‐MTX	  monolayers	  after	  constant	  TEER	  measurements	  were	  obtained	  (Figure	  8.1).	  	  
For	   drug	   transport	   studies,	   the	   TEER	   measurement	   for	   each	   cell	   monolayer	   was	  
recorded.	  	  The	  media	  was	  removed	  and	  replaced	  with	  pre-­‐warmed	  HBSS.	  	  The	  cells	  were	  
allowed	   to	   equilibrate	   for	   one	   hour,	   and	   TEER	  measurements	   were	   recorded	   initially	  
then	  at	  15,	  30,	  45,	  and	  60	  minutes.	  
For	  transport	  studies,	  the	  cell	  media	  consisted	  of	  HBSS	  with	  Ca2+	  and	  Mg2+	  with	  
0.5	  mg/ml	  bovine	  serum	  albumin	  to	  prevent	  protein	  adsorption	  to	  the	  Transwell®	  plates	  
in	  both	  the	  upper	  and	  lower	  chambers.	  	  The	  control	  used	  in	  transport	  studies	  was	  a	  0.2	  
mg/ml	   solution	   of	   insulin	   in	   a	   0.5	   mg/ml	   solution	   of	   BSA	   in	   HBSS.	   	   P(MAA-­‐g-­‐EG-­‐co-­‐
Dextran	  6000)	   and	  P(MAA-­‐g-­‐EG)	  microparticle	   samples	  were	   suspended	   in	  HBSS	   for	   a	  
final	  microparticle	   concentration	  of	   1	  mg/ml	   along	  with	  0.2	  mg/ml	  bovine	   insulin	   and	  
0.5	  mg/ml	  bovine	  serum	  albumin.	   	   	  Samples	  consisting	  of	   insulin-­‐loaded	  microparticles	  
were	  selected	  so	  that	  their	   insulin	   loading	  efficiency	  was	  approximately	  85-­‐88%	  with	  a	  
final	  drug	  to	  polymer	  mass	  ratio	  of	  17-­‐18	  %	  which	  allowed	  the	  ratio	  of	  insulin	  to	  polymer	  
(0.2	   mg/ml	   to	   1	   mg/ml)	   to	   be	   approximately	   matched.	   	   These	   microparticles	   were	  
suspended	  in	  HBSS	  with	  0.5	  mg/ml	  so	  that	  the	  final	  polymer	  concentration	  was	  1	  mg/ml	  
and	  the	  concentration	  of	  the	  entrapped	  drug	  would	  be	  0.2	  mg/ml	   if	   it	  was	  completely	  
released.	  	  	  
	  	  Once	  the	  samples	  were	  added	  to	  the	  apical	  side	  of	  the	  cell	  monolayers,	  a	  100	  μl	  
sample	   from	   the	   apical	   chamber	   was	   removed	   along	   with	   a	   100	   μl	   sample	   from	   the	  
lower	  chamber.	   	  The	  volume	  of	  the	  lower	  chamber	  was	  replaced	  with	  pre-­‐warmed	  0.5	  
mg/ml	   of	   BSA	   in	   HBSS.	   	   The	   TEER	   of	   the	   cell	   monolayer	   was	   also	   recorded.	   	   At	   30	  
minutes,	  60	  minutes,	  and	  120	  minutes,	  the	  TEER	  was	  recorded	  and	  a	  100	  μl	  sample	  from	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the	  basolateral	  chamber	  was	  removed.	  	  An	  additional	  100	  μl	  of	  0.5	  mg/ml	  BSA	  in	  HBSS	  
was	   added	   to	   the	   lower	   chamber	   to	   return	   the	   volume	   to	  1.5	  ml.	   	   After	   3	   hours,	   the	  
TEER	  was	   recorded	   and	   a	   sample	  was	   removed	   from	   both	   the	   apical	   and	   basolateral	  
chambers.	  
The	  cells	  were	  washed	  with	  HBSS	   three	   times	   to	   remove	  microparticles.	   	  Once	  
the	  cells	  were	  washed,	  fresh	  DMEM	  media	  was	  added	  to	  each	  well	  and	  the	  TEER	  values	  
were	  monitored	  for	  24	  hours.	  
8.2.6	  Measurement	  of	  Drug	  Concentrations	  with	  ELISA	  
In	   order	   to	   measure	   the	   amount	   of	   insulin	   transported	   across	   the	   cell	  
monolayers,	   the	   concentration	   of	   the	   insulin	   was	   measured	   using	   an	   enzyme-­‐linked	  
immunosorbent	  assay	  (ELISA	  assay)	  for	  bovine	  insulin	  (Mercodia	  AB,	  Uppsala,	  Sweden).	  	  
The	   samples	   obtained	   from	   the	   basolateral	   chamber	   during	   transport	   studies	   were	  
diluted	  prior	  to	  the	  ELISA	  assay	  by	  a	  dilution	  factor	  of	  100	  in	  HBSS.	  	  The	  assay	  procedure	  
was	  followed	  according	  to	  the	  manufacturer’s	  directions.	  	  The	  concentration	  of	  insulin	  in	  
each	  sample	  was	  determined	  by	  measuring	  the	  optical	  absorbance	  at	  a	  wavelength	  of	  
450	  nm	  using	  a	  UV-­‐Vis	  plate	  reader.	  	  	  	  
8.2.7	  Measurement	  of	  Drug	  Concentrations	  with	  HPLC	  
To	  measure	  the	  insulin	  concentrations	  in	  samples	  taken	  from	  the	  upper	  chamber	  
during	  the	  transport	  study,	  HPLC	  was	  used.	  	  A	  Waters	  Alliance	  HPLC	  unit	  equipped	  with	  
a	  Symmetry	  C4	  5	  μm	  column	  was	  used	  to	  run	  gradient	  elution	  in	  the	  reverse	  direction.	  	  
The	  mobile	  phase	  consisted	  of	  95%	  water	  with	  0.1%	   trifluoroacetic	  acid	   (TFA)	  and	  5%	  
acetonitrile	  with	  0.08%	  TFA.	  	  The	  column	  temperature	  was	  40	  ⁰C.	  	  A	  gradient	  was	  run	  in	  
the	  reverse	  direction	  from	  5%	  to	  60%	  acetonitrile	  over	  18	  minutes.	  	  The	  sample	  run	  time	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was	  22	  minutes,	  and	  the	  sample	  injection	  volume	  was	  20	  μl.	  	  The	  protein	  concentration	  
was	  measured	  by	  UV	  absorbance	  at	  220	  nm.	  	  	  
	  
8.3	  RESULTS	  AND	  DISCUSSION	  
The	   use	   of	   polysaccharide-­‐modified	   P(MAA-­‐g-­‐EG)	  microparticles	   as	   oral	   insulin	  
delivery	   systems	   was	   evaluated	   in	   vitro	   through	   drug	   transport	   studies	   and	   TEER	  
measurements	   of	   an	   intestinal	   epithelial	   cell	   model.	   	   In	   this	   work,	   P(MAA-­‐g-­‐EG-­‐co-­‐
Dextarn	   6000)	   and	   P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	   100000)	   were	   compared	   to	   unmodified	  
P(MAA-­‐g-­‐EG)	   microparticles	   and	   insulin	   alone.	   	   Furthermore,	   insulin	   transport	   across	  
Caco-­‐2/HT29-­‐MTX	   cell	   monolayers	   from	   insulin-­‐loaded	   P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	   6000)	  
and	   P(MAA-­‐g-­‐EG)	   microparticles	   was	   studied.	   	   The	   effect	   on	   the	   TEER	   of	   the	   cell	  
monolayers	  was	  also	  investigated.	  	  
In	   this	   research,	   polysaccharide	   tethers	   were	   incorporated	   into	   P(MAA-­‐g-­‐EG)	  
complexation	   hydrogels	   to	   promote	   mucoadhesion	   of	   the	   carrier	   in	   the	   upper	   small	  
intestine.	  	  Because	  these	  systems	  were	  designed	  to	  interact	  with	  mucus,	  a	  Caco-­‐2/HT29-­‐
MTX	   co-­‐culture	  mucus-­‐secreting	   co-­‐culture	  was	   chosen	   as	   the	   intestinal	   epithelial	   cell	  
model.	  	  The	  use	  of	  Caco-­‐2/HT29-­‐MTX	  models	  for	  evaluating	  insulin	  permeability	  in	  vitro	  
in	  the	  presence	  of	  complexation	  hydrogels	  has	  been	  studied	  for	  several	  carrier	  and	  drug	  
formulations	  by	  Peppas	  and	  co-­‐workers	   [4,	  7,	  8].	   	  Other	  studies	  have	  used	  Caco-­‐2	  cell	  
models	  to	  study	  hydrogel	  drug	  delivery	  systems	  [4,	  5,	  9-­‐11].	  
Prior	  to	  transport	  studies	  the	  formation	  of	  the	  tight	  junctions	  between	  adjacent	  
cells	  was	  monitored	  by	  TEER	  as	  shown	   in	  Figure	  8.1.	   	  The	  TEER	  of	  the	  cell	  monolayers	  
(Rtissue)	  was	   calculated	  using	  Equation	  8.1	  by	   subtracting	   the	  average	  TEER	   from	  blank	  
wells	  consisting	  only	  of	  media	  (Rblank)	  from	  the	  measured	  TEER	  (Rmeasured).	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blankmeasuredtissue RRR −= 	   	   	   	   	   	   	   (8.1)	  
The	  TEER	  of	   the	  co-­‐culture	  monolayer	   increased	  steadily	  over	   the	   first	  10	  days	  
and	  then	  reached	  a	  plateau	  of	  approximately	  200	  Ω·∙cm2.	  	  These	  TEER	  measurements	  are	  
higher	  than	  the	  ones	  reported	  by	  Wood	  et	  al.	   [4]	  which	  were	   less	  than	  200	  Ω·∙cm2	  but	  
still	  much	  lower	  than	  Caco-­‐2	  cultures	  which	  have	  TEER	  values	  of	  approximately	  350-­‐400	  
Ω·∙cm2.	  	  	  
Prior	   to	   transport	   studies,	   the	   TEER	   of	   the	   Caco-­‐2/HT29-­‐MTX	   co-­‐culture	   was	  
measured	   once	   the	   media	   was	   replaced	   with	   HBSS.	   	   The	   cells	   were	   allowed	   to	  
equilibrate	  in	  new	  media	  for	  1	  h	  to	  ensure	  that	  the	  replacement	  of	  the	  media	  with	  HBSS	  
was	  not	  a	  factor	  in	  the	  transport	  study.	  	  The	  results	  are	  shown	  in	  Figure	  8.2	  over	  the	  one	  
hour	  equilibration	  period.	   	  After	   replacement	  of	   the	  media,	   the	  TEER	  values	   returned,	  
and	  there	  was	  no	  indication	  of	  damage	  to	  the	  epithelium.	  	  	  
For	   drug	   transport	   studies,	   the	   ratio	   of	   microparticles	   to	   insulin	   was	   chosen	  
based	  on	   results	  obtained	   from	   loading	   studies	  presented	   in	  Chapter	  6.	   	   The	  maximal	  
insulin	  loading	  efficiencies	  around	  90%	  resulted	  in	  drug	  to	  polymer	  ratios	  of	  around	  18	  
wt%.	  	  As	  a	  result,	  microparticles	  concentrations	  of	  1	  mg/ml	  and	  insulin	  concentrations	  of	  
0.2	  mg/ml	  were	  chosen	  for	  comparison.	  	  	  
During	   the	   transport	   study,	   the	  TEER	  values	  were	  monitored.	   	  The	  TEER	  values	  
were	  measured	  using	  a	  chopstick	  electrode	  and	  an	  EVOM	  epithelial	  voltohmmeter.	  	  The	  
chopstick	   electrode	   allows	   measurement	   of	   the	   electrical	   resistance	   of	   the	   cell	  
monolayer	  using	  an	  applied	  AC	  current.	  	  Typically,	  TEER	  measurements	  obtained	  with	  a	  
chopstick	  electrode	  vary	  10-­‐30	  Ω.	   	  One	  of	  the	  advantages	  of	  this	  measurement	   is	   that	  
AC	  current	  is	  used	  and	  does	  not	  have	  adverse	  effects	  on	  cell	  monolayers	  that	  DC	  current	  
does.	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For	  all	  samples,	  the	  measured	  TEER	  decreased	  over	  the	  course	  of	  the	  transport	  
study	  as	  shown	  in	  Figure	  8.3.	  	  Throughout	  the	  transport	  experiment,	  the	  TEER	  fluctuates	  
close	  to	  the	  initial	  TEER.	  	  	  This	  indicates	  that	  the	  microparticle	  drug	  delivery	  systems	  (at	  
concentrations	  of	  1	  mg/ml)	  do	  not	  adversely	  affect	   the	   tight	   junctions.	   	  A	  decrease	   in	  
TEER	  measurements	   of	   Caco-­‐2	   and	   Caco-­‐2/HT29-­‐MTX	  monolayers	   during	   exposure	   to	  
anionic	   complexation	   hydrogels	  was	   expected	   based	   on	   published	   research	   [4,	   5].	   	   In	  
previous	  results,	  the	  TEER	  measurements	  of	  cell	  monolayers	  treated	  with	  insulin	  did	  not	  
change	  significantly	  [4].	  In	  addition,	  we	  monitored	  the	  pH	  of	  the	  apical	  and	  basolateral	  
chambers	   over	   the	   course	   of	   the	   experiment	   by	   placing	   1	   μl	   droplets	   on	   pH	   paper.	  
Throughout	  the	  experiment,	  the	  pH	  of	  both	  chambers	  was	  approximately	  a	  pH	  value	  of	  
7.	  	  	  	  	  
To	  analyze	  the	  transport	  of	  insulin	  across	  the	  Caco-­‐2/HT29-­‐MTX	  monolayers,	  the	  
apparent	  permeability	  (Papp)	  was	  calculated	  based	  on	  the	  initial	  concentration	  of	  insulin	  
in	  the	  apical	  chamber	  (Co),	   the	  surface	  area	  of	  the	  cell	  monolayer	   (A),	  and	  the	  steady-­‐
state	  flux	  of	  the	  drug	  from	  the	  apical	  to	  the	  basolateral	  chambers	  across	  the	  cell	   layer	  











= 	  	  	   	   	   	   	   	   	   	   (8.2)	  
The	  apparent	  permeability	  of	  insulin	  across	  the	  cell	  monolayers	  when	  insulin	  was	  
mixed	   with	   either	   P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	   6000)	   microparticles	   or	   P(MAA-­‐g-­‐EG)	   as	  
shown	  in	  Table	  8.1.	   	  The	  apparent	  permeability	  of	   insulin	   in	  the	  presence	  of	  P(MAA-­‐g-­‐
EG-­‐co-­‐Dextran	   6000)	   was	   comparable	   to	   insulin	   alone.	   	   Unmodified	   P(MAA-­‐g-­‐EG)	  
microparticles	  had	  higher	  apparent	  permeabilities	  than	  insulin	  alone	  as	  well	  as	  P(MAA-­‐
g-­‐EG-­‐co-­‐Dextran	   6000)	  mixtures.	   	   The	   transport	   profile	   of	   insulin	   into	   the	   basolateral	  
chamber	  is	  shown	  in	  Figure	  8.4	  for	  the	  insulin	  control	  as	  well	  as	  the	  mixtures	  of	  insulin	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with	  either	  P(MAA-­‐g-­‐EG)	  or	  P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	  6000).	  	  The	  concentration	  of	  insulin	  
in	  the	  basolateral	  chamber	  increases	  linearly	  with	  respect	  to	  time	  for	  all	  samples.	   	  The	  
insulin	   transport	   in	   the	   presence	   of	   P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	   6000)	   is	   similar	   to	   the	  
insulin	  control.	   	  However,	   the	   insulin	   transport	   is	  highest	   for	  unmodified	  P(MAA-­‐g-­‐EG)	  
microparticle	  mixtures.	  	  	  
The	  observed	  difference	  between	  insulin	  transport	  in	  the	  presence	  of	  P(MAA-­‐g-­‐
EG)	   in	   comparison	   to	   P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	   6000)	  may	   be	   a	   result	   of	   polymer-­‐drug	  
and	  polymer-­‐cell	   interactions.	   	   The	  dextran	   systems	  may	   interact	  more	   favorably	  with	  
the	   mucus	   layer	   secreted	   by	   the	   Goblet	   cells	   thereby	   forming	   a	   layer	   of	   adhered	  
particles	  atop	  the	  mucus	  layer.	  	  An	  adhered	  layer	  of	  microparticles	  above	  the	  cells	  is	  an	  
additional	  barrier	  to	  diffusion	  of	  insulin	  across	  the	  mucus	  layer.	  	  Furthermore,	  the	  large	  
hydrophilic	   co-­‐macromonomers	   that	   may	   effectively	   charge	   shield	   the	   P(MAA)	  
components	   of	   the	   hydrogel.	   	   In	   the	   case	   of	   insulin	   and	   P(MAA-­‐g-­‐EG),	   the	   negative	  
charge	   of	   the	   P(MAA-­‐g-­‐EG)	   gel	   discourages	   polymer-­‐drug	   interactions	   at	   neutral	   pH	  
because	  both	   insulin	   and	  P(MAA-­‐g-­‐EG)	  have	  a	  negative	   charge.	   	   Interactions	  between	  
insulin	   and	   P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	   6000)	   may	   be	   more	   favorable	   than	   diffusion	  
through	  negatively	  charged	  mucus.	  	  	  
The	  apparent	  permeability	  of	  insulin	  across	  Caco-­‐2/HT29-­‐MTX	  monolayers	  from	  
insulin-­‐loaded	   formulations	   was	   investigated.	   	   The	   apparent	   permeability	   of	   insulin	  
released	   from	  P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	  6000)	  microparticles	  was	  comparable	   to	   insulin	  
alone	  (5.58	  x	  10-­‐8	  cm/s	  and	  5.52	  x	  10-­‐8	  cm/s)	  as	  shown	  in	  Table	  8.2.	  	  However,	  insulin’s	  
apparent	  permeability	  from	  insulin-­‐loaded	  P(MAA-­‐g-­‐EG)	  microparticles	  was	  much	  higher	  
(21.85	  x	  10-­‐8	   cm/s).	   	   In	  comparing	   the	   insulin	  permeability	  measured	   for	  P(MAA-­‐g-­‐EG)	  
and	   insulin	   (that	   was	   not	   loaded),	   the	   P(MAA-­‐g-­‐EG)	   has	   a	   much	   greater	   impact	   on	  
permeability	   causing	   the	  permeability	   to	  quadruple.	   	   The	   insulin	   transport	  profiles	   for	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the	  formulations	   loaded	  with	   insulin	  shown	  in	  Figure	  8.4	   increase	  linearly	  with	  respect	  
to	  time.	  	  The	  flux	  of	  insulin	  across	  the	  monolayer	  is	  relatively	  low	  in	  comparison	  to	  the	  
insulin-­‐polymer	  mixtures.	   	  Due	   to	   the	   lower	  concentration	  of	   the	   released	  drug	   in	   the	  
apical	   compartment	   in	   comparison	   to	   the	   drug-­‐polymer	   mixtures,	   higher	   apparent	  
permeabilities	  were	  obtained.	   	  On	  average,	  the	  concentration	  of	  the	  drug	  in	  the	  apical	  
chamber	  was	   0.1	  mg/ml	   for	   insulin-­‐loaded	   samples.	   	   It	   is	   important	   to	   note	   that	   the	  
apparent	   permeability	   of	   insulin	   released	   from	   loaded	   P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	   6000)	  
was	   greater	   than	   the	   permeability	   of	   insulin	   from	   insulin-­‐	   P(MAA-­‐g-­‐EG-­‐co-­‐Dextran)	  
mixtures.	  
The	  permeabilities	  reported	  here	  are	  higher	  in	  comparison	  to	  the	  permeabilities	  
obtained	  by	  Wood	  et	  al.	  [4]	  (1.61	  x	  10-­‐9	  cm/s	  to	  15.20	  x	  10-­‐9	  cm/s)	  and	  Shofner	  et	  al.	  [8]	  
(4.95	   x	   10-­‐9	   to	   76.8	   x	   10-­‐9	   cm/s).	   	   Caco-­‐2	   cells	   are	   a	   heterogenous	   cell	   line.	   	   It	   is	  well	  
known	  that	  the	  permeability	  of	  Caco-­‐2	  monolayers	  varies	  with	  passage	  number.	  	  In	  this	  
case,	  Caco-­‐2	  cells	  between	  passage	  numbers	  64	  and	  67	  were	  used	  while	  the	  studies	  by	  
Wood	   et	   al.	   and	   Shofner	   et	   al.	   were	   performed	  with	   Caco-­‐2	   cells	  with	  more	   than	   70	  
passages.	  	  	  
8.4	  CONCLUSIONS	  
Based	  on	  the	  effects	  of	  polysaccharide-­‐modified	  P(MAA-­‐g-­‐EG)	  microparticles	  on	  
the	  permeability	  across	  Caco-­‐2/HT29-­‐MTX	  cells,	  these	  systems	  are	  promising	  candidates	  
for	  the	  oral	  delivery	  of	  insulin.	  	  The	  increased	  permeability	  observed	  for	  P(MAA-­‐g-­‐EG-­‐co-­‐
Dextran	   6000)	   hydrogels	   loaded	   with	   insulin	   further	   suggests	   that	   P(MAA-­‐g-­‐EG-­‐co-­‐
Dextran	   6000)	   are	   likely	   to	   perform	   well	   in	   vivo.	   	   Evaluation	   of	   the	   TEER	   of	   these	  
materials	   shows	   the	   tight	   junctions	   remain	   intact	   without	   permanent	   damage	   to	   the	  
epithelium.	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Table	  8.1	  Apparent	  permeability	  of	  insulin	  across	  Caco-­‐2/HT29-­‐MTX	  cell	  monolayers	  in	  
the	  presence	  of	  the	  oral	  delivery	  systems.	  
Formulation	   Apparent	  Permeability	  
Papp	  x	  108	  cm/s	  
Insulin	   5.52	  
P(MAA-­‐g-­‐EG)	   13.31	  
P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	  6000)	  	   5.28	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Table	  8.2	  Apparent	  permeability	  of	  insulin	  across	  Caco-­‐2/HT29-­‐MTX	  cell	  monolayers	  
over	  3	  hours.	  
Formulation	   Apparent	  Permeability	  
Papp	  x	  108	  cm/s	  
Insulin	   5.52	  
Loaded	  P(MAA-­‐g-­‐EG)	   21.85	  



























Figure	   8.1	   The	   average	   TEER	   of	   the	   developing	   Caco-­‐2/HT29-­‐MTX	  monolayer	   during	  
formation	  of	   the	  monolayer	  during	   the	  21	  days	  prior	   to	   the	   transport	   and	  electrical	  
resistance	  experiments.	  	  	  






















Figure	   8.2	   The	   average	   TEER	   of	   the	   Caco-­‐2/HT29-­‐MTX	   monolayer	   in	   the	   transport	  
medium	  during	  a	  one	  hour	  equilibration	  period	  prior	  to	  drug	  transport	  studies.	  	  	  
Data	  are	  mean	  ±	  standard	  deviation.	  	  n	  =	  48.	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Figure	   8.3	   The	   average	   TEER	   of	   the	   Caco-­‐2/HT29-­‐MTX	   monolayer	   during	   drug	  
transport	   studies	  with	   insulin	   in	   the	  presence	  of	  P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	  6000)	   (Í),	  	  
P(MAA-­‐g-­‐EG)	  ().	  	  The	  TEER	  of	  Caco-­‐2/HT29-­‐MTX	  monolayers	  was	  also	  measured	  for	  
systems	   loaded	   with	   drug	   including	   Insulin-­‐loaded	   P(MAA-­‐g-­‐EG)	   (£)	   and	   Insulin-­‐
loaded	  P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	  6000)	  (∆),	  and	  insulin	  alone	  (¯).	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Figure	   8.4	   Cumulative	   insulin	   transport	   to	   the	   basolateral	   side	   of	   Caco-­‐2/HT29-­‐MTX	  
monolayers	   from	   insulin-­‐loaded	   P(MAA-­‐g-­‐EG)	   microparticles	   (£),	   insulin-­‐loaded	  
P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	  6000)	  (r)	  microparticles,	  insulin-­‐P(MAA-­‐g-­‐EG)	  mixtures	  (¢),	  
insulin-­‐P(MAA-­‐g-­‐EG-­‐co-­‐Dextran	  6000)	  mixtures	   ()	   in	  comparison	  to	   insulin	  controls	  
(p).	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Chapter	  9:	  	  
Conclusions	  
The	   use	   of	   protein	   drugs	   is	   a	   rapidly	   growing	   branch	   of	   pharmaceutics.	  While	  
injection	  has	  been	  an	  effective	  administration	  route	  for	  protein	  drugs,	  alternative	  routes	  
of	   administration	   are	   of	   interest.	   In	   particular,	   administration	   via	   the	   oral	   route	   is	  
desirable.	   	   The	   oral	   delivery	   of	   proteins	   such	   as	   insulin	   has	   the	   potential	   to	   increase	  
patient	   adherence,	   reduce	   waste,	   and	   eliminate	   adverse	   effects	   associated	   with	  
repeated	  injections.	  
There	  are	   several	  major	  challenges	  associated	  with	   the	  oral	  delivery	  of	  protein	  
drugs	  such	  as	   insulin.	   	  The	  activity	  of	  the	  therapeutic	  must	  be	  retained	  through	  the	  GI	  
tract,	  and	  the	  active	  drug	  must	  reach	  the	  bloodstream	  at	  levels	  high	  enough	  to	  provide	  
therapeutic	  efficacy.	   	  An	  oral	  protein	  delivery	  system	  must	  protect	   the	  drug	   from	  acid	  
and	  enzymes	  in	  the	  stomach,	  but	  release	  the	  protein	  in	  the	  neutral	  environment	  of	  the	  
small	   or	   large	   intestine.	   	   Anionic	   complexation	   hydrogels	   demonstrate	   pH	   responsive	  
swelling	  behavior	  and	  have	  shown	  potential	  for	  use	  in	  such	  an	  oral	  protein	  fomulation.	  	  	  
In	  this	  work,	  a	  novel	  method	  for	  synthesizing	  complexation	  hydrogels	  containing	  
poly(methacrylic	  acid),	  poly(ethylene	  glycol),	  and	  polysaccharides	  was	  developed.	   	  The	  
synthesis	  of	  these	  materials	  was	  verified	  using	  FT-­‐IR	  spectroscopy.	  
Based	  on	  analysis	  of	  the	  swelling	  of	  these	  hydrogels	  modified	  with	  either	  dextran	  
or	  pullulan,	  pH-­‐responsive	  swelling	   is	  conserved	   in	   the	  presence	  of	   the	  polysaccharide	  
comonomers.	   	  These	  systems	  form	  collapsed	  structures	  with	  minimal	  swelling	  in	  acidic	  
conditions	  and	  swell	  significantly	  in	  more	  neutral	  conditions.	  	  Analysis	  of	  the	  mesh	  size	  
indicates	  that	  these	  gels	  could	  sufficiently	  entrap	  and	  release	  drugs	  as	  large	  as	  protein	  
drugs	   including	   insulin.	   	   In	   comparison	   to	   unmodified	   P(MAA-­‐g-­‐EG)	   hydrogels,	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polysaccharide-­‐modified	   P(MAA-­‐g-­‐EG)	   hydrogels	   exhibited	   similar	   trends	   in	   swelling.	  	  
Several	   differences	   such	   as	   increased	   υ2,s	   at	   low	   pH	   and	   decreased	   υ2,s	   at	   neutral	   pH	  
suggest	  that	  polysaccharide-­‐modified	  P(MAA-­‐g-­‐EG)	  gels	  may	  have	  some	  advantages	  for	  
oral	  delivery	  with	  respect	  to	  their	  complexation	  and	  decomplexation	  behavior.	  
The	   data	   presented	   in	   this	   work	   show	   that	   polysaccharide-­‐modified	   hydrogels	  
have	  the	  potential	  to	  meet	  the	  requirements	  to	  overcome	  the	  major	  challenges	  to	  oral	  
protein	  delivery.	   	  These	  systems	  can	  be	  used	  to	  entrap	  insulin,	  protect	   insulin	  in	  acidic	  
conditions,	  release	  insulin	  in	  response	  to	  changes	  in	  pH,	  and	  the	  release	  profile	  can	  be	  
controlled	  by	  the	  amount	  and	  type	  of	  polysaccharide	  tether.	  	  	  
Based	   on	   the	   in	   vitro	   cytotoxicity	   and	   mucoadhesion	   assessments	   of	  
polysaccharide-­‐modified	  hydrogels,	  these	  materials	  appear	  to	  be	  promising	  for	  the	  oral	  
delivery	   of	   protein	   drugs.	   	   These	  materials	   do	   not	   cause	   a	   significant	   increase	   in	   cell	  
death	  as	  measured	  by	  an	  MTS	  assay	   in	  a	  Caco-­‐2	  enterocyte	  model.	   	   In	  addition,	  these	  
materials	  were	  shown	  to	  adhere	  to	  reconstituted	  mucin	  gels.	   	  The	  ability	  to	  adhere	  to	  
mucus	  membranes	  and	  cause	  limited	  cell	  death	  is	  highly	  desirable	  for	  oral	  protein	  drug	  
delivery	  systems.	  	  	  
Insulin	  drug	  transport	  from	  polysaccharide-­‐modified	  P(MAA-­‐g-­‐EG)	  microparticles	  
was	   evaluated	   by	   measuring	   the	   insulin	   permeability	   across	   Caco-­‐2/HT29-­‐MTX	   cells.	  	  
Transport	  of	   insulin	   in	   the	  presence	  of	  and	  released	  from	  the	  polysaccharide-­‐modified	  
hydrogels	   demonstrate	   that	   they	   are	   promising	   candidates	   for	   the	   oral	   delivery	   of	  
insulin.	   	   Evaluation	   of	   the	   TEER	   of	   epithelial	   monolayers	   exposed	   to	   these	   materials	  
shows	  reversible	  opening	  and	  closing	  of	  tight	   junctions	  without	  permanent	  damage	  to	  
the	  epithelium.	  
To	   fully	   evaluate	   these	   systems	   for	   oral	   insulin	   delivery,	   future	   work	   would	  
include	   an	   in	   vivo	   assessment	   of	   the	   insulin	   bioavailability	   and	   ability	   to	   produce	   a	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hypoglycemic	   affect.	   	   Additional	   optimization	   of	   these	   systems	   could	   include	   the	  
evaluation	   of	   the	   influence	   of	   the	   polysaccharide	   diffusion	   coefficient	   in	   mucus	   as	   it	  
relates	  to	  mucoadhesion.	   	  Overall	   these	  systems	  are	  promising	  candidates	  for	  the	  oral	  
delivery	  insulin	  and	  other	  protein	  drugs.	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ABSTRACT	  
Nanomaterials	  for	  targeted	  delivery	  are	  uniquely	  capable	  of	  localizing	  delivery	  of	  
therapeutics	   and	   diagnostics	   to	   diseased	   tissues.	   	   The	   ability	   to	   achieve	   high,	   local	  
concentrations	   of	   drugs	   or	   image	   contrast	   agents	   at	   a	   target	   site	   provides	   the	  
opportunity	   for	   improved	   system	   performance	   and	   patient	   outcomes	   along	   with	  
reduced	  systemic	  dosing.	  	  In	  this	  review,	  the	  design	  of	  targeted	  nanodelivery	  systems	  is	  
discussed	  with	  an	  emphasis	  on	  in	  vivo	  performance,	  the	  physicochemical	  properties	  that	  




Successful	   targeted	   delivery	   systems	   are	   designed	   to	   allow	   delivery	   of	  
therapeutic	   or	   diagnostic	   agents	   to	   a	   preferential	   site.	   	   As	   targeted	   nanodelivery	  
involves	  local	  delivery	  of	  therapeutics	  and	  diagnostics	  at	  disease	  sites,	  this	  method	  has	  
received	  considerable	  attention	  over	  the	  last	  15	  years	  and	  is	  poised	  to	  have	  a	  significant	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impact	  on	  medicine.	   	   Efficient	   targeted	  delivery	   systems	  allow	   for	   a	   reduced	   systemic	  
dosage	  while	   resulting	   in	   relatively	   higher	   or	  more	   efficient	   dosing	   at	   the	   target	   site.	  	  
The	  promising	  benefits	  of	   reduced	   systemic	   side	  effects	   and	   simultaneously	   improved	  
efficacy	   have	   fueled	   the	   development	   of	   this	   field.	   	   	   To	   date,	   targeted	   delivery	   has	  
become	  a	  rich	  field	  of	  drug	  delivery	  and	  nanomaterials.	  	  	  	  
Nanoscale	  materials	  are	  a	  necessity	  for	  most	  targeted	  delivery	  systems	  as	  these	  
systems	  must	  be	  allowed	  to	  transport	  through	  different	  tissue	  spaces	  in	  order	  to	  localize	  
at	   the	   target	   site.	   	   For	   tumor	   delivery,	   intravenously	   administered	   particles	   must	  
circulate	  in	  the	  bloodstream	  and	  be	  small	  enough	  to	  escape	  circulation	  through	  tumor	  
microvasculature	  which	  typically	  requires	  the	  system	  to	  have	  a	  diameter	   less	  than	  100	  
nm	   to	   2	   μm	   [1].	   	   In	   other	   applications	   such	   as	   the	   treatment	   and	   diagnosis	   of	  
atherosclerotic	  plaques,	  targeted	  delivery	  systems	  have	  been	  developed	  on	  the	  order	  of	  
10	  nm	  to	  greater	  than	  1	  μm.	  
The	  ability	  of	  nanoparticles	  to	  localize	  at	  a	  target	  site	  is	  dependent	  on	  a	  number	  
of	   factors.	   	   	   In	   general,	   it	   is	   unclear	   whether	   chemical	   properties,	   the	   presence	   of	   a	  
targeting	  ligand,	  or	  size	  is	  the	  primary	  determinant	  for	  nanoparticle	  biodistribution.	  	  In	  
many	  cases,	  it	  is	  a	  combination	  of	  these	  properties	  that	  shapes	  biodistribution.	  	  One	  of	  
the	  advantages	  of	  nanoparticle	  delivery	  systems	  is	  that	  the	  circulation	  time	  of	  drugs	  and	  
diagnostic	  agents	  can	  be	  prolonged,	  and	  delivery	  can	  be	  controlled	  through	  targeting.	  	  	  	  	  
Even	  with	   targeted	   delivery,	   only	   a	   fraction	   of	   the	   administered	   dose	   localizes	   at	   the	  
target	   site	  while	   the	   remaining	   nanoparticles	   distribute	   throughout	   the	   body.	   	   At	   this	  
point,	   pharmacokinetics	   pertaining	   to	   the	  nanodelivery	   system	  determine	   the	  dose	   in	  
nontargeted	   tissues.	   	   A	   furthered	   understanding	   of	   nanoparticle	   biodistribution	   and	  
pharmacokinetics	  will	   be	  a	   significant	   contribution	   to	   the	   successful	  development	  and	  
translation	  of	  targeted	  delivery	  systems.	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An	   often	   overlooked	   design	   parameter	   in	   targeted	   delivery	   systems	   is	   the	  
method	   and	   amount	   of	   incorporation	   of	   the	   drug	   or	   diagnostic	   agent.	   	   There	   are	   a	  
variety	   of	   methods	   for	   incorporating	   these	   functions	   into	   a	   delivery	   system	   which	  
depend	   on	   the	   nanomaterial	   and	   the	   agent	   of	   interest.	   	   The	   small	   volumes	   of	  
nanomaterials	   inherently	   limit	   their	   maximum	   payloads,	   and	   their	   sizes	   present	  
challenges	  to	  traditional	  purification	  and	  measurement	  techniques.	  	  	  
From	  current	  work	  in	  the	  field,	  it	  is	  evident	  that	  the	  design	  of	  optimized	  targeted	  
delivery	   systems	  will	  be	  based	  on	   the	  drug	  or	  agent	  of	   interest,	   the	  nanoparticle	   type	  
that	  allows	  sufficient	  loading	  of	  the	  drug,	  and	  the	  physicochemical	  properties	  that	  allow	  
for	  targeting.	   	  We	  will	  highlight	  some	  of	  this	  recent	  work	  on	  targeted	  delivery	  systems	  
and	  focus	  on	   in	  vivo	  performance,	  localization,	  and	  the	  incorporation	  of	  diagnostic	  and	  
therapeutic	  agents	  in	  targeted	  delivery	  systems.	  	  
	  
In	  vivo	  studies	  on	  targeted	  delivery:	  localization,	  uptake,	  and	  performance	  
One	  of	  the	  key	  features	  of	  targeted	  delivery	  systems	  is	  the	  addition	  of	  targeting	  
ligands	   to	   the	   surface	  of	   the	  nanoparticle	   either	   through	  physical	   adsorption	  or	  more	  
commonly	  chemical	  attachment.	   	  Various	   in	  vitro	   and	   in	  vivo	   studies	  have	  shown	  that	  
the	  addition	  of	  these	  targeting	  ligands	  improves	  the	  therapeutic	  effects	  of	  the	  delivery	  
systems	   compared	   to	   control	   systems	   without	   the	   targeting	   ligands.	   	   	   Nanodelivery	  
systems	  with	  targeting	  ligands	  are	  often	  referred	  to	  as	  actively	  targeted	  systems	  but	  will	  
be	   referred	   to	   as	   targeted	   delivery	   systems	   throughout	   this	   paper.	   	   Nanodelivery	  
systems	  without	  targeting	  ligands	  can	  be	  passively	  targeted	  systems	  but	  will	  be	  referred	  
to	  as	  nontargeted	  systems	  in	  this	  paper.	  	  Recent	  in	  vivo	  studies	  have	  shed	  light	  on	  some	  
of	   the	   mechanisms	   behind	   this	   improvement	   in	   therapeutic	   efficacy.	   	   Findings	   from	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these	  studies	  suggest	  that	  the	  targeting	  ligands	  act	  less	  like	  a	  homing	  device	  seeking	  out	  
the	  target	  site	  but	  more	  like	  sticky	  shoes	  that	  improve	  nanoparticle	  association	  with	  the	  
target	  cells’	  membranes	  or	  even	  uptake	  by	  the	  target	  cells.	  	  In	  this	  section,	  we	  will	  cite	  
recent	   studies	   on	   targeted	   delivery	   systems	   focusing	   on	   comparisons	   against	  
nontargeted	   delivery	   systems	   for	   the	   two	   most	   common	   applications	   of	   targeted	  
delivery:	  targeting	  of	  tumors	  and	  atherosclerotic	  plaques.	  
Tumor	  targeting	  
Nanoparticles	  are	  well-­‐suited	  materials	  for	  targeted	  tumor	  delivery	  due	  to	  their	  
ability	  to	  circulate	  in	  the	  bloodstream	  for	  relatively	  long	  time	  periods	  and	  their	  ability	  to	  
accumulate	   in	   tumor	   spaces.	   	   Often,	   actively	   targeted	   nanodelivery	   systems	   are	  
modifications	  of	  passively	  targeted	  delivery	  systems.	  	  A	  number	  of	  studies	  have	  shown	  
improved	   treatment	   in	   vivo	   and	   in	   vitro	   with	   targeted	   systems.	   	   However,	   there	   is	  
growing	  evidence	  to	  suggest	  that	  for	  many	  nanoparticle	  delivery	  systems	  accumulation	  
at	   the	   tumor	   site	   is	   independent	  of	   the	  presence	  or	  absence	  of	  a	   targeting	   ligand.	   	   In	  
these	   cases,	   the	   enhanced	   permeability	   and	   retention	   (EPR)	   effect	   is	   the	   dominating	  
mechanism	   for	   localization	   at	   the	   tumor	   site.	   	   Exploitation	   of	   the	   EPR	   effect	   requires	  
careful	   size	   selection	   of	   nanoparticles	   that	   allows	   nanoparticles	   to	   extravasate	   leaky	  
tumor	   vasculature	   and	   to	   be	   retained	   in	   the	   tumor	   due	   to	   insufficient	   lymphatic	  
drainage.	  	  However,	  in	  a	  number	  of	  studies,	  nanodelivery	  systems	  with	  targeting	  ligands	  
have	  performed	  better	  than	  nontargeted	  systems.	  	  This	  improved	  performance	  or	  more	  
effective	   treatment	   has	   been	   attributed	   to	   improved	   nanoparticle	   association	   with	  
target	  cell	  membranes	  and	  target	  cell	  internalization.	  	  We	  will	  discuss	  a	  variety	  of	  recent	  
in	   vivo	   studies	  which	   have	   compared	   targeted	   and	   nontargeted	   nanodelivery	   systems	  
towards	  understanding	  the	  relationship	  between	  active	  and	  passive	  tumor	  targeting.	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Active	  Tumor	  Targeting	  
This	  relationship	  between	  cell	  uptake	  and	  performance	  of	  targeted	  nanodelivery	  
systems	  has	   been	  demonstrated	   in	   several	   studies	  with	   folate	   targeted-­‐nanoparticles.	  	  
To	   target	   tumor	  cells	  overexpressing	   the	   folate	   receptor,	   folate	  was	   incorporated	   into	  
the	  nanoparticle	  delivery	  system	  as	  a	  targeting	  ligand.	  	  	  
In	   a	   study	   by	  Wang	   et	   al	   [2],	   the	   biodistribution	   and	   performance	   of	   targeted	  
nanoparticles	   composed	   of	   heparin-­‐folate-­‐paclitaxel	   conjugates	   loaded	  with	   paclitaxel	  
(HFT-­‐T)	  were	   compared	   to	   nontargeted	  nanoparticles	   of	   heparin-­‐paclitaxel	   conjugates	  
loaded	   with	   paclitaxel	   (HT-­‐T).	   	   HFT-­‐T	   targeted	   systems	   significantly	   reduced	   tumor	  
volume	   over	   nanoparticle	   and	   paclitaxel	   controls	   in	   a	   KB-­‐3-­‐1	   human	   nasopharyngeal	  
carcinoma	   xenograft-­‐bearing	   mouse	   model.	   	   Despite	   this,	   biodistribution	   studies	  
revealed	   that	   the	   difference	   between	   accumulation	   of	   targeted	   and	   nontargeted	  
systems	   in	   the	   tumor	   was	   not	   statistically	   significant.	   	   However,	   fluorescence	  
microscopy	  of	  the	  tumor	  cells	  showed	  that	  the	  targeted	  systems	  were	  more	  commonly	  
internalized.	   	  These	   results	  were	  confirmed	  by	   flow	  cytometry	  which	  showed	   that	   the	  
targeted	  nanoparticles	  were	   found	   in	   three	   times	  more	   tumor	   cells	   than	  nontargeted	  
nanoparticles	  (21.8	  ±	  2.9%	  cells	  compared	  to	  5.6	  ±	  1.8%	  cells).	  	  	  This	  phenomenon	  was	  
further	  evidenced	  by	  in	  vitro	  studies	  which	  showed	  the	  uptake	  of	  targeted	  nanoparticles	  
was	  higher	  than	  nontargeted	  nanoparticles	  and	  was	  folate-­‐dependent.	  	  In	  this	  study,	  the	  
improved	   performance	   of	   targeted	   nanoparticles	   was	   due	   to	   enhanced	   cell	   uptake,	  
rather	  than	  enhanced	  localization	  compared	  to	  nontargeted	  nanoparticles.	  	  	  
Likewise,	   comparable	   biodistributions	   and	   tumor	   accumulation	   between	   folate	  
receptor-­‐targeted	  and	  nontargeted	  gadolinium	  (Gd)	  nanoparticles	  has	  been	  observed	  in	  
a	  KB	  xenograft-­‐bearing	  athymic	  mouse	  model	  [3].	  	  The	  results	  showed	  that	  the	  targeted	  
and	  nontargeted	  systems	  had	  similar	  biodistributions	  and	  that	   there	  was	  no	  statistical	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difference	  in	  tumor	  localization	  at	  either	  5	  or	  8	  hours.	  	  Furthermore,	  there	  was	  a	  higher	  
tumor	   cell	   uptake	   of	   targeted	   nanoparticles	   in	   vitro	   and	   an	   enhanced	   retention	  
following	  intratumor	  injection	  of	  nanoparticles	  in	  vivo.	  	  While	  this	  study	  did	  not	  examine	  
the	  tumor	  microdistribution	  of	  nanoparticles	  in	  vivo,	  it	  relied	  on	  in	  vitro	  data	  to	  support	  
the	   assertion	   that	   enhanced	   internalization	   was	   a	   feature	   of	   folate-­‐coated	   Gd	  
nanoparticles.	  	  
Tumor	   delivery	   via	   folate	   receptor	   targeting	   has	   also	   been	   evaluated	   using	  
micelles	   with	   differing	   amounts	   of	   the	   targeting	   ligand	   [4].	   	   Targeted	   micelles	   were	  
formed	   with	   varying	   amounts	   of	   folate	   by	   increasing	   the	   molar	   ratio	   of	   folate-­‐PEG-­‐
poly(aspartate-­‐hydrazone-­‐adriamycin)	   [Fol-­‐PEG-­‐p(Asp-­‐Hyd-­‐ADR)]	   to	   methoxy-­‐PEG-­‐
poly(aspartate-­‐hydrazone-­‐adriamycin)	  [PEG-­‐p(Asp-­‐Hyd-­‐ADR)]	  while	  nontargeted	  control	  
micelles	   were	   formed	   entirely	   from	   PEG-­‐p(Asp-­‐Hyd-­‐ADR).	   	   The	   effective	   dose	   for	   the	  
targeted	  system	  improved	  upon	  the	  nontargeted	  system,	  which	  was	  also	  lower	  than	  the	  
effective	  dosage	  for	  the	  free	  drug	  in	  in	  vivo	  studies	  with	  tumor-­‐bearing	  CD-­‐1	  nude	  mice.	  	  
These	  results	  indicated	  that	  targeted	  micelles	  (containing	  10%	  of	  the	  folate-­‐conjugated	  
polymer)	   performed	   more	   effectively	   than	   nontargeted	   micelles	   despite	   similar	  
pharmacokinetic	  profiles	  of	  micelle	  accumulation	  in	  the	  tumor	  and	  relatively	  close	  area	  
under	  the	  curves	  (AUC)	  for	  the	  drug	  accumulation	  in	  tumors	  (132.67	  and	  143.60	  percent	  
initial	  dose	   (%ID)/g	  organ	  x	  h,	   respectively).	   	  While	   the	   internalization	  of	   targeted	  and	  
nontargeted	   nanoparticles	   was	   not	   monitored	   in	   vivo	   in	   this	   study,	   the	   preferential	  
internalization	   of	   targeted	   nanoparticles	   is	   hypothesized	   to	   be	   the	   reason	   for	   the	  
improved	  effective	  dose.	  	  	  
Another	   common	   targeting	   ligand,	   transferrin	   (Tf),	   has	   been	   conjugated	   to	   a	  
variety	   of	   targeted	   delivery	   systems	   to	   target	   overexpressed	   Tf	   receptors	   common	   to	  
many	  cancers.	   	  As	  observed	   in	   folate	  receptor	   targeted	  systems,	  nanoparticles	  with	  Tf	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targeting	   ligands	   improve	  delivery	  but	  have	  a	  biodistribution	  and	   tumor	  accumulation	  
similar	   to	  nontargeted	  systems	   [5].	   	   For	  example,	  Bartlett	  et	  al	   focused	  on	  delivery	  of	  
siRNA	  using	  cyclodextrin-­‐containing	  polycations	  and	  used	  positron	  emission	  tomography	  
(PET)	  and	  bioluminescence	  imaging	  to	  simultaneously	  monitor	  the	  nanoparticle	  location	  
and	  siRNA	  activity	  as	  shown	  in	  Figure	  2.	  	  In	  this	  study,	  siRNA	  activity	  was	  higher	  for	  the	  
targeted	  delivery	  systems	  (Figure	  2c).	   	  The	  improved	  siRNA	  activity	  was	  attributed	  to	  a	  
greater	  tumor	  cell	   internalization	  of	  the	  targeted	  nanoparticles	  versus	  the	  nontargeted	  
nanoparticles,	   because	   the	   tumor	   accumulation	   of	   targeted	   and	   nontargeted	  
nanoparticles	  was	   similar.	   	   Approximately	   1%	   initial	   dose	   (ID)	   accumulated	   per	   tumor	  
volume	   one	   day	   after	   injection.	   	   Additionally,	   Bartlett	   et	   al	   found	   that	   nanoparticle	  
accumulation	  in	  tumors	  was	  independent	  of	  the	  Tf-­‐receptor	  level.	  	  	  
In	  addition	  to	  the	  improvements	  in	  delivery	  via	  folate	  and	  transferrin	  targeting,	  
enhanced	  performances	  due	  to	  nanoparticle	  internalization	  have	  been	  seen	  for	  multiple	  
systems	  with	  antibody-­‐directed	  targeting.	  	  In	  a	  study	  focused	  on	  spectroscopic	  detection	  
of	   cancer	   using	   surface-­‐enhanced	   Raman	   (SERS)	   via	   colloidal	   gold	   Raman	   nanotags,	  
single-­‐chain	  variable	   fragment	  antibodies	   for	  epidermal	  growth	   factor	   receptor	   (EGFR)	  
were	  harnessed	  for	  targeting	  of	  80	  nm	  nanotags	  [6].	  	  Transmission	  electron	  micrographs	  
of	  tumor	  cells	  revealed	  that	  the	  targeted	  nanotags	  were	  more	  readily	  internalized.	  	  The	  
enhanced	   internalization	   of	   targeted	   nanotags	   paralleled	   an	   increase	   in	   Raman	   signal	  
intensity	   from	   tumors	   treated	   with	   the	   targeted	   nanotags.	   	   Biodistribution	  
measurements	  showed	  that	  the	  accumulation	  and	  retention	  of	  EGFR	  targeted	  nanotags	  
in	  the	  tumor	  was	  about	  10	  times	  greater	  than	  that	  of	  nontargeted	  controls.	  	  
Similar	   findings	   have	   been	   reported	   for	   antibody	   targeting	   of	   liposomes.	   	   For	  
example,	   liposomes	  possessing	  an	  anti-­‐HER2	  monoclonal	  antibody	  (MAb)	  composed	  of	  
phosphatidylcholine	   and	   polyethylene	   glycol	   (PEG)-­‐modified	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distearoylphoshphatidylethanolamine	   (DSPE)	   (PEG-­‐DSPE)	   with	   an	   average	   particle	  
diameter	   of	   100	   nm	   were	   shown	   to	   improve	   antitumor	   efficacy	   of	   doxorubicin	   over	  
various	  control	  formulations	  [7].	  	  Kirpotin	  et	  al	  further	  evaluated	  the	  biodistribution	  and	  
uptake	   of	   these	   targeted	   liposomes	   containing	   the	   anti-­‐HER2	   MAb	   compared	   to	  
nontargeted	   liposomes	   [8].	   	   They	   found	   that	   the	   biodistribution	   of	   targeted	   and	  
nontargeted	   liposomes	  was	   similar.	   	   In	   fact,	   localization	   of	   targeted	   and	   nontargeted	  
liposomes	   in	  HER-­‐2	  overexpressing	   xenografts	   (BT-­‐474)	   and	  non-­‐HER-­‐2-­‐overexpressing	  
xenografts	  (MCF-­‐7)	  were	  not	  statistically	  different	  with	  a	  range	  of	  7-­‐8%	  of	  the	  injected	  
dose	  per	  gram	  of	  tumor	  tissue	  (ID/g	  tumor).	  	  Targeted	  and	  nontargeted	  liposomes	  were	  
shown	   to	   extravasate	   tumor	   blood	   vessels	   in	   both	   xenograft	  models,	   yet	   a	   significant	  
difference	   between	   the	   targeted	   and	   nontargeted	   liposomes	   was	   observed	   in	   the	  
microdistribution	  within	   HER-­‐2-­‐overexpressing	   tumor	   xenografts.	   	   Targeted	   liposomes	  
were	   found	  predominantly	   in	   tumor	   cells	  while	   nontargeted	   liposomes	  were	   found	   in	  
the	  extracellular	  spaces	  or	   in	  macrophages	  associated	  with	  tumor	  tissue.	   	  For	  targeted	  
liposomes,	   there	   was	   a	   four-­‐fold	   greater	   preference	   for	   nanoparticle	   localization	   in	  
xenograft	  tumor	  cells	  rather	  than	  host	  cells	  while	  there	  was	  no	  statistical	  preference	  for	  
tumor	  cells	  over	  host	  cells	  in	  the	  case	  of	  nontargeted	  liposomes.	  	  	  
Likewise,	  ElBayoumi	  and	  Torchilin	  used	  antibody	  targeting	  to	  enhance	  delivery	  of	  
doxorubicin	  loaded	  PEGylated	  liposomes	  [9].	  	  The	  targeting	  ligand,	  monoclonal	  antibody	  
2C5	   (mAb	   2C5)	   with	   nucleosome-­‐restricted	   activity,	   increased	   accumulation	   of	  
liposomes	  in	  Lewis	  lung	  carcinoma	  tumor	  models	  over	  nontargeted	  systems.	  	  Following	  
administration	   of	   liposomes,	   a	   greater	   reduction	   in	   tumor	   volume	   was	   achieved	   by	  
doxorubicin	  delivery	  from	  targeted	  liposomes.	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Passive	  Targeting	  of	  Tumors	  
While	  the	  active	  targeting	  schemes	  described	  above	  involve	  the	  use	  of	  molecules	  
designed	   to	   specifically	   interact	   with	   a	   physiological	   target,	   passive	   targeting	   takes	  
advantage	  of	  natural	  properties	  and	  processes	  in	  tissues	  to	  localize	  a	  delivery	  agent	  at	  a	  
desired	  target	  site.	   	   	  The	  most	  common	  type	  of	  passive	  targeting	  is	  tumor	  targeting	  by	  
the	   EPR	   effect.	   	   To	   exploit	   this	   effect,	   the	   size	   of	   nanoparticles	   is	   designed	   to	   allow	  
nanoparticles	  to	  extravasate	  from	  defects	  in	  tumor	  vasculature.	  	  Nanoparticles	  between	  
100-­‐200	   nm	   have	   been	   shown	   to	   accumulate	   in	   tumors	   by	   the	   EPR	   effect.	   	   Larger	  
molecules	  such	  as	  nanoparticles	  can	  diffuse	  out	  of	  defective	  tumor	  vasculature	  but	  are	  
retained	   in	   the	   tumor	   space	  due	   to	   insufficient	   venous	   and	   lymphatic	   clearance.	   	   The	  
retention	   of	   large	   molecules	   such	   as	   nanoparticles	   is	   typically	   higher	   than	   small	  
molecules	  which	  can	  more	  easily	  diffuse	  back	  into	  vasculature	  as	  shown	  in	  Figure	  3	  [10].	  	  
In	  addition	  to	  appropriate	  size,	  nanoparticles	  must	  have	  properties	  that	  allow	  for	  a	  long	  
circulation	   time.	   	   Passive	   tumor	   targeting	   by	   the	   EPR	   effect	   requires	   a	   driving	  
concentration	  gradient	  of	  nanoparticles	  for	  a	  sustained	  time	  period	  of	  at	   least	  6	  hours	  
[10,	  11].	   	  As	  a	   result,	  PEGylation	  and	  surface	  charge	  are	   important	  design	  parameters	  
due	   to	   their	   known	   effect	   on	   circulation	   times.	   	   In	   vivo	   targeting	   delivery	   studies	  
suggested	  that	  the	  presence	  of	  a	  targeting	  ligand	  does	  not	  appear	  to	  significantly	  affect	  
extravasation,	  but	  inefficient	  extravasation	  could	  significantly	  affect	  targeted	  delivery.	  	  	  
Challenges	  to	  Tumor	  Delivery	  
One	   of	   the	   challenges	   to	   developing	   a	   successful	   tumor	   targeting	   delivery	  
platform,	   is	   that	   even	   with	   passive	   and	   active	   targeting	   only	   a	   fraction	   of	   the	  
administered	  dose	  accumulates	  in	  the	  tumor.	  	  This	  brings	  two	  questions	  to	  light:	  is	  there	  
enough	  accumulation	  at	  the	  target	  site	  and	  what	  is	  the	  systemic	  dose?	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In	   short,	   effective	   delivery	   can	   be	   achieved	   at	   the	   tumor	   site.	   	   Whether	   the	   dose	  
administered	   is	  an	  effective	  dose	   is	  easily	  gauged	  by	  a	  sufficient	  suppression	   in	   tumor	  
growth.	  	  The	  effective	  dose	  is	  dependent	  on	  nanoparticle	  localization	  at	  the	  tumor	  site	  
but	  also	  on	  the	  maximum	  payload	  that	  each	  nanoparticle	  can	  deliver.	   	  To	  put	  this	   into	  
perspective,	  nanoparticles	  localize	  in	  tumors	  at	  much	  lower	  levels	  than	  the	  administered	  
dose	  (Table	  1).	   	  So,	   if	  the	  amount	  of	  drug	  or	  image	  contrast	  agent	  is	   increased	  in	  each	  
nanoparticle,	   a	   higher	   dose	   arrives	   at	   the	   tumor	   site.	   	   	   However,	   there	   is	   a	   balance	  
between	   the	   payload	   and	   the	   number	   of	   nanoparticles.	   	   The	   fraction	   of	   the	  
administered	  dose	  that	  localizes	  in	  the	  tumor	  relative	  to	  the	  mass	  of	  the	  tumor	  (%ID/g	  
tumor)	  is	  also	  lower	  than	  other	  in	  organs	  (the	  %	  ID/g	  tissue)	  such	  as	  the	  liver	  [12].	  	  What	  
this	   tells	  us	   is	   that	  other	  organs	  have	  an	   increased	  exposure	  per	  gram	  of	  tissue	  to	  the	  
nanoparticles	  and	  their	  payloads	  than	  the	  tumor	  often	  does.	  	  So,	  an	  increase	  in	  the	  drug	  
or	  contrast	  agent	  could	  be	  detrimental.	  	  	  
A	   greater	   cell	   internalization	   accompanied	   by	   a	   simultaneous	   improvement	   in	  
performance	  of	  targeted	  nanodelivery	  systems	  is	  a	  recurring	  theme	  in	  cancer	  delivery.	  	  
Clearly,	   the	   selection	   of	   the	   targeting	   ligand	   is	   important,	   but	   the	   nanoparticle	  
properties	  that	  influence	  accumulation	  in	  the	  tumor	  are	  important	  design	  parameters	  as	  
well.	  	  
Targeting	  of	  atherosclerotic	  plaques	  
	   Second	   to	   tumor	   targeting,	   the	  most	   common	   application	   of	   targeted	   imaging	  
and	   treatment	   is	   atherosclerosis.	   	   In	   targeting	   atherosclerosis,	   the	   delivery	   system	  
circulates	   in	   the	  bloodstream	  and	  must	  adhere	   to	  a	  specific	   region	  of	   the	  vasculature.	  	  
The	  small	  size	  and	  relatively	   large	  surface	  area	  of	  nanoparticles	  makes	  them	  attractive	  
candidates	   for	   this	   application.	  Because	   circulating	  nanodelivery	   systems	  must	   adhere	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to	   atherosclerotic	   lesions,	   understanding	   nanoparticle	   adhesion	   and	   behavior	   in	   flow	  
conditions	   is	   extremely	   important,	   although	   it	   is	   beyond	   the	   scope	   of	   this	   paper.	   	   To	  
date,	   the	   majority	   of	   in	   vivo	   studies	   have	   focused	   on	   the	   delivery	   of	   image	   contrast	  
agents.	   	   As	   a	   result,	   the	   preferential	   accumulation	   of	   targeted	   nanoparticles	   at	  
atherosclerotic	   lesions	   has	   often	   been	   confirmed	   by	   improved	   image	   contrast	   or	  
increases	  in	  the	  signal	  at	  the	  target	  site	  relative	  to	  the	  background.	  
In	  one	  such	  study,	  an	  improved	  contrast	  in	  fluorescence	  imaging	  and	  delivery	  of	  
a	  heparin	  hirulog	   therapeutic	  was	  achieved	  using	  micelles	  with	  a	  clot-­‐binding	  peptide,	  
cysteine-­‐arginine-­‐glutamic	   acid-­‐lysine-­‐alanine	   (CREKA)	   to	   target	   fibrin	   deposits	   on	  
atherosclerotic	  plaques	  [13].	   	  The	  micelles	  were	  formed	  from	  PEG-­‐DSPE	  polymers	  with	  
variable	  head	  groups	  labeled	  with	  carboxyfluorescein	  (FAM-­‐labeled)	  for	  imaging,	  CREKA	  
for	   targeting,	   or	   a	   heparin	   hirulog	   for	   treatment.	   	   Results	   showed	   that	   the	   targeted	  
micelles	   improved	   the	   fluorescence	   intensity	   of	   atherosclerotic	   plaques	   in	   the	   aortic	  
tree	  over	  nontargeted	  micelles	  as	  well	  as	  the	  delivery	  of	  the	  heparin	  hirulog	  as	  seen	  in	  
Figure	   4.	   	   The	  CREKA	   targeting	   ligand	  was	   shown	   to	   be	   responsible	   for	   this	   improved	  
contrast	   because	   through	   competitive	   inhibition	   studies.	   	   The	   contrast	   provided	   by	  
targeted	   FAM-­‐labeled	   micelles	   was	   depleted	   with	   the	   addition	   of	   excess	   unlabeled	  
targeted	   micelles	   but	   remained	   the	   same	   with	   the	   addition	   of	   excess	   unlabeled	  
nontargeted	  micelles.	   	  Additionally,	  CREKA	  targeted	  micelles	  were	  more	  effective	  than	  
nontargeted	   control	   micelles	   in	   delivering	   hirulog	   to	   plaques	   in	   an	   ApoE-­‐null	   mouse	  
model.	   	   The	   ability	   to	   target	   delivery	   to	   diseased	   tissue	   using	   the	   CREKA	   targeted	  
micelles	  by	   showing	   that	  hirulog	  delivery	  was	   significantly	   lower	   in	  nonatherosclerotic	  
(wild-­‐type)	  mice	  (Figure	  3c).	  
	   Enhanced	   contrast	   of	   magnetic	   resonance	   imaging	   (MRI)	   of	   atherosclerotic	  
plaques	   has	   also	   been	   achieved	   using	   targeted	   nanodelivery	   of	   contrast	   agents.	   	   For	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example,	  magnetofluorescent	   nanoparticles	   targeted	   to	   vascular	   adhesion	  molecule-­‐1	  
(VCAM-­‐1),	   a	   biomarker	   for	   atherosclerosis,	   enhanced	   MRI	   and	   fluorescence	   image	  
contrast	   agent	   delivery	   compared	   to	   nontargeted	   controls	   in	   a	   cholesterol-­‐fed	   apoE-­‐/-­‐	  
mouse	   model	   [14].	   	   In	   another	   study,	   Neubauer	   et	   al	   examined	   targeted	   delivery	   of	  
paramagnetic	   liquid	   perfluorocarbon	   nanoparticles	   which	   incorporated	   a	  
peptidomimetic	  victronectin	  antagonist	  for	  targeting	  the	  αvβ3	  integrins	  [15].	   	   	  Targeted	  
systems	  enhanced	  MRI	   images	  compared	  to	  the	  nontargeted	  systems	  with	  double	  the	  
concentration	   at	   the	   aortic	  wall	   (0.38%	   ID	   compared	   to	   0.18%	   ID	   for	   nontargeted,	   or	  
1.64	   compared	   to	   0.84	   nmol	   Gd/g	   tissue/h,	   respectively)	   in	   a	   cholesterol-­‐fed	   rabbit	  
model.	  	  	  
	   Several	  other	  studies	  have	  focused	  on	  targeted	  delivery	  systems	  as	  platforms	  for	  
image	   contrast	   agents	   in	   atherosclerosis	   and	   have	   shown	   significant	   image	  
enhancement	   over	   controls.	   	   For	   example,	   Park	   et	   al.	   demonstrated	   that	  
hydrophobically	   modified	   chitosan	   nanoparticles	   with	   a	   peptide	   targeting	   ligand	  
selectively	  accumulate	  at	  atherosclerotic	  plaques	  [16].	  	  In	  addition,	  magnetofluorescent	  
nanoparticles	  were	   targeted	   to	  macrophages	   associated	  with	   atheroma	  using	   dextran	  
[17].	   	   Administration	   of	   the	   targeted	   nanoparticles	   resulted	   in	   significant	   image	  
enhancement	   over	   saline	   controls	   in	   the	   blood-­‐plaque	   contrast-­‐to-­‐noise	   ratio	   of	  MRI.	  	  
Improvements	  were	  also	  observed	   in	  near	   infrared	   reflectance	   fluorescence	   images	   in	  
the	   plaque-­‐to-­‐background	   ratio.	   	  While	   these	   studies	   and	   others	   have	   not	   compared	  
targeted	   delivery	   with	   nontargeted	   delivery	   to	   atheroma,	   these	   results	   indicate	   that	  
targeted	  delivery	  is	  a	  promising	  approach	  to	  treatment	  and	  diagnosis	  of	  cardiovascular	  
diseases.	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The	  “fate”	  of	  the	  nanoparticle	  delivery	  system	  
The	   systemic	   biodistribution	   of	   nanoparticle	   delivery	   systems	   after	  
administration	   is	  one	  of	  the	  most	   important	   issues	  and	  design	  elements	  to	  consider	   in	  
targeted	   delivery.	   	   There	   is	   an	   innate	   relationship	   between	   the	   physicochemical	  
properties	   of	   the	   nanoparticle	   and	  what	   happens	   to	   the	   particle	   after	   administration.	  	  
This	   section	   will	   focus	   on	   the	   biodistribution,	   opsonization,	   and	   clearance	   of	  
nanoparticles	  related	  to	  targeted	  delivery.	  	  	  	  	  
Opsonization	  and	  Clearance	  
For	   targeted	   delivery	   applications,	   there	   is	   a	   delicate	   balance	   between	   the	  
circulation	  time	  necessary	  for	  particle	  localization	  at	  the	  target	  site	  and	  a	  suitable	  time	  
frame	   for	   elimination.	   	   The	   eventual	   elimination	   (or	   whole	   body	   elimination)	   of	  
nanomaterials	   is	   particularly	   important	   due	   to	   concerns	   over	   long-­‐term	  exposure	   and	  
interference	  with	  other	  diagnostics	  and	  therapies.	  	  	  
Both	   renal	   filtration	   and	   opsonization	   result	   in	   removal	   of	   nanomaterials	   from	  
the	  bloodstream.	  	  Nanoparticles	  smaller	  than	  the	  renal	  filtration	  cut-­‐off	  of	  50	  kDa	  or	  5-­‐6	  
nm	  are	  rapidly	  cleared	  from	  the	  bloodstream	  and	  excreted	  as	  demonstrated	  by	  Choi	  et	  
al	   and	   summarized	   in	   Figure	   5	   [18].	   	   Larger	   nanoparticles	   can	   be	   removed	   from	   the	  
bloodstream	  by	   the	   reticuloendothelial	   system	   (RES)	   through	  opsonization	   resulting	   in	  
nanoparticle	  accumulation	   in	  the	   liver,	  spleen,	  and	   lungs.	   	  Both	  the	  size	  and	  charge	  of	  
nanoparticles	   is	   known	   to	   affect	   opsonization.	   	   In	   general,	   smaller	   particles	   tend	   to	  
circulate	  longer	  [19].	  	  Surface	  engineering	  such	  as	  charge	  shielding	  and	  the	  reduction	  of	  
the	   adsorption	   of	   opsonin	   proteins	   on	   the	   nanomaterial	   has	   been	   shown	   to	   slow	  
opsonization	   by	   imparting	   ‘stealth’	   properties	   to	   the	   nanoparticle.	   	   For	   example,	   the	  
addition	  of	  hydrophilic	  molecules	  such	  as	  PEG	  has	  been	  used	   in	  a	  variety	  of	  studies	  to	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slow	   opsonization.	   	   While	   we	   have	   alluded	   to	   the	   effect	   that	   PEGylation	   has	   on	  
nanoparticle	  opsonization,	  there	  have	  been	  several	  extensive	  reviews	  that	  give	  a	  more	  
in	   depth	   discussion	   of	   the	   factors	   affecting	   opsonization	   and	   strategies	   for	   slowing	  
opsonization	  [19,	  20].	  
In	  general,	  the	  selection	  of	  nanoparticle	  clearance	  rate	  is	  dependent	  on	  the	  application.	  	  
For	   tumor	   targeting,	   the	   blood	   half-­‐life	   in	   combination	   with	   the	   administered	   dose	  
should	   afford	   a	   high	   blood	   concentration	   of	   nanoparticles	   for	   several	   hours	   [11].	  	  
Shorter	  blood	  half-­‐lives	  may	  be	  desirable	  in	  other	  applications	  like	  image	  contrast	  agent	  
delivery.	   	  Rapid	   localization	  and	  short	  half-­‐lives	  would	  allow	  administration	  of	  contrast	  
agent	  and	  imaging	  to	  be	  performed	  on	  a	  patient	  during	  a	  single	  appointment.	  	  Because	  
nanoparticles	  are	  highly	  tunable,	  shorter	  or	   longer	  blood	  half-­‐lives	  can	  be	  achieved	  on	  
the	  order	  of	  minutes	  to	  hours.	   	  For	  example,	  quantum	  dots	  have	  been	  shown	  to	  have	  
half-­‐lives	  that	  range	  from	  48	  min	  to	  20	  h	  as	  demonstrated	  in	  Figure	  5	  [18].	  	  	  
An	  emerging	  issue	  in	  the	  field	  of	  nanoparticle	  delivery	  is	  the	  overall	  elimination	  
of	   the	   nanoparticles.	   	   Clearance	   from	   the	   bloodstream	   is	   different	   than	   clearance	   or	  
elimination	   from	   the	  body.	   	   Biodegradable	  polymeric	   systems	  do	  address	   the	   issue	  of	  
elimination	  as	  long	  as	  they	  degrade	  to	  eliminable	  byproducts,	  but	  eventual	  elimination	  
is	  an	  issue	  for	  organic	  and	  inorganic	  systems	  that	  are	  not	  degradable.	  	  One	  recent	  study	  
has	  highlighted	  this	  issue	  by	  demonstrating	  that	  quantum	  dots	  can	  remain	  fluorescent	  in	  
vivo	   for	   two	   years	   [21].	   	   This	   nonelimination	   could	   cause	   significant	   problems	   if	   the	  
quantum	  dots	  interfere	  with	  other	  treatments	  or	  diagnostics.	  	  	  
Biodistribution	  
Because	   understanding	   biodistribution	   is	   fundamental	   to	   the	   development	   of	  
successful	   targeted	   nanodelivery	   systems,	   it	   is	   important	   to	   understand	   some	   of	   the	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factors	   affecting	   biodistribution	   both	   from	   an	   experimental	   perspective	   and	   material	  
design	  perspective.	   	  Currently,	   there	  are	  not	   standardized	  practices	   for	  evaluating	   the	  
performance	  of	  targeted	  delivery	  systems.	  	  As	  a	  result,	  it	  is	  difficult	  to	  compare	  results	  
across	  studies.	   	  For	  example,	  some	  of	  the	  experimental	  factors	  affecting	  the	  measured	  
biodistribution	   of	   nanomaterials	   are	   the	   initial	   dose	   [4,	   22]	   the	   method	   of	  
administration	   [23],	   the	  experimental	  model	   (including	   the	   tumor	  mass	   in	   the	   case	  of	  
tumor	   delivery)	   [12],	   and	   the	   experimental	   time	   range.	   As	   targeted	   nanodelivery	  
systems	   continue	   to	   be	   developed,	   standardized	   practices	   and	   the	   effect	   of	  
experimental	  conditions	  on	  results	  will	  become	  key	  experimental	  considerations.	  	  	  	  
Despite	   the	   fact	   that	   there	   are	   not	   standardized	   procedures	   in	   measuring	  
biodistribution,	   there	  are	   some	  commonalities	  and	   trends	   in	   the	  development	  of	  new	  
experimental	   techniques.	   	   Perhaps,	   the	   use	   of	   autoradiography	   in	   monitoring	  
nanoparticle	  biodistribution	  of	  radiolabeled	  nanomaterials	   is	  one	  of	  the	  most	  common	  
elements	  across	  studies	   [19].	   	  The	  widespread	  usage	  of	  autoradiography	   is	  due	   to	   the	  
ability	  to	  easily	  and	  quantitatively	  measure	  small	  concentrations,	  but	  there	  are	  several	  
drawbacks	   to	   radiography.	   	  Autoradiography	   requires	   tissue	  excision	  so	  only	  one	   time	  
point	  can	  be	  measured	  per	  sample,	  and	  there	  are	  safety	  considerations	  in	  practicing	  this	  
technique.	   	   Because	   of	   this,	   there	   is	   a	   growing	   body	   of	   literature	   that	   has	   used	  
alternative	  methods	  to	  quantify	  biodistribution	  (Table	  2).	  	  	  	  
Similar	   biodistributions	   for	   systems	   with	   and	   without	   targeting	   ligands	   is	   a	  
recurring	   theme	   in	   targeted	   delivery.	   	   	   In	   only	   a	   few	   studies,	   has	   the	   presence	   of	  
targeting	   ligands	  been	   shown	   to	  affect	  biodistribution	   in	   tissues	  other	   than	   the	   target	  
site	  [4,	  6].	  	  To	  the	  best	  of	  our	  knowledge,	  there	  have	  not	  been	  any	  studies	  to	  determine	  
whether	   internalization	   is	   improved	   by	   a	   higher	   accumulation	   at	   the	   target	   site.	  	  
However,	  it	  is	  evident	  that	  a	  higher	  concentration	  of	  nanodelivery	  systems	  at	  the	  target	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site	   allows	   a	   greater	   availability	   for	   cell	   uptake.	   	   What	   this	   underscores	   is	   that	   the	  
physicochemical	   properties	   affecting	   biodistribution	   are	   equally	   important	   for	   active	  
and	  passive	   targeting.	   	   Size,	   shape,	   surface	   charge,	   and	  mechanical	   properties	   can	  be	  
selected	  based	  on	  their	  effect	  on	  biodistribution.	  
It	   has	   been	   shown	   that	   the	   biodistribution	   of	   nanoparticles	   is	   size-­‐dependent,	   as	  
demonstrated	   by	   two	   recent	   studies	   on	   gold	   nanoparticles	   and	   PEGylated	   gold	  
nanoparticles	   [24,	   25].	   	   For	   example,	   smaller	   gold	   nanoparticles	   (10	   nm	   in	   diameter)	  
were	  distributed	  in	  more	  tissues	  than	  larger	  particles	  (50,	  100,	  or	  250	  nm)	  [25].	  	  In	  all	  of	  
the	  samples,	  nanoparticle	  accumulation	  occurred	  primarily	  in	  the	  liver,	  spleen,	  and	  the	  
blood	  as	  measured	  by	   the	   concentration	   (ng/g	   tissue)	   and	  percent	  of	   the	   initial	   dose.	  	  
Like	   gold	   nanoparticles,	   PEGylated	   gold	   nanoparticles	   exhibited	   a	   size-­‐dependent	  
biodistribution	   [24].	   	   Accumulation	   of	   20	   nm	   gold	   nanoparticles	   in	   the	   tumor	   was	  
significantly	   higher	   than	   that	   of	   80	   nm	   particles	   in	   an	   A341	   xenograft-­‐bearing	  mouse	  
model.	  	  Outside	  of	  the	  tumor,	  nanoparticles	  of	  both	  sizes	  accumulated	  predominantly	  in	  
the	   liver	   and	   spleen.	   	   As	   expected	   from	   a	   slow	   uptake	   by	   reticuloendothelial	   system	  
(RES)	  organs,	  the	  20	  nm	  particles	  had	  a	  longer	  blood	  half-­‐life	  than	  80	  nm	  particles	  and	  a	  
lower	  accumulation	  in	  the	  liver	  and	  spleen.	  	  	  
Many	   studies	   have	   predicted	   that	   the	   shape	   of	   nanoparticles	   affects	   in	   vivo	  
performance	  [26,	  27],	  but	  the	  influence	  of	  shape	  on	  nanoparticle	  biodistribution	  is	  only	  
beginning	  to	  be	  explored.	  	  To	  the	  best	  of	  our	  knowledge,	  only	  one	  study	  has	  compared	  
the	  in	  vivo	  biodistributions	  of	  nanoparticles	  with	  different	  shapes.	  	  Park	  et	  al.	  evaluated	  
the	   biodistribution	   of	   magnetic	   iron	   oxide	   nanoworms,	   elongated	   iron	   oxide	  
nanoparticles,	   and	   compared	   them	   to	   spherical	   iron	   oxide	   nanoparticles	   [28].	   	   They	  
observed	   that	   nanoworms	   more	   readily	   accumulated	   in	   tumors	   in	   an	   MDA-­‐MB-­‐435	  
xenograft-­‐bearing	   mouse	   model	   than	   nanospheres.	   	   After	   48	   h,	   nanoworms	   still	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remained	   in	   the	  tumor	  while	  nanospheres	  did	  not.	   	  The	  overall	  biodistributions	  of	   the	  
two	  systems	  after	  24	  h	  were	  similar,	  where	  each	  showed	  a	   lower	  accumulation	   in	   the	  
kidney	  relative	  to	  the	  liver	  and	  a	  higher	  accumulation	  in	  the	  spleen	  relative	  to	  the	  liver.	  	  
The	  circulation	  time	  for	  both	  systems	  was	  comparable	  with	  blood	  circulation	  half-­‐lives	  
between	  15	  and	  18	  h.	  	  
In	   conjunction	  with	   size,	   the	   composition	   of	   nanoparticles	   has	   been	   shown	   to	  
affect	   biodistribution	   by	   determining	   the	   “flexibility	   or	   shape	   adaptability”	   of	   the	  
nanoparticle	   [29].	   	   When	   comparing	   the	   biodistribution	   of	   two	   relative	   sizes	   of	   shell	  
cross-­‐linked	  nanoparticles	  having	  diameters	  of	  approximately	  20	  nm	  or	  37	  nm	  and	  core	  
compositions	   of	   either	   glassy	   polystyrene	   or	   fluid-­‐like	   poly(methyl	   acrylate),	   Sun	   et	   al	  
found	  that	  small	  particles	  with	  polystyrene	  cores	  (18	  ±	  3	  nm)	  had	  a	  greater	  retention	  in	  
the	  blood	  compared	  to	  small	  particles	  with	  poly(methyl	  acrylate)	  cores	  (24	  ±	  3	  nm).	  	  The	  
initial	  accumulation	  of	  nanoparticles	   in	  the	   liver,	   lung,	  and	  spleen	  was	  higher	  for	  small	  
particles	  with	  a	  poly(methyl	  acrylate)	  core	  composition	  than	  particles	  with	  polystyrene	  
core	   compositions	   at	   10	   min	   and	   1	   h.	   	   The	   authors	   suggested	   that	   increased	   shape	  
adaptability	  imparted	  by	  the	  more	  flexible	  poly(methyl	  acrylate)	  core	  contributed	  to	  the	  
observed	  differences.	  	  	  
Surface	   properties,	   such	   as	   surface	   charge	   and	   PEGylation,	   also	   affect	   the	  
biodistribution	  of	  nanoparticles.	  	  Generally,	  the	  addition	  of	  neutral	  hydrophilic	  polymers	  
to	  the	  surface	  of	  nanoparticles	  neutralizes	  the	  surface	  charge.	  	  Neutralization	  of	  surface	  
charge	   has	   been	   associated	   with	   improved	   blood	   retention	   time	   and	   decreased	  
opsonization	  by	  the	  RES	  giving	  rise	  to	  the	  term	  ‘stealth	  properties’	   [30].	   	  For	  example,	  
the	   addition	   of	   PEG	   to	   poly(lactide-­‐co-­‐glycolic	   acid)	   (PLGA)	   liposomes	   (PLGA-­‐mPEG	  
liposomes)	  affects	  biodistribution	   in	  a	  manner	  dependent	  on	  the	  ratio	  of	  PLGA	  to	  PEG	  
[31].	   	   A	   comparison	  between	   similarly	   sized	  PLGA	  nanoparticles	   and	  PLGA-­‐mPEG(256)	  
	   206	  
nanoparticles	  revealed	  that	  they	  had	  different	  surface	  charges	  (-­‐54.2	  mV	  and	  -­‐5.9	  mV,	  
respectively).	   	   The	   neutralized	   surface	   charge	   of	   the	   PLGA-­‐mPEG	   system	   increased	  
nanoparticle	  retention	  in	  the	  blood	  after	  3	  hours	  to	  42.6%	  ID	  in	  comparison	  to	  4.1%	  ID	  
of	   the	   PLGA	   dose.	   	  Meanwhile,	   the	   accumulation	   of	   PLGA-­‐mPEG	   nanoparticles	   in	   the	  
liver	  was	  generally	   lower	  than	  PLGA	  nanoparticles.	   	  Similar	  effects	  have	  been	  achieved	  
with	   the	   PEGylation	   of	   poly(caprolactone)	   (PCL)	   nanoparticles	   [31].	   	   For	   example,	   the	  
surface	  charge	  of	  the	  PCL	  nanoparticles	  was	  increased	  from	  -­‐27.17	  mV	  to	  -­‐6.046	  mV	  by	  
the	   addition	   of	   PEG,	   and	   a	   significant	   improvement	   in	   the	   blood	   retention	   time	   was	  
accompanied	   by	   a	   drop	   in	   nanoparticle	   accumulation	   in	   the	   liver	   and	   lungs	   for	  
PEGylated	  PCL	  nanoparticles.	  	  	  
The	  change	   in	  surface	  charge	   imparted	  by	  a	  polymer	  surface	  coating	   is	  not	  the	  
only	  factor	  affecting	  biodistribution.	   	  The	  composition	  of	  the	  polymer	   is	  a	  determining	  
factor	  as	  well.	   	  This	  phenomenon	  was	  explored	  with	  the	  adsorption	  of	  poloxamer	  407,	  
poloxamine	   904,	   and	   poloxamine	   908	   onto	   the	   surface	   of	   polystyrene	   and	   PLGA	  
nanoparticles	   [32].	   	   Following	   administration	   in	   a	   rabbit	   model,	   the	   poloxamer	   407	  
coating	  was	   the	  most	  effective	   in	   reducing	  nanoparticle	  clearance	   from	  the	  blood	  and	  
liver	   accumulation	   after	   3	   hours	   even	   though	   the	   poloxamine	   908	   formulation	   had	   a	  
more	  neutral	  surface	  charge	  than	  those	  with	  a	  poloxamer	  407	  coating.	  	  	  
For	   much	   smaller	   PEGylated	   nanoparticles,	   the	   length	   of	   PEG	   chains	   and	   end	  
group	  functionality	  plays	  a	  greater	  role	  in	  determining	  biodistribution	  as	  demonstrated	  
with	   10	   nm	   diameter	   Gadolinium	   nanoparticles	   [33].	   	   The	   biodistribution	   of	   polymer	  
coated	   Gadolinium	   nanoparticles	   was	   affected	   by	   the	   length	   of	   the	   PEG	   chains.	  	  
Differences	   in	   the	   biodistribution	   of	   nanoparticles	   coated	  with	   similar	   lengths	   of	   PEG	  
revealed	   that	   the	   end	   group	   (carboxylic	   acid,	   methoxy,	   or	   amine)	   of	   the	   PEG	   chain	  
affected	  biodistribution.	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Given	   that	   lowering	   systemic	   toxicity	   is	   a	   goal	   of	   targeted	   delivery	   and	   only	   a	  
fraction	   of	   the	   total	   dose	   administered	   accumulates	   at	   the	   target	   site,	   the	  
biodistribution	  in	  other	  tissues	  and	  clearance	  rate	  are	  extremely	  important.	  	  
	  
Incorporation	  and	  Release	  of	  Therapeutics	  from	  Nanodelivery	  Systems	  
The	   importance	   of	   controlling	   nanoparticle	   localization	   for	   targeted	   delivery	   is	  
inconsequential	  if	  a	  particle	  cannot	  carry	  a	  relevant	  amount	  of	  drug	  and	  release	  it	  at	  the	  
target	   site.	   	   The	   ability	   to	   efficiently	   incorporate	   a	   drug	   into	   nanoparticle	   delivery	  
systems	  is	  dependent	  on	  the	  drug	  itself,	  the	  design	  of	  the	  nanoparticle,	  and	  the	  method	  
of	  loading.	  Countless	  strategies	  have	  been	  used	  to	  synthesize	  organic	  nanoparticles	  with	  
an	  intended	  application	  in	  drug	  delivery,	  however,	  only	  a	  fraction	  of	  these	  systems	  have	  
demonstrated	  a	  definitive	  ability	  to	  entrap	  a	  drug	  or	  model	  molecule,	  and	  most	  of	  these	  
studies	   have	   focused	   on	   a	   relatively	   small	   number	   of	   nanodelivery	   systems,	   most	  
commonly	   biodegradable	   PLGA.	   	   This	   section	   will	   focus	   specifically	   on	   nanoparticle	  
systems	  designed	  to	  successfully	  entrap	  a	   therapeutic,	   the	  strategies	  used	   for	   loading,	  
and	  data	  on	  drug	  release	  when	  available.	  
	   Selection	  of	  a	  general	  nanodelivery	  system,	  be	  it	  targeted	  or	  nontargeted,	  should	  
reflect	   the	   properties	   of	   the	   drug	   and	   the	   intended	   application.	   	   For	   example,	   the	  
nanodelivery	   system	   should	   maintain	   drug	   stability	   and	   should	   be	   hydrophilic	   or	  
hydrophobic	  to	  ensure	  compatibility	  with	  the	  drug.	  	  Properties	  of	  the	  drug,	  such	  as	  size,	  
charge,	   and	   hydrophilicity	   or	   hydrophobicity,	   typically	   determine	   whether	   the	   carrier	  
can	  effectively	  entrap,	  protect,	  and	  release	  the	  drug.	  	  Mechanisms	  for	  drug	  entrapment	  
vary	   depending	   on	   the	   type	   of	   nanoparticle	   and	   the	   drug	   itself.	   	   In	   many	   cases,	   the	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method	  of	  drug	  loading	  determines	  the	  efficiency	  of	  the	  loading	  process	  and	  ultimately	  
whether	  a	  nanodelivery	  system	  is	  suitable	  for	  the	  intended	  application.	  	  
Most	   nanodelivery	   systems	   can	   be	   placed	   into	   one	   or	   more	   of	   three	   large	  
groups:	   biodegradable	   polymer	   nanoparticles;	   self-­‐assembled	   carriers	   including	  
micelles,	   liposomes,	   and	   polymersomes;	   or	   hydrophilic	   crosslinked	   systems	   such	   as	  
nanoscale	  hydrogels,	  also	  called	  nanogels.	  While	  in	  the	  case	  of	  self-­‐assembled	  carriers,	  
therapeutics	   can	   be	   simply	   loaded	   during	   micelle	   or	   vesicle	   assembly,	   biodegradable	  
nanoparticle	   matrices	   are	   loaded	   during	   post-­‐polymerization	   nanoparticle	   formation	  
using	   emulsion	   and	   solvent	   evaporation	   techniques.	   	   On	   the	   other	   hand,	   nanogel	  
systems	  are	  typically	  loaded	  after	  nanoparticle	  formation	  by	  incubating	  the	  particles	  in	  a	  
solution	  containing	  the	  drug.	  	  The	  drug	  becomes	  entrapped	  in	  the	  crosslinked	  network	  
by	   simple	   partitioning	   effects,	   which	   allow	   the	   drug	   to	   diffuse	   into	   the	   nanoparticle	  
matrix.	   	   The	   loading	   of	   hydrophilic	   and	   hydrophobic	   drugs	   in	   some	   of	   these	   types	   of	  
nanodelivery	  systems	  is	  shown	  in	  Figure	  6.	  
	   The	   amount	   of	   a	   drug	   that	   has	   been	   successfully	   loaded	   into	   a	   nanodelivery	  
system	  is	  typically	  quantified	  in	  one	  of	  two	  ways.	   	  The	  most	  common	  measure	  cited	  is	  
the	   entrapment	   efficiency,	   also	   referred	   to	   as	   the	   encapsulation	   or	   incorporation	  
efficiency,	  which	   is	  defined	  as	  the	  fraction	  of	  the	  drug	   loaded	  per	  the	  total	  amount	  of	  
drug	   used	   (or	   available	   for	   loading).	   	   The	   other	   number	   that	   is	   often	   reported	   is	   the	  
loading	  capacity	  or	   loading	  efficiency,	  which	  refers	  simply	  to	  the	  ratio	  of	  the	  weight	  of	  
drug	  incorporated	  to	  the	  weight	  of	  the	  carrier.	  	  These	  quantifications	  will	  be	  cited	  here	  
as	  reported	  in	  the	  studies	  that	  are	  discussed.	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Biodegradable	  Nanoparticles	  
	   Biodegradable	   nanoparticles	   have	   been	   widely	   investigated	   for	   use	   as	   drug	  
delivery	  systems,	  and	  are	  versatile	  platforms	  for	  successful	  encapsulation	  of	  a	  range	  of	  
therapeutics.	   	  These	  biodegradable	  polymer	  nanoparticles	  are	  formed	  most	  commonly	  
using	  emulsion	  and	  solvent	  evaporation	  techniques,	  where	  the	  polymer	  is	  first	  dissolved	  
in	  an	  organic	  phase	  that	  is	  subsequently	  dropped	  into	  a	  continuous	  aqueous	  phase	  and	  
stirred	  until	  the	  solvent	  evaporates.	  	  Hydrophobic	  drugs	  can	  easily	  be	  incorporated	  into	  
particles	  during	  this	  process	  by	  solvating	  the	  drug	  along	  with	  the	  polymer	  in	  the	  organic	  
phase.	   	  These	  oil-­‐in-­‐water	  emulsions	  have	  been	  used	  to	   load	  a	  variety	  of	  hydrophobic	  
drugs,	   such	   as	   anti-­‐cancer	   therapeutics	   [34-­‐36].	   	   In	   addition	   to	   hydrophobic	   drugs,	  
encapsulation	  of	  water-­‐soluble	  drugs	  and	  biomolecules,	   including	  proteins	  and	  certain	  
chemotherapeutics,	   has	   been	   achieved	   with	   water-­‐in-­‐oil-­‐in-­‐water	   double	   emulsion	  
techniques	   [37-­‐39].	   Other	   synthesis	   techniques,	   such	   as	   nanoprecipitation	   and	   spray	  
drying	   have	   also	   been	   used	   effectively	   to	   produce	   PLGA	   nanoparticles	   loaded	   with	  
therapeutics	  [40].	  	  	  
	   Recent	   studies	   have	   carefully	   evaluated	   the	   effects	   of	   PLGA	   nanoparticle	  
properties	  on	  drug	  loading.	  	  For	  example,	  smaller	  nanodelivery	  systems	  have	  a	  smaller	  
volume,	  and	  therefore,	  would	  be	  expected	  to	  have	  a	  smaller	  maximum	  loading	  capacity.	  	  
In	  the	  majority	  of	  studies,	  the	  maximum	  loading	  capacity	  is	  not	  determined	  for	  a	  carrier.	  	  
The	   achieved	   loading	   capacity	   of	   a	   delivery	   system	   is	   dependent	   on	   factors	   beyond	  
volume	   alone.	   	   For	   example,	   drug	   loading	   and	   release	   from	   PLGA	   micro-­‐	   and	  
nanospheres	   have	   been	   shown	   to	   be	   inversely	   correlated	   with	   size.	   	   In	   a	   study	   that	  
compared	   two	   sizes	   of	   PLGA	   particles,	   dexamethasone	   was	   first	   loaded	   into	   PLGA	  
microspheres	  using	  a	  typical	  oil-­‐in-­‐water	  solvent	  evaporation	  method	  to	  produce	  20	  mm	  
particles.	   	   Smaller	   1	   mm	   particles	   loaded	   with	   dexamethasone	   were	   produced	   via	  
	   210	  
emulsion	  polymerization.	  The	  emulsion	  polymerization	  scheme	  for	  the	  smaller	  particles	  
led	   to	   a	   dexamethasone	   encapsulation	   efficiency	   of	   11.2%	   compared	   to	   1%	   for	   the	  
larger	   microparticles	   when	   incubating	   100	   mg	   of	   dexamethasone	   with	   500	   mg	   of	  
polymer	  [41].	  	  	  
	   Drug	   delivery	   systems	   composed	   of	   polyanhydrides	   have	   been	   widely	  
investigated	  because	  of	  their	  surface	  eroding	  mechanism	  which	  can	   lead	  to	  near	  zero-­‐
order	  release	  profiles	  [42,	  43].	  	  In	  general,	  drugs	  have	  been	  successfully	  incorporated	  in	  
polyanhydride	  disks	  such	  as	  the	  Gliadel®	  system	  or	  microparticles	  [44].	  	  However,	  there	  
have	   been	   limited	   studies	   demonstrating	   loading	   and	   release	   from	   polyanhydride	  
carriers	   on	   the	   nanoscale.	   	   In	   one	   study,	   paclitaxel	   or	   2-­‐hydroxypropyl-­‐β-­‐cyclodextrin	  
(HPCD)-­‐complexed	   paclitaxel	   was	   encapsulated	   in	   polyanhydride	   nanoparticles	  
composed	   of	   poly(methyl	   vinyl	   ether-­‐co-­‐maleic	   anhydride)	   during	   particle	   formation	  
using	   a	   solvent	   displacement	   method	   which	   simultaneously	   allowed	   nanoparticle	  
formation	   and	   loading.	   	   Up	   to	   a	   167	   μg/mg	   loading	   capacity	   was	   obtained	   for	  
nanoparticles	  with	   an	   average	   diameter	   of	   302	   nm.	   	   The	   controlled	   release	   of	   HPCD-­‐
paclitaxel	  was	   then	   demonstrated	   in	   different	   simulated	   biological	   fluids.	   	   No	   release	  
was	   observed	   from	   particles	   in	   simulated	   gastric	   fluid	   (pH	   1.2)	   whereas	   there	   was	  
complete	  release	  over	  a	  24	  hour	  period	  in	  simulated	  intestinal	  fluid	  (pH	  7.5)	  [45].	  	  	  
	   Like	   synthetic	   biodegradable	   systems,	   nanodelivery	   systems	   composed	   of	  
naturally	   occurring	   biodegradable	   polymers	   have	   been	   investigated	   for	   drug	   delivery.	  	  
Some	   of	   the	   most	   widely	   studied	   are	   systems	   based	   on	   the	   biodegradable	   and	  
biocompatible	  polysaccharide	  chitosan.	  	  The	  potential	  use	  of	  chitosan	  carriers	  has	  been	  
demonstrated	   for	   a	   vast	   number	   of	   drugs	   and	   applications.	   	   For	   example,	   chitosan	  
carriers	   have	   received	   considerable	   attention	   for	   delivery	   of	   nucleic	   acids	   due	   to	  
chitosan’s	  net	  positive	  charge.	  	  One	  of	  the	  contributing	  factors	  to	  chitosan’s	  versatility	  is	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that	  a	  number	  of	  techniques	  have	  been	  developed	  to	  synthesize	  chitosan	  nanoparticles	  
including	   ionic	   gelation,	   precipitation,	   reverse	   micelle	   formation,	   self-­‐assembly,	   and	  
spray	  drying	  [46,	  47].	  
	   In	  one	  study	  examining	  the	  use	  of	  chitosan	  for	  delivery	  of	  biomolecules,	  a	  model	  
protein,	  bovine	  serum	  albumin	  (BSA),	  was	  loaded	  into	  chitosan	  nanoparticles	  prepared	  
by	   two	  different	  methods	  using	   tripolyphosphate	   (TPP)	  as	  an	   ionic	   crosslinker.	   	   In	   the	  
first	   method	   termed	   “incorporation”,	   BSA	   was	   incorporated	   into	   the	   polymer	   matrix	  
during	  particle	  formation	  by	  adding	  BSA	  to	  a	  chitosan	  solution	  before	  the	  addition	  of	  the	  
TPP	  crosslinker	  at	  which	  point	  particles	  spontaneously	  formed	  during	  mixing.	  	  Using	  the	  
“incubation”	  method,	  BSA	  was	  simply	  adsorbed	  to	   the	  surface	  of	  nanoparticles	  during	  
incubation	   following	  particle	   coacervation.	   	   Encapsulation	  efficiencies	  up	   to	  88%	  were	  
obtained	  and	  BSA	  release	  was	  primarily	  shown	  to	  be	  a	  fast	  release	  over	  a	  6	  hour	  period	  
[48].	   	   In	   another	   study,	   chitosan	  nanoparticles	   crosslinked	  with	  TPP	  were	   loaded	  with	  
methotrexate	  disodium	  (MTX)	  using	  a	  post-­‐polymerization	  incubation	  method.	  	  Loading	  
capacities	  up	   to	  52%	  and	   loading	  efficiencies	  up	   to	  78%	  were	  obtained	  when	  an	  MTX	  
concentration	  of	  1.26	  mg/mL	  was	  incubated	  with	  a	  0.16	  wt%	  nanogel	  solution	  [49].	  
	   Chitosan	   nanoparticles	   have	   also	   been	   formulated	   to	   deliver	   anticancer	   drugs.	  
For	  example,	   a	  water-­‐in-­‐oil	  microemulsion	  method	  was	  used	   to	  entrap	  a	  doxorubicin-­‐
dextran	  conjugate	  in	  chitosan	  nanoparticles	  having	  a	  hydrodynamic	  diameter	  of	  100	  nm.	  
Entrapment	  efficiencies	  were	  measured	  between	  60-­‐65%.	  	  In	  a	  mouse	  model,	  treatment	  
with	  the	   loaded	  nanoparticles	   led	  to	   faster	  and	  more	  complete	  tumor	  regression	  than	  
free	  drug	  or	  empty	  nanoparticles	  [50].	  	  	  
	   Another	   natural	   biodegradable	   material	   used	   to	   synthesize	   nanoparticles	   for	  
drug	   delivery	   applications	   is	   the	   anionic	   biopolymer	   alginate.	   	   Most	   often	   calcium	  
chloride	  is	  added	  to	  a	  solution	  of	  alginate	  to	  induce	  ionic	  crosslinking,	  resulting	  in	  micro-­‐	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and	   nanoparticle	   polymer	   networks.	   In	   one	   case,	   alginate	   gelation	   with	   calcium	   ions	  
followed	   by	   coating	   with	   chitosan	   produced	   nanoparticles	   intended	   for	   oral	   insulin	  
delivery	  applications.	  	  A	  maximum	  insulin	  encapsulation	  efficiency	  was	  measured	  at	  92%	  
with	  loading	  capacities	  up	  to	  14.3%	  [51].	   	   Isoniazid,	  rifampicin,	  and	  pyrazinamide	  were	  
encapsulated	  in	  alginate	  particles	  using	  a	  cation	  gelation	  method	  in	  an	  effort	  to	  design	  
aerosolized	  nanoparticles	  for	  treatment	  of	  tuberculosis.	  	  Calcium	  chloride	  was	  added	  to	  
sodium	  alginate	   solution	  containing	  varying	  amounts	  of	   the	   three	  drugs	   to	   induce	   the	  
gelation	  and	  encapsulation	  of	  the	  drug.	  	  Drug	  encapsulation	  efficiencies	  ranged	  from	  70-­‐
90%	   in	  particles	  at	   the	  upper	   limit	  of	   so-­‐called	  nanoparticles	  with	  an	  average	  size	   just	  
around	  1	  μm	  [52].	  
Self-­‐Assembled	  Nanoparticles	  
	   Self-­‐assembled	  nanoparticles,	  including	  liposomes,	  micelles,	  and	  polymersomes,	  
can	   be	   formed	   using	   various	   amphiphiles	   such	   as	   natural	   lipids	   or	   block	   copolymers.	  	  
Liposomes	   are	   vesicles	   that	   consist	   of	   a	   spherical	   shaped	   lipid	   bilayer,	   or	  multilayers,	  
containing	  an	  inner	  aqueous	  void	  space.	  	  Liposomal	  encapsulation	  is	  a	  versatile	  method	  
to	  load	  therapeutics,	  because	  hydrophilic	  drugs	  and	  biomolecules	  can	  be	  loaded	  in	  the	  
inner	  aqueous	  void,	  while	  hydrophobic	  molecules	  can	  be	  entrapped	  in	  the	  lipid	  bilayer.	  	  
Liposomal	  delivery	  of	  chemotherapeutics	  has	  been	  established	  as	  an	  effective	  method	  
to	   increase	  efficacy	  and	  decrease	   toxicity	  over	   free	  drug,	   evidenced	  by	   the	   success	  of	  
liposomal	   doxorubicin,	   Doxil®,	   which	   has	   been	   approved	   for	   human	   use	   in	   cancer	  
treatment	  [53].	  	  	  
	   In	   addition	   to	   the	   lipid	   structures,	   synthetic	   block	   copolymers	   built	   with	   one	  
hydrophilic	  block	  and	  one	  hydrophobic	  block	  have	  been	   shown	   to	  exhibit	   a	   variety	  of	  
self-­‐assembled	   structures	   including	   spherical	   or	   cylindrical	   micelles	   and	   vesicles	   with	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architectures	   that	   resemble	   liposomes	   known	   as	   polymersomes	   [54].	   	   Micelles,	  
nanoparticles	  with	  a	  hydrophobic	  core	  and	  hydrophilic	  outer	  layer,	  self-­‐assembled	  from	  
amphiphilic	   block	   copolymers	   in	   aqueous	   media,	   are	   frequently	   used	   to	   entrap	  
hydrophobic	  drugs	  during	  micelle	  formation.	   	  During	  spontaneous	  micelle	  formation	  in	  
an	   aqueous	   environment,	   hydrophobic	   drugs	   are	   localized	   in	   and	   around	   the	  
hydrophobic	   core	   [55].	   	   This	   loading	   method	   has	   been	   used	   to	   entrap	   a	   variety	   of	  
therapeutics,	  particularly	  anticancer	  agents,	   in	  block	  copolymers	  of	  poloxamers,	  which	  
consist	   of	   blocks	   of	   poly(ethylene	   oxide)	   (PEO)	   and	   poly(propylene	   oxide)	   (PPO),	   and	  
NK105,	  which	  consists	  of	  blocks	  of	  PEG	  and	  a	  modified	  polyaspartate	  [56-­‐58].	  
	  Using	   this	   method	   of	   drug	   loading,	   micelle	   nanoparticles	   have	   been	   used	   to	   entrap	  
hydrophobic	   anticancer	   therapeutics.	   	   Biodegradable,	   cationic	   micelle	   nanoparticles	  
were	   self-­‐assembled	   using	   amphiphilic	   poly{(N-­‐methyldietheneamine	   sebacate)-­‐co-­‐
[(cholesteryl	   oxocarbonylamido	   ethyl)	   methyl	   bis(ethylene)	   ammonium	   bromide]	  
sebacate},	   P(MDS-­‐co-­‐CES).	   	   In	   this	   study,	  Herceptin®,	  which	   is	   a	  monoclonal	   antibody,	  
was	  attached	  to	  the	  surface	  of	  the	  particles	  while	  paclitaxel	  was	  loaded	  into	  the	  micelles	  
by	  dissolving	  the	  polymer	  and	  drug	  in	  DMF	  and	  dialyzing	  against	  a	  sodium	  acetate/acetic	  
acid	  buffer.	   This	  method	   let	   to	   encapsulation	  efficiencies	  of	   paclitaxel	   of	   58.1%	  and	  a	  
loading	   capacity	   of	   14.3%.	   Release	   studies	   demonstrated	   the	   that	   the	   drug	   could	   be	  
released	  from	  the	  nanoparticles	  over	  a	  69	  hour	  period	  [59].	  	  
	   While	   traditional	   micelle	   systems	   have	   been	   used	   primarily	   to	   incorporate	  
hydrophobic	  drugs,	  adapted	  systems	  have	  been	  used	  to	  entrap	  more	  hydrophilic	  species	  
such	  as	  biomolecules.	   	   For	  example,	  drug	  carrier	   systems	  called	  polyion	  complex	   (PIC)	  
micelles	  have	  been	  synthesized	  from	  PEG	  block	  copolymers.	  The	  PIC	  micelles	  are	  formed	  
using	  block	  copolymers	  consisting	  of	  a	  hydrophilic	  block	  and	  a	  polyionic	  block.	   	   In	   this	  
case,	   electrostatic	   interactions	   between	   the	   ionic	   polymer	   and	   an	   oppositely	   charged	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species	   are	   a	   driving	   force	   for	   the	   formation	   of	   the	   micelles.	   	   Poly(ethylene	   glycol-­‐
grafted-­‐chitosan),	  PEG-­‐g-­‐chitosan,	  block	  copolymers	  were	  used	  to	  entrap	  diammonium	  
glycyrrhizinate	   (DG)	   in	   micelles	   assembled	   in	   acetate	   buffer	   after	   addition	   of	   TPP	   to	  
induce	  chitosan	  aggregation.	   	  Loading	  efficiencies	  of	  DG	  over	  96%	  have	  been	  obtained	  
using	  these	  systems	  and	  the	  average	  diameter	  of	  micelles	  was	  between	  20	  and	  30	  nm.	  	  
Release	   profiles	   varied	   based	   on	   the	   free	   ions	   in	   solution.	   	   In	   ionic	   solution,	   a	   burst	  
release	  was	  observed,	  but	  there	  was	  limited	  release	  in	  DI	  water	  [60].	  
	   Polymer	   vesicles	   called	   polymersomes	   or	   polymerosomes	   have	   been	   used	   to	  
entrap	   a	   variety	   of	   therapeutics	   and	  model	   drugs.	   	   For	   example,	   polymersomes	  with	  
diameters	  around	  100	  nm	  were	  prepared	  from	  triblock	  copolymers,	  poly(caprolactone)-­‐
poly(ethylene	   glycol)-­‐poly(caprolactone),	   PCL-­‐PEG-­‐PCL,	   using	   a	   double	   emulsion	  
method.	   	   Insulin	   was	   incorporated	   during	   self-­‐assembly	   of	   122	   nm	   particles	   [61].	   	   In	  
another	   study,	   triblock	   copolymers,	   poly(ethylene	   oxide)-­‐b-­‐poly(acrylic	   acid)-­‐b-­‐poly(N-­‐
isopropylacrylamide)	   (PEO-­‐PAA-­‐PNIPAM),	   were	   synthesized	   via	   RAFT	   polymerization.	  	  
The	  resulting	  polymers	  were	  water	  soluble	  at	   room	  temperature,	  but	   formed	  polymer	  
vesicles	  with	  diameters	  between	  170	  and	  250	  nm	  above	  32º	  C.	   	   These	  polymersomes	  
were	  loaded	  with	  FITC-­‐dextran	  during	  self-­‐assembly	  at	  elevated	  temperatures	  and	  then	  
crosslinked	  using	  cystamine	  via	  carbodiimide	  chemistry.	   	  The	  crosslinks	  were	  shown	  to	  
degrade	  in	  the	  presence	  of	  dithiothreitol,	  and	  therefore,	  it	  was	  hypothesized	  that	  these	  
systems	  are	  degradable	  in	  vitro	  and	  in	  vivo.	  	  Loading	  capacity	  of	  these	  nanoparticles	  was	  
measured	  at	  levels	  exceeding	  85%	  by	  weight	  [62].	  
	   Recently,	   there	   has	   been	   interest	   in	   creating	   systems	   that	   are	   hybrid	   particles	  
combining	   properties	   of	   liposomes	   and	   synthetic	   polymer	   systems	   for	   nanodelivery	  
applications.	   	   Cationic	   lipids	   have	   been	   combined	   with	   peptide-­‐lipid	   amphiphiles	   and	  
1,2-­‐distearoyl-­‐sn-­‐glycero-­‐3-­‐phosphoethanolamine-­‐N-­‐carboxy(polyethylene	   glycol)	   to	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design	  liposome	  nanoparticles	  targeted	  to	  the	  urokinase	  plasminogen	  activator	  receptor	  
(uPAR)	  overexpressed	  on	  many	  tumors.	  	  The	  particles	  have	  an	  ABCD	  structure,	  an	  inner	  
aqueous	  (A)	  layer	  of	  loaded	  anionic	  nucleic	  acids,	  a	  cationic	  lipid	  bilayer	  (B),	  a	  PEG	  layer	  
for	   stealth	  characteristics	   (C),	   and	  a	  peptide	   sequence	   layer	   for	   targeting	  of	  uPAR	   (D).	  	  
Loading	  efficiencies	  as	  high	  as	  60%	  were	  achieved	  when	  10	  wt%	  docetaxel	  was	  added	  
during	  the	  particle	  self-­‐assembly	  process	  [63].	  In	  another	  example,	  hybrid	  systems	  were	  
formed	  through	  self-­‐assembly	  to	  form	  nanoparticles	  with	  a	  lipid	  monolayer	  surrounding	  
a	   PLGA	   core	   loaded	   with	   a	   hydrophobic	   drug.	   	   This	   unique	   system	   relied	   on	   PEG-­‐
conjugated	   lecithin	   to	   form	   a	   hydrophilic	   outer	   shell	   of	   PEG	   as	   the	   lipid	   monolayer	  
formed	  around	  the	  hydrophobic	  PLGA	  polymer.	  	  Drug	  loading	  of	  docetaxel	  into	  the	  PLGA	  
core	  was	  accomplished	  during	  this	  self-­‐assembly	  process	  by	  first	  dissolving	  polymer	  and	  
drug	   in	   an	   organic	   solvent	   and	   then	   dripping	   this	   solution	   into	   an	   aqueous	   solution	  
containing	   PEG-­‐lecithin.	   	   This	   process	   led	   to	   the	   formation	   of	   the	   particles	   via	   self-­‐
assembly	  and	  the	  solvent	  was	  allowed	  to	  evaporate.	  	  Encapsulation	  efficiencies	  of	  62%	  
were	  obtained	  using	  this	  method	  when	  adding	  10	  wt%	  docetaxel	  to	  the	  organic	  polymer	  
solution.	   	   Controlled	   release	   was	   observed	   over	   a	   100	   h	   period	   and	   shown	   to	   be	   a	  
function	  of	  lipid	  coverage,	  where	  the	  release	  rate	  could	  be	  slowed	  by	  increasing	  the	  lipid	  
to	  polymer	  ratio	  [64].	  	  
Nanogels	  
	   Nanoscale	  hydrogels,	  or	  nanogels,	  are	  hydrophilic	  crosslinked	  polymer	  networks	  
that	  imbibe	  water,	  but	  are	  insoluble	  in	  aqueous	  environments.	  	  Drugs	  can	  be	  loaded	  into	  
the	   polymer	   matrix	   of	   these	   materials	   and	   controlled	   release	   is	   dependent	   on	   the	  
diffusion	  coefficient	  of	   the	  drug	  through	  the	  hydrogel	  network.	   	  Additionally,	  hydrogel	  
nanoparticle	   systems	   have	   been	   developed	   in	   a	   class	   of	   drug	   carriers	   know	   as	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“intelligent”	  or	  “smart”	  delivery	  systems.	   	  Nanogels	  can	  swell	   in	  aqueous	  medium	  and	  
also	   can	   respond	   to	  a	  variety	  of	  environmental	   stimuli	   such	  as	  pH,	   temperature,	   ionic	  
strength,	  or	  electric	  field	  through	  an	  increase	  or	  decrease	  in	  volume	  [65,	  66].	  	  Typically,	  
nanogels	   are	   used	   to	   carry	   a	   drug	   when	   the	   matrix	   is	   in	   a	   more	   collapsed	   state.	  	  
Following	  a	  change	  in	  stimulus	  the	  nanogel	  swells,	  thereby	  increasing	  the	  mesh	  size	  and	  
the	  rate	  of	  diffusion	  of	  the	  drug	  out	  of	  the	  polymer	  matrix.	   	  Alternatively,	  a	  method	  in	  
which	  the	  drug	   is	  squeezed	  out	  of	  the	  nanogel	  has	  been	  used	  to	  obtain	  a	  fast	  release,	  
where	  a	  drug	   is	  entrapped	  in	  a	  hydrogel	   in	  the	  swollen	  state,	  but	  upon	  deswelling	  the	  
drug	  is	  squeezed	  out	  of	  the	  polymer	  matrix	  [67,	  68].	  
	   While	  most	   biodegradable	   or	   self-­‐assembled	   nanoparticle	   systems	   are	   formed	  
from	   previously	   synthesized	   polymers,	   hydrogel	   nanoparticles	   are	   most	   commonly	  
synthesized	   using	   heterogeneous	   polymerization	   techniques.	   	   Because	   the	   hydrogel	  
nanoparticles	   are	   formed	   during	   polymerization,	   incorporating	   a	   therapeutic	   at	   this	  
stage	   requires	   exposing	   the	   drug	   to	   polymerization	   conditions	   that	   could	   potentially	  
damage	  or	  modify	   the	  drug.	   	  However,	   the	  porous	  characteristics	  of	  nanogel	  matrices	  
allows	   for	   drug	   loading	   following	   polymerization	   by	   partitioning	   methods,	   which	  
eliminates	   the	   need	   to	   subject	   the	   drug	   to	   harsh	   polymerization	   conditions.	   	   In	  most	  
situations,	  the	  drug	  is	  loaded	  into	  the	  nanogel	  by	  incubating	  the	  nanoparticles	  with	  the	  
drug	  in	  aqueous	  conditions	  such	  that	  the	  particles	  are	  in	  their	  most	  swollen	  state.	  	  After	  
a	  period	  of	  time	  to	  allow	  the	  therapeutic	  to	  diffuse	  into	  the	  polymer	  matrix,	  a	  condition	  
(most	  commonly	  pH	  or	  temperature)	  is	  altered,	  leading	  to	  a	  particle	  size	  transition	  to	  a	  
more	  collapsed	  state	  with	  a	  smaller	  mesh	  size,	  physically	  entrapping	  the	  therapeutic	  in	  
the	  polymer	  matrix.	  
	   The	  hydrophilic	  nature	  of	  hydrogel	   systems	  makes	   them	  an	   ideal	  candidate	   for	  
the	   loading	   and	   delivery	   of	   water	   soluble	   therapeutics,	   of	   particular	   interest	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biomacromolecules	   such	   as	   proteins	   or	   nucleic	   acids.	   	   Several	   nanogel	   systems	   have	  
been	  investigated	  for	  the	  delivery	  of	   insulin	  to	  the	  small	   intestine.	   	   In	  addition	  to	  their	  
ability	   to	  entrap	   the	  water	   soluble	   insulin,	   some	  of	   these	   systems	  have	  advantageous	  
pH-­‐sensitive	  properties	  allowing	  them	  to	  protect	  insulin	  in	  the	  acidic	  environment	  of	  the	  
stomach	  and	  release	  it	  in	  the	  more	  neutral	  pH	  of	  the	  small	  intestine	  [69,	  70].	  	  Polybasic	  
nanoparticles	  are	  cationic	  pH	  responsive	  hydrogels	  with	  PEG	  grafts.	  	  A	  UV-­‐initiated	  free	  
radical	   emulsion	   polymerization	   was	   used	   to	   synthesize	   poly[2-­‐(diethylamino)	   ethyl	  
methacrylate]	  surface	  grafted	  with	  PEG	  (PDGP)	  nanogels.	   	   Insulin	  as	  a	  model	  drug	  was	  
added	   to	   a	   solution	   of	   the	   nanogels	   and	   the	   pH	   was	   adjusted	   to	   6.5	   to	   swell	   the	  
nanoparticles.	   	  After	  a	   loading	  period	   the	  pH	  was	   raised	  quickly	   to	  7.4	   to	  collapse	   the	  
particles	   and	   entrap	   the	   loaded	   protein.	   	   The	   loaded	   nanogels	   were	   dialyzed	   against	  
water	   for	  5	  days	   to	   remove	  any	  excess	  protein	  not	   loaded.	   	  Encapsulation	  efficiencies	  
were	  measured	  up	  to	  92%	  for	   insulin	   in	  PDGP	  particles	  with	   low	  crosslinking	  densities	  
when	  equal	  weights	  of	  particles	  and	  protein	  were	  added	  to	  the	  loading	  solution	  [71].	  	  	  
	   Controlled	  drug	  loading	  and	  release	  has	  also	  been	  shown	  in	  several	  studies	  using	  
hydrogels	   based	   on	   the	   temperature-­‐sensitive	   polymer	   poly(N-­‐isopropylacrylamide)	  
(PNIPAAm).	  	  PNIPAAm	  exhibits	  a	  negative	  swelling	  transition	  at	  34	  ºC,	  which	  makes	  it	  an	  
attractive	  system	  from	  a	  physiological	  standpoint	  for	  applications	  in	  drug	  delivery.	  	  For	  
example,	   poly(NIPAAm)	   and	   poly(NIPAAm-­‐co-­‐AA)	   nanoparticles	   were	   loaded	   with	   5-­‐
fluorouracil	  and	  release	  was	  shown	  to	  be	  a	  function	  of	  pH	  and	  temperature	  [72].	  	  	  
	   Nanogels	  of	  poly(vinyl	  alcohol),	  PVA,	  and	  poly(vinyl	  pyrrolidone),	  PVP	  have	  also	  
been	   investigated	   for	   drug	   delivery	   applications.	   	   For	   example,	   composite	   systems	   of	  
PVA-­‐crosslinked	   PVP	   nanogels	  were	   used	   to	   entrap	   ferromagnetic	   particles	   as	  well	   as	  
bleomycin	   A5	   hydrochloride.	   	   Nanogels	   were	   prepared	   using	   a	   water-­‐in-­‐oil	   emulsion	  
polymerization	   initiated	   by	   gamma	   ray	   irradiation.	   	   For	   this	   emulsion	   polymerization,	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the	  aqueous	  phase	  contained	  the	  PVA,	  PVP,	  and	  ferromagnetic	  particles.	  	  The	  resulting	  
nanogels	  entrapped	  the	  ferromagnetic	  particles	  and	  were	  then	  used	  to	  load	  bleomycin	  
A5	   hydrochloride.	   	   Dry	   nanoparticles	   were	   allowed	   to	   swell	   in	   an	   aqueous	   solution	  
containing	   the	  drug,	   sonicated,	  and	   then	  placed	  on	  a	   shaker	  plate	   for	  12	  h	  of	   storage	  
until	  no	  apparent	  liquid	  was	  visible.	  	  Encapsulation	  efficiency	  was	  not	  reported,	  because	  
it	  was	  assumed	  that	  all	  of	  the	  drug	  had	  been	  immobilized,	  but	  in	  vitro	  release	  occurred	  
over	  a	  minimum	  period	  of	  8	  hours	  [73].	  
	   While	  most	  hydrogel	  nanodelivery	  systems	  have	  been	  used	  to	  entrap	  hydrophilic	  
molecules,	  recent	  work	  on	  modified	  hydrogels	  has	  demonstrated	  the	  potential	  to	   load	  
hydrophobic	  drugs	  as	  well.	   	   In	  order	   to	  do	  so,	   the	  hydrophobicity	  of	   the	  nanogels	  has	  
been	  increased	  through	  the	  incorporation	  of	  amphiphiles	  into	  the	  hydrogel	  matrix.	  	  An	  
acrylated	   PEG-­‐PPG-­‐PEG	   triblock	   copolymer	   with	   both	   hydrophobic	   and	   hydrophilic	  
groups	  was	  used	   to	   synthesize	  crosslinked	  nanoparticles	  via	  an	   inverse	  microemulsion	  
using	   a	   PEG	   crosslinker.	   	   Properties	   of	   the	   emulsion	   could	   be	   altered	   to	   control	   for	  
particle	   sizes	   ranging	   from	   50	   to	   500	   nm.	   	   These	   nanogels	   were	   then	   loaded	   with	  
doxorubicin	   to	   determine	   their	   ability	   to	   carry	   hydrophobic	   drugs.	   	   Doxorubicin,	  
solubilized	   in	   CHCl3	   with	   triethylamine,	   was	   added	   to	   an	   aqueous	   solution	   of	  
nanoparticles	  and	  the	  CHCl3	  was	  allowed	  to	  evaporate	  overnight.	  The	  results	   indicated	  
that	   the	   formation	  of	  nanogels	   from	  amphiphilic	  macromers	  was	  a	  successful	   strategy	  
for	   loading	   hydrophobic	   drugs	   in	   a	   hydrogel	   with	   up	   to	   9.8%	   loading	   capacity	   of	  
doxorubicin	  [74].	  
While	   the	   control	   and	   optimization	   of	   drug	   loading	   and	   release	   are	   key	  
challenges	  in	  the	  field	  of	  nanodelivery,	  there	  is	  not	  a	  single	  carrier	  or	  loading	  mechanism	  
that	   is	   ideal	   for	   any	   drug	   and	   any	   application.	   	   Each	   nanodelivery	   system	   and	   drug	  
pairing	  is	  unique.	  	  Future	  studies	  on	  the	  interplay	  between	  the	  properties	  of	  the	  carrier,	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properties	   of	   the	   drug,	   and	   the	   mechanisms	   of	   loading	   will	   to	   significantly	   improve	  
nanodelivery	  from	  a	  drug	  loading	  and	  release	  vantage	  point.	  
	  
Conclusion	  
As	   the	   field	   of	   targeted	   drug	   delivery	   continues	   to	   move	   forward,	   it	   will	   be	  
increasingly	   important	   to	   design	   nanoscale	   systems	   with	   tailorable	   properties	   for	  
efficient	   delivery	   and	   improved	   therapeutic	   efficacy.	   	   Important	   design	   considerations	  
will	   include	   the	  physicochemical	   properties	   that	   govern	   targeting,	   biodistribution,	   and	  
clearance	   as	   well	   as	   the	   system’s	   effectiveness	   in	   carrying,	   protecting,	   and	   even	  
releasing	  active	  therapeutic	  and	  diagnostic	  agents.	  
The	   selection	   and	   addition	   of	   targeting	   ligands	   to	   the	   surface	   of	   nanoparticles	  
has	  already	  been	  shown	  to	  improve	  therapeutic	  efficacy	  over	  systems	  without	  targeting	  
ligands.	   	  We	   are	   only	   beginning	   to	   understand	   the	   role	   that	   targeting	   ligands	   play	   in	  
interfacing	  interactions	  of	  nanoparticles	  and	  cells.	  	  The	  few	  studies	  that	  have	  compared	  
targeted	  and	  nontargeted	  systems	  have	  demonstrated	  that	  the	  role	  of	  targeting	  ligands	  
in	   localization	   at	   the	   target	   site	   is	   application	   dependent.	   	   Targeted	   delivery	   to	  
atherosclerotic	   lesions	   is	   greatly	   enhanced	   by	   targeting	   ligands	   which	   impart	   an	  
improved	   ability	   to	   accumulate	   at	   the	   target	   site.	   	   However,	   in	   the	   case	   of	   tumor	  
targeting,	   improved	   performances	   of	   targeted	   systems	   over	   nontargeted	   systems	   has	  
been	  accomplished	  by	  improved	  cellular	  uptake	  as	  well	  as	  improved	  accumulation	  at	  the	  
target	   site.	   	   Some	   of	   these	   studies	   have	   suggested	   that	   the	   primary	   benefit	   of	  
incorporating	  targeting	  ligands	  is	  to	  mediate	  cell	  internalization.	  	  Only	  a	  small	  number	  of	  
studies	   have	   focused	   on	   comparing	   the	   in	   vivo	   performance	   and	   biodistribution	   of	  
	   220	  
targeted	   and	   nontargeted	   delivery	   systems.	   	   Further	   study	   is	   necessary	   to	   truly	  
determine	  how	  the	  presence	  of	  a	  targeting	  ligand	  affects	  targeted	  delivery.	  	  	  
Design	  of	  the	  physicochemical	  properties,	   including	  size,	  shape,	  surface	  charge,	  
and	  mechanical	  characteristics,	  of	  the	  nanoparticle	  itself	  will	  continue	  to	  be	  key	  design	  
parameters	  due	  to	   their	  effect	  on	  biodistribution.	   	   It	   is	   important	   to	  account	   for	  all	  of	  
these	   factors	   in	   concert	   with	   targeting	   strategies	   to	   understand	   how	   to	   predict	   and	  
control	   nanoparticle	   distribution.	   	   Many	   of	   the	   same	   properties	   that	   govern	  
biodistribution	  also	  determine	  the	  clearance	  rate.	  	  The	  challenge	  in	  designing	  materials	  
for	   targeted	   delivery	   is	   that	   the	   material	   properties	   should	   allow	   an	   appropriate	  
residence	  time	  that	   is	   long	  enough	  for	  particle	   localization	  and	  delivery	  of	   the	  drug	  or	  
diagnostic	  but	  does	  not	  prevent	  the	  system	  from	  being	  fully	  eliminated	  in	  an	  acceptable	  
amount	   of	   time.	   	   The	   desired	   particle	   residence	   time	   will	   vary	   with	   the	   intended	  
application,	   and	   this	   time	   frame	   can	   be	   tuned.	   	   Ultimately,	   the	   challenge	   lies	   in	  
designing	  a	  system	  that	  has	  the	  perfect	  combination	  of	  properties	  to	  allow	  for	  sufficient	  
interaction	  of	  the	  targeted	  nanoparticles	  with	  the	  target	  site,	  desirable	  biodistribution,	  
and	  efficient	  removal.	  
	   The	   material	   properties	   that	   contribute	   to	   targeting,	   biodistribution,	   and	  
elimination	  must	  also	  be	  balanced	  with	  the	  properties	  that	  affect	  the	  ability	  to	  entrap	  a	  
therapeutic	   or	   diagnostic.	   	   The	   primary	   consideration	   in	   determining	   the	   ability	   of	   a	  
nanoparticle	  system	  to	  entrap	  a	  molecule	   is	   the	   interaction	  between	  the	  polymer	  and	  
the	   therapeutic.	   	   This	   relationship	   is	   often	   a	   balance	   of	   intermolecular	   interactions	  
including	  hydrophobic/hydrophilic	  and	  electrostatic	  interactions.	  	  Another	  consideration	  
is	  the	  method	  in	  which	  the	  drug	  can	  be	  incorporated	  into	  the	  material,	  and	  whether	  the	  
available	  methods	  will	  allow	  an	  acceptable	  amount	  of	  the	  therapeutic	  to	  be	  loaded	  into	  
the	  carrier.	  	  Both	  the	  loading	  strategy	  and	  stability	  of	  the	  entrapped	  drug	  must	  also	  be	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carefully	  considered	  in	  order	  to	  design	  systems	  that	  are	  able	  to	  carry	  a	  sufficient	  amount	  
of	  drug	  to	  the	  target	  site.	  	  	  
As	   we	   move	   towards	   developing	   optimally	   effective,	   high	   performance	  
nanodelivery	  systems,	  it	  will	  be	  necessary	  to	  design	  new	  materials	  that	  incorporate	  the	  
best	  properties	  for	  targeting,	  biodistribution,	  clearance,	  drug	  incorporation,	  and	  release	  
at	  the	  target	  site.	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Figure	  A.1.	   	  The	   in	  vivo	  biodistribution	  of	   intravenously	  administered	  targeted	  HFT-­‐T	  
nanodelivery	   systems	  and	  nontargeted	  HT-­‐T	  was	   investigated	   in	  a	  KB-­‐3-­‐1	   xenograft-­‐
bearing	  mouse	  model.	  	  
Near-­‐infrared	  fluorescence	  imaging	  of	  mice	  at	  1,	  24,	  and	  48	  h	  showed	  the	  
biodistribution	  of	  nanodelivery	  systems.	  	  (b)	  At	  48	  h,	  the	  biodistribution	  of	  nanoparticles	  
in	  various	  tissues	  was	  quantified	  by	  fluorescence	  intensity.	  	  (c)	  Nanoparticle	  (red)	  uptake	  
by	  xenograft	  cells	  was	  shown	  by	  colocalization	  with	  EpCAM-­‐positive	  (green)	  xenograft	  
cells.	  	  Targeted	  systems	  were	  found	  predominantly	  in	  cells	  while	  nontargeted	  systems	  
were	  less	  likely	  to	  be	  internalized	  remaining	  in	  the	  extracellular	  matrix.	  	  (d)	  Flow	  
cytometry	  of	  disaggregated	  xenograft	  cells	  stained	  with	  a	  FITC-­‐conjugated	  EpCAM	  
antibody	  distinguished	  nanoparticle	  uptake	  in	  human	  xenograft	  tumor	  cells	  from	  
nanoparticle	  uptake	  in	  host	  non-­‐tumor	  cells	  for	  targeted	  and	  control	  nanoparticles.	  	  
Human	  tumor	  cells	  were	  EpCAM	  positive	  in	  Q4-­‐2	  (green	  in	  lower	  right	  quadrant)	  and	  
Q2-­‐2	  (yellow).	  	  Nanoparticle	  uptake	  by	  tumor	  cells	  are	  shown	  in	  Q2-­‐2	  (yellow),	  and	  
nanoparticle	  uptake	  in	  host	  cells	  are	  shown	  in	  Q1-­‐2	  (red).	  	  Reprinted	  with	  permission	  
from	  [2].	  	  Copyright	  2009	  American	  Chemical	  Society.	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Figure	   A.2.	   	   The	   in	   vivo	   performance	   of	   siRNA	   administered	   via	   targeted	   and	  
nontargeted	  nanodelivery	  systems.	  	  	  
(a)	  Micro-­‐PET/CT	  images	  of	  mice	  show	  the	  distribution	  of	  targeted	  and	  nontargeted	  
nanoparticles	  in	  tumors	  (arrow)	  1	  day	  after	  administration.	  	  (b)	  Bioluminescence	  
imaging	  of	  mice	  shows	  luciferase	  expression	  in	  the	  tumor	  before	  and	  1	  day	  after	  
administration	  of	  nontargeted	  and	  targeted	  nanoparticles.	  	  (c)	  A	  decrease	  in	  luciferase	  
activity	  was	  associated	  with	  siRNA	  activity	  1	  day	  after	  administration	  of	  targeted	  (Tf)	  
nanoparticles	  and	  nontargeted	  (PEG)	  nanoparticles.	  	  Error	  bars	  represent	  standard	  
error.	  	  Reproduced	  from	  [5].	  Copyright	  2007	  National	  Academy	  of	  Sciences,	  U.S.A.	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Figure	   A.3.	   Transport	   of	   small	   and	   large	   molecular	   weight	   drugs	   and	   nanoparticles	  
from	  defective	  tumor	  vasculature	  into	  tumor	  space.	  	  	  
(a)	  Small	  molecular	  weight	  drugs	  (black)	  can	  diffuse	  out	  of	  tumor	  vasculature	  but	  can	  
also	  diffuse	  back	  into	  tumor	  vasculature	  which	  allows	  clearance	  of	  these	  compounds	  
from	  the	  tumor	  space.	  	  (b)	  Larger	  molecular	  weight	  drugs	  or	  nanoparticles	  (green)	  can	  
diffuse	  into	  the	  tumor	  space	  but	  are	  retained	  due	  to	  the	  EPR	  effect.	  	  Reprinted	  from	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Figure	  A.4.	  	  Delivery	  of	  image	  contrast	  agent	  and	  a	  heparin	  hirulog	  to	  atherosclerotic	  
plaques	  in	  the	  aortic	  tree	  of	  ApoE-­‐null	  mice	  using	  micelles.	  	  	  
(a)	  Fluorescence	  images	  of	  excised	  aortic	  trees	  show	  that	  image	  contrast	  with	  
fluorescently	  labeled	  (FAM-­‐labeled)	  nontargeted	  micelles	  is	  improved	  upon	  by	  targeted	  
(FAM-­‐CREKA)	  micelles.	  	  The	  contrast	  provided	  by	  FAM-­‐CREKA	  micelles	  disappears	  with	  
the	  addition	  of	  excess	  targeted	  micelles	  lacking	  a	  fluorescent	  label.	  	  Contrast	  is	  not	  
significantly	  decreased	  when	  FAM-­‐CREKA	  targeted	  micelles	  are	  administered	  along	  with	  
nontargeted	  micelles	  without	  a	  fluorescent	  label.	  	  (b)	  The	  average	  fluorescence	  intensity	  
of	  image	  pixels	  for	  the	  various	  studies.	  	  (c)	  The	  delivery	  of	  the	  anticoagulant	  peptide	  
hirulog-­‐2	  to	  atherosclerotic	  plaques	  from	  micelles	  was	  quantified	  with	  a	  thrombin	  
activity	  assay.	  	  In	  an	  ApoE	  null	  mouse	  model,	  hirulog	  delivery	  was	  significantly	  improved	  
using	  targeted	  micelles	  compared	  to	  nontargeted	  micelles.	  	  The	  delivery	  of	  hirulog	  via	  
targeted	  micelles	  in	  wild-­‐type	  mice	  was	  significantly	  lower	  than	  targeted	  delivery	  in	  the	  
ApoE	  atherosclerotic	  model.	  	  Reproduced	  from	  [13].	  Copyright	  2009	  National	  Academy	  
of	  Sciences,	  U.S.A.	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Figure	   A.5.	   	   CdSe	   core	   and	   ZnS	   shell	   quantum	   dot	   clearance	   from	   blood,	  
biodistribution,	  and	  renal	  clearance.	  	  	  
(a)	  The	  concentration	  of	  radiolabeled	  quantum	  dots	  in	  blood	  after	  intravenous	  injection	  
in	  a	  CD-­‐1	  mouse	  model	  decreases	  with	  nanoparticle	  size.	  	  (b)	  For	  quantum	  dots	  between	  
4	  and	  9	  nm,	  the	  blood	  half-­‐life	  of	  quantum	  dots	  increases	  with	  size.	  	  (c)	  Color	  video	  (left)	  
and	  gamma-­‐ray	  images	  taken	  with	  an	  Anger	  camera	  (middle)	  to	  show	  the	  
biodistribution	  of	  4.36	  nm	  quantum	  dots	  in	  animals	  immediately	  after	  sacrifice	  (top	  row)	  
and	  in	  organs	  (bottom	  row).	  	  The	  merged	  color	  image	  and	  gamma-­‐ray	  image	  show	  
nanoparticles	  in	  the	  bladder	  (Bl)	  (top	  right).	  	  The	  overall	  biodistribution	  of	  quantum	  dots	  
in	  each	  organ	  is	  also	  quantified	  (bottom	  right).	  	  Abbreviations	  are:	  skin	  (Sk),	  adipose	  
(Ad),	  muscle	  (Mu),	  bone	  (Bo),	  heart	  (He),	  lungs	  (Lu),	  spleen	  (Sp),	  liver	  (Li),	  kidneys	  (Ki),	  
stomach	  (St),	  intestine	  (In),	  and	  brain	  (Br).	  	  (d)	  Biodistribution	  of	  8.65	  nm	  quantum	  dots	  
following	  intravenous	  injection.	  	  Data	  corresponds	  to	  Figure	  5c.	  	  (3)	  Quantum	  dot	  
excretion	  via	  urine	  4	  h	  post-­‐injection	  (blue)	  decreases	  with	  size	  and	  retention	  in	  the	  
body	  (red)	  increases	  with	  size.	  	  Data	  is	  mean	  ±	  standard	  deviation.	  	  Reprinted	  by	  
permission	  from	  Macmillan	  Publishers	  Ltd:	  [18],	  Copyright	  2007.	  
	  
	  




Figure	  A.6.	  Drug	  loading	  of	  various	  nanodelivery	  systems.	  	  
(a)	  Liposome	  loaded	  with	  hydrophilic	  (green)	  and	  hydrophobic	  drugs	  (purple).	  	  (b)	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Table	  A.1.	  Summary	  of	  studies	  on	  tumor	  accumulation	  of	  nanodelivery	  systems	  
List	  of	  abbreviations	  for	  Table	  1:	  initial	  dose	  (ID),	  nanoparticles	  (NPs),	  poly(ethylene	  
glycol)-­‐poly(aspartate-­‐hydrazone-­‐adriamycin)	  (PEG-­‐p(ASP-­‐Hyd-­‐ADR)),	  Gadolinium	  (Gd),	  
poly(acrylic	  acid-­‐b-­‐methyl	  acrylate)	  (PAA-­‐b-­‐PMA),	  	  epidermal	  growth	  factor	  receptor	  
(EGFR),	  single-­‐chain	  variable	  fragment	  antibody	  (ScFv),	  transferrin	  (Tf),	  α-­‐melanocyte-­‐






 Formulation Tumor Accumulation Dose Tumor and 
Animal Model 
Study 
PEGylated Gadolinium nanoparticles Folate and PEG-coated 
PEGylated 
5% ID at 5 h, 7% ID at 8 h 
4% ID at 5 h, 9% ID at 8 h 
 
10 mg NPs/kg mouse 
weight (1.6 mg Gd/kg)  






6-8% ID at 4 h, 4-7 % ID at 24 h 
~6% ID at 4 h, ~4% ID at 24 h 
 
10 mg/kg ADR KB, CD-1 nude 
mice 
[4] 
64Cu labeled shell-crosslinked 




5.9 ± 2.8% ID/g, 0.04 ± 0.02 %ID 
6.0 ± 1.9% ID/g, 0.13 ± 0.04 %ID 
at 4 h 
 
370-440 kBq NPs 
or 3-5 mg/kg mouse 
weight 
KB, folate-deficient 
athymic nude mice 
[12] 
64Cu labeled nanoparticles with 




< 2% ID/cm3 over 60 min 
< 2% ID/cm3 
100-300 µCi 64Cu Neuro2A-Luc, 
NOD/SCID mice 
[5] 
Colloidal gold nanoparticles 
 
 
EGFR ScFv nanotags 
PEGylated nanotags 
~ 8 ppm (gold/g tissue) at 5 h 
<1 ppm 










8.34% ID/g tissue at 24 h 
7.18% ID/g tissue 
7.32% ID/g tissue 
8.59% ID/g tissue 












6.63 % ID at 48 hours 
0.30% ID 
2.6 x 1011 NPs /mouse A431, mouse [24] 






4.3 +-1.2% ID/g  at 4 hours 
12.6 +- 3.1% ID/g  
 
2 x 1012 NPs/mouse B16/F10, mouse [75] 
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Table	  A.2.	  Measurement	  techniques	  for	  quantifying	  biodistribution	  
	  
Technique Agent Study 
















[6, 22, 25] 
[77] 
Micro-positron emission tomography 





MRI imaging Gd 
 
[15] 













Superconducting quantum interference 





Gold nanorods [80] 
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ABSTRACT	   	  
The	  oral	  delivery	  of	   insulin	  has	  been	   investigated	  through	  a	  variety	  of	  different	  
approaches.	  	  One	  of	  the	  major	  barriers	  in	  achieving	  high	  bioavailability	  of	  insulin	  in	  the	  
bloodstream	   is	   transport	   across	   the	   epithelial	   cell	   layer	   in	   the	   small	   intestine.	   	   To	  
address	   this	   challenge,	   insulin-­‐transferrin	   conjugates	   were	   synthesized	   to	   utilize	   the	  
transport	  pathway	  of	  transferrin	  while	  retaining	  the	  bioactivity	  of	   insulin.	   	   In	  this	  work	  
the	  effect	  on	  transport	  of	  insulin	  by	  using	  insulin-­‐transferrin	  conjugates	  was	  investigated	  
using	   cellular	  models.	   	   Transport	   studies	  were	   performed	  using	   the	   insulin-­‐transferrin	  
conjugates	   with	   and	   without	   the	   presence	   of	   P(MAA-­‐g-­‐EG)	   microparticles	   in	   contact	  
with	   a	   co-­‐culture	   of	   Caco-­‐2/HT29-­‐MTX	   cells.	   	   During	   the	   transport	   studies,	   the	  
transepithelial	   electrical	   resistance	   was	   monitored	   to	   determine	   the	   effect	   of	   the	  
proteins	  and	  particles	  on	  cell	   integrity.	   	   In	  the	  transport	  studies,	  the	   insulin-­‐transferrin	  
conjugate	  was	  shown	  to	  increase	  transport	  relative	  to	  insulin	  by	  a	  factor	  of	  7,	  achieving	  
an	   apparent	   permeability	   of	   37	   x	   109	   cm/s.	   	   Also,	   in	   the	   presence	   of	   polymer	  
microparticles,	   the	   insulin-­‐transferrin	   conjugate	   increased	   transport	   by	   a	   factor	   of	   14	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times	   relative	   to	   insulin,	   achieve	   an	   apparent	   permeability	   of	   72.8	   x	   109	   cm/s.	   	   The	  
presence	  of	  the	  microparticles	  in	  solution	  was	  found	  to	  improve	  conjugate	  transport	  by	  
nearly	  100%	  with	  little	  to	  no	  change	  in	  cell	  monolayer	  integrity.	  	  Based	  on	  these	  cellular	  
studies,	   it	   is	   concluded	   that	   the	   conjugation	   of	   a	   transporter	   molecule	   such	   as	  
transferrin	  to	  proteins	  such	  as	  insulin	  is	  a	  promising	  option	  for	  overcoming	  the	  epithelial	  
transport	  barrier	  and	  merits	  consideration	   in	  the	  design	  of	  future	  oral	  protein	  delivery	  
systems.	  
INTRODUCTION	  
Bioavailability	   of	   orally	   administered	   therapeutic	   proteins	   depends	   on	   several	  
factors	   such	   as	   the	   degree	   of	   protein	   degradation	   and	   residence	   time	   at	   the	   site	   of	  
absorption.	  	  However,	  one	  of	  the	  most	  significant	  factors	  which	  affects	  absorption	  into	  
the	   bloodstream	   is	   transport	   across	   the	   epithelial	   cell	   layer.	   	   The	   purpose	   of	   the	  
epithelial	   cell	   layer	   is	   to	  absorb	  only	   required	  nutrients	   such	  as	  vitamins	  and	  minerals	  
and	  to	  expel	  unrecognized	  or	  unwanted	  entities	  such	  as	  toxins	  or	  viruses.	  	  Additionally,	  
tight	   junctions	  between	  the	  cells	  will	  only	  permit	  the	  transport	  of	  molecules	  with	  radii	  
<11	  Ǻ	  [1].	   	  Because	  of	  its	  ability	  to	  limit	  transport	  of	  large	  molecules,	  it	   is	  necessary	  to	  
create	   strategies	   to	   significantly	   increase	   epithelial	   transport	   in	   order	   to	   effectively	  
deliver	  therapeutic	  proteins.	  	  	  
We	  have	  successfully	  developed	  strategies	  to	  overcome	  the	  inherent	  challenges	  
to	  oral	  protein	  delivery	  such	  as	  protein	  degradation	  and	  the	  narrow	  absorption	  window	  
in	   the	   small	   intestine	   by	   incorporation	   into	   complexation	   hydrogels.	   	   Hydrogels	   are	  
three-­‐dimensional,	   hydrophilic	   polymer	   networks	   which	   can	   imbibe	   water	   and	   swell	  
under	  certain	  conditions.	  	  Yamagata	  et	  al.[2]	  demonstrated	  the	  potential	  of	  the	  hydrogel	  
carriers	  to	  protect	  proteins	  by	  encapsulating	  insulin	  within	  P(MAA-­‐g-­‐EG)	  microparticles	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and	  achieving	  preservation	  of	  over	  80%	  of	  the	  loaded	  insulin	  after	  being	  treated	  for	  one	  
hour	  in	  gastric	  fluid.	  	  In	  contrast,	  only	  20%	  of	  free	  insulin	  remained	  intact	  after	  the	  same	  
treatment	  with	  gastric	  fluid.	  	  Also,	  increased	  residence	  time	  at	  the	  site	  of	  absorption	  has	  
been	   achieved	  by	   the	   addition	   of	   polymers	  which	   are	   known	   to	   be	  mucoadhesive	   [3]	  
and	   through	   the	   implementation	   of	   polymer	   tethers.	   	   Serra	   et	   al.[4]	   showed	   that	   the	  
addition	   of	   PEG	   tethers	   to	   a	   poly(acrylic	   acid)	   (PAA)	   hydrogel	   system	   increased	   the	  
mucoadhesive	   capacity	   of	   the	   microparticles,	   generating	   a	   work	   of	   adhesion	   of	  
approximately	   130	   x	   10-­‐3	  mJ,	   or	   five	   times	   that	   of	   a	   pure	   PAA	   system.	   	  Madsen	   and	  
Peppas	   [5]	  were	  able	   to	  show	  that	   the	  calcium	  binding	  effect	  of	   the	  anionic	  hydrogels	  
near	  the	  epithelial	  cell	  layer	  helped	  to	  reversibly	  loosen	  the	  cellular	  tight	  junctions	  and	  
consequently	  allowed	  increased	  paracellular	  transport	  of	  therapeutic	  proteins.	   	  Finally,	  
Morishita	  et	  al.[6]	  demonstrated	  the	  overall	  effectiveness	  and	  potential	  of	  the	  hydrogel	  
system	  by	  performing	  in	  vivo	  studies	  in	  which	  insulin	  was	  administered	  in	  P(MAA-­‐g-­‐EG)	  
carriers	  to	  diabetic	  rats,	  resulting	  in	  a	  bioavailability	  of	  12.8%,	  a	  significant	  increase	  over	  
insulin	   administered	   alone.	   	   Hydrogels	   have	   been	   shown	   to	   effectively	   protect	   the	  
protein	   in	   the	   stomach,	   to	   create	   extended	   residence	   time	   in	   the	   small	   intestine	   for	  
protein	   release,	   and	   even	   to	   enhance	   paracellular	   transport	   of	   therapeutic	   proteins,	  
altogether	  demonstrating	  the	  promise	  of	  complexation	  hydrogels	  as	  carriers	  for	  the	  oral	  
delivery	  of	  proteins.	  	  	  
The	   use	   of	   complexation	   hydrogels	   addresses	   many	   of	   the	   challenges	   of	   oral	  
protein	   delivery,	   but	   further	   design	   strategies	   are	   required	   to	   significantly	   increase	  
cellular	  transport	  in	  order	  to	  increase	  bioavailability	  in	  the	  bloodstream.	  	  A	  large	  portion	  
of	  the	  design	  strategies	  to	   improve	  epithelial	  transport	  focuses	  on	  paracellular	  protein	  
transport,	   or	   protein	   transport	   between	   the	   cells.	   	   System	   designs	   based	   on	   large	  
molecule	  absorption	   through	   the	  paracellular	   route	  contain	  an	   inherent	  disadvantage.	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Because	   of	   naturally	   poor	   protein	   transport	   across	   the	   epithelial	   cell	   layer,	   the	  
monolayer	  must	  be	  disrupted	  or	  loosened	  to	  allow	  for	  increased	  protein	  transport.	  	  The	  
monolayer	  disruption	  is	  typically	  non-­‐specific	  to	  the	  protein	  of	  interest,	  translating	  to	  an	  
increased	  probability	  of	  toxins	  or	  viruses	  entering.	  	  	  
An	  alternative	  to	  protein	  absorption	  through	  the	  paracellular	  route	  is	  to	  absorb	  
the	   protein	   through	   the	   cell	   itself,	   utilizing	   the	   transcellular	   route	   for	   absorption.	  	  
Transcellular	   transport	   can	   be	   utilized	   to	   be	   specific	   to	   the	   protein	   and	  may	   result	   in	  
increased	  bioavailability	  as	  well.	   	   In	  our	   laboratory,	  we	  have	  been	  able	   to	   successfully	  
synthesize	   and	   characterize	   protein-­‐transporter	   conjugates	   which	   utilize	   the	   specific	  
targeting	   mechanisms	   of	   ligand-­‐receptor	   interactions	   for	   use	   with	   complexation	  
hydrogels	   to	   ultimately	   deliver	   a	   significant	   amount	   of	   protein	   to	   the	   bloodstream	  
through	  the	  transcellular	  route	  [7].	  	  	  
The	   goal	   of	   this	   work	   was	   to	   synthesize	   insulin-­‐transferrin	   conjugates	   for	  
evaluation	  of	  cellular	  transport	  characteristics	  using	  a	  Caco-­‐2/HT29-­‐MTX	  cellular	  model.	  	  
This	   work	   achieves	   several	   objectives	   beyond	   the	   scope	   of	   the	   prior	   work	   from	   our	  
laboratory	  on	  the	  subject	  [7].	  	  As	  evident	  in	  the	  results	  and	  discussion	  section,	  this	  work	  
addresses	   new	   factors	   related	   to	   the	   insulin-­‐transferrin	   oral	   delivery	   system	   such	   as	  
conjugate	  size	  related	  to	  diffusion,	  the	  use	  of	  a	  co-­‐culture	  for	  more	  reliable	  diffusion	  and	  
permeability	  results,	  and	  determination	  of	  a	  more	  realistic	  microparticle	  concentration	  
for	   cellular	   studies,	   resulting	   in	   an	   increased	   understanding	   of	   their	   effect	   on	  
transcellular	  transport	  versus	  the	  previous	  work	  on	  the	  subject.	  	  	  
The	   addition	   of	   the	   transporter	   transferrin	   to	   the	   therapeutic	   protein	   insulin	  
allows	   for	  specific	   targeting	  of	   the	  bioconjugate	  entity	  as	  well	  as	  potentially	   increased	  
transport.	  	  Transferrin	  is	  a	  glycoprotein	  which	  is	  normally	  involved	  in	  iron	  transport.	  	  The	  
transferrin	  receptor	  is	  expressed	  on	  human	  intestinal	  epithelial	  cells.	   	  When	  evaluating	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the	  potential	   of	   a	  novel	  oral	   dosage	   form	   for	  oral	   delivery,	   it	   is	   necessary	   to	  examine	  
cellular	   interactions	   with	   the	   therapeutic	   entity	   using	   cellular	   models.	   	   The	   cellular	  
model	   used	   for	   evaluation	   of	   insulin-­‐transferrin	   bioconjugates	   was	   a	   co-­‐culture	  
consisting	  of	  both	  absorptive	  enterocyte-­‐like	  Caco-­‐2	  cells	  which	  are	  commonly	  used	  to	  
determine	  molecule	   permeability	   [8-­‐11]	   and	  mucus-­‐producing	   HT29-­‐MTX	   goblet	   cells	  
[12].	   	   The	   advantage	   of	   using	   a	   Caco-­‐2/HT29-­‐MTX	   co-­‐culture	   versus	   a	   simpler	   Caco-­‐2	  
cellular	  model	  is	  in	  observing	  the	  effect	  that	  intestinal	  mucus	  will	  play	  in	  the	  diffusion	  of	  
the	  large	  insulin-­‐transferrin	  conjugate	  molecules,	  resulting	  in	  a	  more	  accurate	  depiction	  
of	   overall	   permeability.	   	   A	   system	   consisting	   solely	   of	   Caco-­‐2	   cells	   used	   to	   measure	  
permeability	   of	   large	   molecules	   the	   size	   of	   the	   insulin-­‐transferrin	   conjugates	   would	  
disregard	   the	   significant	   effect	   that	   diffusion	   through	   the	  mucus	   has	   on	   permeability.	  	  
The	  Caco-­‐2/HT29MTX	  co-­‐culture	  was	  used	  to	  compare	  the	  permeability	  and	  transport	  of	  
insulin-­‐transferrin	   conjugates	   to	   native	   insulin.	   	   Additionally,	   cellular	   studies	   were	  
performed	   in	   the	   presence	   of	   the	   P(MAA-­‐g-­‐EG)	  microparticles	   to	   give	   insight	   into	   the	  
effect	   of	   complexation	   hydrogels	   on	   the	   transport	   processes	   of	   the	   epithelial	   cell	  
monolayer.	   	   Based	   on	   the	   results	   of	   the	   cellular	   transport	   studies,	   the	   overall	   rate	   of	  
transport	  was	   quantified	   as	   an	   overall	   apparent	   permeability,	   Papp,	   for	   the	   study.	   	   By	  
comparing	   the	   apparent	   permeability	   values	   for	   each	   set	   of	   conditions,	   conclusions	  
were	  drawn	  regarding	  the	  effect	  of	  protein-­‐transporter	  conjugation	  and	  the	  presence	  of	  
complexation	  hydrogels	  on	  epithelial	  transport	  of	  insulin.	  
	  
MATERIALS	  AND	  METHODS	  
Hydrogel	   Synthesis.	   	   P(MAA-­‐g-­‐EG)	   was	   prepared	   using	   a	   free	   radical	   UV	  
polymerization	   in	   solution.	   	  P(MAA-­‐g-­‐EG)	  was	  prepared	  by	  mixing	  MAA	   (Sigma-­‐Aldrich	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Inc.,	   St.	   Louis,	   MO)	   with	   poly(ethylene	   glycol)	   monomethyl	   ether	   monomethacrylate	  
with	   a	   approximate	   molecular	   weight	   of	   1000	   (PEGMA1000,	   Polysciences	   Inc.,	  
Warrington,	   PA)	   in	   a	   1:1	   molar	   ratio	   of	   MAA:EG.	   	   The	   crosslinker	   used	   within	   the	  
polymer	   network	   was	   poly(ethylene	   glycol)	   dimethacrylate	   with	   an	   approximately	  
molecular	   weight	   of	   1000	   (PEGDMA1000,	   Polysciences	   Inc.,	   Warrington,	   PA).	   	   The	  
amount	  of	  crosslinker	  added	  to	  each	  monomer	  mixture	  was	  equal	  to	  1	  mol%	  of	  the	  total	  
amount	   of	   monomer.	   	   In	   order	   to	   eventually	   initiate	   the	   polymerization,	   the	  
photoinitiator	  1-­‐hydroxycyclohexyl	  phenyl	  ketone	   (Irgacure	  184,	  Sigma-­‐Aldrich	   Inc.,	   St.	  
Louis,	  MO)	  was	  added	  to	  the	  polymerization	  mixture	  in	  the	  amount	  of	  1	  wt%	  of	  the	  total	  
monomer	   added.	   	   A	   solvent	   mixture	   consisting	   of	   50:50	   by	   weight	   deionized	   water	  
(Milli-­‐Q	  Plus	  system,	  Millipore)	  and	  ethanol	  (AAPER	  Alcohol,	  Shelbyville,	  KY)	  was	  added	  
to	   the	   polymer	  mixture	   in	   a	   1:1	   ratio	   by	   weight	   relative	   to	  monomer	   present	   in	   the	  
prepolymer	   mixture.	   	   The	   presence	   of	   the	   solvent	   solution	   is	   essential	   to	   prevent	  
autopolymerization	  as	  well	  as	  to	  produce	  a	  workable	  thin	  polymer	  film.	  
To	  ensure	  all	  components	  dissolved	  and	  went	   into	  a	  homogenous	  solution,	  the	  
polymer	  mixture	  was	  sonicated	  for	  15	  minutes.	  	  After	  sonication,	  nitrogen	  was	  bubbled	  
through	   the	   polymer	   solution	   within	   a	   nitrogen	   environment	   to	   eliminate	   oxygen.	  	  
Oxygen	  is	  a	  free	  radical	  scavenger	  and	  significant	  oxygen	  levels	  could	  prematurely	  end	  
the	  polymerization	  process.	  	  After	  removal	  of	  oxygen	  by	  nitrogen	  purging,	  the	  polymer	  
mixture	  was	  poured	  between	  two	  glass	  slides	  (153	  x	  153	  x	  3	  mm)	  separated	  by	  a	  Teflon	  
spacer	   (0.7	   mm)	   while	   still	   in	   a	   nitrogen	   environment.	   	   The	   glass	   slide	   apparatus	  
containing	  the	  polymer	  solution	  spread	  into	  a	  thin	  film	  was	  then	  placed	  under	  a	  UV	  light	  
source	  while	   still	   in	   a	  nitrogen	  environment.	   	   The	   solution	  was	  allowed	   to	  polymerize	  
under	  the	  light	  source	  within	  an	  intensity	  range	  of	  16-­‐17	  mW/cm2	  for	  30	  minutes.	  	  After	  
the	  polymerization	  was	  completed,	  the	  polymer	  gels	  were	  removed	  from	  the	  nitrogen	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environment,	   separated	   from	   the	   glass	   slides,	   and	   placed	   in	   deionized	   water.	   	   The	  
polymer	   films	   were	   washed	   in	   the	   deionized	   water	   for	   7	   days	   to	   remove	   excess	  
monomer	  and	  contaminants.	  	  After	  washing	  was	  completed,	  the	  polymers	  were	  dried	  in	  
a	  vacuum	  oven	  at	  approximately	  30°	  C	  for	  2	  days.	  	  After	  completely	  drying	  the	  polymer	  
films,	  they	  were	  crushed	  into	  microparticles	  using	  a	  mortar	  and	  pestle	  to	  sizes	  less	  than	  
75	  microns.	  	  The	  sieved	  microparticles	  were	  then	  stored	  in	  a	  vial	  within	  a	  desiccator	  to	  
prevent	  moisture	  entering	  until	  further	  use.	  	  	  
	  
Synthesis	  of	  Insulin-­‐Transferrin	  Conjugates	  
	  	  The	   method	   for	   protein	   conjugation	   outlined	   in	   this	   section	   was	   originally	  
developed	  by	  Carlsson	  et	  al	  [13].	  	  The	  protein	  conjugation	  method	  was	  first	  utilized	  for	  
the	  conjugation	  of	  insulin	  to	  transferrin	  by	  Shah	  and	  Shen	  [14].	  	  The	  conjugation	  scheme	  
consists	   of	   using	   N-­‐succinimidyl	   3-­‐(2-­‐pyridyldithio)propionate	   (SPDP)	   as	   a	   protein	  
crosslinker	  to	  conjugate	  insulin	  (Ins)	  to	  transferrin	  (Tf)	  to	  form	  insulin-­‐transferrin	  (Ins-­‐Tf)	  
heteroconjugates.	  	  	  
To	  begin	  the	  reaction,	  the	  n-­‐terminal	  primary	  amines	  of	  the	  insulin	  chains	  were	  
effectively	   “blocked”	   by	   reaction	   of	   insulin	   with	   dimethylmaleic	   anhydride	   (DMMA,	  
Fluka/Sigma	  Aldrich	   Inc.,	  St.	  Louis,	  MO),	  excluding	  possible	  reactive	  sites	   for	  SPDP.	   	  To	  
begin	  the	  reaction,	  10.5	  mg	  of	  DMMA	  was	  added	  to	  a	  stock	  solution	  of	   insulin	   (Sigma	  
Aldrich	  Inc.,	  St.	  Louis,	  MO)	  and	  reacted	  for	  approximately	  one	  hour.	  	  During	  the	  reaction	  
period,	  the	  pH	  was	  maintained	  within	  the	  pH	  range	  of	  6.8-­‐6.9	  by	  adding	  small	  volumes	  
of	   a	   1	   M	   Na2CO3	   (Fisher	   Scientific,	   Fair	   Lawn,	   NJ)	   solution.	   	   After	   the	   reaction	   had	  
finished,	   the	   insulin-­‐DMMA	   intermediate	   was	   purified	   by	   dialysis	   (MWCO	   3,500,	  
Spectrum	   Laboratories	   Inc.,	   Rancho	   Dominguez,	   CA)	   for	   at	   least	   24	   hours	   to	   remove	  
unreacted	  DMMA.	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Insulin-­‐DMMA	   was	   reacted	   with	   6.0	   mg	   of	   SPDP	   (Pierce	   Biotechnology	   Inc.,	  
Rockford,	  IL)	  to	  add	  disulfide	  bonds	  to	  the	  remaining	  unblocked	  primary	  amine	  at	  B29-­‐
Lysine.	  	  The	  reaction	  was	  performed	  at	  4°C	  under	  constant	  stirring	  within	  a	  pH	  range	  of	  
8.8-­‐9.0.	   	   The	   pH	   was	   maintained	   by	   adding	   small	   volumes	   of	   1	   M	   Na2CO3.	   	   Upon	  
completion	  of	  the	  reaction	  time	  period,	  the	  insulin-­‐PDP	  product	  was	  purified	  by	  dialysis	  
(MWCO	  3,500)	  at	  4°C	  for	  at	  least	  24	  hours	  to	  remove	  unreacted	  SPDP	  reagent.	  	  
In	  addition	  to	  the	  modification	  of	  insulin,	  transferrin	  (Sigma	  Aldrich	  Inc.,	  St.	  Louis,	  
MO)	  was	  also	   reacted	  with	  SPDP	  to	   form	  PDP	  groups	  on	  the	   transferrin	  molecule.	   	  To	  
initiate	   the	   reaction,	   8.0	   mg	   of	   SPDP	   was	   added	   to	   a	   solution	   containing	   120	   mg	   of	  
human	  holo-­‐transferrin	  in	  PBS	  buffer	  (pH	  7.0).	  	  The	  reaction	  was	  held	  at	  approximately	  
4°C	  and	  allowed	  to	  react	  for	  2	  hours.	  	  The	  transferrin-­‐PDP	  product	  was	  purified	  through	  
dialysis	  (MWCO	  12,000-­‐14,000,	  Spectrum	  Laboratories	  Inc.,	  Rancho	  Dominguez,	  CA)	  in	  a	  
solution	  of	  PBS	  buffer	  (pH	  8.0)	  overnight	  to	  remove	  unreacted	  SPDP.	  	  After	  formation	  of	  
PDP	   groups	   on	   transferrin,	   the	  modified	   protein	  was	   reduced	   by	   the	   addition	   of	   1	  M	  
dithiothreitol	  (DTT,	  Sigma	  Aldrich	  Inc.,	  St.	  Louis,	  MO).	  	  The	  transferrin-­‐PDP	  was	  reduced	  
using	  DTT	  for	  one	  hour,	  forming	  a	  product	  with	  attached	  sulfohydryl	  groups	  (Tf-­‐SH).	  	  The	  
transferrin-­‐SH	  product	  was	  purified	  by	  dialysis	  for	  at	  least	  24	  hours	  to	  remove	  unreacted	  
DTT.	  
Upon	   formation	  of	   transferrin-­‐SH,	   the	  product	  was	  purified	  by	  elution	   from	  D-­‐
Salt	   Dextran	   Desalting	   Columns	   (10	   mL,	   Pierce	   Biotechnology	   Inc.,	   Rockford,	   IL).	   	   To	  
initiate	  the	  final	  step	  in	  the	  conjugation	  reaction,	  the	  product	  solutions	  of	  Ins-­‐PDP	  and	  
Tf-­‐SH	  were	   combined	  and	  allowed	   to	   react	  under	   constant	   stirring.	   	   The	   reaction	  was	  
allowed	  to	  proceed	  for	  approximately	  90	  minutes	  before	  it	  was	  stopped	  by	  the	  addition	  
of	  n-­‐ethylmaleimide	  (NEM,	  ACROS	  Organics,	  Geel,	  Belgium),	  which	  reacts	  with	  free	  thiol	  
groups	  [15]	  and	  prevents	  further	  crosslinking.	  	  The	  final	  insulin-­‐transferrin	  product	  was	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purified	  by	  dialysis	   (MWCO	  12,000-­‐14,000)	   for	  at	   least	  48	  hours	   to	   remove	  unreacted	  
reagents.	   	  To	  determine	   the	  concentration	  of	   the	  conjugate	  solution,	   the	  product	  was	  
analyzed	  using	  HPLC	   (Waters	  Corporation,	  Milford,	  MA).	   	  After	  analysis,	   the	  conjugate	  
solution	  was	  refrigerated	  until	  further	  use.	  
	  
Development	  of	  Caco-­‐2/HT29-­‐MTX	  Monolayers	  	  	  
To	   form	   the	   Caco-­‐2/HT29-­‐MTX	   monolayer,	   both	   Caco-­‐2	   and	   HT29-­‐MTX	   cells	  
were	  initially	  cultured	  in	  culturing	  flasks	  (75	  cm2,	  VWR	  Scientific,	  West	  Chester,	  PA)	  with	  
10	   mL	   of	   culture	   media	   (DMEM,	   Biofluids	   Inc.,	   Rockville,	   MD)	   containing	   additional	  
supplements.	  	  Cultivation	  was	  performed	  at	  a	  seeding	  density	  of	  2.5	  x	  105	  cells	  per	  flask	  
for	   the	   Caco-­‐2	   cells	   and	   1.25	   x	   105	   cells	   per	   flask	   for	   the	   HT29-­‐MTX	   cells.	   	   During	  
cultivation,	  the	  cells	  were	  incubated	  at	  37°	  C,	  95%	  relative	  humidity,	  and	  5%	  CO2	  while	  
the	   culture	   media	   was	   replaced	   every	   other	   day	   until	   the	   cells	   reached	   70-­‐80%	  
confluency.	  	  After	  reaching	  the	  desired	  confluency,	  both	  types	  of	  cells	  were	  passaged	  at	  
least	  once	  prior	  to	  combination	  of	  the	  cell	  types.	  	  After	  passaging,	  the	  Caco-­‐2	  and	  HT29-­‐
MTX	  cells	  were	  transferred	  at	  the	  desired	  seeding	  density	  to	  experimental	  wells	  in	  a	  1:1	  
ratio	  as	  to	  obtain	  a	  50%	  Caco-­‐2/50%	  HT29-­‐MTX	  experimental	  co-­‐culture	  monolayer.	  
For	  the	  transport	  studies,	  a	  co-­‐culture	  of	  Caco-­‐2/HT29-­‐MTX	  cells	  was	  grown	  in	  6-­‐
well	  Transwell®	  plates	  (4.71	  cm2/well,	  Costar	  Corning	  Inc.,	  Corning,	  NY).	  	  The	  cell	  density	  
in	   the	   experimental	   wells	   was	   approximately	   3	   x	   105	   cells/well	   with	   the	   composition	  
being	   50%	   of	   each	   cell	   type.	   	   The	   co-­‐culture	   was	   grown	   in	   the	   culture	   medium	   for	  
approximately	   21-­‐23	   days	   until	   the	   monolayer	   achieved	   a	   constant	   transepithelial	  
electrical	   resistance	   (TEER)	   as	   measured	   by	   a	   chopstick	   electrode	   (World	   Precision	  
Instrument,	  Sarasota,	  FL).	  	  Typically,	  a	  constant	  TEER	  value	  indicates	  that	  the	  monolayer	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has	  formed	  tight	  junctions	  [16,	  17].	  	  During	  the	  formation	  of	  the	  monolayer,	  the	  culture	  
media	  was	  changed	  every	  other	  day	  and	  the	  TEER	  was	  monitored	  regularly.	  	  	  
Upon	   the	   formation	  of	   tight	   junctions,	   the	   transport	   studies	  began	  by	  allowing	  
the	  cells	   to	  equilibrate	  with	  Hank’s	  Balanced	  Salt	  Solution	  (HBSS,	  HyClone,	  Logan,	  UT),	  
the	   experimental	   medium	   for	   the	   study.	   	   HBSS	   is	   typically	   listed	   having	   a	   pH	   of	   7.1,	  
which	  closely	  mimics	  the	  conditions	  at	  the	  targeted	  site	  of	  delivery	  in	  the	  upper	  ileum.	  	  
Though	   the	   pH	   of	   the	   small	   intestine	   varies	   throughout	   its	   length,	   the	  mucoadhesive	  
nature	   of	   the	   hydrogels	   ensures	   that	   delivery	   should	   occur	   early	   in	   transit	   and	   in	   the	  
upper	   ileum4.	   	   The	  HBSS	  also	   contained	  Ca2+	   ions	   to	  ensure	   regulation	  of	   intracellular	  
Ca2+	   ions,	   which	   are	   instrumental	   in	   maintaining	   the	   integrity	   of	   the	   tight	   junctions.	  	  
After	  addition	  of	  the	  HBSS,	  the	  TEER	  of	  the	  cell	  monolayer	  was	  monitored	  for	  the	  next	  
hour	  with	  samples	  regularly	  withdrawn.	  	  The	  conclusion	  of	  the	  equilibration	  period	  was	  
marked	   by	   the	   achievement	   of	   a	   constant	   TEER,	   indicating	   adjustment	   to	   the	   HBSS	  
solution	  as	  well	  as	  the	  ability	  to	  begin	  the	  transport	  studies.	  
Protein	  Transport	  Across	  the	  Cell	  Monolayer	  
For	  the	  studies	  in	  which	  only	  protein	  was	  present	  in	  the	  apical	  chamber,	  insulin	  
or	  insulin-­‐transferrin	  was	  dissolved	  in	  warm	  HBSS	  at	  a	  concentration	  of	  0.2	  mg/mL.	  	  To	  
begin	   the	   study,	   the	   previous	   HBSS	   solution	   was	   removed	   from	   the	   apical	   chamber.	  	  
Approximately	  1.5	  mL	  of	  the	  solution	  containing	  either	  the	  insulin	  or	  insulin-­‐transferrin	  
was	   placed	   in	   the	   apical	   chamber.	   	   The	   Transwell®	   plates	   were	   then	   placed	   in	   an	  
incubator	  at	  37°	  C.	  	  Samples	  of	  100	  μL	  were	  withdrawn	  from	  the	  basolateral	  chambers	  
at	   time	  points	  of	  0,	  0.5,	  1,	  2,	  and	  3	  hours	  after	  the	  addition	  of	  protein	  solution	  to	  the	  
well.	  	  The	  TEER	  of	  the	  monolayer	  was	  also	  measured	  at	  the	  withdrawal	  of	  each	  sample.	  	  
Throughout	   the	   course	   of	   the	   transport	   study,	   all	   measurements	   were	   taken	   while	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maintaining	   the	  Transwell®	  plate	  at	  37°	  C,	  ensuring	  no	  changes	   in	   the	   integrity	  of	   the	  
tight	   junctions	  or	   in	   the	  amount	  of	   transcellular	   transport	  as	  both	  vary	  significantly	  as	  
temperature	  varies.	  	  The	  samples	  were	  placed	  in	  small	  vials	  and	  refrigerated	  until	  they	  
could	   be	   analyzed.	   	   Analysis	   of	   protein	   concentration	   of	   the	   apical	   chamber	   was	  
performed	   by	   HPLC	   and	   protein	   concentration	   in	   the	   basolateral	   chamber	   was	  
determined	  by	  use	  of	  an	  ELISA	  kit.	  
 
Protein	  Transport	  Across	  the	  Cell	  Monolayer	  in	  the	  Presence	  of	  P(MAA-­‐g-­‐EG)	  
Microparticles	  	  	  
In	   addition	   to	   transport	   studies	   using	   only	   proteins,	   more	   transport	   studies	   were	  
performed	   to	  determine	   the	   effect	   of	   the	  presence	  of	   P(MAA-­‐g-­‐EG)	  microparticles	   on	  
the	  cellular	  transport	  of	  both	  insulin	  and	  insulin-­‐transferrin	  conjugates.	  	  	  
As	   with	   the	   previous	   transport	   studies,	   solutions	   of	   either	   insulin	   or	   insulin-­‐
transferrin	  conjugates	  were	  prepared	  at	  a	   concentration	  of	  0.2	  mg/mL	   in	  warm	  HBSS.	  	  
After	   removing	   the	   HBSS	   used	   for	   equilibration	   of	   the	   monolayer	   from	   the	   apical	  
chamber,	  approximately	  1.5	  mL	  of	  either	  of	  the	  protein	  solutions	  was	  added	  to	  refill	  the	  
apical	  chamber	  with	  sample.	  	  Immediately	  after	  addition	  of	  the	  protein	  solutions	  to	  the	  
apical	   side,	   dry	   P(MAA-­‐g-­‐EG)	   microparticles	   were	   added	   to	   the	   apical	   chamber	   at	   a	  
concentration	   of	   1	   mg/mL.	   	   Sampling	   of	   both	   the	   apical	   and	   basolateral	   chambers	  
occurred	  in	  the	  same	  manner	  as	  previously	  described	  and	  all	  samples	  were	  analyzed	  by	  
either	  HPLC	  (apical	  samples)	  or	  using	  an	  ELISA	  kit	  (basolateral	  samples).	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RESULTS	  AND	  DISCUSSION	  
Protein	  Transport	  Across	  the	  Cell	  Monolayer	  
Solutions	   of	   either	   insulin	   or	   insulin-­‐transferrin	   conjugates	   were	   investigated	  
through	  transport	  studies.	  	  In	  the	  studies,	  samples	  were	  withdrawn	  from	  the	  basolateral	  
chamber	  at	   regular	   time	  points	   to	  determine	   the	  amount	  of	  protein	   transported	  over	  
time.	   	  The	   transport	  profiles	  were	   fit	  using	  a	   linear	   regression	  model	  and	  the	  slope	  of	  
the	  fit	  was	  used	  to	  calculate	  apparent	  permeability	  values,	  Papp,	  for	  each	  of	  the	  protein	  
samples.	  
In	   order	   to	   calculate	   an	   apparent	   permeability	   for	   protein	   transport,	   the	  
following	  equation	  was	  used:	  	  	  
	  
	  
In	   the	   equation	   above,	   Q(t)	   is	   the	   cumulative	   amount	   of	   protein	   (mg)	  
transported	   at	   time	   t,	   A	   is	   the	   area	   of	   the	   cell	  monolayer	   (cm2),	   and	   CA0	   is	   the	   initial	  
protein	  concentration	  in	  the	  apical	  (donor)	  compartment	  (mg/cm3).	  	  The	  term	  dQ(t)/dt	  
is	   represented	   by	   the	   slope	   of	   the	   linear	   fit	   to	   the	   data	   plotting	   cumulative	   protein	  
transported	  (Q(t))	  versus	  time	  (t).	  	  It	  should	  be	  noted	  that	  the	  lines	  drawn	  on	  Figures	  1,	  
3,	  4,	  and	  6	  are	  slope	  lines	  representative	  of	  the	  dQ(t)/dt	  term	  in	  determining	  apparent	  
permeability	   values.	   	   The	   lines	  are	  only	   a	   reflection	  of	   average	  protein	   transport	  over	  
the	  entire	  course	  of	   the	  study,	  not	  a	  predictive	  model	   intended	   to	   represent	   the	  data	  
trends.	   	   In	  fact,	  certain	  types	  of	  transport,	  particularly	  transcellular	  transport,	  may	  not	  
transport	   protein	   linearly	   but	   instead	   in	   a	   non-­‐linear	   fashion	   based	   on	   the	   timing	   of	  
cellular	  processes.	  	  Apparent	  permeability	  values	  were	  calculated	  over	  the	  course	  of	  the	  
entire	   study	   versus	   between	   each	   data	   point	   to	   provide	   an	   overall	   comparison	   of	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As	  an	  experimental	  control,	  a	  solution	  of	  insulin	  dissolved	  in	  HBSS	  was	  added	  to	  
the	  apical	  chamber	  and	  was	  allowed	  to	  interact	  with	  the	  cell	  monolayer.	  	  The	  apparent	  
permeability	  of	   the	   insulin	  relative	  to	  the	  cell	  monolayer	  was	  determined	  to	  be	  4.95	  x	  
109	   cm/s	   using	   the	   equation	   shown	   above.	   	   The	   extent	   of	   transport	   as	   well	   as	   the	  
apparent	  permeability	  of	  the	  insulin	  control	  served	  as	  a	  standard	  of	  comparison	  for	  the	  
experimental	   protein	   solutions.	   	   To	   determine	   the	   effect	   of	   the	   conjugation	   of	   a	  
transporter	   protein	   to	   insulin,	   the	   transport	   of	   a	   solution	   of	   insulin-­‐transferrin	  
conjugates	  across	  the	  cell	  monolayer	  was	  measured	  and	  analyzed.	  	  In	  comparison	  to	  the	  
insulin	   control,	   the	   transport	   occurred	   to	   a	   much	   greater	   extent	   and	   also	   in	   a	   much	  
more	  linear	  fashion.	  	  The	  linearity	  of	  the	  transport	  can	  most	  likely	  be	  attributed	  to	  the	  
timing	  of	  cellular	  mechanisms	  involved	  in	  transcellular	  transport,	  leading	  to	  a	  slower	  but	  
more	  linear	  transport	  profile.	  	  The	  apparent	  permeability,	  Papp,	  of	  the	  insulin-­‐transferrin	  
conjugates	  across	  the	  Caco-­‐2/HT29-­‐MTX	  monolayer	  was	  calculated	  and	  found	  to	  be	  37.0	  
x	   109	   cm/s.	   	   The	   transport	   profiles	   of	   the	   insulin	   control	   and	   insulin-­‐transferrin	   are	  
shown	   in	   Figure	   B1.	   	   To	   compare	   the	   protein	   transport	   studies,	   the	  most	   simple	   and	  
direct	  method	   is	   to	   compare	   the	   apparent	   permeability	   values	   between	   the	   different	  
protein	   solutions.	   	   According	   to	   the	   values,	   the	   insulin-­‐transferrin	  molecule	   has	  more	  
than	   seven	   times	   the	   permeability	   compared	   to	   unmodified	   insulin.	   	   Increasing	  
transport	   of	   a	   potential	   therapeutic	   more	   than	   sevenfold	   has	   dramatic	   potential	  
ramifications	  on	  the	  bioavailability	  of	  the	  drug	  in	  the	  bloodstream.	  	  Based	  on	  the	  results	  
of	  the	  transport	  studies	  conducted	  using	  solutions	  containing	  only	  protein,	  the	  transport	  
of	   an	  orally	   administered	   therapeutic	   protein	   can	  be	   greatly	   increased	  by	   conjugating	  
the	  drug	  to	  a	  transporter	  molecule	  such	  as	  transferrin.	  
While	  performing	  the	  transport	  studies,	  it	  was	  important	  to	  monitor	  the	  integrity	  
of	   the	  cell	  monolayer	  and	   the	   tight	   junctions	  as	   to	  ensure	   that	  administration	  of	   such	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therapeutics	  would	  not	  cause	  the	  epithelial	  cell	  layer	  to	  have	  a	  lessened	  ability	  to	  expel	  
dangerous	  viruses	  or	  toxins.	  	  Over	  the	  course	  of	  each	  transport	  study,	  the	  transepithelial	  
electrical	   resistance	   was	  measured	   as	   a	  means	   of	  monitoring	   tight	   junction	   integrity.	  	  
The	  TEER	  values	  throughout	  both	  transport	  studies	  are	  shown	  as	  Figure	  B2.	  	  As	  evident	  
in	   Figure	   B.2,	   the	   TEER	   of	   the	   Caco-­‐2/HT29-­‐MTX	  monolayer	   stayed	   near	   100%	   of	   the	  
initial	  value	  throughout	  the	  course	  of	  each	  transport	  study.	   	  The	  absolute	  TEER	  values	  
for	   all	   the	   co-­‐cultures	   in	   the	   transport	   studies	   were	   recorded	   in	   the	   range	   of	   85-­‐95	  
Ω*cm2.	  It	  should	  be	  noted	  that	  Caco-­‐2/HT29-­‐MTX	  co-­‐cultures	  have	  been	  shown	  to	  have	  
lower	  TEER	  values	  relative	  to	  pure	  Caco-­‐2	  cell	  monolayers	  [18].	  	  However,	  it	  should	  also	  
be	   noted	   that	   the	   typical	   TEER	   values	   of	   Caco-­‐2/HT29-­‐MTX	   co-­‐cultures	   more	   closely	  
represent	   the	   TEER	   values	   of	   the	   human	   intestine,	   known	   to	   range	   from	   50-­‐100	  
Ω*cm2.[19]	  	  The	  maintenance	  of	  steady	  TEER	  values	  in	  these	  experiments	  indicates	  that	  
the	  proteins	  (insulin	  and	   insulin-­‐transferrin)	  do	  not	  have	  a	  disruptive	  effect	  on	  the	  cell	  
monolayer,	   ensuring	   their	   presence	   upon	   administration	  will	   not	   cause	   illness	   due	   to	  
uptake	  of	  dangerous	  toxins	  or	  viruses	  through	  a	  weakened	  epithelial	  cell	  barrier.	  
Protein	  Transport	  Across	  the	  Cell	  Monolayer	  in	  the	  Presence	  of	  P(MAA-­‐g-­‐EG)	  
Microparticles	  
	  	  To	  determine	   the	  effect	  of	   the	  presence	  of	  polymer	  microparticles	  on	  cellular	  
insulin	  transport,	  a	  prepared	  solution	  of	  insulin	  dissolved	  in	  HBSS	  with	  added	  P(MAA-­‐g-­‐
EG)	  microparticles	  was	  added	   to	   the	  apical	   chamber	  and	  was	  allowed	  to	   interact	  with	  
the	  cell	  monolayer.	   	   The	  apparent	  permeability,	  Papp,	  of	   the	   insulin	   in	   the	  presence	  of	  
polymer	   microparticles	   was	   determined	   to	   be	   5.20	   x	   109	   cm/s.	   	   The	   apparent	  
permeability	  of	  insulin	  in	  the	  presence	  of	  polymer	  microparticles	  is	  slightly	  higher	  than	  
the	  value	  obtained	  for	   insulin	  alone,	   indicating	  that	  the	  presence	  of	  the	  microparticles	  
may	  have	  a	  slight	  permeation	  enhancing	  effect	  for	  the	  paracellular	  transport	  of	  insulin.	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However,	  while	   the	   apparent	   permeability	   value	   is	   slightly	   higher	   for	   transport	   in	   the	  
presence	   of	   microparticles,	   the	   difference	   in	   amount	   of	   protein	   transported	   is	   not	  
significant	   between	   the	   cases.	   	   Therefore,	   the	   presence	   of	   microparticles	   at	   this	  
concentration	   has	   little	   to	   no	   effect	   on	   insulin	   transport.	   	   The	   transport	   profiles	   of	  
insulin	   with	   and	   without	   the	   presence	   of	   microparticles	   are	   shown	   in	   Figure	   B3.	   	   A	  
higher	   concentration	   of	   microparticles	   in	   solution	   would	   have	   most	   likely	   caused	   a	  
significant	   increase	   in	   insulin	   transport	   due	   to	   concurrently	   increased	   calcium	  binding	  
capacity,	   further	   loosening	   the	   tight	   junctions	   of	   the	   cell	   monolayer	   as	   shown	   in	  
previous	  work	  from	  our	  laboratory5.	  
Similar	   transport	   studies	  were	   also	   conducted	  which	   used	   solutions	   of	   insulin-­‐
transferrin	   conjugates	   in	   the	   presence	   of	   P(MAA-­‐g-­‐EG)	  microparticles	   to	   determine	   if	  
the	  microparticles	   had	   a	  more	   pronounced	   effect	   on	   insulin	   transport.	   	   The	   apparent	  
permeability	   of	   the	   insulin-­‐transferrin	   conjugates	   across	   the	   Caco-­‐2/HT29-­‐MTX	  
monolayer	   in	   the	  presence	  of	   polymer	  microparticles	  was	   calculated	   and	   found	   to	  be	  
72.8	  x	  109	  cm/s.	  	  In	  comparison	  to	  the	  transport	  of	  insulin-­‐transferrin	  conjugates	  alone,	  
the	   permeability	   of	   the	   conjugate	   nearly	   doubled	   in	   the	   presence	   of	   polymer	  
microparticles.	   	   The	   transport	   profiles	   of	   insulin-­‐transferrin	   with	   and	   without	   the	  
presence	  of	  microparticles	   are	   shown	   in	   Figure	  B4.	   	   Though	   it	   is	   not	   completely	   clear	  
whether	   the	   presence	   of	   the	   microparticles	   enhanced	   transcellular	   transport	   of	   the	  
conjugate	  or	   simply	  opened	  up	  paracellular	  pathways,	   it	   is	  evident	   that	   transport	  was	  
greatly	   increased.	   	   The	   previous	   study	   showed	   that	   the	   presence	   of	   polymer	  
microparticles	   had	   little	   to	   no	   effect	   on	   insulin	   transport	   at	   the	   given	   microparticle	  
concentration.	   	   However,	   at	   the	   same	   concentration,	   the	  microparticles	  were	   able	   to	  
enhance	   insulin-­‐transferrin	   transport	   by	   nearly	   100%.	   	   The	   drastic	   difference	   in	  
enhanced	   transport	   suggests	   that	  P(MAA-­‐g-­‐EG)	  microparticles	  act	  as	  better	  enhancers	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for	  transport	  that	  has	  been	  hypothesized	  to	  be	  transcellular	  versus	  that	  which	  has	  been	  
thought	  to	  be	  paracellular.	  	  In	  this	  study,	  while	  improved	  conjugate	  transport	  could	  be	  
attributed	  to	  newly	  opened	  paracellular	  pathways,	  the	  absence	  of	  improved	  transport	  in	  
the	  previous	  case	  seems	  to	  negate	  this	   idea.	   	  Our	  hypothesis	   is	  that	  the	  microparticles	  
facilitated	  transcellular	  transport,	  possibly	  through	  calcium	  binding,	  the	  consequent	  loss	  
of	   intracellular	   calcium,	   and	   the	   resultant	   effect	   which	   lowered	   calcium	   has	   on	  
transcytotic	   processes.	   	   However,	   to	   rigorously	   determine	   the	   effect	   of	   the	  
microparticles	   on	   the	   transport	   mechanism	   of	   insulin-­‐transferrin	   conjugates,	   further	  
investigation	   into	   the	  cellular	   transport	  mechanisms	  of	   intestinal	   cells	  as	  well	  as	  more	  
in-­‐depth	   public	   knowledge	   about	   the	   intracellular	   transferrin	   mechanisms	   would	   be	  
required.	  
To	  gain	  a	  greater	  understanding	  of	  the	  effect	  of	  microparticles	  on	  the	  integrity	  of	  
the	   tight	   junctions	   and	   the	  monolayer,	   the	   transepithelial	   electrical	   resistance	   (TEER)	  
was	  measured	  over	  the	  course	  of	  the	  transport	  studies.	  	  The	  TEER	  values	  throughout	  the	  
two	  transport	  studies	  are	  shown	  as	  Figure	  B5.	  	  As	  can	  be	  seen	  in	  Figure	  B5,	  the	  TEER	  of	  
the	  Caco-­‐2/HT29-­‐MTX	  monolayer	  stayed	  near	  100%	  of	  the	  initial	  value	  throughout	  the	  
course	  of	  both	   transport	   studies.	   	   Steady	  TEER	  values	   throughout	   the	   studies	   indicate	  
little	  to	  no	  disruption	  of	  the	  monolayer	  in	  the	  presence	  of	  both	  proteins	  and	  P(MAA-­‐g-­‐
EG)	  microparticles.	  While	   previous	   studies	   have	   shown	   that	   the	   TEER	   values	   and	   the	  
tight	   junctions	  will	  be	  affected	  by	   the	  presence	  of	  polymer	  microparticles	   [20,21],	   the	  
microparticles	   used	   in	   this	   study	   were	   likely	   not	   introduced	   at	   a	   high	   enough	  
concentration	   to	   achieve	   the	   significant	   disruptive	   effect	   that	   had	   been	   observed	   in	  
previous	  studies.	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  It	   is	   also	   useful	   to	   determine	   the	   effect	   of	   transferrin	   conjugation	   on	   insulin	  
transport	  while	  in	  the	  presence	  of	  microparticles.	  	  The	  transport	  profiles	  of	  insulin	  and	  
insulin-­‐transferrin	   in	   the	   presence	   of	   microparticles	   can	   be	   compared	   in	   Figure	   B6.	  	  
Simply	   replacing	   insulin	  with	   insulin-­‐transferrin	   conjugates	   at	   the	   same	   concentration	  
but	  in	  the	  presence	  of	  microparticles	  increased	  the	  apparent	  permeability	  by	  a	  factor	  of	  
nearly	   fourteen.	   	  Assuming	   that	  a	   formulation	  of	   insulin-­‐transferrin	   conjugates	   loaded	  
into	  P(MAA-­‐g-­‐EG)	  microparticles	  could	  deliver	  the	  same	  amount	  of	  protein	  to	  the	  site	  of	  
absorption	  as	  an	  insulin-­‐loaded	  microparticle,	  the	  benefit	  of	  having	  potentially	  fourteen	  
times	   the	   cellular	   transport	   would	   translate	   into	   a	   much	   more	   effective	   drug	   with	  
significantly	  higher	  bioavailability.	  
To	  compare	  all	  of	  the	  transport	  studies	  quantitatively,	  it	  is	  important	  to	  compare	  
the	   apparent	   permeability	   values.	   	   The	   apparent	   permeability	   values	   for	   all	   of	   the	  
transport	  studies	  can	  be	  directly	  examined	  in	  Table	  1.	  	  Based	  on	  the	  permeability	  values,	  
the	  insulin-­‐transferrin	  conjugate	  alone	  achieves	  more	  than	  seven	  times	  the	  transport	  of	  
insulin	  alone.	  	  Meanwhile,	  the	  addition	  of	  P(MAA-­‐g-­‐EG)	  microparticles	  increases	  insulin-­‐
transferrin	  transport	  by	  nearly	  100%.	  	  Due	  to	  the	  ability	  of	  the	  microparticles	  to	  enhance	  
conjugate	  transport,	  the	  insulin-­‐transferrin	  conjugate	  achieves	  nearly	  fourteen	  times	  the	  
transport	  that	  insulin	  does	  in	  the	  presence	  of	  the	  microparticles.	  	  The	  progress	  achieved	  
in	  this	  work	  is	  significant	  relative	  to	  previous	  work	  from	  the	  laboratory	  in	  the	  area	  [7].	  	  
While	   the	  protein	   (insulin)	  and	   transporter	   ligand	   (transferrin)	  used	  are	   the	  same,	   the	  
conjugates	   in	   this	   work	   were	   constructed	   to	   be	   slightly	   smaller	   (i.e.	   lower	   insulin	   to	  
transferrin	  ratio)	  than	  the	  previous	  work	  to	  improve	  epithelial	  transport.	  	  The	  conjugate	  
size	  can	  have	  a	  profound	  effect	  on	  the	  diffusion	  of	  the	  entity	  through	  the	  mucosa	  of	  the	  
small	  intestine.	  	  Thus,	  the	  use	  of	  a	  smaller	  conjugate	  has	  resulted	  in	  increased	  transport	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characteristics	  relative	  to	  studies	  performed	  previously	  in	  our	  laboratory	  [7].	  	  The	  effect	  
of	  conjugate	  size	  is	  magnified	  by	  the	  use	  of	  a	  co-­‐culture	  of	  Caco-­‐2/HT29-­‐MTX	  cells;	  the	  
use	  of	  these	  cells	  provides	  a	  more	  accurate	  depiction	  of	  condition	  in	  the	  small	  intestine	  
as	   well	   as	   more	   accurate	   conditions	   for	   diffusion	   due	   to	   the	   mucus	   secreted	   by	   the	  
HT29-­‐MTX	  cells.	   	  A	  simple	  Caco-­‐2	  cell	  study	  is	  acceptable	  for	  determining	  permeability	  
of	  small	  molecules,	  but	  the	  diffusion	  in	  the	  mucus	  of	  the	  intestine	  cannot	  be	  ignored	  for	  
large	  molecules	  such	  as	  the	  insulin-­‐transferrin	  conjugate,	  thus	  requiring	  the	  need	  for	  the	  
co-­‐culture	  permeability	  study	  as	  contrasted	  with	  the	  previous	  work	  from	  our	  laboratory	  
[7].	  	  Also,	  this	  study	  is	  the	  first	  from	  our	  laboratory	  to	  accurately	  measure	  the	  effect	  of	  
the	   microparticles	   on	   overall	   transport	   of	   insulin-­‐transferrin	   conjugates.	   	   In	   previous	  
studies,	   the	   concentration	   of	   particles	   used	   was	   too	   high	   to	   the	   point	   of	   adversely	  
affecting	   cell	   integrity.	   	   Using	   a	   more	   realistic	   concentration	   yields	   no	   loss	   of	   cell	  
integrity	  but	  instead	  a	  possible	  enhancement	  to	  transcellular	  transport.	  	  Moreover,	  the	  
concentration	  of	  microparticles	  used	  in	  the	  transport	  study	  more	  accurately	  reflects	  the	  
estimated	  amount	  of	  particles	  per	  approximate	  area	  of	  the	  small	  intestine.	  	  All	  of	  these	  
factors	   combined	   result	   in	   significant	   research	   findings	   that	   further	   the	   possibility	   of	  
insulin-­‐transferrin	  systems	  being	  used	  in	  future	  drug	  delivery	  designs.	  
Considering	  all	  of	  the	  transport	  studies	  performed	  in	  this	  work,	  modification	  of	  
therapeutic	   proteins	   by	   conjugation	   to	   transporter	   molecules	   remains	   an	   attractive	  
option	  for	  increasing	  epithelial	  transport	  and	  achieving	  high	  bioavailability.	  	  	  
	  
CONCLUSIONS	  
Cellular	  evaluation	  of	  the	  insulin-­‐transferrin	  conjugate	  was	  performed	  using	  a	  co-­‐
culture	   Caco-­‐2/HT29-­‐MTX	   cell	   model.	   	   The	   conjugate	   was	   investigated	   by	   conducting	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transport	   studies	  on	  both	   the	   insulin-­‐transferrin	   conjugate	  and	  an	   insulin	   control	  with	  
and	   without	   the	   presence	   of	   microparticles.	   	   The	   results	   of	   the	   transport	   studies	  
indicated	  a	   sevenfold	   increase	   in	   transport	  by	   replacing	   insulin	  with	   insulin-­‐transferrin	  
conjugates.	   	  Also,	   the	  presence	  of	  P(MAA-­‐g-­‐EG)	  microparticles	  enhanced	   transport	   for	  
the	   insulin-­‐transferrin	   conjugate	   by	   nearly	   100%	  while	   having	  minimal	   effect	   on	   pure	  
insulin	   transport,	   indicating	   that	   the	   polymer	  microparticles	  may	   assist	   in	   transcytotic	  
processes.	   	   Finally,	   the	   transport	   studies	   also	  demonstrated	   that	   a	   14-­‐fold	   increase	   in	  
transport	   can	   be	   achieved	   by	   switching	   from	   insulin	   in	   the	   presence	   of	   polymer	  
microparticles	   to	   insulin-­‐transferrin	   conjugates	   in	   the	   presence	   of	   polymer	  
microparticles.	  	  The	  specific	  targeting	  and	  increased	  transport	  of	  the	  insulin-­‐transferrin	  
conjugate	   in	   combination	   with	   the	   protection	   and	   site-­‐specific	   release	   capabilities	   of	  
P(MAA-­‐g-­‐EG)	   microparticles	   combine	   synergistically	   to	   form	   a	   potential	   dosage	   form	  
which	   could	   effectively	   deliver	   therapeutics	   to	   the	   small	   intestine	   and	   across	   the	  























Figure	   B.1.	   	   Insulin	   and	   insulin-­‐transferrin	   conjugates	   were	   placed	   in	   the	   apical	  
chamber	  at	  a	  concentration	  of	  0.2	  mg/mL	  and	  were	  allowed	  to	  diffuse	  through	  a	  cell	  
monolayer	   of	   Caco-­‐2/HT29-­‐MTX	   for	   3	   hours.	   	   The	   protein	   concentrations	   in	   the	  
basolateral	   chamber	   were	  measured	   at	   time	   points	   of	   0.5,	   1,	   2,	   and	   3	   hours	   using	  







































	   	  
	  
Figure	   B.2.	   	   Transepithelial	   electrical	   resistances	   (TEER)	   of	   cell	   monolayers	   of	   Caco-­‐
2/HT29-­‐MTX	  co-­‐cultures	  over	  the	  course	  of	  a	  3	  hour	  transport	  study	  using	  insulin	  	  and	  
insulin-­‐transferrin	   conjugates	   	   at	   a	   protein	   concentration	  of	   0.2	  mg/mL.	   	   The	   values	  
are	  percentages	  of	  the	  TEER	  as	  compared	  to	  the	  initial	  values	  before	  the	  study	  began.	  	  












































Figure	  B.3.	  	  Insulin	  was	  placed	  in	  the	  apical	  chamber	  without	  the	  presence	  of	  P(MAA-­‐
g-­‐EG)	   microparticles	   and	   while	   in	   the	   presence	   of	   P(MAA-­‐g-­‐EG)	   microparticles	   at	   a	  
protein	  concentration	  of	  0.2	  mg/mL	  and	  a	  microparticle	  concentration	  of	  1	  mg/mL.	  	  	  
The	  insulin	  was	  allowed	  to	  diffuse	  through	  a	  cell	  monolayer	  of	  Caco-­‐2/HT29-­‐MTX	  for	  3	  
hours.	  	  The	  protein	  concentrations	  in	  the	  basolateral	  chamber	  were	  measured	  at	  time	  
points	  of	  0.5,	  1,	  2,	  and	  3	  hours	  using	  ELISA	  and	  compared	  to	  standards	  of	  known	  















































Figure	  B.4.	  	  Insulin-­‐transferrin	  was	  placed	  in	  the	  apical	  chamber	  without	  the	  presence	  
of	   P(MAA-­‐g-­‐EG)	   microparticles	   and	   while	   in	   the	   presence	   of	   P(MAA-­‐g-­‐EG)	  
microparticles	   at	   a	   protein	   concentration	   of	   0.2	   mg/mL	   and	   a	   microparticle	  
concentration	  of	  1	  mg/mL.	  	  	  
The	  insulin-­‐transferrin	  conjugates	  were	  allowed	  to	  diffuse	  through	  a	  cell	  monolayer	  of	  
Caco-­‐2/HT29-­‐MTX	  for	  3	  hours.	  	  The	  protein	  concentrations	  in	  the	  basolateral	  chamber	  
were	  measured	  at	  time	  points	  of	  0.5,	  1,	  2,	  and	  3	  hours	  using	  ELISA	  and	  compared	  to	  














































Figure	   B.5.	   	   Transepithelial	   electrical	   resistances	   (TEER)	   of	   cell	   monolayers	   of	   Caco-­‐
2/HT29-­‐MTX	  co-­‐cultures	  over	  the	  course	  of	  a	  3	  hour	  transport	  study	  using	  insulin	  	  and	  
insulin-­‐transferrin	  conjugates	  	  at	  protein	  concentrations	  of	  0.2	  mg/mL.	  	  Also	  present	  in	  
the	  apical	  chamber	  were	  P(MAA-­‐g-­‐EG)	  microparticles	  at	  a	  concentration	  of	  1	  mg/mL.	  	  	  
The	  values	  are	  percentages	  of	  the	  TEER	  as	  compared	  to	  the	  initial	  values	  before	  the	  
























































Figure	   B.6.	   	   Insulin	   and	   insulin-­‐transferrin	   conjugates	   were	   placed	   in	   the	   apical	  
chamber	  at	  a	  protein	  concentration	  of	  0.2	  mg/mL	  while	  in	  the	  presence	  of	  P(MAA-­‐g-­‐
EG)	  microparticles	  at	  a	  particle	  concentration	  of	  1	  mg/mL	  and	  were	  allowed	  to	  diffuse	  
through	  a	  cell	  monolayer	  of	  Caco-­‐2/HT29-­‐MTX	  for	  3	  hours.	  	  	  
The	  protein	  concentrations	  in	  the	  basolateral	  chamber	  were	  measured	  at	  time	  points	  of	  
0.5,	  1,	  2,	  and	  3	  hours	  using	  ELISA	  and	  compared	  to	  standards	  of	  known	  concentrations.	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Appendix	  C	  
Anionic	  Complexation	  Hydrogels	  for	  the	  Oral	  Delivery	  of	  Protein	  Vaccines	  
	  
INTRODUCTION	  
Oral	  administration	  of	  vaccines	  is	  the	  preferred	  route	  of	  administration	  and	  has	  
the	  potential	   to	   improve	  vaccine	  efficacy	  by	  directly	   targeting	   the	  GI	   tract	  mucosa	   for	  
generation	   of	   mucosal	   immunity.	   	   Oral	   administration	   of	   vaccines	   is	   particularly	  
attractive	  because	   it	  would	  reduce	  production	  costs	  as	  well	  as	  administration	  costs	  by	  
eliminating	  needles	  and	  the	  requirement	  of	  trained	  personnel	  to	  administer	  them	  [1].	  	  	   	  
The	   generation	   of	   mucosal	   immunity	   offers	   an	   alternative	   mechanism	   to	  
systemic	   immunity	   generated	   by	   parenteral	   vaccine	   administration.	   	   The	   mucosal	  
immune	   system	   is	   distinct	   in	   function	   and	   anatomy	   from	   the	   peripheral	   (systemic)	  
immune	   system.	   	   The	   mucosal	   immune	   system	   functions	   to	   locally	   protect	   against	  
microbe	   colonization	   and	   entry,	   to	   prevent	   entry	   of	   undegraded	   antigens,	   and	   to	  
prevent	   harmful	   systemic	   immune	   responses	   in	   the	   event	   that	   antigens	   do	   enter	   the	  
body	  [2].	  	  	  
One	  of	  the	  most	  interesting	  features	  of	  the	  common	  mucosal	  immune	  system	  is	  
that	   exposure	   to	   antigens	   at	   one	   mucosal	   site	   can	   lead	   to	   IgA	   secretion	   at	   distant	  
mucosal	  sites	  and	  antigen-­‐specific	  IgA	  can	  also	  be	  found	  in	  serum	  [3,	  4].	  	  Immunization	  
at	   one	   site	   can	   generate	   protective	   immunity	   at	   the	   local	   mucosal	   site,	   at	   distant	  
mucosal	  sites,	  and	  may	  also	  lead	  to	  a	  systemic	  immunity.	  	  	  
The	  common	  mucosal	   immune	  system	  consists	  of	  mucosa-­‐associated	   lymphoid	  
tissue	  (MALT),	  which	  contains	  80%	  of	  all	  immune	  cells	  [2].	  	  MALT	  tissue	  can	  be	  classified	  
by	  its	  function	  as	  either	  organized	  inductive	  sites	  where	  naïve	  B	  and	  T	  cells	  are	  primed	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after	   antigen	   exposure	   or	   diffuse	   effector	   sites	   where	   activated	   B	   and	   T	   cells	   reside.	  	  
Mucosal	   immunity	   is	   associated	   primarily	   with	   secretory	   IgA	   dominant	   responses	   to	  
antigens.	  
The	   intestinal	   mucosal	   immune	   system,	   or	   the	   gut-­‐associated	   lymphoid	   tissue	  
(GALT),	   includes	   Peyer’s	   patches,	   mesenteric	   lymph	   nodes,	   and	   lymphoid	   cells	   in	   the	  
epithelium	  and	  in	  the	  lamina	  propria.	  	  A	  schematic	  overview	  of	  the	  gut	  mucosal	  immune	  
system	  is	  shown	  in	  Figure	  1.	  	  Peyer’s	  patches	  are	  aggregated	  lymphoid	  nodules	  that	  act	  
as	  inductive	  sites	  in	  the	  GALT.	  	  Peyer’s	  patches	  appear	  as	  dome	  like	  regions	  that	  extend	  
into	  the	  lumen	  of	  the	  GI	  tract.	  	  The	  Peyer’s	  patch	  epithelium	  is	  composed	  of	  specialized	  
follicle-­‐associated	   epithelium	   (FAE)	   including	   enterocyte-­‐like	   cells	   and	   microfold	   (M-­‐)	  
cells.	   	   These	   epithelial	   cells	   have	   no	  mucosal	   layer	   and	   have	   a	   thin	   glycocalyx,	   which	  
allows	   Peyer’s	   patch	   FAE	   cells	   to	   directly	   contact	   luminal	   contents	   [5].	   	   M-­‐cells	  
endocytose	   or	   phagacytose	   antigens	   adhered	   to	   their	   membrane	   [6-­‐10].	   	   	   M-­‐cell	  
anatomy,	   such	   as	   short	   microvilli,	   cytoplasmic	   vesicles,	   and	   few	   lysosomes,	   allows	  
antigen	  transport	  across	  the	  M-­‐cell	  below	  the	  dome	  region	  of	  the	  Peyer’s	  patch	  [5].	  	  	  
Beneath	   the	   dome	   region	   of	   the	   Peyer’s	   patch,	   a	   variety	   of	   immune	   cells	   are	  
present	  including	  B	  cells,	  T	  cells,	  dendritic	  cells,	  and	  macrophages.	  	  Antigens	  transported	  
across	   the	   dome	   region	   are	   then	   taken	   up	   by	   professional	   antigen	   presenting	   cells	  
(APCs)	  (dendritic	  cells	  or	  possibly	  neighboring	  epithelial	  cells).	  	  APCs	  present	  the	  antigen	  
to	   CD4+	   T	   cells	   causing	   activation	   shown	   in	   Figure	   C1.	   	   Activated	   CD4+	   T	   cells	   in	   turn	  
activate	  B	  cells	  via	  CD40L	  and	  TGF-­‐beta	  and	  cause	  them	  to	  switch	  to	  IgA	  isotype	  [11,	  12].	  	  
Following,	   T	   cell	   activation	   and	   B	   cell	   IgA	   switching,	   B	   and	   T	   cells	  migrate	   out	   of	   the	  
inductive	   site	   to	   effector	   sites.	   	   These	   cells	   typically	   leave	   the	   Peyer’s	   patch	   follicle	  
inductive	   site	   via	   the	   mesenteric	   lymph	   node	   and	   circulate	   back	   (through	   the	  
bloodstream)	  to	  differentiate	  into	  memory	  cells	  at	  mucosal	  effector	  sites	  typically	  at	  the	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tissue	  of	  origin	  (the	  GI	  tract	  lamina	  propria)	  [2].	  	  The	  mechanism	  for	  relocation	  of	  the	  B	  
and	  T	  cells	   is	  attributed	  to	  addressins	  on	  the	  surface	  of	   the	  cells.	   	  The	  cells	  associated	  
with	  the	  lamina	  propria	  include	  B	  cells,	  J-­‐chain	  expressing	  IgA	  and	  IgM	  plasma	  cells,	  IgG	  
plasma	  cells,	  and	  CD4+	  T	  cells	  shown	  in	  Figure	  C1.	  	  Of	  these	  antibodies	  produced,	  IgA	  is	  
the	  most	   abundant	   and	   protects	   the	  GI	   tract	   from	   infection	   by	   preventing	   pathogens	  
from	  binding	  enterocytes	  [13].	  	  	  
Because	   most	   pathogens	   enter	   the	   body	   through	   mucosal	   membranes,	  
vaccination	   to	   produce	  mucosal	   immunity	   is	   highly	   desirable.	   	   Generation	   of	  mucosal	  
immune	  responses	   is	  highest	  when	  the	  antigen	   is	  administered	  directly	  to	  the	  mucosa	  
[14].	   	   In	  addition,	   there	   is	   some	   indication	   that	   stimulation	  of	   local	  mucosal	   immunity	  
can	   lead	   to	   immunity	   at	   other	  mucosal	   membranes	   as	   well	   as	   systemic	   immunity	   as	  
activated	  B	  and	  T	  cells	  at	  mucosal	  inductive	  sites	  can	  relocate	  to	  other	  mucosal	  effector	  
sites.	  	  Therefore,	  it	  is	  thought	  that	  mucosal	  immunization	  and,	  in	  some	  cases,	  systemic	  
immunity,	  may	   be	   achieved	   by	   inoculation	   at	   just	   a	   single	  mucosal	   inductive	   site	   [2].	  	  
Furthermore,	   the	   highly	   effective	   protective,	   local	   immune	   responses	   associated	  with	  
mucosal	  immunity	  could	  improve	  vaccine	  efficacy	  as	  most	  pathogens	  enter	  the	  body	  via	  
mucosal	  membranes,	   and	   infection	  would	   not	   be	   required	   for	   generating	   an	   immune	  
response	   as	   infection	   is	   required	   for	   a	   systemic	   immune	   response	   due	   to	   systemic	  
immunization	  by	  parenteral	  vaccination.	  	  	  	  
Vaccines	   may	   consist	   of	   either	   a	   killed	   or	   attenuated	   form	   of	   a	   pathogen,	   a	  
protein	  from	  the	  pathogen,	  DNA,	  or	  a	  toxoid	  produced	  by	  a	  pathogen.	  	  One	  of	  the	  main	  
challenges	  to	  oral	  delivery	  of	  a	  vaccine	  is	  maintaining	  the	  immunogenicity	  of	  the	  antigen	  
in	   the	  GI	   tract	   and	  uptake	  of	   a	   large	  molecular	  weight	   compound	  by	  Peyer’s	  patches.	  	  	  
Often,	  vaccines	  are	  administered	  through	  injection	  because	  of	  the	  challenges	  associated	  
with	   delivering	   a	   sufficient	   amount	   of	   an	   intact	   antigen	   orally.	   	   Several	   vaccines	   have	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been	  shown	  to	  be	  effective	  after	  oral	  administration.	  	  Most	  notably	  Sabin’s	  polio	  vaccine	  
was	   one	   of	   the	   vaccines	   used	   to	   eradicate	   polio	   in	   the	   1960s.	   	   The	   safety	   concerns	  
associated	  with	  a	  live	  vaccine	  were	  not	  attributed	  to	  the	  oral	  route	  of	  administration	  but	  
rather	  that	  the	  vaccine	  was	  an	  attenuated	  live	  polio	  virus	  that	  in	  rare	  cases	  could	  lead	  to	  
infection	   [2].	   	   Other	   examples	   of	   licensed	   oral	   mucosal	   vaccines	   include	   cholera	  
(Dukoral,	   Orochol),	   typhoid	   (TyphimVi,	   Vivotif),	   rotavirus	   (RotaRix),	   and	   influenza	  
(FluMist)	  [2].	  	  
Safety	   concerns	   regarding	   the	   possibility	   of	   attenuated	   virus	   vaccines	   to	   cause	  
infection	   in	   addition	   to	   the	   rapid	   development	   of	   genetic	   and	   protein	   engineering	  
technologies	   have	   shifted	   focus	   to	   the	   design	   of	   DNA,	   protein,	   and	   peptide	   vaccines.	  	  
The	  development	  of	  oral	  vaccine	  formulations	  especially	  of	  protein-­‐based	  vaccines	  faces	  
similar	  challenges	  to	  the	  oral	  delivery	  of	  protein	  drugs.	  	  For	  example,	  the	  vaccine	  must	  
arrive	  in	  tact	  at	  the	  site	  of	  absorption,	  the	  ileum,	  must	  retain	  its	  immunogenicity,	  must	  
be	  absorbed	  by	  Peyer’s	  patches,	  and	  taken	  up	  by	  APCs	  [1].	  	  	  
To	   address	   these	   challenges,	   polymer	   particulate	   drug	   delivery	   systems	   have	  
been	   investigated	   for	   oral	   protein	   vaccine	   delivery.	   	  Most	   strategies	   have	   focused	   on	  
biodegradable	  microparticle	  formulations	  designed	  for	  uptake	  by	  M-­‐cells	   [15,	  16].	   	  For	  
example,	   poly(lactic	   acid-­‐co-­‐glycolic	   acid)	   (PLGA)	   microparticles	   have	   been	   the	   most	  
widely	   studied	   polymer	   microparticles	   to	   deliver	   antigens	   orally.	   	   Antigens	   delivered	  
using	  PLGA	  have	  been	  shown	  to	  elicit	  increased	  serum	  immune	  responses	  and	  mucosal	  
immune	  responses	  (via	  increased	  antibody	  titers)	  [17,	  18].	  	  Generation	  of	  secretory	  IgA	  
responses	   locally	   and	   at	   distant	   mucosa	   has	   also	   be	   demonstrated	   [18].	   	   Systemic	  
cytotoxic	  T	  lymphocytes	  have	  also	  been	  detected	  after	  orally	  administered	  antigens	  via	  
PLGA	   [19].	   	   In	   one	   study,	   oral	   immunization	   using	   PLGA	   delivery	   systems	   provided	  
protective	   immunity	   upon	   a	   nasal	   challenge	   with	   Bordetella	   pertussis	   [20].	   	   Other	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biodegradable	   polymers	   have	   also	   been	   investigated	   for	   oral	   delivery	   of	   vaccines	  
including	  alginate,	  sodium	  alginate	  and	  spermine	  hydrochloride	  [21-­‐23],	  starch	  [24-­‐26],	  
poly(ε-­‐caprolactone)	  (PCL)	  [27,	  28],	  and	  chitosan	  [29,	  30].	  
The	  majority	  of	   these	  studies	  have	  highlighted	  that	  microparticle	  uptake	  by	  M-­‐
cells	   is	   important	   for	   the	   generation	   of	   an	   immune	   response,	   and	   as	   a	   result,	  
biodegradable	   polymers	   are	   necessary.	   	   In	   a	   recent	   study	   by	   Yamamoto	   et	   al.,	   it	  was	  
shown	   that	   protective	   immunity,	   IgA	   responses,	   can	   be	   achieved	   outside	   Peyer’s	  
patches	  in	  mice	  [31].	  	  Therefore,	  it	  may	  not	  be	  entirely	  necessary	  for	  an	  oral	  vaccine	  to	  
be	  taken	  up	  only	  at	  M-­‐cells.	  	  Delivery	  of	  an	  intact	  antigen	  to	  the	  intestinal	  wall	  may	  be	  
sufficient.	   	   In	   this	   work,	   we	   take	   an	   alternative	   approach	   in	   which	   non-­‐degradable	  
hydrogel	  microparticles	  are	  designed	   to	  orally	  deliver	  a	  vaccine	  via	  bioadhesion	   to	  M-­‐
cells.	  	  One	  of	  the	  advantages	  of	  a	  non-­‐degradable	  system	  is	  the	  increased	  stability	  of	  the	  
formulation	  in	  the	  GI	  tract	  [1].	  	  	  
Our	   laboratory	   has	   developed	   anionic	   complexation	   hydrogels	   composed	   of	  
poly(methacrylic	  acid-­‐grafted-­‐ethylene	  glycol)	  (P(MAA-­‐g-­‐EG)	  for	  oral	  delivery	  of	  protein	  
drugs,	   and	   we	   believe	   that	   these	   systems	   can	   successfully	   deliver	   a	   protein	   based	  
vaccine	  orally.	  	  	  P(MAA-­‐g-­‐EG)	  microgels	  protect	  protein	  drugs	  from	  degradation	  in	  the	  GI	  
tract	   through	   the	   formation	   of	   interpolymer	   complexes	   in	   stomach	   conditions	   which	  
limit	   diffusion	   into	   and	   out	   of	   the	   gel	   [32].	   	   Release	   of	   the	   drug	   occurs	   in	   intestinal	  
conditions	  due	   to	  decomplexation	   and	   subsequent	   swelling	  of	   the	   gels.	   	   P(MAA-­‐g-­‐EG)	  
gels	  have	  the	  ability	  to	  interact	  with	  intestinal	  mucosa	  through	  mucoadhesion	  as	  well	  as	  
reversibly	   open	   tight	   junctions	   between	   neighboring	   epithelial	   cells	   [32-­‐36].	   	   Both	  
mucoadhesion	  and	  the	  ability	  to	  improve	  absorption	  make	  P(MAA-­‐g-­‐EG)	  gels	  attractive	  
vaccine	  delivery	  systems.	   	  For	  example,	  mucoadhesion	   improves	  the	  residence	  time	  of	  
the	  carrier	  at	  the	  site	  of	  absorption	  allowing	  for	  a	   longer	  window	  for	  drug	  release	  and	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therefore	  more	  drug	  absorption.	  	  These	  systems	  have	  been	  shown	  to	  effectively	  deliver	  
a	  variety	  of	  protein	  drugs	  including	  insulin,	  growth	  hormone,	  calcitonin,	  and	  interferon-­‐
β.	  	  	  
Because	  Peyer’s	   patches	   are	   the	  major	   inductive	   site	   of	   the	   intestinal	  mucosal	  
immune	   system,	   localizing	   P(MAA-­‐g-­‐EG)	   microgels	   to	   Peyer’s	   patches	   could	   enhance	  
vaccine	   absorption	   and	   the	   resulting	   immune	   response.	   	   For	   example,	   PLGA	  
microparticles	  have	  been	  modified	  with	  RGD	  [37]	  and	  other	  peptides	  [38]	  to	  target	  the	  
apical	   surface	  of	  M-­‐cells.	   	   Because	  multiple	   pathogens	   target	   and	   invade	  M-­‐cells	   very	  
effectively,	  we	  believe	  that	  a	  biomimetic	  approach	  using	  invasin,	  a	  bacterial	  protein	  that	  
mediates	  M-­‐cell	   invasion,	  may	  be	  high	  affinity	  and	  high	  specificity	  targeting	  ligands	  for	  
localizing	  P(MAA-­‐g-­‐EG)	  microgels	  at	  Peyer’s	  patches.	  	  	  
The	  main	  objectives	  in	  this	  work	  were	  1)	  to	  develop	  and	  optimize	  P(MAA-­‐g-­‐EG)	  
gels	  for	  the	  delivery	  of	  a	  model	  protein	  vaccine,	  ovalbumin,	  and	  2)	  to	  optimize	  a	  method	  
for	  conjugation	  of	  targeting	  ligands	  to	  the	  surface	  of	  P(MAA-­‐g-­‐EG)	  hydrogels.	  	  	  
	  
MATERIALS	  AND	  METHODS	  
Preparation	  of	  P(MAA-­‐g-­‐EG)	  Hydrogels	  
Thin	  films	  of	  P(MAA-­‐g-­‐EG)	  hydrogels	  were	  synthesized	  using	  a	  UV-­‐initiated	  free	  
solution	  radical	  polymerization.	  	  A	  solution	  of	  the	  monomers,	  crosslinker,	  initiator,	  and	  
solvent	  were	  prepared.	  	  The	  solvent	  was	  50	  wt%	  water	  and	  50	  wt%	  ethanol.	  	  The	  solvent	  
and	  an	  equal	  mass	  of	  the	  monomers	  were	  combined.	  	  The	  monomers,	  methacrylic	  acid	  
(Sigma	   Aldrich)	   and	   poly(ethylene	   glycol)	   monomethyl	   ether	   monomethacrylate	  
(PEGMA;	  Polysciences)	  with	  an	  average	  molecular	  weight	  of	  1000,	  were	  added	   to	   the	  
solvent	   such	   that	   there	   was	   an	   equal	   molar	   ratio	   between	   the	   methacrylic	   acid	   and	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PEGMA	   ethylene	   glycol	   mer	   units.	   	   A	   1%	   molar	   feed	   ratio	   of	   the	   crosslinker,	  
poly(ethylene	   glycol)	   dimethacrylate	   (Polysciences),	  was	   added	   to	   the	  monomers	   and	  
solvent	  mixture.	  	  Irgacure	  184	  (1-­‐hydroxycyclohexy	  benzoephenone;	  Sigma	  Aldrich),	  the	  
photoinitiator,	  was	  added	  at	  0.5	  wt%	  of	  the	  total	  monomers.	  
The	  solution	  was	  sonicated	  for	  20	  minutes	  to	  ensure	  full	  dissolution	  of	  reactants.	  	  
After	   sonication,	   the	   solution	   was	   placed	   in	   a	   glove	   box	   which	   was	   sealed	   and	   then	  
purged	  with	  nitrogen.	  	  The	  glove	  box	  was	  purged	  with	  nitrogen	  to	  reduce	  the	  amount	  of	  
oxygen	  (in	  the	  glove	  box	  and	  dissolved	  in	  the	  solution	  of	  reactants)	  which	  acts	  as	  a	  free	  
radical	  scavenger.	   	  The	  solution	  of	  reactants	  was	  placed	   in	  a	  glass	  mold	  and	   irradiated	  
with	  UV	  light	  for	  30	  minutes.	  	  The	  polymer	  film	  was	  washed	  in	  Ultrapure	  water	  for	  5-­‐7	  
days	  to	  remove	  any	  unreacted	  components	  and	  noncrosslinked	  polymer.	  	  The	  water	  was	  
changed	  twice	  every	  day.	  
After	  washing	   the	   film	  was	   drawer	   dried	   for	   24	   hours	   followed	   by	   drying	   in	   a	  
vacuum	   oven	   at	   37	   ⁰C	   for	   24	   hours.	   	   The	   dry	   P(MAA-­‐g-­‐EG)	   film	  was	   crushed	   using	   a	  
mortar	  and	  pestle	  to	  form	  microparticles.	  	  The	  microparticles	  were	  sieved	  to	  achieve	  a	  
microparticle	  size	  range	  of	  53-­‐75	  μm.	  	  	  
Fourier	  Transform	  Infrared	  Spectroscopy	  
To	  confirm	   the	   synthesis	  of	  P(MAA-­‐g-­‐EG)	  hydrogels,	   Fourier	   transform	   infrared	  
spectroscopy	   was	   used	   to	   show	   the	   functional	   groups	   present	   in	   the	   polymer.	   	   The	  
sample	  was	  prepared	  from	  2	  mg	  of	  dry	  P(MAA-­‐g-­‐EG)	  and	  198	  mg	  of	  dry	  KBr.	  	  The	  sample	  
powder	  was	  mixed	   using	   a	  mortar	   and	   pestle	   then	   placed	   in	   a	   steel	   die.	   	   A	   hydraulic	  
press	  was	  used	  to	  form	  a	  13	  mm	  sample	  pellet	  in	  the	  die.	  	  The	  sample	  pellet	  was	  then	  
placed	   in	  a	  FTIR	   sample	  holder.	   	   Infrared	   spectroscopy	  was	  performed	  using	  a	  Nicolet	  
FT-­‐IR.	  	  Samples	  were	  read	  at	  4	  cm-­‐1	  at	  either	  40	  or	  100	  scans.	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HPLC	  of	  Ovalbumin	  
A	  method	  for	  performing	  high	  throughput	  liquid	  chromatography	  for	  ovalbumin	  
was	   developed	   in	   order	   to	   accurately	  measure	   the	   amount	   of	   ovalbumin	   loaded	   and	  
released.	  	  A	  Waters	  Alliance	  Chromatography	  instrument	  equipped	  with	  a	  Symmetry	  C4	  
5	   μm	   column	   was	   used.	   	   The	   mobile	   phase	   consisted	   of	   95%	   water	   with	   0.1%	  
trifluoroacetic	  acid	  (TFA)	  and	  5%	  acetonitrile	  with	  0.8%	  TFA.	  	  A	  gradient	  was	  applied	  to	  
the	   column	   in	   the	   reverse	  direction	   (to	  40%	  water,	   60%	  acetonitrile).	   	   Typically,	   a	   0.6	  
mL/min	   flowrate	   was	   used	   and	   a	   gradient	   time	   of	   6-­‐10	  minutes	   was	   sufficient.	   	   The	  
concentration	  of	  ovalbumin	  was	  measured	  by	  an	  inline	  dual	  wavelength	  UV	  detector	  (at	  
220	   nm	   and	   280	   nm).	   	   The	   performance	   of	   the	   HPLC	   method	   was	   determined	   by	  
comparing	   spectra	   of	   ovalbumin	   with	   spectra	   from	   a	   water	   sample	   run	   immediately	  
after	  the	  sample.	  	  The	  HPLC	  spectra	  were	  used	  to	  determine	  ovalbumin	  concentrations	  
by	  integrating	  the	  area	  under	  the	  curve	  (AUC)	  of	  the	  absorbance	  peak	  corresponding	  to	  
ovalbumin	  and	  comparing	  to	  the	  AUC	  for	  a	  set	  of	  known	  concentrations.	  	  	  
Loading	  of	  Ovalbumin	  
P(MAA-­‐g-­‐EG)	   microgels	   were	   loaded	   with	   ovalbumin	   (Sigma	   Aldrich)	   by	  
equilibrium	   partitioning.	   	   All	   glassware	   used	   in	   protein	   loading	   was	   first	   cleaned	   in	   a	  
base	   bath	   and	   then	   coated	   with	   Sigmacote	   (Sigma	   Aldrich).	   	   A	   stock	   solution	   of	  
ovalbumin	   (0.5	  mg/ml)	  was	  prepared	   fresh	   in	  phosphate	  buffered	  saline	  at	  pH	  7.4.	   	  A	  
100	   μl	   sample	   of	   the	   original	   stock	   solution	  was	   taken	   and	   passed	   through	   a	   0.2	   μm	  
filter.	  	  	  
Dry	  P(MAA-­‐g-­‐EG)	  microgels	  were	  slowly	  added	  to	  the	  solution	  to	  achieve	  a	  final	  
concentration	  of	  2	  mg/ml	  of	  microgels.	  	  After	  addition	  of	  the	  P(MAA-­‐g-­‐EG)	  gels,	  the	  pH	  
of	  the	  solution	  was	  checked.	  	  The	  suspension	  was	  allowed	  to	  stir	  for	  4	  hours.	  	  At	  4	  hours,	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a	  200	  μl	  sample	  was	  removed	  from	  the	  suspension	  and	  passed	  through	  a	  0.2	  μm	  filter.	  	  
The	  pH	  of	  the	  suspension	  was	  lowered	  to	  pH	  3	  by	  adding	  0.1	  N	  HCl.	  	  The	  volume	  of	  HCl	  
added	  was	  recorded.	   	  After	  briefly	  stirring	  the	  suspension,	  the	  suspension	  was	  filtered	  
through	   a	   Whatman	   54	   filter	   using	   vacuum	   aspiration.	   	   The	   collected	   microparticles	  
were	  washed	  with	  a	  fixed	  volume	  of	  Ultrapure	  water,	  and	  the	  wash	  was	  filtered	  off	  the	  
particles.	   	   The	   microparticles	   were	   collected	   from	   the	   filter	   paper.	   	   Loaded	  
microparticles	  were	  dried	  by	  lyophilization	  overnight	  and	  stored	  in	  a	  -­‐80	  ⁰C	  freezer	  until	  
use.	  	  	  
Release	  Studies	  
In	  order	  to	  determine	  the	  release	  kinetics	  of	  ovalbumin	  from	  P(MAA-­‐g-­‐EG)	  gels,	  
release	  studies	  were	  performed	  in	  phosphate	  buffered	  saline	  with	  a	  pH	  of	  7.4.	  	  Release	  
studies	   were	   carried	   out	   in	   a	   USP	   2	   dissolution	   apparatus	   to	   maintain	   a	   constant	  
temperature	  of	  37	  ⁰C	  and	  solutions	  were	  constantly	  stirred	  at	  100	  rpm.	   	  Dry	  P(MAA-­‐g-­‐
EG)	  gels	  loaded	  with	  ovalbumin	  (20	  mg)	  were	  slowly	  added	  to	  20	  ml	  of	  pre-­‐warmed	  PBS.	  	  
Over	  the	  8	  hour	  period,	  200	  μl	  samples	  were	  taken	  with	  replacement	  (with	  pre-­‐warmed	  
PBS)	  using	  a	  Norm-­‐Eject	  Syringe	  and	  19	  gauge	  needle.	  	  Each	  sample	  was	  filtered	  through	  
a	  0.22	  μm	  PVDF	  syringe	  filter	  (Millipore)	  and	  placed	  in	  an	  HPLC	  sample	  vial.	  	  The	  sample	  
time	  points	  were	  0,	  5	  minutes,	  10	  minutes,	  15	  minutes,	  30	  minutes,	  60	  minutes	   (1	  h),	  
120	  minutes	  (2	  h),	  240	  minutes	  (4	  h),	  and	  480	  minutes	  (8	  h).	  	  	  
	  	  Samples	   were	   stored	   at	   4	   ⁰C	   until	   the	   concentration	   in	   each	   sample	   was	  
measured	  with	  HPLC.	   	  For	  HPLC	  of	  samples	  from	  release	  studies,	  the	  HPLC	  procedures	  
remained	  the	  same,	  but	  the	  injected	  sample	  volume	  was	  increased	  from	  20	  μl	  to	  40	  μl.	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Attachment	  of	  Ligands	  to	  Hydrogels	  
Optimization	  of	  Reaction	  with	  a	  Model	  Protein	  
Ovalbumin	   was	   attached	   to	   the	   P(MAA-­‐g-­‐EG)	   microgels	   as	   a	   model	   protein	  
ligand.	   	  A	  variety	  of	  different	  reaction	  parameters	  were	  tested	  to	  optimize	  the	  protein	  
conjugation	  protocol.	  	  A	  list	  of	  the	  reaction	  parameter	  can	  be	  found	  in	  Table	  1.	  	  	  
Briefly,	   dry	  P(MAA-­‐g-­‐EG)	  microgels	  were	   suspended	   in	   the	   reaction	  buffer	   at	   a	  
given	  concentration.	   	  Then,	  varying	  amounts	  of	  EDC	  and	  sulfo-­‐NHS	  were	  added	  to	  the	  
suspension.	   	   The	   suspension	   was	   mixed	   for	   varying	   activation	   times.	   	   The	   pH	   of	   the	  
suspension	  was	   increased	  from	  6	  to	  ~8	  with	  the	  addition	  of	  1	  N	  sodium	  hydroxide.	   	  A	  
solution	   of	   ovalbumin	   was	   then	   added	   to	   the	   reaction	   mixture	   at	   various	  
concentrations.	   	   The	   reaction	   was	   allowed	   to	   proceed	   for	   a	   set	   reaction	   time.	   	   The	  
reaction	   conditions	   are	   given	   in	   Table	   1.	   	   The	   suspension	   was	   centrifuged	   and	   the	  
supernatant	  removed.	  	  The	  supernatant	  was	  used	  to	  measure	  the	  concentration	  of	  un-­‐
reacted	  protein.	  	  The	  particles	  were	  washed	  with	  water	  several	  times	  by	  centrifugation	  
and	  resuspension	  in	  Ultrapure	  water.	  
Attachment	  of	  Invasin	  to	  P(MAA-­‐g-­‐EG)	  Hydrogels	  
Based	  on	  the	  optimized	  method	  for	  covalently	  attaching	  ovalbumin	  to	  P(MAA-­‐g-­‐
EG)	  gels,	  invasin,	  an	  M-­‐cell	  targeting	  ligand,	  was	  covalently	  attached	  to	  the	  P(MAA-­‐g-­‐EG)	  
hydrogels.	  	  Briefly,	  CONC	  P(MAA-­‐g-­‐EG)	  was	  suspended	  in	  1X	  PBS	  buffer.	  	  EDC	  was	  added	  
and	   then	   the	   reaction	  mixture	  was	   placed	   on	   a	   shaker	   overnight.	   	   Finally,	   NaOH	  was	  
added	  to	  the	  solution	  to	  raise	  the	  pH	  and	  a	  solution	  of	   invasin	  composed	  of	  50%	  conc	  
and	   50%	   conc	   was	   added	   to	   the	   reaction	   mixture.	   	   The	   solution	   was	   placed	   on	   the	  
shaker	   for	   24	   hours.	   	   The	   microparticles	   were	   removed	   by	   centrifugation.	   	   The	  
concentration	  of	  invasin	  in	  the	  supernatant	  of	  the	  conjugation	  reaction	  was	  determined	  
	   279	  
by	  measuring	  the	  UV	  absorbance	  at	  280	  nm.	  	  The	  conjugation	  efficiency	  was	  calculated	  
by	  mass	  balance.	  	  	  
UV/Vis	  Spectroscopy	  
The	   concentration	  of	   ovalbumin	  before	   and	   after	   conjugation	   to	   the	  P(MAA-­‐g-­‐
EG)	   microgels	   was	  measured	   by	   UV	   absorbance	   at	   280	   nm.	   	   The	   supernatant	   of	   the	  
conjugation	   reaction	   was	   read	   in	   a	   UV	   free	   96-­‐well	   plate	   on	   a	   Biotek	   UV/Vis	   plate	  
reader.	  	  A	  calibration	  curve	  from	  ovalbumin	  at	  several	  different	  concentrations	  was	  used	  
to	   calculate	   the	   concentration	   of	   ovalbumin	   in	   the	   supernatant	   of	   the	   conjugation	  
reaction.	   	   The	  mass	   of	   ovalbumin	   after	   conjugation	  was	   subtracted	   from	   the	   starting	  
mass	  of	  ovalbumin	  to	  determine	  the	  amount	  of	  ovalbumin	  conjugated	  to	  the	  P(MAA-­‐g-­‐
EG)	  gels.	  	  	  
RESULTS	  AND	  DISCUSSION	  
Material	  Synthesis	  and	  Characterization	  
P(MAA-­‐g-­‐EG)	   hydrogels	   were	   successfully	   synthesized	   by	   a	   UV-­‐initiated	   free	  
radical	   solution	   polymerization.	   	   The	   resulting	   hydrogel	   films	   were	   transparent	   and	  
flexible.	  	  After	  washing	  and	  drying,	  the	  film	  was	  brittle	  and	  easily	  crushed	  and	  sieved	  to	  
form	  microparticles.	  	  	  
The	  synthesis	  of	  P(MAA-­‐g-­‐EG)	  gels	  was	  confirmed	  with	  FT-­‐IR	  spectroscopy	  shown	  
in	   Figure	   C2.	   	   The	   spectrum	   clearly	   shows	   the	   presence	   of	   both	   the	   PEG	   grafts	   and	  
poly(methacrylic	   acid)	   backbone.	   	   The	   broad	   peak	   2500-­‐3500	   cm-­‐1	   is	   due	   to	   hydroxyl	  
stretching	   on	   the	   carboxylic	   acid	   groups	   and	  O-­‐H	   groups	   associated	  with	  water.	   	   The	  
peak	   and	   shoulders	   near	   this	   region	   2850-­‐3000	   cm-­‐1	   corresponds	   to	   asymmetric	   and	  
symmetric	  vibrations	  from	  PEG’s	  methylene	  groups.	  	  A	  peak	  at	  1730	  cm-­‐1	  appears	  which	  
corresponds	   to	   the	   carboxylic	   acid	   groups.	   	   The	   C=O	   vibration	   band	   for	   pure	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poly(methacrylic	   acid)	   would	   be	   expected	   to	   fall	   closer	   to	   1700	   cm-­‐1,	   but	   hydrogen	  
bonding	  is	  known	  to	  shift	  the	  peak	  (cite	  20).	  	  The	  smaller	  band	  at	  1390	  cm-­‐1	  is	  associated	  
with	  C-­‐O	  stretching	  and	  O-­‐H	  deformation	  vibrations	  on	  the	  MAA.	  	  	  	  	  
HPLC	  of	  Ovalbumin	  
	   In	  order	   to	  quantify	   loading	  and	   release	  of	  ovalbumin,	  an	  HPLC	  procedure	  was	  
developed.	   	  First,	  the	  run	  time	  was	  set	  to	  1	  hour	  to	  make	  sure	  that	  there	  was	  enough	  
time	  for	  gradient	  elution	  to	  occur.	  	  Next,	  the	  mobile	  phase	  and	  gradient	  were	  optimized.	  	  
Ovalbumin	   is	   readily	   soluble	   aqueous	   solutions,	   and	   starting	   with	   a	   mostly	   aqueous	  
mobile	  phase	  allows	  elution	  with	  a	  steeper	  gradient	  in	  the	  reverse	  direction.	  	  Therefore,	  
the	  solubility	  of	  ovalbumin	  in	  95%	  water	  and	  5%	  acetonitrile	  was	  tested.	  	  In	  addition,	  an	  
acidic	  mobile	  phase	  is	  highly	  desirable	  in	  HPLC	  of	  proteins	  so	  the	  solubility	  of	  ovalbumin	  
in	   95%	   water	   containing	   0.1%	   TFA	   and	   5%	   acetronitrile	   containing	   0.08%	   TFA	   was	  
verified.	  	  	  
	   Optimization	   of	   the	   reverse	   gradient	   took	   into	   account	   several	   important	  
variables:	  the	  steepness	  of	  the	  gradient,	  the	  solubility	  of	  ovalbumin	  in	  a	  solvent	  with	  a	  
greater	   percentage	  of	   organic	   solvent,	   and	   the	   ability	   of	   ovalbumin	   to	   elute	   from	   the	  
column.	   	  The	  steepness	  of	   the	  gradient	  depends	  on	   the	   time	  period	   that	   the	  gradient	  
runs	   over	   as	   well	   as	   the	   change	   in	   solvent	   composition.	   	   We	   found	   that	   a	   reverse	  
gradient	   that	   changed	   the	   solvent	   composition	   to	   40%	  water	  with	   0.1%	  TFA	  and	  60%	  
acetonitrile	  with	  0.08%	  TFA.	  	  It	  was	  important	  to	  note	  that	  as	  the	  organic	  component	  to	  
the	  solvent	  increases,	  it	  becomes	  increasingly	  more	  likely	  that	  protein	  precipitation	  can	  
occur.	   	   This	   caveat	   was	   taken	   into	   account	   in	   optimization	   of	   the	   gradient	   by	  
determining	   the	   amount	   of	   sample	   retention	   after	   a	   sample	   run	   by	   running	   a	   water	  
sample	  through	  the	  column.	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   The	  total	  run	  time	  and	  the	  gradient	  time	  were	  optimized	  to	  allow	  for	  relatively	  
fast	  sample	  runs	  without	  causing	  peak	  broadening.	  	  Several	  spectra	  from	  the	  optimized	  
procedure	  are	  shown	   in	  Figure	  C3	  and	  4.	   	  Ovalbumin	  appears	  as	  a	   sharp	  peak	  at	  10.8	  
minutes	  when	  absorbance	  was	  measured	  at	  either	  a	  wavelength	  of	  220	  nm	  (Figure	  C3)	  
or	  280	  nm	  (Figure	  C4).	  	  	  	  	  
Loading	  and	  release	  of	  ovalbumin	  
P(MAA-­‐g-­‐EG)	   microparticles	   were	   loaded	   with	   ovalbumin	   by	   equilibrium	  
partitioning	  for	  4	  hours.	  	  In	  previous	  work	  by	  Shofner	  et	  al.,	  a	  4	  hour	  loading	  time	  was	  
shown	  to	  be	  sufficient	  for	  loading	  of	  large	  molecular	  weight	  proteins	  into	  P(MAA-­‐g-­‐EG)	  
hydrogel	  microparticles.	  	  The	  results	  from	  loading	  studies	  with	  ovalbumin	  confirm	  these	  
results.	   	  We	  achieved	  up	   to	  40%	   loading	   in	  one	   study.	   	  However,	   the	  average	   loading	  
efficiency	   obtained	   was	   23%.	   	   This	   loading	   efficiency	   is	   lower	   than	   what	   has	   been	  
achieved	  with	  P(MAA-­‐g-­‐EG)	  microparticles	  in	  part	  due	  to	  the	  size	  and	  hydrophobicity	  of	  
ovalbumin.	  	  Ovalbumin	  is	  a	  relatively	  hydrophobic	  protein	  so	  a	  lower	  loading	  efficiency	  
than	  more	  hydrophilic	  proteins	  in	  a	  hydrogel	  is	  expected.	  	  	  
In	  order	  to	  verify	  that	  release	  of	  ovalbumin	  from	  P(MAA-­‐g-­‐EG)	  gels	  was	  possible,	  
a	   release	   study	  was	  carried	  out.	   	   In	   the	   first	   iteration	  of	   the	   release	   study,	  no	   release	  
was	  measured	  by	  HPLC.	  	  It	  was	  assumed	  that	  no	  ovalbumin	  release	  was	  detected	  due	  to	  
the	  low	  amount	  of	  loading	  and	  dilution	  by	  the	  relatively	  volume	  of	  buffer	  used	  for	  the	  
release	  solution.	  	  In	  subsequent	  release	  studies,	  the	  release	  buffer	  volume	  was	  reduced	  
to	  20	  ml.	  	  The	  release	  data	  is	  shown	  in	  Figure	  C5.	  	  	  
There	   are	   a	   few	   phenomena	   that	  may	   explain	   the	   unexpected	   release	   profile.	  	  
First,	  ovalbumin	  is	  a	  relatively	  hydrophobic	  drug.	  	  It	  is	  possible	  that	  the	  protein	  interacts	  
with	   the	   P(MAA-­‐g-­‐EG)	   network	   and	   preferentially	   stays	   in	   the	   network	   rather	   than	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diffusing	  out	  into	  an	  aqueous	  buffer.	  	  Because	  the	  release	  buffer	  volume	  was	  decreased	  
relative	   to	   the	   amount	   of	   P(MAA-­‐g-­‐EG)	   microparticles,	   it	   is	   possible	   that	   released	  
ovalbumin	   adsorbed	   to	   neighboring	  microparticles	   instead	   of	   staying	   dissolved	   in	   the	  
release	  media.	  	  In	  addition,	  a	  comparison	  between	  the	  AUCs	  used	  to	  determine	  protein	  
concentration	  are	   less	   than	  50000.	   	   If	   the	  AUCs	  are	  very	   low,	  detector	   resolution	  and	  
signal-­‐to-­‐noise	   ratio	   may	   have	   significant	   effects	   on	   the	   data.	   	   Therefore,	   further	  
investigation	   of	   the	   release	   of	   ovalbumin	   from	  P(MAA-­‐g-­‐EG)	  microgels	   are	   needed	   to	  
fully	   understand	   the	   phenomena	   affecting	   ovalbumin	   release.	   	   Despite	   this,	   we	  were	  
able	   to	   confirm	   that	   ovalbumin	   is	   released	   from	   P(MAA-­‐g-­‐EG)	   gels	   at	   neutral	   pH	  
although	  there	  are	  still	  questions	  to	  be	  answered	  regarding	  the	  release	  kinetics.	  	  	  	  	  
Covalent	  Attachment	  of	  Ligands	  
For	   the	   covalent	   attachment	   of	   protein	   targeting	   ligands	   such	   as	   invasin,	   a	  
method	   for	   attachment	   of	   proteins	   to	   P(MAA-­‐g-­‐EG)	   microparticles	   was	   optimized.	  	  
Bioconjugation	  of	  molecules	  via	  reaction	  of	  carboxylic	  acid	  groups	  with	  primary	  amines	  
under	   mild,	   aqueous	   reaction	   conditions	   is	   most	   commonly	   performed	   with	  
carbodiimide	  coupling.	  	  Typically,	  EDC	  and	  sulfo-­‐NHS	  are	  used	  to	  activate	  and	  stabilize	  a	  
carboxylic	   acid	   groups,	   respectively.	   	   The	   activated	   carboxylic	   acid	   group	   and	   primary	  
amine	  react	  forming	  an	  amide	  bond.	  	  
We	   chose	   to	   use	   EDC/NHS	   chemistry	   to	   form	   an	   amide	   bond	   between	   the	  
carboxylic	   acid	   groups	   of	   P(MAA-­‐g-­‐EG)	  microparticles	   and	   primary	   amine	   groups	   on	   a	  
protein	   targeting	   ligand.	   	   In	   this	   work,	   we	   optimized	   the	   reaction	   mechanism	   for	  
attaching	   ovalbumin	   to	   the	   surface	   of	   P(MAA-­‐g-­‐EG)	  microgels	   as	   a	  model	   for	   invasin.	  	  
The	  reason	  that	  we	  used	  a	  model	  protein	  instead	  of	  invasin	  was	  primarily	  based	  on	  cost	  
and	   time	   efficiency.	   	   The	   Maynard	   Laboratory	   at	   the	   University	   of	   Texas	   at	   Austin	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synthesizes	  an	  invasin	  ligand	  using	  E.	  coli.	  	  However,	  the	  process	  to	  synthesize	  invasin	  is	  
time	  consuming	  and	  yields	  a	  relatively	  small	  amount	  of	  product.	  	  	  
A	   variety	   of	   conjugation	   reaction	   conditions	   were	   tested	   to	   determine	   what	  
yielded	   the	   largest	   amount	   of	   conjugation.	   	   We	   found	   that	   the	   reaction	   efficiency	  
increased	   when	   sulfo-­‐NHS	   was	   omitted	   from	   the	   reaction.	   	   Sulfo-­‐NHS	   forms	   an	   NHS	  
ester	  with	  carboxylic	  acid	  groups	  and	   increases	  the	  half	   life	  of	  the	  activated	  carboxylic	  
acid.	   	   In	   the	   conjugation	   reaction,	   the	   NHS	   ester	   serves	   as	   a	   leaving	   group	   in	   the	  
conjugation	  reaction.	  	  Our	  results	  show	  that	  EDC	  is	  sufficient	  in	  activating	  carboxylic	  acid	  
groups	   and	   that	   24	   hours	   is	   a	   sufficient	   activation	   time.	   	   Our	   results	   coincide	   with	  
findings	   in	   which	   greater	   conjugation	   efficiencies	   in	   carbodiimide	   coupling	   of	   poly(N-­‐
isopropylacrylamide-­‐co-­‐acrylic	   acid)	   hydrogel	   particles	  were	   observed	  with	   EDC	   alone.	  	  
They	   hypothesized	   that	   the	   NHS	   esters	   formed	   on	   the	   acrylic	   acid	   groups	   of	   the	  
copolymer	   were	   much	   more	   stable	   than	   in	   aqueous	   solutions	   and	   was	   not	   a	   good	  
leaving	  group.	  	  	  
Our	  results	  for	  using	  EDC	  without	  sulfo-­‐NHS	  are	  summarized	  in	  Figures	  6-­‐8.	  	  We	  
were	  primarily	  interested	  in	  determining	  the	  optimal	  ratios	  of	  EDC	  to	  polymer,	  protein	  
to	  polymer,	  and	  reaction	  time.	  	  At	  low	  protein	  feed	  ratios,	  we	  saw	  a	  range	  of	  outcomes.	  	  
The	  supernatant	  for	  several	  had	  high	  absorbance	  values	  which	  corresponded	  to	  protein	  
concentrations	   higher	   than	   the	   initial	   concentrations	   and	   negative	   conjugation	  
efficiencies	  as	  well	  as	  several	  absorbance	  values	  that	  were	  lower	  than	  the	  range	  of	  the	  
calibration	   curve	  which	   caused	   the	   conjugation	   efficiency	   to	   exceed	   100%.	   	   At	   higher	  
protein	   feed	   ratios,	   we	   saw	   more	   reasonable	   data.	   	   At	   protein	   concentrations	   of	   2	  
mg/ml	   and	   0.2	  mg/ml,	   we	   saw	   a	   reduction	   in	   the	   concentration	   of	   the	   protein	   after	  
incubation	  with	  activated	  P(MAA-­‐g-­‐EG)	  microparticles.	   	  Similarly,	  we	  saw	  more	  protein	  
conjugation	  at	  greater	  concentrations	  of	  EDC.	  	  While	  a	  24	  hour	  reaction	  time	  achieved	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the	   highest	   conjugation	   efficiency	   compared	   to	   shorter	   reaction	   times,	   it	   is	  
recommended	  that	  future	  work	  focus	  on	  reaction	  times	  less	  than	  4	  hours	  to	  prevent	  a	  
significant	  amount	  of	  protein	  loading.	  	  	  
In	   performing	   the	   conjugation	   reaction	   with	   invasin,	   very	   low	   conjugation	  
efficiencies	   were	   observed	   (1%).	   	   The	   data	   suggest	   that	   optimized	   protocol	   for	  
ovalbumin	  may	  not	  be	  the	  optimal	  procedure	  for	  covalent	  attachment	  of	  invasin	  to	  the	  
surface	  of	  P(MAA-­‐g-­‐EG)	  gels.	  
CONCLUSIONS	  
In	   this	   work,	   we	   developed	   P(MAA-­‐g-­‐EG)	   hydrogels	   for	   potential	   use	   as	   oral	  
vaccine	  delivery	  systems.	  	  The	  methods	  to	  measure	  ovalbumin	  concentration	  for	  loading	  
and	  release	  studies	  were	  optimized.	  	  We	  demonstrated	  as	  a	  proof	  of	  concept	  for	  invasin	  
attachment	  to	  P(MAA-­‐g-­‐EG)	  microgels	  that	  conjugation	  of	  ovalbumin	  to	  the	  surface	  of	  
the	   P(MAA-­‐g-­‐EG)	   microgels	   was	   possible.	   	   The	   ability	   to	   load	   and	   release	   a	   model	  
protein	   vaccine,	   ovalbumin,	  was	  demonstrated.	   	   Future	  work	   includes	  optimization	  of	  
the	  conjugation	  of	  invasin	  to	  the	  surface	  of	  the	  P(MAA-­‐g-­‐EG)	  microgels	  and	  optimization	  
of	   loading	   and	   release	   of	   a	   vaccine	   from	   invasin	  modified-­‐P(MAA-­‐g-­‐EG)	  microgels.	   	   In	  
vivo	   studies	  would	  need	   to	  be	  performed	   to	  determine	  whether	   vaccine	   formulations	  
with	   P(MAA-­‐g-­‐EG)	   elicit	   an	   immune	   response,	   generate	   protective	   immunity,	   and	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Figure	  C.3.	  HPLC	  absorbance	  spectrum	  of	  ovalbumin	  (wavelength	  of	  220	  nm)	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Table	  C.1.	  Variables	  used	  to	  optimize	  surface	  decoration	  
Polymer:	  Sulfo-­‐NHS	  
	  
Polymer:	  EDC	   Polymer:	  Protein	   Activation	  time	   Reaction	  time	  
1:0	   1:0.5	   1:2	   15	  min	   2	  hours	  
1:1	   1:0.05	   1:0.2	   30	  min	   4	  hours	  
1:0.1	   1:0.005	   1:0.02	   2	  hours	   24	  hours	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